Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
25800.0 | 2017-12-19 00:00:00 UTC | First Week of August 2018 Options Trading For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/first-week-august-2018-options-trading-abbvie-abbv-2017-12-19 | nan | nan | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the August 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new August 2018 contracts and identified one put and one call contract of particular interest.
The put contract at the $97.50 strike price has a current bid of $7.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $97.50, but will also collect the premium, putting the cost basis of the shares at $90.20 (before broker commissions). To an investor already interested in purchasing shares of ABBV, that could represent an attractive alternative to paying $98.14/share today.
Because the $97.50 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 54%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 7.49% return on the cash commitment, or 11.34% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $97.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $100.00 strike price has a current bid of $6.20. If an investor was to purchase shares of ABBV stock at the current price level of $98.14/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $100.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.21% if the stock gets called away at the August 2018 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $100.00 strike highlighted in red:
Considering the fact that the $100.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 52%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.32% boost of extra return to the investor, or 9.57% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example, as well as the call contract example, are both approximately 24%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $98.14) to be 18%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of S.A.F.E. Dividend Stocks »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $100.00 strike highlighted in red: Considering the fact that the $100.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the August 2018 expiration. | Below is a chart showing ABBV's trailing twelve month trading history, with the $100.00 strike highlighted in red: Considering the fact that the $100.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the August 2018 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new August 2018 contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $97.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $100.00 strike price has a current bid of $6.20. Below is a chart showing ABBV's trailing twelve month trading history, with the $100.00 strike highlighted in red: Considering the fact that the $100.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the August 2018 expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new August 2018 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $100.00 strike highlighted in red: Considering the fact that the $100.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the August 2018 expiration. |
25801.0 | 2017-12-19 00:00:00 UTC | Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma | ABBV | https://www.nasdaq.com/articles/bristol-myers-yervoy-gets-positive-chmp-opinion-for-melanoma-2017-12-19 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Yervoy for pediatric patients of 12 years and older with unresectable or metastatic melanoma.
We note that the European Commission will take the CHMP recommendation into account while considering the application but is not bound by it.
The FDA had approved the drug for the same indication in July 2017.
We remind investors that Yervoy 3 mg/ kg monotherapy was approved in 2011.
So far this year, Bristol-Myers' shares have rallied 9.6% compared with the industry 's gain of 20.9%.
Last week, the company announced that the FDA has accepted its supplemental Biologics License Application for priority review of Opdivo plus Yervoy for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). The application is based on data from the phase III study, Checkmate-214. The study was stopped ahead of schedule based on the recommendation of an independent Data Monitoring Committee following a planned interim analysis of overall survival. The study evaluated the combination of Opdivo plus Yervoy versus Sutent for previously untreated advanced or metastatic RCC. The FDA will make a decision by Apr 16, 2018.
Meanwhile, the company continues to evaluate its blockbuster immune-oncology drug Opdivo alone or in combination therapies with Yervoy and other anti-cancer agents. Label expansion of the combination into additional indications will give the product an access to a higher patient population and increase its commercial potential.
However, Opdivo is facing competitive challenges in the United States. With the FDA approving Merck's MRK Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the company is expected to suffer further loss of market share.
The virology business is also under pressure. The company is also looking to counter generic threat for key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO .
Zacks Rank
Bristol-Myers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. Last week, the company announced that the FDA has accepted its supplemental Biologics License Application for priority review of Opdivo plus Yervoy for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Bristol-Myers Squibb CompanyBMY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Yervoy for pediatric patients of 12 years and older with unresectable or metastatic melanoma. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Bristol-Myers Squibb CompanyBMY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Yervoy for pediatric patients of 12 years and older with unresectable or metastatic melanoma. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . The FDA had approved the drug for the same indication in July 2017. |
25802.0 | 2017-12-18 00:00:00 UTC | The 5 Best-Selling Drugs of 2017 | ABBV | https://www.nasdaq.com/articles/5-best-selling-drugs-2017-2017-12-18 | nan | nan | We spent $328.6 billion on prescription drugs in 2016 -- and that's just the United States. The amount will no doubt be higher when the books are closed on 2017.
Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE) . Some of these drugs could make even more money in 2018, but others are likely to drop off the list. Here are the top five best-selling drugs in the world so far in 2017.
1. Humira
Humira has been the best-selling drug in the world for years. AbbVie is on course to make well over $18 billion from the autoimmune-disease drug this year.
Will Humira retain its top spot next year also? It's highly likely. Although Amgen won FDA approval for its biosimilar to Humira in 2016, the drug still isn't on the market. Thanks to an agreement between AbbVie and Amgen , the biosimilar won't be sold in the U.S. until early 2023. While Amgen will market the product in Europe beginning Oct. 16, 2018, around two-thirds of Humira's total revenue comes from the United States.
2. Revlimid
Blood cancer drug Revlimid pulled in nearly $7 billion in sales in 2016. That total should increase to more than $8 billion this year, giving Celgene the second-best-selling drug in the world.
Three factors drove Revlimid's sales higher in 2017: Celgene achieved greater market penetration, treatment duration increased for patients with multiple myeloma who took Revlimid, and Celgene raised prices for the drug. There's no reason to think 2018 won't be even better for Revlimid. Sales for the drug are likely to top $9 billion next year, according to market research firm EvaluatePharma. The momentum for Revlimid isn't likely to slow down soon, either: By 2022, the drug will probably make over $14 billion annually .
3. Enbrel
Humira isn't the only autoimmune-disease drug generating big bucks. Enbrel, marketed by Amgen in the U.S. and Canada and by Pfizer in other markets, is on pace to rake in more than $7.5 billion in 2017. That's enough to land the drug the No. 3 position among the best-selling drugs in the world.
Look for Enbrel to stay on the list next year, albeit with lower revenue numbers. Pfizer faces biosimilar competition for Enbrel in Europe. Meanwhile, Amgen has cut prices for the drug in the U.S. in the midst of a market crowded with alternative therapies.
4. Rituxan
Roche's Rituxan, sold under the brand name MabThera outside the U.S., has been something of a Swiss army knife among drugs, with approvals for treating non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. There aren't many drugs that can treat both cancer and autoimmune diseases. There also aren't many drugs that should generate sales of around $7.5 billion this year, but Rituxan probably will.
Next year, however, Rituxan just might fall short of the world's top five best-selling drugs. Roche is already feeling the effects of biosimilar rivals in Europe. Biosimilars could also be on the U.S. market within the next couple of years.
5. Herceptin
Another of Roche's drugs is on course to take the No. 5 ranking among the world's top drugs in 2017. Herceptin, which is approved for treating breast cancer and gastric cancer, should pull in close to $7 billion this year.
Like Rituxan, though, Herceptin's days in the top five could be numbered. On Dec. 1, the FDA approved Mylan 's (NASDAQ: MYL) biosimilar to the drug. Only a few days earlier, the first European biosimilar to Herceptin won approval. Roche is also suing Pfizer to keep another Herceptin biosimilar off the U.S. market.
The big picture
Are all of the companies behind these drugs are great choices for investors, since each one of them claims at least one of the best-selling drugs on the planet? Not necessarily. You need to look at the big picture for each of these stocks.
As we saw earlier, Roche is facing challenges for its top-selling cancer drugs. Although the company has a strong pipeline, it won't be easy to replace the revenue that will dwindle over the next few years. Amgen and Pfizer also face some headwinds for older products. It's not that any of these are horrible picks for investors, but you need to know the bad as well as the good.
Celgene lowered its outlook for autoimmune-disease treatment Otezla. However, with Revlimid and other blockbusters in its lineup, along with a strong pipeline, I like the biotech's prospects.
It's a similar story for AbbVie. With Humira likely to keep its momentum going, fast-growing sales for cancer drug Imbruvica, and a deep pipeline, AbbVie should be able to generate solid growth in the coming years. Overall, I'd say that the companies with the top two best-selling drugs in the world are also two of the best drug stocks to buy.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of AbbVie, Celgene, and Pfizer. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With Humira likely to keep its momentum going, fast-growing sales for cancer drug Imbruvica, and a deep pipeline, AbbVie should be able to generate solid growth in the coming years. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie, Celgene, and Pfizer. Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE) . | Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE) . AbbVie is on course to make well over $18 billion from the autoimmune-disease drug this year. Thanks to an agreement between AbbVie and Amgen , the biosimilar won't be sold in the U.S. until early 2023. | Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE) . AbbVie is on course to make well over $18 billion from the autoimmune-disease drug this year. Thanks to an agreement between AbbVie and Amgen , the biosimilar won't be sold in the U.S. until early 2023. | AbbVie is on course to make well over $18 billion from the autoimmune-disease drug this year. Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE) . Thanks to an agreement between AbbVie and Amgen , the biosimilar won't be sold in the U.S. until early 2023. |
25803.0 | 2017-12-18 00:00:00 UTC | Why No Large-Cap Biotech Franchise Is Safe From Threats In 2018 | ABBV | https://www.nasdaq.com/articles/why-no-large-cap-biotech-franchise-safe-threats-2018-2017-12-18 | nan | nan | No franchise is safe in 2018 among large-cap biotechs, which are feeling pressure as the Food and Drug Administration speeds approvals for rival branded and generic medicines, analysts said Monday.
[ibd-display-video id=3031092 width=50 float=left autostart=true] The theme is a continuation from 2017, Leerink analyst Geoffrey Porges said in a note to clients.
"Despite the near-record number of drug approvals, the large-cap biopharmaceutical sector fell out of a favor with investors, with no names more punished than those with concentrated product portfolios and looming branded or generic competitors," he said.
Heading into 2018, management confidence is low as revenue trajectories for high-profile products face a slowdown courtesy of payers and competitive pressures. Porges doesn't see the uncertainty lifting in 2018 - and "possibly not ever."
In 2017, competitive pressures slugged the likes of Celgene ( CELG ) and Gilead Sciences ( GILD ). Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ).
Conservative Outlook
Early next year, Porges expects guidance from the lion's share of large-cap biotechs to be conservative. The most stock-moving guidance will come from Alexion Pharmaceuticals (ALXN) and Gilead, he predicted.
Alexion is working on a drug dubbed ALXN1210 to treat a pair of rare blood diseases. It's also undergoing a restructuring. Meanwhile, Gilead's hepatitis C franchise will again come under the microscope even as it attempts to pivot further into HIV with its drug bictegravir.
"We believe there is $16 per share of value in Gilead's stock for hepatitis C, and the stock price could move up or down 5% if hepatitis C revenue guidance meaningfully differs from the consensus $5.5 billion to $6 billion estimate," Porges said.
IBD'S TAKE:Small-cap biotechs performed well in the third quarter, but large-caps suffered mounting competitive concerns. See how that translated in the stock prices by visiting the Industry Snapshot .
He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. AbbVie recently launched Mavyret to treat all six genotypes of hepatitis C. AbbVie will likely provide guidance on its fourth-quarter call ahead of Gilead.
Porges expects 2018 sales outlooks from Celgene, Alexion, Vertex Pharmaceuticals (VRTX), Gilead, Amgen (AMGN) and AbbVie to miss analyst estimates. Biogen (BIIB) could provide an outlook that encompasses analyst views, he said.
Later in the year, the large-cap universe will face political pressure, Porges predicted.
"By midyear the congressional midterm elections will be underway, and these campaigns are likely to renew the focus on pharmaceutical companies and their pricing policies," he said. "We continue to favor stocks of companies that are structural demand growth stories, with products protected by commercial, scientific, clinical or legal barriers to entry."
For 2018, his top picks are Vertex and Alexion.
Oncology Biotechs Differentiate
Another Leerink analyst, Michael Schmidt, pegs Clovis Oncology (CLVS) and Puma Biotechnology (PBYI) as his top picks among small- and midsize biotechs focused on treating cancer.
This group of stocks has outperformed the broader biotech market by 52% thus far in 2017, Schmidt wrote in a note to clients. This dynamic is set to continue in 2018 in a "favorable regulatory environment" and as large caps expand their portfolios via acquisitions.
In 2018, Incyte (INCY), Seattle Generics (SGEN), Exelixis (EXEL), Clovis, Agios Pharmaceuticals (AGIO), Puma and Array Biopharma (ARRY) are set to launch key products. He counts nine in the group set to unveil pivotal trial results and pending regulatory decisions for a total of seven firms.
Emerging technologies remain of interest. CAR-T therapy , which trains a patient's immune cells to fight cancer, and precision oncology had a strong 2017. But success in immuno-oncology combinations, cancer vaccines and certain antibodies has only been modest.
"We think next-generation antibody-drug conjugates could be an underappreciated re-emerging area of interest in 2018, representing a clinically validated category but with significant room for upside," Schmidt said.
Antibody-drug conjugates are antibodies linked to cell-killing agents. The antibody binds to specific marks at the surface of a cancer cell. ImmunoGen (IMGN), Mersana Therapeutics (MRSN) and Seattle are working in this area with the latter the furthest along, he said.
RELATED:
Why Big Pharma And Biotech Companies Are Girding For A Pricing 'Knife Fight'
Teva's Restructuring Plan: Another Case Of Been Here, Done That?
Generic Drug Makers Face Pricing Issues That Other Pharmas Don't
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ). He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. AbbVie recently launched Mavyret to treat all six genotypes of hepatitis C. AbbVie will likely provide guidance on its fourth-quarter call ahead of Gilead. | Porges expects 2018 sales outlooks from Celgene, Alexion, Vertex Pharmaceuticals (VRTX), Gilead, Amgen (AMGN) and AbbVie to miss analyst estimates. Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ). He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. | Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ). He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. AbbVie recently launched Mavyret to treat all six genotypes of hepatitis C. AbbVie will likely provide guidance on its fourth-quarter call ahead of Gilead. | Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ). He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. Porges expects 2018 sales outlooks from Celgene, Alexion, Vertex Pharmaceuticals (VRTX), Gilead, Amgen (AMGN) and AbbVie to miss analyst estimates. |
25804.0 | 2017-12-17 00:00:00 UTC | 3 Top Dividend Aristocrats to Buy for 2018 | ABBV | https://www.nasdaq.com/articles/3-top-dividend-aristocrats-buy-2018-2017-12-17 | nan | nan | It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends for 25 or more years in a row. But some Dividend Aristocrats are better than others.
Several of the nearly 50 Dividend Aristocrats look like good picks as the new year approaches. Which are the best? I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. Here's why these are three top Dividend Aristocrats to buy for 2018.
Abbott Labs
Abbott Labs' track record of 45 consecutive years of dividend increases easily landed the healthcare company on the list of Dividend Aristocrats. The company's dividend currently yields a respectable 1.94%. However, it's not the dividend that interests me the most with Abbott.
2017 has been a tremendous year for Abbott, with the stock gaining over 40%. Revenue and earnings soared, thanks primarily to what I view as a really smart acquisition. In January, Abbott closed on its $23.6 billion buyout of St. Jude Medical. This acquisition positioned the company as an even more formidable competitor in the cardiovascular market.
That wasn't the only major deal for the company this year. Abbott completed its acquisition of Alere in October. This purchase established Abbott Labs as the leader in point of care testing, which is the fastest-growing segment of the $50 billion global in vitro diagnostics market.
Acquisitions aren't the only reason I like Abbott stock, though. The company won FDA approval in September for its FreeStyle Libre Flash Glucose Monitoring System, the first approved continuous glucose monitoring system that doesn't require a finger-stick blood sample. The potential for this system is so great that I recently picked Abbott as the best diabetes stock on the market .
AbbVie
There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. AbbVie claims a more appealing dividend than its parent, with a yield of 2.96%.
The drugmaker also enjoyed its best year ever in 2017, with its stock soaring more than 50%. AbbVie benefited greatly from an agreement with Amgen that keeps a biosimilar rival to top-selling Humira off the U.S. market until early 2023.
With Humira's position more secure, AbbVie now projects sales for the drug of close to $21 billion by 2020. The company also has time for its current products and pipeline programs to contribute more revenue. AbbVie's sales for cancer drug Imbruvica are expected to double over the next three years. New hepatitis C drug Mavyret should become the company's next blockbuster.
AbbVie also claims a strong pipeline. The pharma company expects tremendous success from several candidates, particularly cancer drug Rova-T, autoimmune-disease drug upadacitinib, and endometriosis drug elagolix. Big current winners like Humira and Imbruvica combined with a promising pipeline and an attractive dividend make AbbVie the best big pharma stock of all, in my view.
General Dynamics
General Dynamics has increased its dividend for 26 consecutive years -- just over the threshold for joining the Dividend Aristocrats club. The defense contractor's dividend now yields 1.68%. General Dynamics is in the best position of any of the three companies mentioned to increase its dividend in the future, though, with a low payout ratio of 31%.
2017 hasn't been the greatest of times for General Dynamics shareholders. The stock is up by a double-digit percentage so far this year, but shares have dropped over the past couple of months with the company's mixed results in the third quarter.
I think 2018 could be better for General Dynamics. Corporate tax reform in the U.S. holds the potential to boost spending, which could benefit the company's Gulfstream business jet business. It could also spur General Dynamics to make some strategic acquisitions that could fuel growth.
General Dynamics stock, like other defense stocks, is cyclical in nature. However, with potential hot spots such as North Korea and the Middle East, I suspect U.S. military spending won't slow down anytime soon. That's good news for General Dynamics.
Best pick?
I own shares of one of these Dividend Aristocrats and think it's the best of the group. Which stock is it? AbbVie.
Don't take my word for it, though. Just look at the numbers. As we already saw, AbbVie has the highest dividend yield of the three. It also has the most attractive valuation, with shares currently trading at less than 15 times expected earnings. In addition, AbbVie should have the greatest growth prospects over the next few years. Add all this up, and I think you'll agree with me that AbbVie stands out as the best investing option among these three solid Dividend Aristocrats.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. | Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. | Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. | AbbVie. I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. |
25805.0 | 2017-12-15 00:00:00 UTC | Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA | ABBV | https://www.nasdaq.com/articles/bristol-myers-opdivo-yervoy-sbla-for-rcc-accepted-by-fda-2017-12-15 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for priority review of Opdivo plus Yervoy (ipilimumab) for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).
We note that the FDA had granted Breakthrough Therapy Designation for this application which will expedite the development and review of the same.
The FDA will make a decision by Apr 16, 2018.
The application is based on data from the phase III study, Checkmate -214 study. The study was stopped ahead of schedule based on the recommendation of an independent Data Monitoring Committee following a planned interim analysis of overall survival. The study evaluated the combination of Opdivo plus Yervoy versus Sutent for previously untreated advanced or metastatic RCC.
The study met the co-primary endpoints of improved overall survival and objective response rate compared to Sutent in intermediate- and poor-risk patients. Although the combination demonstrated an improvement in progression-free survival relative to Sutent, another co-primary endpoint, it did not reach statistical significance.
So far this year, Bristol-Myers' shares have rallied 9.2% compared with the industry gain of 20.2%.
We note that Opdivo is already approved for a number of indications. These include classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy. Additionally, it is approved as a monotherapy for the treatment of squamous cell carcinoma of the head and neck in adults progressing on or after platinum-based therapy.
Opdivo is also approved for intravenous use for patients with hepatocellular carcinoma, who have been previously treated with Nexavar. The drug received approval for liver and colorectal cancers.
Meanwhile, the company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti-cancer agents. Label expansion of the drug into additional indications will give the product an access to a higher patient population and increase its commercial potential.
However, Opdivo is facing competitive challenges in the United States. With the FDA approving Merck's MRK Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the company is expected to suffer further loss of market share.
The virology business is also under pressure. The company is also looking to counter generic threat for key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO .
Zacks Rank & Stock to Consider
Bristol-Myers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for priority review of Opdivo plus Yervoy (ipilimumab) for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Bristol-Myers Squibb CompanyBMY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for priority review of Opdivo plus Yervoy (ipilimumab) for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Bristol-Myers Squibb CompanyBMY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for priority review of Opdivo plus Yervoy (ipilimumab) for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The study evaluated the combination of Opdivo plus Yervoy versus Sutent for previously untreated advanced or metastatic RCC. |
25806.0 | 2017-12-15 00:00:00 UTC | AbbVie a Top Socially Responsible Dividend Stock With 3.0% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-top-socially-responsible-dividend-stock-30-yield-abbv-2017-12-15 | nan | nan | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources. Social criteria include elements such as human rights, child labor, corporate diversity, and the company's impact on society - for instance, taken into consideration would be business activities tied to weapons, gambling, tobacco, and alcohol.
According to the ETF Finder at ETF Channel , AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 0.21% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where ABBV makes up 1.40% of the underlying holdings of the fund.
The annualized dividend paid by AbbVie Inc is $2.84/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 01/11/2018. Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
ABBV operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson ( JNJ ), and Pfizer Inc ( PFE ).
Top 25 Socially Responsible Dividend Stocks - Income To Feel Good About »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 0.21% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where ABBV makes up 1.40% of the underlying holdings of the fund. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 0.21% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where ABBV makes up 1.40% of the underlying holdings of the fund. The annualized dividend paid by AbbVie Inc is $2.84/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 01/11/2018. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 0.21% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where ABBV makes up 1.40% of the underlying holdings of the fund. The annualized dividend paid by AbbVie Inc is $2.84/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 01/11/2018. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 0.21% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where ABBV makes up 1.40% of the underlying holdings of the fund. The annualized dividend paid by AbbVie Inc is $2.84/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 01/11/2018. |
25807.0 | 2017-12-15 00:00:00 UTC | Galapagos Cozies Up Closer to Gilead Sciences | ABBV | https://www.nasdaq.com/articles/galapagos-cozies-closer-gilead-sciences-2017-12-15 | nan | nan | Gilead Sciences (NASDAQ: GILD) inked a collaboration deal with Galapagos NV (NASDAQ: GLPG) in 2015 to gain rights to the latter's JAK1 inhibitor filgotinib. Today, Galapagos decided to execute its co-commercialization rights to filgotinib in several European countries. The move comes only weeks ahead of a standstill agreement between the two companies expires and positions Galapagos to split profit in regions covered by the co-marketing agreement. Since Galapagos' decision could have a big impact on its financials, let's learn more about filgotinib and the company's relationship with Gilead Sciences.
What's the story?
Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs.
Gilead Sciences gave Galapagos $300 million in up-front cash for its license and handed over $425 million in cash for its ownership stake. As part of the agreement, Gilead Sciences agreed to give Galapagos up to an additional $1.35 billion in development and commercial milestones, and if filgotinib is approved, tiered royalties beginning at 20%.
Gilead Sciences also agreed to allow Galapagos to opt in to co-promote filgotinib in various European markets, an option that Galapagos took advantage of this week. After exercising its option, Galapagos will split profit on filgotinib sales in Germany, France, Italy, Spain, the U.K., the Netherlands, Belgium, and Luxembourg.
Since agreeing to license filgotinib, Gilead Sciences has advanced it into phase 3 trials in rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Filgotinib is also in phase 2 trials for eight more autoimmune disease indications.
A massive market
The market for autoimmune disease drugs is massive, especially for rheumatoid arthritis drugs. Globally, up to 1% of the population suffers from rheumatoid arthritis, including about 1.5 million people in the United States and Europe.
In 2016 alone, the rheumatoid arthritis market was worth $19 billion and the market for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, was worth $8 billion. In those indications, anti-TNF therapies such as Humira dominate first-line treatment and they represent over 40% and 70% of the second-line market, respectively.
We won't know how much of these markets filgotinib can win away until its ongoing phase 3 trials wrap up, but phase 2 results in rheumatoid arthritis and Crohn's disease were encouraging. In those trials, Filgotinib was efficacious and well tolerated, with an arguably lower risk of drug interactions than other autoimmune disease treatment options.
If filgotinib performs similarly in its pivotal trials, then Gilead Sciences and Galapagos could stand a very good chance of shaking up treatment. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year Humira, can interact with other medications, making their use less than ideal. Filgotinib also has a dosing advantage over biologics because it's taken orally rather than injected or infused.
Overall, Galapagos decision to execute its option suggests that it's beginning to take the steps needed to prepare to shift from a clinical-stage to a commercial-stage company. Frankly, it couldn't ask for a better partner to help it along. Gilead Sciences is among the biggest biopharma's in the world and it's got plenty of experience tapping multibillion-dollar markets, so if any company can help make filgotinib a success, it's Gilead Sciences.
10 stocks we like better than Galapagos
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Galapagos wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned.
The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year Humira, can interact with other medications, making their use less than ideal. As part of the agreement, Gilead Sciences agreed to give Galapagos up to an additional $1.35 billion in development and commercial milestones, and if filgotinib is approved, tiered royalties beginning at 20%. | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year Humira, can interact with other medications, making their use less than ideal. Since agreeing to license filgotinib, Gilead Sciences has advanced it into phase 3 trials in rheumatoid arthritis, ulcerative colitis, and Crohn's disease. | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year Humira, can interact with other medications, making their use less than ideal. Gilead Sciences also agreed to allow Galapagos to opt in to co-promote filgotinib in various European markets, an option that Galapagos took advantage of this week. | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year Humira, can interact with other medications, making their use less than ideal. The move comes only weeks ahead of a standstill agreement between the two companies expires and positions Galapagos to split profit in regions covered by the co-marketing agreement. |
25808.0 | 2017-12-15 00:00:00 UTC | Noteworthy ETF Inflows: VYM, ABBV, GILD, LLY | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-vym-abbv-gild-lly-2017-12-15 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $209.2 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 246,531,656 to 248,982,448). Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average:
Looking at the chart above, VYM's low point in its 52 week range is $75.19 per share, with $86.14 as the 52 week high point - that compares with a last trade of $86.05. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $75.19 per share, with $86.14 as the 52 week high point - that compares with a last trade of $86.05. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $75.19 per share, with $86.14 as the 52 week high point - that compares with a last trade of $86.05. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $209.2 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 246,531,656 to 248,982,448). For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $75.19 per share, with $86.14 as the 52 week high point - that compares with a last trade of $86.05. | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $209.2 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 246,531,656 to 248,982,448). For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $75.19 per share, with $86.14 as the 52 week high point - that compares with a last trade of $86.05. |
25809.0 | 2017-12-15 00:00:00 UTC | Stocks With Rising Relative Price Strength: Horizon Pharma | ABBV | https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-horizon-pharma-2017-12-15 | nan | nan | Horizon Pharma ( HZNP ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday.
[ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
While the stock is not near a proper entry right now, see if it goes on to form and break out of a proper chart pattern.
While earnings growth decreased in the prior quarter from -27% to -63%, revenue grew 30%, up from 12% in the previous report.
The company holds the No. 6 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday. Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against that of all other stocks. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against that of all other stocks. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? |
25810.0 | 2017-12-15 00:00:00 UTC | Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion | ABBV | https://www.nasdaq.com/articles/pfizers-arthritis-drug-gets-fda-nod-for-label-expansion-2017-12-15 | nan | nan | Pfizer Inc.PFE announced that the FDA has approved a label expansion for its janus kinase (JAK) inhibitor, Xeljanz (tofacitinib), for two doses - 5 mg twice daily and 11 mg once-daily extended-release (XR) formulation.
With this latest approval, Xeljanz can now be administered for treating adult patients with active psoriatic arthritis (PsA), who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and tumor necrosis factor inhibitors, respectively.
Notably, Xeljanz (5 mg twice daily) is approved in the United States as a second-line treatment option for patients with moderate-to-severely active rheumatoid arthritis ("RA"), who have had an inadequate response to or cannot tolerate methotrexate (MTX). The drug was approved in Europe and China in March for RA. Significantly, this is the first and only JAK inhibitor approved in the United States for both moderate to severe RA and an active PsA.
Shares of Pfizer have gained 12.3% so far this year, underperforming the industry 's rally of 16.5%.
Both OPAL Broaden and OPAL Beyond trials evaluated the efficacy and safety of Xeljanz on adult patients with PsA. The programs achieved the primary efficacy endpoint of a statistically significant improvement with twice-daily Xeljanz 5 mg compared with placebo at three months as per measurement by American College of Rheumatology 20 response and the change from baseline in the Health Assessment Questionnaire Disability Index score.
Overall safety results from these studies were found to be consistent with those observed in the broader rheumatology development program for Xeljanz.
We remind investors that the company is also looking to get the drug's label expanded to include treatment of adult patients suffering from moderate-to-severe active ulcerative colitis. A response from the FDA is expected in March next year.
Additionally, Pfizer is conducting a phase IIIb/IV head-to-head study comparing Xeljanz with AbbVie's ABBV Humira. In February, the company announced top-line results from the assessment. Outcomes from the trial demonstrated non-inferiority of combo therapy comprising Xeljanz plus MTX compared with the other combo agents Humira plus MTX, thus meeting the primary endpoint.
We are encouraged by Pfizer's label expansion efforts. Xeljanz's U.S. sales surged 44% year over year to $935 million in the first nine months of 2017. The drug's label expansion should boost further the sales.
Blockbuster drugs approved to treat PsA and RA include Johnson & Johnson's JNJ Remicade and Amgen, Inc.'s AMGN Enbrel that Pfizer markets outside the United States and Canada.
In another Pfizer press release, the company announced that it has started a phase III study, evaluating the efficacy and safety of its once-daily janus kinase 1 (JAK1) inhibitor, PF-04965842, for treatment of moderate-to-severe atopic dermatitis. This initiation surfaces as the first trial in the JAK1 Atopic Dermatitis Efficacy and safety global development program.
Pfizer, Inc. Price
Pfizer, Inc. Price | Pfizer, Inc. Quote
Zacks Rank
Pfizer carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additionally, Pfizer is conducting a phase IIIb/IV head-to-head study comparing Xeljanz with AbbVie's ABBV Humira. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. With this latest approval, Xeljanz can now be administered for treating adult patients with active psoriatic arthritis (PsA), who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and tumor necrosis factor inhibitors, respectively. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, Pfizer is conducting a phase IIIb/IV head-to-head study comparing Xeljanz with AbbVie's ABBV Humira. Blockbuster drugs approved to treat PsA and RA include Johnson & Johnson's JNJ Remicade and Amgen, Inc.'s AMGN Enbrel that Pfizer markets outside the United States and Canada. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, Pfizer is conducting a phase IIIb/IV head-to-head study comparing Xeljanz with AbbVie's ABBV Humira. Pfizer Inc.PFE announced that the FDA has approved a label expansion for its janus kinase (JAK) inhibitor, Xeljanz (tofacitinib), for two doses - 5 mg twice daily and 11 mg once-daily extended-release (XR) formulation. | Additionally, Pfizer is conducting a phase IIIb/IV head-to-head study comparing Xeljanz with AbbVie's ABBV Humira. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Xeljanz (5 mg twice daily) is approved in the United States as a second-line treatment option for patients with moderate-to-severely active rheumatoid arthritis ("RA"), who have had an inadequate response to or cannot tolerate methotrexate (MTX). |
25811.0 | 2017-12-15 00:00:00 UTC | What to Expect From AbbVie Inc. in 2018 | ABBV | https://www.nasdaq.com/articles/what-expect-abbvie-inc-2018-2017-12-15 | nan | nan | In the words of the legendary James Brown, I feel good.
Early this year, I bought a position in AbbVie (NYSE: ABBV) . The big pharma stock is on track for 2017 to be its best year ever . And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock.
Now that 2017 is drawing to an end, though, it's time to focus on the new year. Will AbbVie's success continue into 2018? Here's what I think investors should expect from the drugmaker next year.
Another great year for Humira and Imbruvica
As Humira goes, so goes AbbVie. That statement has been true since AbbVie was spun off from Abbott Labs in 2013. And it will still be true in 2018.
The good news for investors is that Humira should enjoy another great year. AbbVie expects that the drug will generate sales topping $18 billion this year. I wouldn't be surprised if Humira brings in close to $20 billion in 2018. Sure, the drug's sales growth rate will taper off with biosimilar competition in Europe in the second half of the year. But I look for AbbVie to be quite pleased 12 months from now with Humira's performance.
While Humira will remain critical for AbbVie's fortunes, Imbruvica is becoming increasingly important as well. AbbVie should make around $2.5 billion from the cancer drug in 2017. This total doesn't reflect revenue that Imbruvica generates for AbbVie's partner, Johnson & Johnson (NYSE: JNJ) . AbbVie is on track to double its revenue from Imbruvica by 2020. I expect 2018 sales for the drug will increase by 30% to 35%, which would add at least $750 million to AbbVie's top line next year.
Successful launches
AbbVie's dependence on Humira will decrease even more in 2018 as a result of launches of new products. The drugmaker won Food and Drug Administration approval in August for hepatitis C drug Mavyret. AbbVie's list price for Mavyret was lower than that for Gilead Sciences ' Epclusa, although net prices for the drugs are roughly equivalent. My view is that Mavyret will quickly gain significant market share, with 2018 sales of $1 billion or more.
Look for AbbVie's endometriosis drug elagolix to also make a splash next year. The FDA granted priority review for the drug in October. An approval decision is expected in the early part of the second quarter of 2018. AbbVie is also evaluating the drug in a late-stage study for treatment of uterine fibroids. Elagolix should have blockbuster potential, although the financial impact won't be as great next year assuming the drug wins approval. I think that the FDA will approve the drug for treating endometriosis, and I expect another successful launch for AbbVie.
Pipeline progress
Next year should also be a busy one for AbbVie's development program. The company will likely report data from the aforementioned late-stage study of elagolix in treating uterine fibroids. AbbVie and J&J should announce results from a late-stage study of Imbruvica in combination with other drugs in treating diffuse large B-cell lymphoma (DLBCL) in mid-2018 as well.
Perhaps the biggest news from AbbVie's pipeline, though, could come from two new drugs. The company will report results from a pivotal study of Rova-T as a third-line treatment for small cell lung cancer next year. Assuming all goes well, AbbVie thinks that it could potentially launch Rova-T as early as late 2018.
And Humira could soon have company. AbbVie reported positive results in September from its second late-stage study of upadacitinib (ABT-494) in treating rheumatoid arthritis. The company expects data from a couple of other pivotal studies in 2018 and plans to file for regulatory approval of the drug.
Overall
Based on its impressive track record, I believe that AbbVie is the best big pharma stock on the market today. I think AbbVie will retain that honor in 2018.
My view is that investors can expect even stronger earnings growth next year than AbbVie will produce in 2017. The company recently boosted its dividend by 11%. I think we'll see another dividend hike of around that level in the fourth quarter of 2018.
What I don't expect is another year of 50% or higher gains. Much of the expected growth for AbbVie is baked into the stock price. However, I think 2018 will still be a solid year for investors. This time next year, I fully expect to still be feeling good.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie and J&J should announce results from a late-stage study of Imbruvica in combination with other drugs in treating diffuse large B-cell lymphoma (DLBCL) in mid-2018 as well. Early this year, I bought a position in AbbVie (NYSE: ABBV) . And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock. | AbbVie expects that the drug will generate sales topping $18 billion this year. This total doesn't reflect revenue that Imbruvica generates for AbbVie's partner, Johnson & Johnson (NYSE: JNJ) . Early this year, I bought a position in AbbVie (NYSE: ABBV) . | Another great year for Humira and Imbruvica As Humira goes, so goes AbbVie. AbbVie expects that the drug will generate sales topping $18 billion this year. I expect 2018 sales for the drug will increase by 30% to 35%, which would add at least $750 million to AbbVie's top line next year. | I think that the FDA will approve the drug for treating endometriosis, and I expect another successful launch for AbbVie. Early this year, I bought a position in AbbVie (NYSE: ABBV) . And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock. |
25812.0 | 2017-12-14 00:00:00 UTC | Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors | ABBV | https://www.nasdaq.com/articles/stock-market-overpriced-yes-not-these-3-sectors-2017-12-14 | nan | nan | Is the stock market overpriced? Consider that the historical price-to-earnings (P/E) ratio for the S&P 500 over the past 146 years is 15.6. The current earnings multiple is over 25.5 -- more than 63% higher than its historical average value.
The problem with using valuation metrics that look in the rearview mirror, though, is that the future is more important than the past for stock market performance. However, even using forward earnings multiples, the S&P 500 is still valued more highly than it has been in the last 13 years. The bottom line is that the stock market, at least as represented by 500 of the largest companies in the world, is overpriced. Sooner or later, there will be a reversion to the mean.
But not every sector in the market is overpriced. One sector is priced very close to its historic average. And, believe it or not, two sectors are actually trading at discounts to their historical averages. Here are these three sectors -- along with promising stock picks for each one.
Healthcare
Healthcare stocks as a group are up nearly 21% so far in 2017. Even though that's higher than the 19% year-to-date gain for the S&P 500 index, healthcare stock valuations are still in line with their historical levels. Over the last five years, for example, the healthcare sector has traded at 16.3 times expected earnings. Currently, healthcare stocks as a whole trade at 16.4 times expected earnings.
It might seem strange that healthcare hasn't become as overpriced as the overall S&P 500. However, uncertainty over the fate of Obamacare and the prospects of potential federal changes to control drug pricing dampened the outlook for biotechs and pharmaceutical companies for a while. As concerns eased, healthcare stocks took off.
Two healthcare stocks stand out, in my view, as being valued at especially attractive levels. Celgene (NASDAQ: CELG) shares currently trade at less than 12.4 times expected earnings. The biotech was enjoying a great year until October, when a pipeline setback and revised financial outlook caused investors to panic . Celgene, however, should still grow adjusted earnings per share by 19.5% annually over the next several years. The stock is dirt cheap at its current price.
AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. The big pharma stock trades at less than 14.7 times expected earnings, despite paying a dividend yielding nearly 3% and with the likelihood of growing earnings by more than 15% annually over the next five years. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy.
Technology
The technology sector's forward earnings multiple of 18.8 is a good bit lower than its historical average. And that's despite tech stocks racking up year-to-date gains of nearly 33%, easily trouncing the S&P 500.
There is something of a catch with technology stocks looking like bargains right now, though. The historical average forward earnings multiple for tech stocks is skewed by the heady days in the late 1990s and early 2000s. Tech valuations prior to the bursting of the dot-com bubble were so high, that nearly anything now looks cheap by comparison.
Still, there are some intriguing value opportunities in the technology sector. Seagate Technology (NASDAQ: STX) , for example, trades at less than 10 times expected earnings. The stock took a big hit in July following disappointing fiscal fourth-quarter results.
However, Seagate rebounded somewhat with its fiscal 2018 first-quarter results announced in October. The company remains a major player in the hard disk drive (HDD) market and is building its presence in the solid state drive (SSD) market. I think Seagate stock will rise in the coming years, and its dividend yield of over 6% pays investors to wait while the company turns things around.
Telecommunication services
Pretty much everything I mentioned above for the technology sector applies to telecommunication services stocks as well. Telecom stocks are cheap compared to historical levels, with an average forward earnings multiple of 12.7. As with tech stocks, the dot-com bubble inflated the historical forward earnings multiple average for the telecom sector.
But there is one key difference between the telecom and tech sectors: While technology stock valuations have risen quite a bit over the last five years, that hasn't been the case for telecom stocks.
There are several telecom stocks that trade at discounts right now. One that investors should consider is AT&T (NYSE: T) . It hasn't been a great year for the telecom giant, with its stock falling more than 10% in 2017 so far. However, AT&T now trades at less than 12.7 times expected earnings. And it pays out a dividend yielding north of 5.4%.
The company faces some obstacles in closing its planned acquisition of Time Warner . AT&T also has a really high debt load. However, the telecom provider is selling off some assets to lower its debt and will likely make more divestitures. Investments in high-speed 5G networks and growth in connecting cars, drones, and wearables to the internet should pay off for AT&T over the long run.
Spreading the risk around
For investors who are nervous about buying only one or two stocks in these sectors, exchange-traded funds (ETFs) could be a good alternative. Several ETFs are available that allow you to buy a basket of stocks in the healthcare, technology, or telecommunication services sectors.
Keep in mind, though, that just because a given sector is undervalued relative to the broader market or its historical averages doesn't mean that it will achieve a better performance in the short run. It's quite possible that all three of these sectors perform worse than the overall S&P 500 in 2018. But in my view, buying stocks or ETFs in sectors that aren't overpriced should pay off over the long run.
10 stocks we like better than AT&T
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AT&T wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of AbbVie and Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Time Warner. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Celgene. | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Celgene. | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Celgene. | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Celgene. |
25813.0 | 2017-12-14 00:00:00 UTC | Pfizer's Second Biosimilar of Remicade Receives FDA Approval | ABBV | https://www.nasdaq.com/articles/pfizers-second-biosimilar-of-remicade-receives-fda-approval-2017-12-14 | nan | nan | Pfizer Inc.PFE announced that the FDA has approved Ixifi its second biosimilar version of Johnson & Johnson's JNJ blockbuster rheumatoid arthritis ("RA") drug, Remicade (infliximab). Notably, Ixifi is a chimeric human-murine monoclonal antibody against tumor necrosis factor.
Ixifi received the nod for all approved indications of Remicade including RA, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.
Shares of Pfizer have risen 12.8% so far this year, underperforming the industry 's rally of 17.7%.
Notably, in February 2016, Pfizer had divested the rights to development, commercialization and manufacturing of Ixifi in the European Economic Area ("EEA") to Novartis' generic arm, Sandoz. However, Pfizer retains the commercialization and manufacturing rights to Ixifi in all countries outside the EEA.
We remind investors that Pfizer's first biosimilar product to Remicade, Inflectra, was launched last November in the United States. The company has exclusive commercialization rights to Inflectra in the United States and on certain other territories.
In September, Pfizer filed a lawsuit in a U.S. district court alleging that J&J is resorting to unfair practices to prevent the sale of Inflectra, available at a Wholesale Acquisition Cost, which is 19% lower than J&J's referenced product.
Pfizer alleged in a complaint filed in the U.S. District Court for the Eastern District of Pennsylvania that J&J has entered into biosimilar-exclusion contracts with U.S. insurers. These contracts boost insurers not to cover Inflectra, thus making it difficult to access by patients and protecting its referenced product.
Pfizer also claimed that anticompetitive contracts with discounts were offered to hospitals on purchase of Remicade on condition that they do not buy the biosimilar versions. Pfizer claims that these unfair practices benefit sales of J&J's referenced product, a key revenue generator for the latter.
Pfizer is evaluating 13 biosimilar molecules in various stages of development. Biosimilar products in late-stage development include biosimilar versions of Roche's RHHBY Rituxan and Avastin and AbbVie's ABBV Humira. A biosimilar version of Herceptin is under review in the United States and the EU. In Europe, Pfizer markets Nivestim, biosimilar versions of Amgen's Neupogen and Retacrit as well as biosimilar versions of Amgen's Epogen.
Pfizer, Inc. Price
Pfizer, Inc. Price | Pfizer, Inc. Quote
Zacks Rank
Pfizer carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biosimilar products in late-stage development include biosimilar versions of Roche's RHHBY Rituxan and Avastin and AbbVie's ABBV Humira. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Ixifi received the nod for all approved indications of Remicade including RA, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilar products in late-stage development include biosimilar versions of Roche's RHHBY Rituxan and Avastin and AbbVie's ABBV Humira. Pfizer Inc.PFE announced that the FDA has approved Ixifi its second biosimilar version of Johnson & Johnson's JNJ blockbuster rheumatoid arthritis ("RA") drug, Remicade (infliximab). | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilar products in late-stage development include biosimilar versions of Roche's RHHBY Rituxan and Avastin and AbbVie's ABBV Humira. Pfizer Inc.PFE announced that the FDA has approved Ixifi its second biosimilar version of Johnson & Johnson's JNJ blockbuster rheumatoid arthritis ("RA") drug, Remicade (infliximab). | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilar products in late-stage development include biosimilar versions of Roche's RHHBY Rituxan and Avastin and AbbVie's ABBV Humira. The company has exclusive commercialization rights to Inflectra in the United States and on certain other territories. |
25814.0 | 2017-12-14 00:00:00 UTC | Horizon Pharma Earns RS Rating Upgrade | ABBV | https://www.nasdaq.com/articles/horizon-pharma-earns-rs-rating-upgrade-2017-12-14 | nan | nan | Horizon Pharma ( HZNP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 64 to 77.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. See if Horizon Pharma can continue to show renewed price strength and clear that threshold.
Looking For Winning Stocks? Try This Simple Routine
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to form a base and break out.
Earnings growth fell in the most recent quarter from -27% to -63%. But sales moved higher, from 12% to 30%.
The company earns the No. 7 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 64 to 77. Try This Simple Routine Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to form a base and break out. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 64 to 77. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Ratings Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Over 100 years of market history reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Ratings Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database. Over 100 years of market history reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. |
25815.0 | 2017-12-13 00:00:00 UTC | 6 Dividend Growth Stocks to Stay Ahead of Rising Interest Rates | ABBV | https://www.nasdaq.com/articles/6-dividend-growth-stocks-stay-ahead-rising-interest-rates-2017-12-13 | nan | nan | For years, America's low-interest-rate environment has pushed income hunters out of bonds and into other cash-producing investments - namely, dividend stocks . However, the Federal Reserve has been slowly turning the volume back up on interest rates, and is poised to do so again Wednesday, Dec. 13, at the conclusion of the Federal Open Market Committee meeting.
If the Fed raises rates yet again, as it has telegraphed, it would mark the third increase to the Fed funds rate in 2017, and the fifth since the Federal Reserve started budging two years ago. The central banking system now targets a 1%-1.25% interest-rate level, up from 0%-0.25% as recently as 2015.
As interest rates rise, more income investors may be tempted to flee dividend-paying companies for the perceived safety of higher-yielding bonds. But you don't have to shift to debt - several dividend stocks should remain plenty competitive.
History has shown companies with a record of consistently raising their dividends can offset much of the negative effect of rising rates. Moreover, certain companies may be able to compound the benefits of an improving economy with their growing payouts. Here are six dividend growth stocks that should withstand the Fed's continued push on interest rates.
SEE ALSO: 50 Dividend Stocks You Can Count On in 2018
Dividend Yield: 3.0%
AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darling, with the stock steadily advancing roughly 175% since it opened around $35 per share.
But AbbVie has grown more than its share price. The company technically boasts a streak of 45 consecutive annual dividend raises thanks to its history as part of Abbott. But ABBV has held up its end of the bargain since being spun off, hiking its quarterly payout from 40 cents to 64 cents - a 9.9% annualized rate.
Analysts at Wells Fargo praise the company's pipeline, which includes 30 trial-stage drugs across numerous indications, meant to treat everything from rheumatoid arthritis to Crohn's disease to lung cancer. Meanwhile, AbbVie is still raking in money off marketable treatments include Humira - one of the best-selling drugs of all time - as well as Imbruvica and Venclexta.
Health care is hardly a discretionary purchase, though a better economy means fewer tough choices about whether to put off medical treatments and procedures. So a humming U.S. economic engine should help keep AbbVie's wheels greased.
SEE ALSO: 11 Best Health Care Stocks to Buy
Dividend Yield: 1.5%
Analysts may have a hard time agreeing on many of Apple's ( AAPL , $171.70) fundamental attributes -- things such as future growth rates and margins, or the competitiveness of its product pipeline.
But they'll largely agree that Apple and its premium-priced iPhones, iPads and Macs are clear beneficiaries from an expanding U.S. economy. And no one can deny that Apple has a boatload of money to put to work.
Right now, the company's hoard of cash and investments sits at $269 billion, though most of that is held overseas to avoid taxation at U.S. corporate rates. However, right now, Congress is working on a tax bill that may result in a one-time repatriation holiday that could coax the iPhone maker to bring that cash home and put it to use.
"Under an attractive cash repatriation reform, we think investors could consider Apple's willingness to bring back the majority (if not all) of its internationally held cash and investments ($250B+), from which we believe $100B+ could be considered in terms of an incremental capital return," say Wells Fargo analysts. "Capital return" is code for dividends and share repurchases. That's to say nothing about the potential for a lower overall corporate tax rate that could put more income in Apple's pockets every year, which it could return to shareholders via its regular payout.
Apple is about due for another dividend increase. The last one, in February 2017, saw the quarterly payout grow 10.5%, from 57 cents per share to 63 cents. That's a bit more than its annualized average increase of 8.9% since re-establishing its regular payout in 2012. That likelihood of dividend growth, combined with the potential for continued price increases, should mitigate any risks from another interest-rate hike.
SEE ALSO: 11 Best Tech Stocks to Buy for the Dividends
Dividend Yield: 2.4%
Boeing ( BA , $290.00) raised its quarterly dividend by 30% to the current rate of $1.42 last December, indicating confidence in its growth prospects.
But that was well before the administration's proposal to increase the military budget by $54 billion - a move that could provide an additional boost to earnings. With that wind at Boeing's back, the defense and aerospace player raised its dividend another 20% this December, to $1.71 per share - and piled on a new $18 billion share buyback authorization. Based on the new payout, Boeing's yield at current prices is 2.4%.
In good times and bad, the Boeing dividend has proven as durable as one of its revolutionary 707 jets. Even in the darkest days of the Great Recession, when Boeing's shares sank from as high as $104 to below $30, the company not only paid its quarterly dividend, but increased it twice, from 35 cents to 40 cents, then to 42 cents.
Analysts at Bank of America/Merrill Lynch expect Boeing to continue to use its strong cash flow to repurchase shares and pay dividends. Thus, while Boeing's 2.4% yield for new money might not impress, the yield on cost should rise significantly over time.
SEE ALSO: 7 Dow Jones Stocks That Pack a Growthy Punch
Dividend Yield: 2.1%
JPMorgan Chase ( JPM , $106.86) is a "Big Four" American bank that offers everything from consumer financial services to business banking to asset management.
JPMorgan and other financials directly benefit from rising rates. When interest rates go up, the interest that banks earn on lending rise while the rates they pay on deposits -- which fund their loans -- do not. The result is a higher net interest margin (i.e., more profitable loans).
The degree to which any bank's earnings grow in response to interest-rate increases depends in large measure on their balance sheet and the ways in which they fund loans. Analysts at Bank of America/Merrill Lynch, who recently reiterated their "Buy" rating on JPM shares, say JPMorgan Chase "is quite interest rate sensitive" and project $55 billion of net interest income in 2018 on the strength of higher net interest margins.
While JPM shares only yield 2.1%, the company has been an admirable dividend grower since being forced to cut payouts during the financial crisis. JPMorgan started increasing its dividend in 2011, and has ramped up the quarterly payout by an average of 41% annually since then. To give you an idea of how that affects yield over time, consider that investors who bought into JPMorgan Chase in January 2011 did so at a roughly 0.5% yield - but now are enjoying a nearly 5% yield on their original cost.
SEE ALSO: The 6 Best Bank ETFs for American Bulls
Dividend Yield: 2.3%
McDonald's ( MCD , $172.23) is a Dividend Aristocrat that has improved its payout on an annual basis every year since 1976.
The knock against McDonald's is that growth can be hard to achieve given intense competition and often razor-thin margins. But McDonald's has proven adept at pulling growth out of its hat, via items such as all-day breakfast, upscale coffee and now mobile ordering and curbside pick-up. McDonald's is on track to double the number of restaurants that offer delivery, from 5,000 to 10,000 by the end of the year - a bet that is much likelier to pay off for the fast-food restaurateur should the economy continue to click on all cylinders.
Analysts at Morgan Stanley are bullish on MCD shares, saying they have "appeal as a total return vehicle, including a long-established history of annual dividend increases. The company's competitive position is strong across the globe. MCD is in the early stage of a turnaround."
Indeed, McDonald's quarterly dividend has been a beacon of consistency and growth, blossoming from 37.5 cents per share in 2008 to $1.01 today - a 10.4% annualized rate.
SEE ALSO: 10 Top Stock Picks for the Next Decade
Dividend Yield: 2.3%
Medtronic ( MDT , $81.99) is another health care play with an impressive dividend growth record, boasting Dividend Aristocrat membership thanks to four decades of consecutive annual payout increases.
Medtronic makes numerous medical devices, including defibrillators, pacemakers, surgical staplers and insulin pumps. Those devices are used around the world, with the company boasting a reach of roughly 160 countries.
Medtronic, unlike most American companies, isn't waiting on Republicans to give it a tax break. In January 2015, it completed a so-called tax inversion when it acquired Ireland-based Covidien. Since being domiciled overseas for tax purposes, MDT has increased its payout from 30.4 cents when the inversion was completed to 46 cents in the most recent quarter. But even before that, MDT had an impressive track record, growing its distribution at a compound annual rate of nearly 14% over the past decade.
Analysts at BMO Capital Markets are bullish on MDT shares, saying, "Medtronic's expanded product portfolio ... along with its healthy cash flow, dividend yield, and valuation, makes it a compelling investment." The firm raised its 2018 earnings per share forecast for Medtronic by 9.3% in November.
SEE ALSO: 10 Blockbuster Drugs of the Future
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darling, with the stock steadily advancing roughly 175% since it opened around $35 per share. But AbbVie has grown more than its share price. | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darling, with the stock steadily advancing roughly 175% since it opened around $35 per share. But AbbVie has grown more than its share price. | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darling, with the stock steadily advancing roughly 175% since it opened around $35 per share. But AbbVie has grown more than its share price. | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darling, with the stock steadily advancing roughly 175% since it opened around $35 per share. But AbbVie has grown more than its share price. |
25816.0 | 2017-12-12 00:00:00 UTC | AbbVie Makes Progress on Quest to Diversify | ABBV | https://www.nasdaq.com/articles/abbvie-makes-progress-quest-diversify-2017-12-12 | nan | nan | AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. Fortunately, there's still time to develop blockbuster drugs that can help offset any eventual slowing in Humira demand.
Today, AbbVie and collaboration partner Roche Holdings (NASDAQOTH: RHHBY) reported new data on Venclexta that could significantly expand its use and drive its revenue higher, helping AbbVie make up for any drop in future sales.
Two titans team up
AbbVie's global Humira sales are clocking in at an annualized $18 billion annually, and that makes expanding the addressable market for drugs like Venclexta important. However, AbbVie isn't alone in facing the patent cliff. Roche Holdings also risks seeing sales decline due to the launch of biosimilars to Rituxan, a multibillion-dollar per year cancer drug. Given that both companies are hunting for new sources of revenue, it's fitting that the two are teamed up on Venclexta, a treatment that's currently only approved for use in a limited subset of late-stage chronic lymphocytic leukemia (CLL) patients with a specific genetic mutation.
Venclexta won't offset all the potential risk to these companies' top lines, but based on the data released earlier today, Venclexta could become a go-to option in second- or third-line CLL, regardless of a patient's genetic make-up.
In trials, relapsing or refractory CLL patients who were given Venclexta and Rituxan had progression-free survival (PFS) of 84.9%. For comparison, the PFS for the commonly used bendamustine chemotherapy plus Rituxan was only 36.3%. The complete response rate of 26.8% for Venclexta plus Rituxan also easily outperformed the 8.2% for bendamustine plus Rituxan.
As for safety, the percentage of patients suffering an adverse event was higher in the Venclexta-plus-Rituxan arm, but severe adverse events were about the same between the two groups.
What's next
The potential to expand Venclexta earlier in CLL treatment could provide significant revenue tailwinds for these companies. A Food and Drug Administration (FDA) approval of Venclexta in relapsing and refractory CLL could come next year. If so, analysts think Venclexta could add about $700 million in sales in 2019. Eventually, industry watchers think Venclexta's peak sales opportunity could be $3 billion if efforts allowing Venclexta's use in even more patients pans out.
That's a heady figure, but investors probably should take those forecasts with a grain of salt. After all, industry analyst's sales predictions are often wrong. Nevertheless, a multibillion dollar forecast doesn't seem too off base when you consider that Imbruvica, a J&J and AbbVie drug, is a multibillion-dollar drug and it generates most of its sales from treating CLL. Obviously, Venclexta isn't going to cure AbbVie and Roche's patent ills all on it's own, but it's a step in the right direction.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. Today, AbbVie and collaboration partner Roche Holdings (NASDAQOTH: RHHBY) reported new data on Venclexta that could significantly expand its use and drive its revenue higher, helping AbbVie make up for any drop in future sales. Two titans team up AbbVie's global Humira sales are clocking in at an annualized $18 billion annually, and that makes expanding the addressable market for drugs like Venclexta important. | Two titans team up AbbVie's global Humira sales are clocking in at an annualized $18 billion annually, and that makes expanding the addressable market for drugs like Venclexta important. AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. Today, AbbVie and collaboration partner Roche Holdings (NASDAQOTH: RHHBY) reported new data on Venclexta that could significantly expand its use and drive its revenue higher, helping AbbVie make up for any drop in future sales. | Today, AbbVie and collaboration partner Roche Holdings (NASDAQOTH: RHHBY) reported new data on Venclexta that could significantly expand its use and drive its revenue higher, helping AbbVie make up for any drop in future sales. Two titans team up AbbVie's global Humira sales are clocking in at an annualized $18 billion annually, and that makes expanding the addressable market for drugs like Venclexta important. AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. | Nevertheless, a multibillion dollar forecast doesn't seem too off base when you consider that Imbruvica, a J&J and AbbVie drug, is a multibillion-dollar drug and it generates most of its sales from treating CLL. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. |
25817.0 | 2017-12-12 00:00:00 UTC | Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug | ABBV | https://www.nasdaq.com/articles/bristol-myers-bmy-reports-positive-data-on-leukemia-drug-2017-12-12 | nan | nan | Bristol-Myers Squibb CompanyBMY announced positive data from phase II study, CA180-372, on Sprycel.
Patients received Sprycel 60 mg/m2tablets or powder for oral suspension, once daily, in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years or until the occurrence of unacceptable toxicity in the ongoing CA180-372 (NCT01460160) study.
The study evaluated Sprycel in pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when added to a chemotherapy regimen. The combination demonstrated an event-free survival rate, the study's primary endpoint, of 65.5% and an overall survival rate of 91.5% after three years.
Meanwhile, patients who had minimal residual disease (MRD) ≥0.05% at the end of the first block of treatment and those with MRD 0.005-0.05% who remained MRD-positive at any detectable level after three additional high-risk chemotherapy blocks, were eligible for hematopoietic stem cell transplantation (HSCT) in first remission.
We remind investors that Sprycel was approved in the United States for the treatment of adults with Ph+ chronic myeloid leukemia (CML) in chronic phase (CP) who are resistant or intolerant to prior therapy including imatinib. Sprycel was also approved for adults with Ph+ ALL who are resistant or intolerant to prior therapy.
The drug is also approved for the treatment of adults with newly diagnosed CP Ph+ CML. Sprycel received FDA approval for the expanded indication for treatment in pediatric patients with CP Ph+ CML in November 2017.
The label expansion should improve sales further.
So far this year, Bristol-Myers' shares have rallied 11.6% compared with the industry 's gain of 20%.
Bristol-Myers' immuno-oncology Opdivo continues to perform well along with Eliquis and Orencia. The company is looking to expand Opdivo's label further and recently obtained FDA approval for liver and colorectal cancer. However, Opdivo is currently facing competitive challenges in the United States.
The virology business is also under pressure. The company is also looking to counter generic threat for key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO .
Zacks Rank & Stock to Consider
Bristol-Myers currently carries a Zacks Rank #3 (Hold).
A better-ranked health care stocks is Sucampo Pharmaceuticals SCMP with a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Sucampo's earnings per share estimates have moved up from 97 cents to $1.19 for 2018 over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 15.63%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. Patients received Sprycel 60 mg/m2tablets or powder for oral suspension, once daily, in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years or until the occurrence of unacceptable toxicity in the ongoing CA180-372 (NCT01460160) study. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . We remind investors that Sprycel was approved in the United States for the treatment of adults with Ph+ chronic myeloid leukemia (CML) in chronic phase (CP) who are resistant or intolerant to prior therapy including imatinib. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . We remind investors that Sprycel was approved in the United States for the treatment of adults with Ph+ chronic myeloid leukemia (CML) in chronic phase (CP) who are resistant or intolerant to prior therapy including imatinib. | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The drug is also approved for the treatment of adults with newly diagnosed CP Ph+ CML. |
25818.0 | 2017-12-12 00:00:00 UTC | Novartis Announces Positive Data on Sickle Cell Disease Drug | ABBV | https://www.nasdaq.com/articles/novartis-announces-positive-data-on-sickle-cell-disease-drug-2017-12-12 | nan | nan | Novartis AGNVS announced positive results from a post hoc subgroup analysis of the phase II study, SUSTAIN on pipeline candidate, crizanlizumab.
The multicenter, multinational, randomized, placebo-controlled, double-blind, 12-month study was conducted to evaluate the safety and efficacy of the anti-P-selectin antibody crizanlizumab with or without concomitant use of hydroxyurea therapy in patients with sickle cell-related pain crises.
Results from the study showed that crizanlizumab deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell. crizanlizumab at 5.0 mg/kg per month increased the estimated median time to first SCPC versus placebo by approximately two-fold or more.
The results were published in The New England Journal of Medicine .
The data from the study will enable the company to conduct discussions with regulatory agencies. A filing in the United States is expected by the end of 2018.
We believe that the approval of new drugs and label expansion of existing drugs will boost the company's top line.
Novartis' stock has rallied 2.9% in the last six months compared with the industry 's 6.3% gain.
Novartis is currently going through a transitional stage. The company's blockbuster drug, Diovan, is facing stiff generic competition in the United States, EU and Japan. The loss of patent protection for these top-selling drugs continue to hurt sales. Exforge is also facing generic competition in the United States and the EU. Oncology drugs are facing new competition from immuno-oncology therapies. Moreover, certain patents and extensions covering Afinitor and Gilenya will expire in 2018, 2019 and 2020. The negative impact of generic competition will impact sales by $2.5 billion in 2017.
Moreover, Sandoz holds a leading position in the biosimilars space with a portfolio of five marketed biosimilars currently and a deep pipeline. The biosimilar version of Roche Holdings' RHHBY Rituxan (rituximab) is one of them. Rixathon was approved by the European Commission in June 2017. It is currently under review in the United States. The biosimilar version of AbbVie, Inc. ABBV 's Humira is also under review in the EU.
Zacks Rank & Key Pick
Novartis currently carries a Zacks Rank #3 (Hold).
A better-ranked health care stock is Sucampo Pharmaceuticals SCMP with a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Sucampo's earnings per share estimates have moved up from 99 cents to $1.19 for 2018 over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 15.63%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The biosimilar version of AbbVie, Inc. ABBV 's Humira is also under review in the EU. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced positive results from a post hoc subgroup analysis of the phase II study, SUSTAIN on pipeline candidate, crizanlizumab. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The biosimilar version of AbbVie, Inc. ABBV 's Humira is also under review in the EU. Results from the study showed that crizanlizumab deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The biosimilar version of AbbVie, Inc. ABBV 's Humira is also under review in the EU. Results from the study showed that crizanlizumab deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell. | The biosimilar version of AbbVie, Inc. ABBV 's Humira is also under review in the EU. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. We believe that the approval of new drugs and label expansion of existing drugs will boost the company's top line. |
25819.0 | 2017-12-10 00:00:00 UTC | Is Gilead Sciences, Inc. a Buy? | ABBV | https://www.nasdaq.com/articles/gilead-sciences-inc-buy-2017-12-10 | nan | nan | With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish roughly at the same level that it began the year. After getting off to a rocky start, the biotech's share price gained significant momentum beginning in June thanks to better-than-expected second-quarter results and an acquisition of Kite Pharma. However, the euphoria faded in the fourth quarter.
Is Gilead Sciences a smart pick for investors now? The best way to answer the question is to evaluate the reasons for investing in the biotech and weigh them against the reasons not to buy it.
Why buy Gilead?
One important reason to buy Gilead stock right now is its valuation. The biotech's shares currently trade at less than 11 times expected earnings. That level is well below Gilead's peers.
Income investors should like Gilead's dividend. Its yield stands at 2.84%. Since initiating the dividend program in 2015, Gilead has increased its dividend twice by 10% or more. The company appears to be in excellent shape for further dividend increases, with an ultra-low payout ratio of 23%.
After suffering steep revenue and earnings declines over the past couple of years due to deteriorating dynamics for the hepatitis C virus (HCV) franchise, Gilead CEO John Milligan said last month that he expects 2018 will be "the beginning of a growth phase" for the company. Milligan's optimism stemmed primarily from two factors: stabilization for Gilead's HCV franchise and solid growth for its HIV drugs.
A stop to the bleeding in HCV would be huge for Gilead. It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. The two companies aren't far apart on net prices (which reflect rebates and discounts from the list prices). Gilead thinks that the overall profile of its drugs should allow it to fare well against its rival.
As for HIV, Milligan's confidence is based on Gilead's current market dominance and the prospects for a promising new drug. Gilead expects to receive U.S. regulatory approval for its bictegravir/F/TAF combo by Feb. 12, 2018. Milligan thinks the combination therapy will become the most important drug for treating HIV. He's not alone. Credit Suisse analyst Alethia Young wrote recently that the bictegravir combo could be "the greatest of all time."
Then there's the pipeline opportunities outside of HIV. Gilead claims a solid lineup of experimental drugs targeting treatment of non-alcoholic steatohepatitis (NASH). ASK-1 inhibitor selonsertib is in a late-stage clinical study, while FXR agonist GS-9674 and ACC inhibitor GS-0976 are in phase 2 studies. Gilead thinks that the potential for combinations of these and perhaps other drugs in fighting NASH is significant. If it's successful, the biotech could have yet another multibillion-dollar franchise on its hands.
Gilead also has a promising autoimmune disease candidate in filgotinib. The JAK1 inhibitor is being evaluated in late-stage studies for treating Crohn's disease, rheumatoid arthritis, and ulcerative colititis.
The Kite acquisition immediately made Gilead one of the top leaders in use of cell therapy in treating cancer. Gilead recently won Food and Drug Administration approval for lead drug Yescarta in treating certain types of large B-cell lymphoma. The biotech also has several phase 2 studies underway for the CAR-T drug in treating other types of cancer.
Last but not least is Gilead's enormous cash stockpile. As of Sept. 30, 2017, Gilead had $41.4 billion of cash, cash equivalents, and marketable securities. With U.S. corporate tax reform more likely than ever, there seems to be a high probability, if not certainty, that the company will put a lot of this cash to use in funding additional acquisitions and licensing deals to beef up its pipeline.
Why not buy Gilead?
I think there are basically two major reasons why not to buy Gilead. The first is risk.
Pretty much all of the pluses for buying the biotech stock mentioned above come with risks. John Milligan might be wrong about Gilead's HCV sales stabilizing. Maybe the bictegravir/F/TAF combo won't be the huge hit that many expect. Gilead experienced its fair share of pipeline setbacks in the past. There's a real possibility more could follow with its NASH drugs, filgotinib, or Yescarta.
Gilead does have plenty of money to use for more acquisitions, but buying other companies doesn't always turn out to be as successful as hoped. Several of Gilead's acquisitions in recent years haven't panned out.
What's the second reason why not to buy Gilead? Opportunity cost. Several of the reasons to buy the stock will take time to play out. That's especially true for Gilead's pipeline candidates. We're looking at a few years before most of its experimental drugs could reach the market -- and that's only if the clinical studies are successful and they win regulatory approval. An argument could be made that other stocks should generate gains more quickly.
Final analysis
So is Gilead Sciences a buy? I say "yes."
Obviously, risks exist. However, that's true with any stock, especially any biotech stock. I suspect that John Milligan is right that next year will be a turning point for the company. I like Gilead's pipeline, and don't think its value is adequately factored into the stock price right now. And while Gilead's track record isn't perfect on acquisitions, my view is that the biotech has done a pretty good job overall, particularly on big deals.
I don't dispute that there is an opportunity cost associated with buying Gilead. Frankly, if I could only buy one stock right now, it would be another biotech . But most investors aren't limited to just buying one stock. On balance, Gilead Sciences appears to be a smart long-term pick. And it's the long term that investors should keep in mind.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. After getting off to a rocky start, the biotech's share price gained significant momentum beginning in June thanks to better-than-expected second-quarter results and an acquisition of Kite Pharma. | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish roughly at the same level that it began the year. | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Why buy Gilead? | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. But most investors aren't limited to just buying one stock. |
25820.0 | 2017-12-10 00:00:00 UTC | Better Buy: Pfizer (PFE) vs. AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/better-buy-pfizer-pfe-vs-abbvie-abbv-2017-12-10 | nan | nan | For Pfizer (NYSE: PFE) , 2017 so far has looked better than the past couple of years in terms of stock performance. However, the stock's 9% year-to-date gain isn't anything to jump up and down about. AbbVie 's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. The stock is up more than 50% and is on track for its best yearly gain ever .
All that's water under the bridge, though. What really matters for investors is how stocks will perform in the future. Both Pfizer and AbbVie have solid potential, but which is the better choice for long-term investors? Here's how the two big pharma stocks compare.
Growth
Pfizer's current growth stems in large part from five products: blood thinner Eliquis, breast cancer drug Ibrance, nerve pain drug Lyrica, rheumatoid arthritis drug Xeljanz, and prostate cancer drug Xtandi. However, the company faces headwinds for many of its products that have either lost exclusivity or soon will do so.
The drugmaker's pipeline includes an impressive 95 clinical programs. Pfizer awaits regulatory approval for 10 of those, with another 28 programs in late-stage testing. Some of these programs are pursuing additional indications for already-approved drugs, but others, such as pain drug tanezumab and breast cancer drug talazoparib, haven't hit the market yet.
AbbVie, meanwhile, has relied on its powerhouse autoimmune disease drug Humira to drive growth in the past, and the company expects continued, albeit slowing sales growth for the drug. AbbVie also has cancer drug Imbruvica in its lineup, which is on track to generate sales of $2.5 billion this year -- up more than 40% year over year. In addition, it recently launched hepatitis C drug Mavyret, which could become another blockbuster for AbbVie.
Although AbbVie's pipeline doesn't match Pfizer's quantity of drugs in development, quality is a different story. Earlier this year, market researcher EvaluatePharma ranked AbbVie's pipeline as the third best in the biopharmaceutical industry. Two especially promising candidates for AbbVie are autoimmune disease drug upadacitinib and cancer drug Rova T.
Wall Street analysts project that Pfizer will increase annual earnings by around 6% in the coming years, an improvement over the drugmaker's recent growth. Analysts think that AbbVie will grow its earnings by 15% annually.
Valuation
Both of these pharma stocks appear to be attractively valued. Pfizer shares currently trade at 22 times trailing-12-month earnings and less than 13 times expected earnings. AbbVie's trailing earnings multiple stands at 23, with a forward earnings multiple of 14.
Dividend
Investors also have a lot to like about both companies' dividends. Pfizer's dividend yields 3.6% right now, while AbbVie's yield is just under 3%. Pfizer currently uses around 78% of its earnings to fund its dividend program. AbbVie's dividend payout ratio is 60%. Neither company's dividend appears to be in jeopardy.
AbbVie claims the better track record of dividend hikes. Since being spun off from parent Abbott Labs in 2013, the company's dividend has increased by nearly 78%. Pfizer has also increased its dividend, with growth of 33% over the last five years.
Better buy
I like both of these stocks. In fact, I own shares of both of them. Pfizer has the higher dividend yield, which is a big plus. It also has an advantage in valuation based on earnings multiples.
However, AbbVie's growth prospects are much higher than Pfizer's. Factoring that potential growth in, AbbVie is the more attractively valued stock. And while its yield is lower than Pfizer's, that's mainly a factor of its tremendous stock performance this year.
Of course, the dynamics could change for either of these companies. Both Pfizer and AbbVie have made key acquisitions in recent years and could do more in the future. I'd bet on both of them doing more deals in 2018. Also, Pfizer is considering spinning off or selling its consumer healthcare business. Shareholders have enjoyed nice gains as a result of the company's spinoff of its animal health business, now known as Zoetis . It's possible that they could have similar prospects if Pfizer chooses to spin off the consumer unit.
Still, I don't think any changes resulting from acquisitions, divestitures, or spinoffs would fundamentally alter the decision before us right now. AbbVie is the better buy. Some stocks offer only growth, attractive valuation, or solid income, and not all of them. AbbVie, on the other hand, is strong on all three counts, making it the best big pharma stock on the market in my view.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Pfizer. AbbVie 's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. Both Pfizer and AbbVie have solid potential, but which is the better choice for long-term investors? | AbbVie, meanwhile, has relied on its powerhouse autoimmune disease drug Humira to drive growth in the past, and the company expects continued, albeit slowing sales growth for the drug. Two especially promising candidates for AbbVie are autoimmune disease drug upadacitinib and cancer drug Rova T. Wall Street analysts project that Pfizer will increase annual earnings by around 6% in the coming years, an improvement over the drugmaker's recent growth. Factoring that potential growth in, AbbVie is the more attractively valued stock. | Two especially promising candidates for AbbVie are autoimmune disease drug upadacitinib and cancer drug Rova T. Wall Street analysts project that Pfizer will increase annual earnings by around 6% in the coming years, an improvement over the drugmaker's recent growth. AbbVie's trailing earnings multiple stands at 23, with a forward earnings multiple of 14. Dividend Investors also have a lot to like about both companies' dividends. AbbVie 's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. | * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie 's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. Both Pfizer and AbbVie have solid potential, but which is the better choice for long-term investors? |
25821.0 | 2017-12-08 00:00:00 UTC | Noteworthy Friday Option Activity: UAL, GILD, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-ual-gild-abbv-2017-12-08 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in United Continental Holdings Inc (Symbol: UAL), where a total of 16,533 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 44.2% of UAL's average daily trading volume over the past month of 3.7 million shares. Especially high volume was seen for the $63 strike call option expiring December 15, 2017 , with 1,149 contracts trading so far today, representing approximately 114,900 underlying shares of UAL. Below is a chart showing UAL's trailing twelve month trading history, with the $63 strike highlighted in orange:
Gilead Sciences Inc (Symbol: GILD) saw options trading volume of 31,042 contracts, representing approximately 3.1 million underlying shares or approximately 42.9% of GILD's average daily trading volume over the past month, of 7.2 million shares. Especially high volume was seen for the $73.50 strike call option expiring December 15, 2017 , with 3,324 contracts trading so far today, representing approximately 332,400 underlying shares of GILD. Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange:
And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over the past month, of 4.5 million shares. Especially high volume was seen for the $95 strike call option expiring February 16, 2018 , with 5,584 contracts trading so far today, representing approximately 558,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange:
For the various different available expirations for UAL options , GILD options , or ABBV options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $95 strike call option expiring February 16, 2018 , with 5,584 contracts trading so far today, representing approximately 558,400 underlying shares of ABBV. Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over the past month, of 4.5 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: For the various different available expirations for UAL options , GILD options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over the past month, of 4.5 million shares. Especially high volume was seen for the $95 strike call option expiring February 16, 2018 , with 5,584 contracts trading so far today, representing approximately 558,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: For the various different available expirations for UAL options , GILD options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over the past month, of 4.5 million shares. Especially high volume was seen for the $95 strike call option expiring February 16, 2018 , with 5,584 contracts trading so far today, representing approximately 558,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: For the various different available expirations for UAL options , GILD options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over the past month, of 4.5 million shares. Especially high volume was seen for the $95 strike call option expiring February 16, 2018 , with 5,584 contracts trading so far today, representing approximately 558,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: For the various different available expirations for UAL options , GILD options , or ABBV options , visit StockOptionsChannel.com. |
25822.0 | 2017-12-08 00:00:00 UTC | The No. 7 Drug Maker Is This Week's No. 1 Pick | ABBV | https://www.nasdaq.com/articles/no-7-drug-maker-weeks-no-1-pick-2017-12-08 | nan | nan | Note From The Editor:Today's issue is written by Amber Hestla, a former military intelligence operative. She's spent the last few years using an income-producing strategy she first began developing while serving in Iraq.
But before we get to today's issue, we want to take just a quick second to share something with you first.
Amber just released a brand-new report where she spills all of her secrets on an income-producing strategy that rakes in an average of $568 every week. That's $29,577 a year. Even more, it boasts a success rate of 90.5% -- something you'd be hard-pressed to find anywhere else.
At the very least, you need to check out this incredible chart . It perfectly illustrates just how much income this can produce for you.
You can access the report right here .
Sincerely,
The StreetAuthority team
Many years ago, I had time to kill waiting for a flight in Denver. I called a friend who said he was nearby and could be there in a few minutes. He'd been teaching me about the markets and I was looking forward to another lesson.
As he sat down, he handed me a copy of Investor's Business Daily and began explaining why I should be familiar with it. We spent the next couple of hours looking at how the newspaper applied relative strength and fundamentals. There was a complete trading method in those pages, and at a single meeting in an airport, I was able to understand all of it.
As we wrapped up our meeting, I knew how it would end. He would assign me homework as he always did. This time, the assignment was to read "The Battle for Investment Survival" by Gerald Loeb.
My friend explained that he had seen William O'Neil, the founder of Investor's Business Daily , speak several times. O'Neil always mentioned that he had read hundreds of books on the stock market and there were only two that he believed every investor should read: First, of course, was O'Neil's book, "How to Make Money in Stocks." The second was Loeb's book, which was written in 1935.
Both books are quick reads and complement each other. They both advise buying stocks that are going up and cutting losses quickly. Of the two, I think Loeb's book provides a better understanding of the philosophy of trading, while O'Neil provides more information about the mechanics of selecting good stocks.
In his book, O'Neil says that it's better to buy stocks that are going up, a strategy that can make many investors uncomfortable. Individuals often focus on value and look for bargains in the market. They might look at a stock trading near its 52-week low and assume that means the stock is on sale. And it might be... but it also might be in a strong downtrend and on the verge of dropping more.
O'Neil explained that we should think about how a stock reached a new 52-week high. He wrote, "As a final appeal to your trusty common sense and judgment, it should be stated that if a security has traded between $40 and $50 a share over many months and is now selling at $50 and is going to double in price, it positively must first go through $51, $52, $53, $54, $55, and the like, before it can reach $100."
In other words, if a stock is going up, it has definitely been setting new 52-week highs along the way. Because the trend is up -- and there are likely more 52-week highs in the stock's future -- the best choice could be to buy it on a pullback.
Spotting This Trend In Real Life
O'Neil cited a pattern to identify the ideal buy candidate that he called a "cup with handle" pattern. There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidation, like the ones highlighted below in the chart of AbbVie (NYSE: ABBV ) .
The cup portion of the pattern is highlighted in blue. This is the pullback. ABBV sold off about 13% from its 52-week high, but buyers emerged and prevented the stock from falling too much.
After the stock recovered its losses, resistance developed near the old highs. This is common. Resistance likely formed when short-term traders took profits in ABBV. They may have bought near the lows and were happy with an 8% gain in less than two weeks.
But, the selling pressure was less intense and the decline was relatively shallow. This is the price consolidation, or the handle of the cup, which I've highlighted in green.
Based solely on the chart pattern, we could say ABBV is a "buy." But digging deeper, I'm still bullish on the stock for other reasons.
This Long-Time Favorite Still Has Room To Run
I've written about AbbVie a few times before. It is one of the world's largest drug makers (the seventh-largest by market cap), known to many for its best-selling drug, Humira, a biologic therapy for autoimmune diseases including rheumatoid arthritis, Crohn's disease and other inflammatory conditions. This is the best-selling drug in the world, with sales of more than $15 billion a year.
Other blockbusters include the blood cancer drug Imbruvica, which is now the first-line treatment for many variations of the disease. Another treatment for leukemia, Venclexta, is expected to bring in more than $1.5 billion by the end of the decade.
The company also offers Viekira Pak for the treatment of hepatitis C, but it has not had much success in that market, which is largely controlled by Gilead Sciences (NASDAQ: GILD ). AbbVie is working to develop other drugs before sales of Humira start to decline (expected next year). But the impending loss of patent protection for that drug is affecting the company.
The stock is trading at a below average price-to-sales (P/S) ratio and a below average PEG ratio, which is a metric that compares the price-to-earnings (P/E) ratio to the growth rate of earnings. This ratio recognizes that companies growing rapidly should trade at higher multiples than those with slow growth.
One surprise in the pipeline or an acquisition by AbbVie could significantly affect the company's earnings and push the stock up sharply. Downside risks appear to be limited by the company's below-average valuation.
While I am optimistic about the long term, I am most bullish about the short term, which is where I've identified a high-income opportunity in the stock.
How You Can Win Almost Every Time
What many investors don't know is that this expected price move also sets up a high-probability, high-income opportunity in AbbVie using short-term options. Rather than buying the stock and hoping for the best, this surprisingly simple options trade allows us to take a greater gain in a shorter time.
The strategy I'm using for this trade, selling put options, is the same one my Income Trader readers and I have been using to make thousands of dollars in extra income each month. In this case, a rise in the price of ABBV would earn you a 2.5% return in just days, which equates to an exceptional 60% annualized return.
And what happens in case of a drop in price could be even better. If ABBV is trading under the expected price when your options expire in 15 days, you get to essentially buy the stock at an even greater discount (a full 6.0% less), leaving you with a solid stock at a price you could never get by waiting for price drops.
I'm saving the specifics of my income trade for my Income Trader subscribers, but if you'd like to get started selling puts, I'm here to guide you through the process. I'll tell you which trades to make and when. Even better, you can start trading in just seven minutes.
To learn more about my process and start making extra income today, click here .
Related Articles
The Market-Shifting News You Missed Last Month
How You Can Catch The Market's Biggest Fish
3 Cryptocurrencies You Need To Know
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2016 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | How You Can Win Almost Every Time What many investors don't know is that this expected price move also sets up a high-probability, high-income opportunity in AbbVie using short-term options. There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidation, like the ones highlighted below in the chart of AbbVie (NYSE: ABBV ) . ABBV sold off about 13% from its 52-week high, but buyers emerged and prevented the stock from falling too much. | AbbVie is working to develop other drugs before sales of Humira start to decline (expected next year). There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidation, like the ones highlighted below in the chart of AbbVie (NYSE: ABBV ) . ABBV sold off about 13% from its 52-week high, but buyers emerged and prevented the stock from falling too much. | If ABBV is trading under the expected price when your options expire in 15 days, you get to essentially buy the stock at an even greater discount (a full 6.0% less), leaving you with a solid stock at a price you could never get by waiting for price drops. There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidation, like the ones highlighted below in the chart of AbbVie (NYSE: ABBV ) . ABBV sold off about 13% from its 52-week high, but buyers emerged and prevented the stock from falling too much. | AbbVie is working to develop other drugs before sales of Humira start to decline (expected next year). How You Can Win Almost Every Time What many investors don't know is that this expected price move also sets up a high-probability, high-income opportunity in AbbVie using short-term options. There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidation, like the ones highlighted below in the chart of AbbVie (NYSE: ABBV ) . |
25823.0 | 2017-12-06 00:00:00 UTC | AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan | ABBV | https://www.nasdaq.com/articles/abbvie-jjs-imbruvica-succeeds-in-combo-study-with-rituxan-2017-12-06 | nan | nan | AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruvica in Waldenström's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, met the primary endpoint.
Interim data from the phase III iNNOVATE study showed that a combination of Imbruvica and Roche's RHHBY Rituxan led to improved progression-free survival (PFS) in treatment-naive and previously-treated patients with WM compared to Rituxan alone. Based on the early positive results, the Independent Data Monitoring Committee (IDMC) recommended an unblinded study. AbbVie and J&J plan to discuss the positive interim data with regulatory authorities
Imbruvica is already approved as a monotherapy for the treatment of WM. In fact, including WM, Imbruvica is presently approved for six distinct patient populations including mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL) and chronic graft versus host disease (GVHD).
Imbruvica was added to AbbVie's pipeline with the May 2015 acquisition of Pharmacyclics. It has become a key revenue driver for AbbVie. In 2017, AbbVie expects to record Imbruvica global revenues of more than $2.4 billion with sales in the United States expected to cross $2 billion. In the first nine months of 2017, Imbruvica had recorded sales of $1.87 billion, representing growth of 41.2% year over year. In fact, AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020
At present, the CLL segment is the largest revenue contributor to Imbruvica's growth while expansion into non-Hodgkin's lymphoma (NHL) and other indications will be major growth drivers in the future.
Imbruvica has multi-billion dollar potential and AbbVie is exploring the potential to expand its label into solid tumors and autoimmune diseases. Imbruvica is in phase III studies for diffuse large B-cell lymphoma and follicular lymphoma. AbbVie is positioning Imbruvica as a "pipeline in a molecule" with the treatment featuring in several company-sponsored studies.
AbbVie's shares have gained 52.3% so far this year, comparing favorably with a gain of only 15% recorded by the industry .
The share price surge was supported by a series of positive news in the past few months. AbbVie presented promising data from several pivotal studies, gained regulatory approvals in the United States, Europe, and Japan for its competitive HCV medicine, Mavyret; received FDA approval for the sixth indication for Imbruvicaand settled its Humira patent disputes with Amgen, Inc. AMGN .
AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie and J&J plan to discuss the positive interim data with regulatory authorities Imbruvica is already approved as a monotherapy for the treatment of WM. AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruvica in Waldenström's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, met the primary endpoint. Imbruvica was added to AbbVie's pipeline with the May 2015 acquisition of Pharmacyclics. | In 2017, AbbVie expects to record Imbruvica global revenues of more than $2.4 billion with sales in the United States expected to cross $2 billion. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruvica in Waldenström's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, met the primary endpoint. | AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruvica in Waldenström's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, met the primary endpoint. In fact, AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020 At present, the CLL segment is the largest revenue contributor to Imbruvica's growth while expansion into non-Hodgkin's lymphoma (NHL) and other indications will be major growth drivers in the future. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie and J&J plan to discuss the positive interim data with regulatory authorities Imbruvica is already approved as a monotherapy for the treatment of WM. In fact, AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020 At present, the CLL segment is the largest revenue contributor to Imbruvica's growth while expansion into non-Hodgkin's lymphoma (NHL) and other indications will be major growth drivers in the future. AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruvica in Waldenström's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, met the primary endpoint. |
25824.0 | 2017-12-06 00:00:00 UTC | Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-amgen-pcsk9-inhibitor-revance-rt002-data-2017-12-06 | nan | nan | This week, companies like Amgen AMGN , Revance Therapeutics, Inc. RVNC and AbbVie ABBV were in the news. While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates.
Recap of the Week's Most Important Stories
Revance Soars on RT002 Data: Revance's shares shot up 33.7% on positive top-line data from late-stage studies evaluating the company's next-generation neuromodulator RT002. RT002 met the primary as well as all secondary endpoints in the studies that were conducted for the reduction of moderate-to-severe glabellar lines (the frown lines or wrinkles between the brows).
A long-term safety study is currently ongoing with the study scheduled to complete in the second half of 2018. The successful completion of this study would allow Revance to file for FDA approval in the first half of 2019 and potentially launch the product in 2020. The company believes that FDA approval would make RT002 the first neuromodulator with a long-acting duration of six months as currently marketed neuromodulators have shown duration of three to four months in treating glabellar lines. RT002's approval could well change the neuromodulator treatment landscape as it would be needed only twice a year.
According to information provided by the company, the treatment of glabellar lines is the most popular aesthetic procedure for an injectable neuromodulator with almost a third of the $3.6 billion in global neuromodulator sales in 2016 coming from this area. Currently approved treatments include Botox and Dysport.
Amgen's PCSK9 Inhibitor Label Approved for Cardiovascular Outcomes Data: Amgen's PCSK9 inhibitor, Repatha, got a bit of a boost with the FDA granting approval to the company's request to add cardiovascular outcomes data to the drug's label. This makes Repatha the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease. Repatha was also approved for use as an adjunct to diet, alone or in combination with other lipid-lowering therapies like statins, for the treatment of adults with primary hyperlipidemia to reduce low density lipoprotein cholesterol (LDL-C).
The updated label will provide physicians with a new treatment option to prevent cardiovascular events by dramatically lowering LDL cholesterol with Repatha, especially in the case of patients who are already on maximally-tolerated statin therapy and need to lower their LDL cholesterol level further.
The cardiovascular outcomes data should help drive Repatha sales which are yet to take off as expected with factors like strict utilization management criteria and processes employed by insurers and pharmacy benefit managers (PBMs) impacting sales. However, Amgen has been working with payers to improve access for appropriate patients and Repatha remains a growth brand for the company (Read more: Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention ). Amgen is a Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Positive Data on AbbVie's Risankizumab and Imbruvica: AbbVie's risankizumab met the primary endpoint in the fourth pivotal phase III study conducted for the treatment of patients with moderate to severe plaque psoriasis. After 16 weeks of treatment, almost half (47%) of risankizumab patients achieved complete skin clearance (PASI 100) compared to 1% of patients on placebo. Risankizumab is being developed in collaboration with Boehringer Ingelheim (Read more: AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study ).
AbbVie also presented data on a combination of its BTK inhibitor, Imbruvica, and Rituxan for the treatment of both newly and previously-treated patients with Waldenström's macroglobulinemia ("WM"). The primary endpoint of progression-free survival ("PFS") was achieved in the late-stage study. Imbruvica is approved for different indications including chronic lymphocytic leukemia, previously treated mantle cell lymphoma and WM as well as chronic graft-versus-host-disease. AbbVie expects Imbruvica revenues of $5 billion in 2020.
Priority Review for Clovis sNDA: Clovis Oncology's CLVS supplemental New Drug Application (sNDA) for the use of its PARP inhibitor, Rubraca (rucaparib), has been granted priority review status by the FDA. The company is looking to get Rubraca approved for use as maintenance treatment for women with recurrent ovarian cancer who are platinum sensitive, and in complete or partial response to platinum chemotherapy, with no requirement for diagnostic testing. With the FDA granting priority review, a response should be out on Apr 6, 2018.
Clovis's shares are up 29.9% year to date, compared to the 1.3% gain recorded by the industry it belongs to.
Galectin Down on NASH Data: Galectin Therapeutics Inc.'s shares fell 30.7% on data from a phase IIb study on GR-MD-02. Although the candidate showed statistically significant and clinically meaningful results in a sub-group of non-alcoholic steatohepatitis ("NASH") cirrhosis patients, it failed to achieve statistical significance in the total group of patients.
Positive 48-Week Data on Ultragenyx Drug: Ultragenyx Pharmaceutical Inc. RARE and partner Kyowa Kirin announced positive 48-week data from a late-stage study of burosumab (KRN23) in adults with X-linked hypophosphatemia ("XLH"). The companies said that further improvement in disease symptoms and fracture healing were observed through 48 weeks of treatment with burosumab. Burosumab is currently under priority review for the treatment of pediatric and adult patients with XLH with a response from the FDA expected on Apr 17, 2018.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index declined slightly (0.5%) over the last five trading sessions. Among major biotech stocks, Amgen was up 4.9% while Vertex declined 6.1%. Over the last six months, Biogen BIIB was up 23.7% while Regeneron REGN lost 22.5% (See the last biotech stock roundup here: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal ).
What's Next in the Biotech World?
Watch out for the usual pipeline and regulatory updates.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
Revance Therapeutics, Inc. (RVNC): Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie also presented data on a combination of its BTK inhibitor, Imbruvica, and Rituxan for the treatment of both newly and previously-treated patients with Waldenström's macroglobulinemia ("WM"). This week, companies like Amgen AMGN , Revance Therapeutics, Inc. RVNC and AbbVie ABBV were in the news. While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Revance Therapeutics, Inc. (RVNC): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. This week, companies like Amgen AMGN , Revance Therapeutics, Inc. RVNC and AbbVie ABBV were in the news. While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates. | While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Revance Therapeutics, Inc. (RVNC): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. This week, companies like Amgen AMGN , Revance Therapeutics, Inc. RVNC and AbbVie ABBV were in the news. | While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates. Positive Data on AbbVie's Risankizumab and Imbruvica: AbbVie's risankizumab met the primary endpoint in the fourth pivotal phase III study conducted for the treatment of patients with moderate to severe plaque psoriasis. This week, companies like Amgen AMGN , Revance Therapeutics, Inc. RVNC and AbbVie ABBV were in the news. |
25825.0 | 2017-12-05 00:00:00 UTC | AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study | ABBV | https://www.nasdaq.com/articles/abbvie-psoriasis-candidate-succeeds-in-4th-phase-iii-study-2017-12-05 | nan | nan | AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints.
Top line data from the IMMhance study showed that a significant portion of patients treated with risankizumab achieved high levels of skin clearance. Nearly half (47%) of the patients treated with risankizumab achieved complete skin clearance versus placebo (1%) after 16 weeks of treatment.
On continuous treatment with risankizumab, at week 28, 87% of the risankizumab patients maintained this response for one year. This data shows that patients can achieve better disease improvement over time on continuous treatment with risankizumab rather than withdrawing from the therapy after an initial response. Results from this study will support regulatory filings for the candidate.
The 16-week results from this study were presented at the 8th International Congress of Psoriasis from Gene to Clinic meeting in London.
AbbVie had in-licensed risankizumab from Boehringer Ingelheim in 2016. AbbVie is responsible for the future development and commercialization of the candidate.
We remind investors that in October, AbbVie had announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and AbbVie's Humira, for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. Top-line data presented from the studies showed that risankizumab achieved significantly greater response of clear or almost clear skin versus Stelara and Humira or placebo after 16 weeks of treatment.
Risankizumab is also being evaluated in phase II studies for other immunological disorders like Crohn's disease and psoriatic arthritis.
AbbVie's shares have gained 52% so far this year, comparing favorably with a gain of only 16.5 % recorded by the industry .
The share price surge was supported by a series of positive news in the past few months. AbbVie presented promising data from several pivotal studies, gained regulatory approvals in the United States, Europe, and Japan for its competitive HCV medicine, Mavyret, received FDA approval for the sixth indication for Imbrivicaand settled its Humira patent disputes with Amgen, Inc. AMGN .
AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
A better-ranked large-cap pharma stock is H. Lundbeck A/S HLUYY , carrying a Zacks Rank #2 (Buy).
Shares of Lundbeck have risen 21.7% so far this year while 2018 earnings estimates have gone up 3.2% in the past 30 days.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
H Lundbeck A/S (HLUYY): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. AbbVie had in-licensed risankizumab from Boehringer Ingelheim in 2016. AbbVie is responsible for the future development and commercialization of the candidate. | AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. We remind investors that in October, AbbVie had announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and AbbVie's Humira, for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | We remind investors that in October, AbbVie had announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and AbbVie's Humira, for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. AbbVie had in-licensed risankizumab from Boehringer Ingelheim in 2016. |
25826.0 | 2017-12-05 00:00:00 UTC | Valeant Pharmaceuticals Joins Elite Club Of Stocks With RS Ratings Over 90 | ABBV | https://www.nasdaq.com/articles/valeant-pharmaceuticals-joins-elite-club-stocks-rs-ratings-over-90-2017-12-05 | nan | nan | Valeant Pharmaceuticals ( VRX ) had its Relative Strength ( RS ) Rating upgraded from 88 to 91 Tuesday.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the market's biggest winners typically have an RS Rating of over 80 at the beginning of a new climb.
See How IBD Helps You Make More Money In Stocks
Valeant Pharmaceuticals is now considered extended and out of buy range after clearing a 15.84 buy point in a first-stage cup with handle . See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Valeant Pharmaceuticals reported negative growth for both sales and earnings last quarter.
The company earns the No. 10 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. History reveals that the market's biggest winners typically have an RS Rating of over 80 at the beginning of a new climb. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Valeant Pharmaceuticals ( VRX ) had its Relative Strength ( RS ) Rating upgraded from 88 to 91 Tuesday. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Ratings Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Ratings Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database. Valeant Pharmaceuticals reported negative growth for both sales and earnings last quarter. |
25827.0 | 2017-12-04 00:00:00 UTC | Top Biotech Stock Near Buy Zone, Shows Positive Drug Trial Results | ABBV | https://www.nasdaq.com/articles/top-biotech-stock-near-buy-zone-shows-positive-drug-trial-results-2017-12-04 | nan | nan | On Monday, leading drugmaker AbbVie ( ABBV ) announced positive Phase 3 trial results for its psoriasis treatment, risankizumab. On Tuesday, the IBD Big Cap 20 was up fractionally and within 3% of a potential new buy zone.
[ibd-display-video id=2102289 width=50 float=left autostart=true] Results of the ongoing study showed that "nearly half (47%) of risankizumab patients achieved complete skin clearance (PASI 100) vs. placebo (1%) at week 16."
AbbVie, which generated just under $7 billion in revenue in Q3, is a megacap medical stock, with a market cap of north of $150 billion.
It's joined on the IBD Big Cap 20 by fellow medical stocks Edwards Lifesciences ( EW ), Align Technology ( ALGN ) and Centene ( CNC ).
Intuitive Surgical ( ISRG ) was dropped from list after the maker of the da Vinci robot-assisted surgical system fell nearly 7% in volume 155% higher than normal Monday. On Tuesday, the stock tried, but failed to retake its 50-day moving average.
Align Technology, which has a proprietary system for treating maloccclusion or teeth misalignment, also sold off Monday, but has managed to stay above that benchmark line. The stock edged 0.7% higher Tuesday.
Like AbbVie, Edwards Lifesciences is working on a new base, and managed health care provider Centene, which broke out last week, is again testing the 98.82 buy point. Centene has bounced back into buy range with a 1.7% rise Tuesday and closed the session 1% above the buy point.
Dividend Stock With Growth
For a company of its size, AbbVie continues to generate solid growth, with revenue gains ranging from 8% to 18% over the last eight quarters.
The North Chicago, Ill.-based company has posted three straight quarters of rising earnings growth, with bottom line gains ranging rising from 6% to 17% over that period.
Plus, AbbVie also pays a dividend currently yielding 2.9% on an annual basis. (Check out IBD's new special report on income investing for tips on how to generate income without taking big risks .)
Support For Another Breakout?
AbbVie blasted past a 75.14 buy point in early September, reaching a peak of 98.26 on Oct. 20 before pulling back to begin forming its current second-stage flat base.
While forming that chart pattern, AbbVie sold off sharply on Oct. 26, but found support at the 50-day moving average and bounced back to close the day in near the top of the day's price range.
Since then, the stock has continued to edge higher as it closes in on the 98.36 buy point.
While AbbVie slipped over 1% Monday, volume was below average and the stock found support right around its 10-day line. On Tuesday, AbbVie gave back most of its morning gains, but managed to close the day up fractionally.
Look for the indexes to rebound from the recent selling pressure and see if AbbVie can climb into buy range in heavy volume.
RELATED:
Biotech Stock And Pharmaceutical Industry News
Video: How To Find Top-Rated Stocks Before They Break Out
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Like AbbVie, Edwards Lifesciences is working on a new base, and managed health care provider Centene, which broke out last week, is again testing the 98.82 buy point. AbbVie blasted past a 75.14 buy point in early September, reaching a peak of 98.26 on Oct. 20 before pulling back to begin forming its current second-stage flat base. On Monday, leading drugmaker AbbVie ( ABBV ) announced positive Phase 3 trial results for its psoriasis treatment, risankizumab. | Dividend Stock With Growth For a company of its size, AbbVie continues to generate solid growth, with revenue gains ranging from 8% to 18% over the last eight quarters. On Monday, leading drugmaker AbbVie ( ABBV ) announced positive Phase 3 trial results for its psoriasis treatment, risankizumab. AbbVie, which generated just under $7 billion in revenue in Q3, is a megacap medical stock, with a market cap of north of $150 billion. | Dividend Stock With Growth For a company of its size, AbbVie continues to generate solid growth, with revenue gains ranging from 8% to 18% over the last eight quarters. While forming that chart pattern, AbbVie sold off sharply on Oct. 26, but found support at the 50-day moving average and bounced back to close the day in near the top of the day's price range. On Monday, leading drugmaker AbbVie ( ABBV ) announced positive Phase 3 trial results for its psoriasis treatment, risankizumab. | Dividend Stock With Growth For a company of its size, AbbVie continues to generate solid growth, with revenue gains ranging from 8% to 18% over the last eight quarters. While AbbVie slipped over 1% Monday, volume was below average and the stock found support right around its 10-day line. On Monday, leading drugmaker AbbVie ( ABBV ) announced positive Phase 3 trial results for its psoriasis treatment, risankizumab. |
25828.0 | 2017-12-04 00:00:00 UTC | Lilly's (LLY) Taltz Gets Approval for Label Expansion in US | ABBV | https://www.nasdaq.com/articles/lillys-lly-taltz-gets-approval-for-label-expansion-in-us-2017-12-04 | nan | nan | Eli Lilly and CompanyLLY announced that the FDA has approved the label expansion of its psoriasis drug, Taltz, to include the treatment of active psoriatic arthritis (PsA) in adults.
We note that Taltz is presently approved for treating moderate-to-severe plaque psoriasis in adults who can have systemic therapy or phototherapy.
The drug has grown more than 50% in the first nine months of 2017 and contributed significantly to revenues and volumes. This approval for an expanded label in the United States is expected to further boost its growth.
Lilly's stock price has increased 26.9% in the past one year, outperforming the industry 's gain of 20%.
The drug achieved a reduction of 20% or more in a composite measure of disease activity (ACR20) in more than half of the patient population in both the studies at 24 weeks.
The drug (80 mg/mL) can be injected as single agent or in combination with any disease-modifying antirheumatic drug like methotrexate.
However, Taltz will face competition from several drugs, especially Novartis' NVS Cosentyx, as both the drug works by targeting IL-17A. Cosentyx is also approved for PsA and plaque psoriasis.
PsA is a chronic form of inflammatory arthritis, which is painful and progressive as well. Per the press release, approximately 1.6 million people in the United States are affected by the disease. Apart from Cosentyx, Johnson & Johnson's JNJ Stelara and AbbVie Inc.'s ABBV Humira among others are fighting for market share.
Eli Lilly and Company Price
Eli Lilly and Company Price | Eli Lilly and Company Quote
Lilly carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Apart from Cosentyx, Johnson & Johnson's JNJ Stelara and AbbVie Inc.'s ABBV Humira among others are fighting for market share. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and CompanyLLY announced that the FDA has approved the label expansion of its psoriasis drug, Taltz, to include the treatment of active psoriatic arthritis (PsA) in adults. | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Cosentyx, Johnson & Johnson's JNJ Stelara and AbbVie Inc.'s ABBV Humira among others are fighting for market share. Eli Lilly and Company Price Eli Lilly and Company Price | Eli Lilly and Company Quote Lilly carries a Zacks Rank #3 (Hold). | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Cosentyx, Johnson & Johnson's JNJ Stelara and AbbVie Inc.'s ABBV Humira among others are fighting for market share. Eli Lilly and CompanyLLY announced that the FDA has approved the label expansion of its psoriasis drug, Taltz, to include the treatment of active psoriatic arthritis (PsA) in adults. | Apart from Cosentyx, Johnson & Johnson's JNJ Stelara and AbbVie Inc.'s ABBV Humira among others are fighting for market share. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and CompanyLLY announced that the FDA has approved the label expansion of its psoriasis drug, Taltz, to include the treatment of active psoriatic arthritis (PsA) in adults. |
25829.0 | 2017-12-04 00:00:00 UTC | Does Steady Earnings Growth Lead To Big Dividends? | ABBV | https://www.nasdaq.com/articles/does-steady-earnings-growth-lead-big-dividends-2017-12-04 | nan | nan | You're looking for dividend stocks to invest in as a source of steady income, so how much emphasis should you put on fundamentals? A lot.
[ibd-display-video id=2531707 width=50 float=left autostart=true] That's because if you want steady income you want to own the best dividend stocks - companies that offer above-market yields and a solid earnings and stock price track record to boot.
And if that's the case, IBD's The Income Investor column can help. Each day on Investors.com and every week in IBD Weekly, the column features one or more companies that meet those criteria and have the potential to rise in price. That puts these stocks in more of the growth-and-income camp vs. simply, income.
Why is it important to pay attention to earnings, yield and other factors? If a company hits a tough patch or its profits falter, that could hurt its ability to keep making those payouts.
Where To Find Income Without Taking Big Risks
Top Dividend Fund Manager Expects Growth In These Three Sectors
How Growth Stocks Can Yield Solid Income Too
What Does Trump Tax Cut Mean For Dividends?
General Electric ( GE ) provides a recent example. Shares dived 13% over two sessions after the diversified giant halved its prized dividends and lowered its outlook for 2018. The dividend cut was a shock to investors who've been relying on it for income. Its yield before the fall: 4.7%. The stock fell to its lowest levels in nearly six years. At the predividend cut annual payout of 96 cents a share, the stock's $13 decline this year offset the payouts earned over the past 13 years.
GE's earnings have been volatile the past few years. They fell sharply in 2014 and 2015, increased last year and are expected to fall 8% this year.
That's why a steady earnings track record is key, as is dividend growth rate. Most income investors would likely prefer to see a company raise its dividend rate, instead of reducing or keeping it the same.
In addition to the daily column, you'll find three accompanying screens online and on The Income Investor page in the weekly edition. The Dividend, Utility and REIT Leaders offer other stocks that meet the same criteria as companies featured in the column, while the mini charts above the lists provide further details about six of those stocks. The mini charts appear only in the print edition.
To access the dividend screens at Investors.com, go to the home page and click on the Stock Lists tab.
The broadest screen is Dividend Leaders, featuring names such as Blackstone Group ( BX ). It's paid out a total of $2.32 per share in the past four quarters (or $2,303 per 1,000 shares). With the stock trading at 31.49, that amounts to a 7.35% annualized dividend yield. Plus the company sports a 24% dividend growth rate. Shares are up 18% this year, in line with the S&P 500, which yields just 1.91%. Blackstone is not your grandfather's dividend stock.
A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ).
But Steady Eddie names known for a steady earnings track record and dependable dividends like Coca-Cola (KO) and Chevron (CVX) often make the cut, too. Both stocks are S&P 500 Dividend Aristocrats, companies that have increased their dividends for at least the past 25 consecutive years.
Utility Leaders show utility stocks, which are known for their defensive nature. They tend to hold up well when growth stocks are weakening. Their reliable revenue streams also enable most utilities to pay a steady dividend.
IBD'S TAKE:Cisco has outperformed the broader market this year, but how does it rank in its industry group? Find out now at IBD Stock Checkup .
Like utilities, real estate investment trusts (REITs) offer a relative safe haven in a volatile market. REITs are structured in a way that allows them to avoid paying corporate taxes if they pass the bulk of their earnings through to shareholders. Since that's done in the form of cash dividends, many income investors favor REITs. Though not immune to a slowing economy, these companies enjoy a fairy stable revenue stream via rent payments and lease proceeds from buildings or other real estate assets they own and operate.
That said, keep in mind that utilities and REITs can also fall sharply if the stock market enters a steep slide. For instance, the Dow utility average dropped 45% during the 2008-09 bear market. In such severe corrections, it's important to cut stock losses and raise cash.
The three screens offer plenty of dividend stock ideas that have to meet certain fundamental and technical criteria. From there, investors can conduct further due diligence to narrow down their choices.
Subscribers to MarketSmith, a sister company to IBD, have access to a proprietary metric: Earnings Stability. This metric is calculated using a company's quarterly per-share earnings over the past three to five years. The resulting number runs on a scale from 0 (most stable) to 99 (least stable).
The accompanying table shows stocks with a dividend yield of 2% or higher and an Earnings Stability of 4 or lower. In general, a number below 25 is considered stable. For further details on how this metric is derived, read this Investor's Corner column .
RELATED:
What A Red Bull Air Race Champion Can Teach About Winning In Stocks
Yielding To A Higher Power: Dividends and Fed Rate Hikes
Can This Big Dividend Retail Stock Have A Joyous Holiday Season And 2018?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). In addition to the daily column, you'll find three accompanying screens online and on The Income Investor page in the weekly edition. Though not immune to a slowing economy, these companies enjoy a fairy stable revenue stream via rent payments and lease proceeds from buildings or other real estate assets they own and operate. | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). [ibd-display-video id=2531707 width=50 float=left autostart=true] That's because if you want steady income you want to own the best dividend stocks - companies that offer above-market yields and a solid earnings and stock price track record to boot. The Dividend, Utility and REIT Leaders offer other stocks that meet the same criteria as companies featured in the column, while the mini charts above the lists provide further details about six of those stocks. | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). [ibd-display-video id=2531707 width=50 float=left autostart=true] That's because if you want steady income you want to own the best dividend stocks - companies that offer above-market yields and a solid earnings and stock price track record to boot. Where To Find Income Without Taking Big Risks Top Dividend Fund Manager Expects Growth In These Three Sectors How Growth Stocks Can Yield Solid Income Too What Does Trump Tax Cut Mean For Dividends? | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). At the predividend cut annual payout of 96 cents a share, the stock's $13 decline this year offset the payouts earned over the past 13 years. In addition to the daily column, you'll find three accompanying screens online and on The Income Investor page in the weekly edition. |
25830.0 | 2017-12-01 00:00:00 UTC | 3 Drug/Biotech Stocks in Focus on World AIDS Day | ABBV | https://www.nasdaq.com/articles/3-drug-biotech-stocks-in-focus-on-world-aids-day-2017-12-01 | nan | nan | Every year, World Aids Day is celebrated on Dec 1 to raise public awareness about Acquired Immuno Deficiency Syndrome, popularly known as AIDS. The day is observed to make people aware about proper cure and prevention of the disease. In this regard, this year, the theme for the day this year is "Right to Health." This day also commemorates those who have died from an AIDS-related illness.
World AIDS Day is one of the eight official global public health campaigns marked by the World Health Organization (WHO). According to WHO, globally, about 36.7 million people were suffering from HIV/AIDS at the end of 2016. Of the total, 2.1 million were children less than 15 years old.
AIDS is a pandemic disease caused due to the infection of Human Immunodeficiency Virus (HIV). The virus weakens the immune system by destroying cells that fight diseases and infections, eventually leading to AIDS. Medicines for the treatment of HIV are called antiretroviral therapy (ART) that slow or put a check on the progression of the virus.
Currently, companies are investigating new medicines to treat, prevent and ultimately cure HIV. Scientists also are exploring new treatment paradigms like two drug regimens, making therapies/drugs drugs with improved long-term safety profiles and new mechanisms of actions.
Despite improved medical understanding of HIV and significant efforts made by leading government and medical bodies to prevent and treat HIV/AIDS, this disease still has limited treatment options. In 2016, 1 million people died of AIDS-related illnesses, totaling to 35.0 million since the start of the epidemic.
Based on these statistics, it is not surprising that several healthcare companies are investing a significant amount of their R&D expenditures on developing treatments and devices for HIV and AIDS.
Stocks to Watch For
On World AIDS Day, here are some of the key pharma companies in the HIV market that investors can rely on.
GlaxoSmithKlineGSK has a long-standing commitment to HIV and AIDS. The company had developed the widely used antibiotic amoxycillin around 40 years ago, which was the first medicine approved to treat HIV. The sales of older HIV products - Epzicom and Selzentry - have been declining. However, the newer HIV drugs -Triumeq and Tivicay - are witnessing a consistent increase in sales and gaining market share.
Meanwhile, a significant portion of its R&D expenditures are being used toward developing HIV medicines to treat/prevent HIV.
Last week, Glaxo and partner Johnson & Johnson announced the FDA approval for Juluca - a combination of Glaxo's Edurant/dolutegravir and J&J's Tivicay/rilpivirine into a single tablet - for the treatment of HIV. Most medicines for HIV treatment are made up of three or more antiretroviral drugs. Juluca is the first two-drug regimen to be approved that reduces the number of medicines HIV patients take without compromising on the efficacy of a conventional three-drug regimen.
This week ViiV Healthcare, an HIV company majorly owned by Glaxo and Pfizer PFE , announced the start of a large late-stage African study that will evaluate long-acting cabotegravirinjection for the prevention of HIV in sexually active women. If approved, cabotegravir injections will be administered every two months as opposed to presently available oral anti-retroviral medication, which needs to be taken every day.
Already, ViiV Healthcare has started conducting a HPTN 083 study on cabotegravirin HIV-uninfected men and transgender women who have sex with men, under co-funding with National Institute of Allergy and Infectious Diseases (NIAID). Meanwhile, cabotegraviris also being evaluated in three late stage studies as atwo drug regimen withEdurant, with the third study initiation announced earlier this week.
Furthermore, Glaxo is developing two drug regimen ofdolutegravir + lamivudine.
GileadGILD is a dominant player in the HIV market with an impressive portfolio. In fact, Gilead's HIV franchise is a major contributor to sales with approved drugs like Genvoya, Truvada, Atripla, Stribild, Descovy, Odefsey and Complera.
The company was the first to introduce a single-tablet regimen (STR) for the treatment of HIV - Atripla. Gilead's other STRs for HIV include Complera/Eviplera and Stribild. Its TAF-based product, Genvoya, happens to be a bestseller surpassing both Truvada and Atripla since fourth-quarter 2016.
Currently, Gilead's bictegravir single table regimen (STR) for HIV treatment is under priority review in the United States. The FDA is expected to announce its decision in February 2018.
The STR is a fixed-dose combination of bictegravir, an INSTI, and emtricitabine/tenofovir alafenamide (FTC/TAF), a dual-NRTI backbone. This combination is also under review in the EU.
Another company working towards developing HIV drugs is Johnson and JohnsonJNJ . The company along with partner Glaxo recently received FDA approval for first two-drug regimen- Juluca, as discussed above. Further, the company along with The Bill & Melinda Gates Foundation and National Institutes of Health is conducting an efficacy study for an investigational mosaic HIV-1 preventive vaccine.
The study will evaluate whether the vaccine is safe and is able to reduce the incidence of HIV infection among women in sub-Saharan Africa. HIV has a significant unmet need and women and girls account for about 60% of people living with HIV in eastern and southern Africa.
Others
Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress.
Mylan MYL also recently received a tentative FDA approval for its combination tablet comprising efavirenz, lamivudine and tenofovir disoproxil fumarate.
Meanwhile, Merck is developing an investigational non-nucleoside reverse transcriptase inhibitor, doravirine both as a single-entity tablet and in combination (fixed dose tablet) with other antiretroviral agents - lamivudine and tenofovir disoproxil fumarate (TDF). The company plans to file regulatory applications for the same before the end of 2017.
Conclusion
AIDS/HIV is a life threatening disease which has limited medical cure. However, there are numerous companies that are developing drugs for the treatment and care for people suffering from HIV and for them who are at risk of becoming infected with HIV, thereby making the space competitive.
While Johnson & Johnson sports a Zacks Rank #1 (Strong Buy), both Glaxo and Gilead carry a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Others Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, Gilead's HIV franchise is a major contributor to sales with approved drugs like Genvoya, Truvada, Atripla, Stribild, Descovy, Odefsey and Complera. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Others Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Last week, Glaxo and partner Johnson & Johnson announced the FDA approval for Juluca - a combination of Glaxo's Edurant/dolutegravir and J&J's Tivicay/rilpivirine into a single tablet - for the treatment of HIV. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Others Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. This week ViiV Healthcare, an HIV company majorly owned by Glaxo and Pfizer PFE , announced the start of a large late-stage African study that will evaluate long-acting cabotegravirinjection for the prevention of HIV in sexually active women. | Others Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Last week, Glaxo and partner Johnson & Johnson announced the FDA approval for Juluca - a combination of Glaxo's Edurant/dolutegravir and J&J's Tivicay/rilpivirine into a single tablet - for the treatment of HIV. |
25831.0 | 2017-11-30 00:00:00 UTC | AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why | ABBV | https://www.nasdaq.com/articles/abbvie-stock-up-more-than-30-so-far-in-2h17%3A-heres-why-2017-11-30 | nan | nan | AbbVie Inc.ABBV shares have gained 32.1% so far in the second half of the year, comparing favorably with a gain of only 3.8 % recorded by the industry .
Resolution of Amgen Lawsuit
AbbVie announced the resolution of a patent dispute with Amgen Inc. AMGN in September, which has delayed the launch of the latter's biosimilar version of AbbVie's blockbuster arthritis drug, Humira in the United States to 2023 and in most countries in the EU to October 2018.
This agreement has removed a major overhang on AbbVie's shares though the company is still facing a patent challenge from Boehringer Ingelheim, which gained approval for its biosimilar version of Humira, Cyltezo, in August. Moreover, the agreement gives AbbVie ample time to focus on developing its pipeline and launching new products that will help make up for the loss of revenues once biosimilar Humira enters the market.
Key Regulatory Approvals
AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment, Mavyret/Maviret, gained approval in the United States, EU and Canada in the third quarter of 2017. Mavyret, AbbVie's next-generation HCV program, is a combination of glecaprevir, a potent protease inhibitor and pibrentasvir, a NS5A inhibitor. Maviret has the potential to rejuvenate growth in the HCV franchise. According to AbbVie, Mavyret may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history.
In August, AbbVie gained approval for the sixth indication for Imbruvica. The drug was approved for chronic graft versus host disease (GVHD), a serious and potentially life-threatening condition with high unmet medical need. cGVHD is the first indication of Imbruvica outside of cancer. Also, Imbruvica is the first treatment specifically approved for cGVHD.
Positive Data from Studies
AbbVie announced positive data from the phase III MURANO study of Venclexta plus plus Roche's RHHBY Rituxan in relapse/refractory CLL last month. The data showed that Venclexta plus Rituxan met the primary endpoint of prolonged progression-free survival compared with Treanda (bendamustine) plus Rituxan in patients with relapsed/refractory chronic lymphocytic leukemia ("CLL"). Label expansion for this indication should expand the patient population for Venclexta significantly and boost its commercial potential.
AbbVie's oral JAK-1 selective inhibitor, upadacitinib (ABT-494) met primary endpoints in a phase III study for the treatment of RA with highly statistically significant and clinically meaningful results for both the doses (15 mg and 30 mg) of upadacitinib compared to placebo. Upadacitinib also met primary endpoints in a phase IIb study for the treatment of adult patients with atopic dermatitis, also known as eczema. The company plans to advance the candidate into phase III studies next year. Data from both the upadacitinib studies were announced in September.
In October, AbbVie announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and Humira, for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints.
Conclusion
With several pivotal data readouts and regulatory milestones expected in 2018, the bullish run in the stock should continue next year. Importantly Humira has been generating strong sales. Despite new competition, AbbVie raised its long-term target for Humira sales in October based on strong demand trends for the drug. Imbruvica, AbbVie's second most important drug, is also doing consistently well and has multibillion dollar potential. AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. All these factors bode well for the stock.
AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This agreement has removed a major overhang on AbbVie's shares though the company is still facing a patent challenge from Boehringer Ingelheim, which gained approval for its biosimilar version of Humira, Cyltezo, in August. Moreover, the agreement gives AbbVie ample time to focus on developing its pipeline and launching new products that will help make up for the loss of revenues once biosimilar Humira enters the market. AbbVie Inc.ABBV shares have gained 32.1% so far in the second half of the year, comparing favorably with a gain of only 3.8 % recorded by the industry . | Positive Data from Studies AbbVie announced positive data from the phase III MURANO study of Venclexta plus plus Roche's RHHBY Rituxan in relapse/refractory CLL last month. In October, AbbVie announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and Humira, for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | Resolution of Amgen Lawsuit AbbVie announced the resolution of a patent dispute with Amgen Inc. AMGN in September, which has delayed the launch of the latter's biosimilar version of AbbVie's blockbuster arthritis drug, Humira in the United States to 2023 and in most countries in the EU to October 2018. In October, AbbVie announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and Humira, for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | In August, AbbVie gained approval for the sixth indication for Imbruvica. AbbVie's oral JAK-1 selective inhibitor, upadacitinib (ABT-494) met primary endpoints in a phase III study for the treatment of RA with highly statistically significant and clinically meaningful results for both the doses (15 mg and 30 mg) of upadacitinib compared to placebo. Imbruvica, AbbVie's second most important drug, is also doing consistently well and has multibillion dollar potential. |
25832.0 | 2017-11-30 00:00:00 UTC | The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amazon-abbvie-biogen-mccormick-and-hyatt-2017-11-30 | nan | nan | For Immediate Release
Chicago, IL - November 30, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AmazonAMZN , AbbVieABBV , BiogenBIIB , McCormickMKC and HyattH .
Here are highlights from Wednesday's Analyst Blog:
Top Research Reports for Amazon, AbbVie and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Amazon 's shares have outperformed the broader market in the year-to-date period (the stock is up +59.2% vs. the +17.7% gain for the S&P 500 as a whole). Amazon is benefiting from strong growth in all its businesses and especially the retail business remains very hard to beat on price, choice and convenience.
The Zacks analyst likes Amazon's solid loyalty system, Prime. Its FBA strategy and content additions continue to add selection to Prime memberships. AWS generates much higher margins than retail, thus significantly impacting Amazon's profitability. Devices and IoT are also potential growth areas.
However, increased operating expenses to support expansion of its business into new markets and territories, localize the availability of products and grow its content will keep margins under pressure.
(You can read the full research report on Amazon here >>> ).
Shares of AbbVie have gained +52.4% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +16.2% over the same period. AbbVie's key drug Humira has been performing well. At the Q3earnings call AbbVie raised its long-term target for Humira sales based on strong demand trends for the drug, despite new competition.
Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Meanwhile, the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies and gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret.
Additionally, it gained FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition.
(You can read the full research report on AbbVie here >>> ).
Biogen 's shares have outperformed the Zacks Biomedicals/Genetics industry in the last six months (+28.6% vs. +2.3%). Biogen has a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera & Plegridy. The Zacks analyst also likes Biogen's efforts to diversify beyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others.
Meanwhile, Spinraza has witnessed strong patient uptake in the U.S. and internationally. However, weakening MS trends is a concern. Tecfidera is witnessing slight decline in U.S. patient demand due to increasing competition from oral medicines and a slowdown in the overall MS market.
The recent Ocrevus launch by Roche is beginning to have a negative impact on MS franchise sales in the U.S., mainly Tysabri. At the call, the company said that seasonality and continued competitive pressure from Ocrevus' launch will hurt the performance of its MS franchise in Q4.
(You can read the full research report on Biogen here >>> ).
Other noteworthy reports we are featuring today include McCormick and Hyatt.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
McCormick & Company, Incorporated (MKC): Free Stock Analysis Report
Hyatt Hotels Corporation (H): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include AmazonAMZN , AbbVieABBV , BiogenBIIB , McCormickMKC and HyattH . Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Biogen The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. | Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Biogen The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Hyatt Hotels Corporation (H): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Biogen The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Hyatt Hotels Corporation (H): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. | Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. Stocks recently featured in the blog include AmazonAMZN , AbbVieABBV , BiogenBIIB , McCormickMKC and HyattH . Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Biogen The Zacks Research Daily presents the best research output of our analyst team. |
25833.0 | 2017-11-30 00:00:00 UTC | Notable Thursday Option Activity: MA, ABBV, ADP | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-ma-abbv-adp-2017-11-30 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mastercard Inc (Symbol: MA), where a total of 12,971 contracts have traded so far, representing approximately 1.3 million underlying shares. That amounts to about 41.3% of MA's average daily trading volume over the past month of 3.1 million shares. Especially high volume was seen for the $144 strike put option expiring December 15, 2017 , with 3,017 contracts trading so far today, representing approximately 301,700 underlying shares of MA. Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past month, of 4.6 million shares. Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 11,749 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange:
And Automatic Data Processing Inc. (Symbol: ADP) options are showing a volume of 9,394 contracts thus far today. That number of contracts represents approximately 939,400 underlying shares, working out to a sizeable 40.6% of ADP's average daily trading volume over the past month, of 2.3 million shares. Especially high volume was seen for the $120 strike call option expiring January 19, 2018 , with 2,536 contracts trading so far today, representing approximately 253,600 underlying shares of ADP. Below is a chart showing ADP's trailing twelve month trading history, with the $120 strike highlighted in orange:
For the various different available expirations for MA options , ABBV options , or ADP options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 11,749 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past month, of 4.6 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: And Automatic Data Processing Inc. (Symbol: ADP) options are showing a volume of 9,394 contracts thus far today. | Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past month, of 4.6 million shares. Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 11,749 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: And Automatic Data Processing Inc. (Symbol: ADP) options are showing a volume of 9,394 contracts thus far today. | Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past month, of 4.6 million shares. Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 11,749 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: And Automatic Data Processing Inc. (Symbol: ADP) options are showing a volume of 9,394 contracts thus far today. | Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past month, of 4.6 million shares. Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 11,749 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: And Automatic Data Processing Inc. (Symbol: ADP) options are showing a volume of 9,394 contracts thus far today. |
25834.0 | 2017-11-30 00:00:00 UTC | Valeant Pharmaceuticals Shows Rising Price Performance With Jump To 83 RS Rating | ABBV | https://www.nasdaq.com/articles/valeant-pharmaceuticals-shows-rising-price-performance-jump-83-rs-rating-2017-11-30 | nan | nan | Valeant Pharmaceuticals ( VRX ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 78 to 83.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against that of all other stocks.
History reveals that the best stocks tend to have an 80 or higher RS Rating as they launch their biggest climbs.
Looking For Winning Stocks? Try This Simple Routine
Valeant Pharmaceuticals is now considered extended and out of buy range after clearing a 15.84 buy point in a first-stage cup with handle . See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company reported negative growth for both sales and earnings last quarter.
The company earns the No. 13 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Valeant Pharmaceuticals ( VRX ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 78 to 83. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Rising Relative Strength? Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against that of all other stocks. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Rising Relative Strength? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Try This Simple Routine Valeant Pharmaceuticals is now considered extended and out of buy range after clearing a 15.84 buy point in a first-stage cup with handle . Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Rising Relative Strength? |
25835.0 | 2017-11-29 00:00:00 UTC | iShares Russell Top 200 Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-top-200-growth-etf-experiences-big-outflow-2017-11-29 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $83.5 million dollar outflow -- that's a 8.1% decrease week over week (from 14,200,000.00 to 13,050,000.00). Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average:
Looking at the chart above, IWY's low point in its 52 week range is $55.04 per share, with $72.74 as the 52 week high point - that compares with a last trade of $72.04. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $55.04 per share, with $72.74 as the 52 week high point - that compares with a last trade of $72.04. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $55.04 per share, with $72.74 as the 52 week high point - that compares with a last trade of $72.04. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $83.5 million dollar outflow -- that's a 8.1% decrease week over week (from 14,200,000.00 to 13,050,000.00). For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $55.04 per share, with $72.74 as the 52 week high point - that compares with a last trade of $72.04. | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $55.04 per share, with $72.74 as the 52 week high point - that compares with a last trade of $72.04. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
25836.0 | 2017-11-29 00:00:00 UTC | 3 Top Big Pharma Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-big-pharma-stocks-buy-now-2017-11-29 | nan | nan | Big pharma stocks have been longtime favorites among investors for several reasons. The fact that they're big means that that they generate huge cash flow, which typically translates to attractive dividends. And big pharma companies operate in a growing industry, with demand for prescription drugs continuing to rise -- especially with expanding elderly populations across the world.
Some big pharma stocks particularly stand out from the crowd. I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. Here's why these are three big pharma stocks you can buy now and hold for years to come.
AbbVie
There's a lot for investors to like about AbbVie. For starters, the drugmaker's dividend currently yields 3%. Since being spun off from Abbott Labs in 2013, AbbVie has increased its dividend by a whopping 77.5%. And there's plenty of room for more dividend hikes, with the company using 60% of earnings to fund the dividend program.
AbbVie's ability to pay such an enticing dividend stems from its enormously successful product lineup. Humira is on track to rake in over $18 billion in 2017. AbbVie thinks the autoimmune drug will generate close to $21 billion by 2020. A threat from biosimilar rivals to Humira is also much less worrisome after the company struck a deal with Amgen that keeps Amjevita, its Humira biosimilar, off the U.S. market until early 2023.
The hottest drug for AbbVie right now, though, is Imbruvica. Sales for the cancer drug soared more than 41% year over year in the first three quarters of 2017 and are on pace to reach around $2.5 billion for the full year. That's just AbbVie's portion; Johnson & Johnson co-markets Imbruvica with AbbVie.
Hepatitis C is another area that should be increasingly lucrative for AbbVie. Although sales have dropped for the company's hepatitis C virus (HCV) franchise so far in 2017, the U.S. Food and Drug Administration granted approval for pan-genotypic HCV drug Mavyret in August.
AbbVie also appears to be poised for strong growth in the coming years thanks to its deep pipeline. The company currently awaits regulatory approval for elagolix for management of endometriosis. The potential blockbuster drug is in a late-stage study targeting treatment of uterine fibroids as well.
Several other late-stage candidates also hold the potential to become huge winners for AbbVie. Cancer drugs Rova-T and Venclexta are high on that list, as are autoimmune disease drugs risankizumab and upadacitinib.
Johnson & Johnson
Johnson & Johnson's dividend yield of 2.37% isn't as high as AbbVie's. And its dividend hasn't grown as fast as AbbVie's has, either. But few companies in any industry can claim the impressive track record of dividend hikes that J&J has, with 55 consecutive years of dividend increases. The likelihood of Johnson & Johnson keeping that streak going seems to be quite good. The company uses roughly 55% of its earnings (and less than half of its free cash flow) to pay out dividends.
While J&J ranks as a big pharma stock, it's also a leader in consumer healthcare products as well as a major medical device maker. The company's consumer segment is on track to generate sales of close to $13.5 billion this year, while its medical device business should bring in revenue topping $26 billion in 2017.
Still, Johnson & Johnson makes most of its money from its pharmaceutical business. The segment is also poised to be J&J's largest growth driver in the future. Although the company faces competitive pressures for its top-selling drug, Remicade, it also continues to enjoy strong growth for several current products, including Darzalex, Imbruvica, and Stelara.
More growth is coming from J&J's business development efforts. Earlier this year, the company acquired Swiss drugmaker Actelion. This deal allowed J&J to pick up Actelion's pulmonary hypertension franchise, which includes three currently approved drugs.
Like AbbVie, Johnson & Johnson also has a pipeline ranked in the top five among all big pharma companies. Quite a few of J&J's late-stage programs target additional indications for already-approved drugs. However, the company also claims several promising new candidates, including prostate cancer drug apalutamide and antidepressant esketamine.
Pfizer
If you're looking for a mouth-watering dividend yield, Pfizer could be right up your alley. The big drugmaker's dividend currently yields around 3.6%. That dividend appears to be pretty safe as well, with Pfizer using only 57% of its free cash flow to fund the dividend program.
Pfizer's product lineup includes eight blockbusters. Leading the way is the company's pneumococcal vaccine Prevnar 13. However, Pfizer's top drugs with the fastest sales growth are blood thinner Eliquis, breast cancer drug Ibrance, and prostate cancer drug Xeljanz. These three drugs typify how Pfizer will likely grow in the future. The company partners with Bristol-Myers Squibb on Eliquis. Pfizer picked up Ibrance from its acquisition of Warner-Lambert in 2000. It developed Xeljanz in house.
The company does face headwinds for its legacy drugs, though, and for some of its drugs that have either recently or soon will lose exclusivity. These drugs are part of Pfizer's essential health segment, which also includes sterile injectables and biosimilars gained from its acquisition of Hospira in 2015. There is some potential good news, however: Pfizer CEO Ian Read has stated that the negative impact from the legacy drugs will decrease in the coming years.
What about Pfizer's pipeline prospects? They appear to be pretty good. The company awaits regulatory approval for 10 programs and has another 28 late-stage clinical programs. Among Pfizer's top late-stage candidates are pain drug tanezumab and cancer drug Bavencio (which is co-developed with partner Merck KGaA ).
Pfizer announced recently that it is evaluating strategic options for its consumer healthcare business. Those options include selling or spinning off the unit, as well as keeping it within Pfizer. Investors stand to win if the company chooses to sell or spin off the consumer business.
Best pick?
I like all three of these big pharma stocks. My favorite, though, is AbbVie. The stock has pretty much everything an investor looks for -- a solid dividend, great growth prospects, and an attractive valuation.
In my view, the biggest knock against AbbVie is its heavy dependence on Humira. However, the company seems to have secured several more years of growth for its top drug. That should give AbbVie plenty of time for Imbruvica and Mavyret to grow revenue and for its pipeline candidates to flourish. I think AbbVie is the best big pharma stock of all right now.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. AbbVie There's a lot for investors to like about AbbVie. Since being spun off from Abbott Labs in 2013, AbbVie has increased its dividend by a whopping 77.5%. | Johnson & Johnson Johnson & Johnson's dividend yield of 2.37% isn't as high as AbbVie's. I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. AbbVie There's a lot for investors to like about AbbVie. | Johnson & Johnson Johnson & Johnson's dividend yield of 2.37% isn't as high as AbbVie's. Like AbbVie, Johnson & Johnson also has a pipeline ranked in the top five among all big pharma companies. I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. | Like AbbVie, Johnson & Johnson also has a pipeline ranked in the top five among all big pharma companies. I think AbbVie is the best big pharma stock of all right now. I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. |
25837.0 | 2017-11-29 00:00:00 UTC | 12 Best Dividend Stocks for the Next 12 Months | ABBV | https://www.nasdaq.com/articles/12-best-dividend-stocks-next-12-months-2017-11-29 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Finding the best dividend stocks involves looking beyond the next few weeks and thinking about a long-term investment. After all, if you're only in a dividend stock for a short time then you may not get the full yield that's based on a full year of payouts.
And heck, if you don't pay attention to dividend dates, you may not get a single payment!
It's much better, then, to focus on the best dividend stocks for the next year instead of just the next month. That is the only way to ensure that you get a full battery of payments from your investments, and that you maximize the income potential of your portfolio.
In truth, all investors are too short-sighted with their portfolios. They fear short-term volatility, and make rash decisions. But particularly if you're a dividend investor, thinking in any less than 12-month increments can be very detrimental to your performance.
7 Stocks to Double Your Money
To help you make the most of 2018, then, here are 12 dividend stocks that will continue to profit for the next 12 months, not just the short term.
Dividend Stocks to Buy Now: Enterprise Products Partners (EPD)
Source: Bilfinger via Flickr
Sector: Energy
Market Cap: $52 billion
Yield: 7%
YTD Return: -10% vs. 17% for the S&P 500
Pipeline operator Enterprise Products Partners L.P. (NYSE: EPD ) is a great example of the income potential in energy stocks. While exploration and production companies have to take on big debts on the hopes that they will strike enough oil to turn a profit, EPD is just a middleman between those producers and the marketplace. That insulates it from the volatility of energy prices, and allows for a more reliable revenue stream.
In addition to the reliable revenue stream of its business, EPD also boasts an impressive scale that should be attractive to low-risk investors. The energy company operates more than 49,000 miles of pipeline, 260 million barrels of crude oil storage and another 14 billion cubic feet of natural gas storage.
Currently, Enterprise Products offers a great yield of 7%, and has a strong track record of raising distributions over time, too. It's this constant and growing payout that is the hallmark of a good MLP investment.
Dividend Stocks to Buy Now: Ladder Capital (LADR)
Source: Yuriy Trubitsyn via Unsplash
Sector: REITs
Market Cap: $2 billion
Yield: 9.2%
YTD Return: 1% vs. 17% for the S&P 500
Ladder Capital Corp (NYSE: LADR ) is not your typical real estate investment trust. Unlike other stocks that own shopping malls or office parks, LADR doesn't own physical properties. Instead, it invests as a third party in these real estate holdings either through lending, equity investments or other financing.
This makes Ladder Capital more of a financial stock than a real estate play in a way, since its stock is tied to the performance of its underlying investments in properties. But the difference is that while banks can operate with a bit more flexibility, the designation as an REIT demands that the firm delivers 90% of taxable income back to shareholders. That is a mandate for big dividends, with LADR being a pass-through for shareholders who want to share in the fruits of its investments.
Those investments are looking pretty strong, too, with loans and investment in properties that span the country from New York to L.A. Those deals collectively deliver a more than 9% dividend to shareholders via the interest on those loans and other capital appreciation. And as the American economy continues to thrive with low unemployment, high consumer confidence and a roaring stock market, these investments are sure to keep delivering.
The 10 Best Stocks for Your 401k
This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018.
Dividend Stocks to Buy Now: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Sector: Healthcare
Market Cap: $153 billion
Yield: 3%
YTD Return: 52% vs. 17% for the S&P 500
AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbott Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. It's home to current blockbusters, including psoriasis treatment Humira as well as a research-driven drugmaker looking for the next generation of big-name cures.
Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 15% or better both years thanks to a strong pharmaceutical portfolio. And that success has translated into generous dividends, as the company has ramped up its payout from 40 cents after its initial spin-off to 64-cents-per-share just four years later.
With decent profit growth resulting in continued dividend growth, investors can enjoy not just a robust payout now, but the hopes of continued payouts from this healthcare giant going forward.
Dividend Stocks to Buy Now: Southern Company (SO)
Source: Desiree Kane via Flickr
Sector: Utilities
Market Cap: $51 billion
Yield: 4.5%
YTD Return: 4% vs. 17% for the S&P 500
Southern Co (NYSE: SO ) is one of the largest utilities in the U.S., serving 19 states through various subsidiaries. While its oldest core holdings, including Alabama Power and Georgia Power, are electric utilities, the company's Southern Company Gas operates a massive natural gas distribution business from Maryland to Florida and its Southern Telecom is a play on fiber optics in the Southeast as well.
SO stock offers scale and stability, and is a consistent dividend payer that has mailed check to shareholders since 1982. On top of that, Southern Company has raised dividend payouts at least once each year since 2001 even as it has continued to expand aggressively into other businesses and geographies.
The 10 Best ETFs to Buy for Yield-Starved Investors
Utility stocks are some of the safest bets out there thanks to geographic monopolies and a highly regulated industry that doesn't allow for new entrants or much competition. As one of the nation's leading utilities with a reliable customer base, SO is sure to prosper in 2018.
Dividend Stocks to Buy Now: Phillips 66 Partners (PSXP)
Source: Shutterstock
Sector: Energy
Market Cap: $5 billion
Yield: 5.8%
YTD Return: -7% vs. 17% for the S&P 500
Many of the most successful MLPs have been created by large energy companies that want the benefit from the unique structure of this kind of business. It's often a win-win for both the primary stock that is the general partner as well as for the new partnership that has been created, and that's exactly the case with Phillips 66 Partners LP (NYSE: PSXP ) and its corporate parent ConocoPhillips (NYSE: COP ).
Spun off in 2013, Phillips 66 Partners consists of pipelines, terminals and other midstream assets that help power the broader ConocoPhillips business. The tax benefits and a generous yield of over 5% kicked back to COP as a major investor make it great for the parent, but the MLP benefits nicely too. Consider PSXP received more than $2.3 billion in projects from its parent company last year alone!
Phillips 66 Partners has raised its distribution for 16 consecutive quarters since entering public markets, and is clearly committed to delivering consistent income to its shareholders.
Dividend Stocks to Buy Now: Medical Properties Trust (MPW)
Source: Shutterstock
Sector: REITs
Market Cap: $5 billion
Yield: 7%
YTD Return: 12% vs. 17% for the S&P 500
Medical Properties Trust, Inc. (NYSE: MPW ) is a fast-growing REIT seeing brisk expansion of its funds from operations - the most important measure we can get from this special class of tax-sheltered companies. That reliable and growing flow of cash also helps fuel reliable and growing dividends, to the tune of 7% currently.
But it's not just the income potential that's worth a look here. Aging baby boomers are increasing demand for care in the U.S., inflationary trends guarantee pricing power in the sector, and even in an economic downturn you'll see Americans cut back on everything but their healthcare.
7 Best Dividend Funds for Retirement
MPW is well-positioned to capitalize on this trend thanks to its ownership of community hospitals and acute-care centers - and a recent acquisition of 11 more facilities will certainly boost its numbers in the year ahead.
Dividend Stocks to Buy Now: Altria (MO)
Source: Peyri Herrera via Flickr (Modified)
Sector: Consumer staples
Market Cap: $129 billion
Yield: 3.9%
YTD Return: -2% vs. 17% for the S&P 500
Altria Group Inc (NYSE: MO ) may strike some as a no-growth company without much upside. However, this pick is not just a dividend stock; consider that over the past five years, it has actually outperformed the S&P 500 in share price performance alone thanks to aggressive buybacks and shrewd management of profitability.
And of course, MO stock is a go-to for dividend investors after 48 consecutive years of increases in its payout. Those increases aren't a penny here and there, either - as evidenced most recently with an 8% bump in 2017 from 61 cents to 66 cents.
Yes, traditional tobacco products are on the outs. But keep in mind that Altria is not merely Philip Morris USA - the name behind iconic cigarette brands like Marlboro and Parliament. Altria also dabbles in smokeless products and even wines via producer Ste. Michelle. This provides an added level of long-term stability.
Shares haven't done much lately in 2017, but with a forward price-to-earnings ratio of less than 18 and reliable profit growth ahead in 2018, I'd bank on Altria regardless of short-term market trends.
Dividend Stocks to Buy Now: Cisco (CSCO)
Source: Shutterstock
Sector: Technology
Market Cap: $186 billion
Yield: 3.1%
YTD Return: 25% vs. 17% for the S&P 500
When investors look for reliable dividend stocks, often they overlook the tech sector. That's in part because even tech companies like Apple Inc. (NASDAQ: AAPL ) that pay some kind of dividend still offer less than 10-year Treasuries - or on the flip side, because many tech stocks that do yield a decent amount don't have much to offer investors beyond their dividends.
But Cisco Systems, Inc. (NASDAQ: CSCO ) stands apart. Not only does the IT giant currently offer an attractive dividend, with payouts that have jumped from 6 cents in 2011 to 29 cents a quarter at present, it also has a good growth story to tell after an impressive earnings report before Thanksgiving. Not only did it beat on earnings and boost its outlook, but the company showed Wall Street it is effectively transitioning away from networking hardware and into cloud-based solutions that are the norm in 2017. Shares are up about 20% in the last three months as a result.
5 'Strong Buy' Dividend Growth Stocks for 2018
These structural improvements at CSCO bode well for 2018 and beyond. And given Cisco's commitment to increased dividends and deep pockets with some $72 billion in cash and investments in the bank, you can be certain this company will keep rewarding shareholders for the next decade to come.
Dividend Stocks to Buy Now: Diageo (DEO)
Source: Puamella via Flickr (Modified)
Sector: Consumer staples
Market Cap: $87 billion
Yield: 2.3%
YTD Return: 35% vs. 17% for the S&P 500
Diageo plc (ADR) (NYSE: DEO ) is a world leader in the spirits business, with mega-brands including Johnnie Walker whisky, Smirnoff vodka, Tanqueray and Guinness beer, among a host of others. And thanks to a focus mainly on liquor, DEO stock has been largely insulated from the shakeup we've seen in the beer biz as craft brews have eroded share.
For instance, even as Anheuser Busch InBev NV (ADR) (NYSE: BUD ) has struggled since 2015 despite a $200 billion operation with some of the biggest mainline beers on the planet, Diageo has slightly outperformed the market thanks to modest but consistent growth.
As a "sin stock," Diageo also has the unique benefit of seeing stable or even increased demand during hard times. After all, why give up your cocktails if the market is crashing, hurricanes are bearing down on your house and North Korea is thinking of detonating a nuke?
Dividend Stocks to Buy Now: Dominion Energy (D)
Source: Riccardo Annandale Via Unsplash
Sector: Utilities
Market Cap: $52 billion
Yield: 3.7%
YTD Return: -10% vs. 17% for the S&P 500
Dominion Energy Inc (NYSE: D ) is a safe play for a host of reasons. But chief among them are the facts that it is a low-risk utility stock with reliable operations and a significant yield.
Dominion generates electricity mainly in the mid-Atlantic region of the U.S. from North Carolina to Pennsylvania and distributes natural gas across a wide swath of the American West. The consistent cash flow from these operations has fueled consistent dividend payouts for almost 90 years, and has allowed Dominion to grow payouts substantially over time; distributions were 39.5 cents quarter at the end of 2008 and are now 77 cents, an increase of about 95% in about nine years.
The icing on the cake is that Dominion is one of the most adaptable and diversified utilities in the U.S., with numerous nuclear and renewable power generation facilities in its portfolio. This isn't just good as a hedge against the long-term decline of fossil fuels, but also a bridge to new business. One recent headline that should really pique investor interest is a recent contract to provide renewable energy to a Facebook Inc (NASDAQ: FB ) data center in Virginia.
7 Dividend Funds Yielding Over 5.3%
That kind of willingness to meet big corporations where they live is a strong sign that Dominion is forward-thinking and isn't just sitting back collecting monthly checks from customers.
Dividend Stocks to Buy Now: Merck (MRK)
Source: Shutterstock
Sector: Healthcare
Market Cap: $151 billion
Yield: 3.4%
YTD Return: -6% vs. 17% for the S&P 500
Merck & Co., Inc. (NYSE: MRK ) continues to see growth as its drugs look to fight common American health conditions. Its blockbuster diabetes drug Januvia, which helps lower blood sugar, accounts for some $4 billion in annual sales and its Zetia cholesterol medication racks up over $2 billion in annual sales.
And it's not done, either, with a strong product pipeline that includes cancer drug Keytruda. The pipeline could open avenues to much bigger revenue after a very nice showing so far in 2017. The marriage of so-called "maintenance" drugs to provide regular revenue will fuel dividends now, and new drugs could yield continued dividend growth going forward.
With one of the biggest and most stable brands in medicine, this healthcare stock is a great long-term play for dividend investors. The healthcare company has paid consistent dividends since 1970, and is a rock-solid bet for the coming year.
Dividend Stocks to Buy Now: Procter & Gamble (PG)
Source: Mike Mozart via Flickr (Modified)
Sector: Consumer staples
Market Cap: $1225 billion
Yield: 3.1%
YTD Return: 6% vs. 17% for the S&P 500
You couldn't have a list of safe-haven investments without Procter & Gamble Co (NYSE: PG ), one of the most reliable consumer names on the planet.
Powered by amazing brands from Dawn dish soap to Gillette shaving products to Crest toothpaste, P&G has its fingerprints all over the typical household. And best of all for low-risk investors, these products will keep selling no matter what the macro picture is like because people still need to clean their bodies and their kitchens regardless of where the S&P is headed.
It also has a consistent commitment to dividends, increasing its payout for the last 60 straight years, and has been generous with those increases to boot; distributions have roughly doubled in the last decade, meaning P&G dividend hikes are in the ballpark of 10% each year.
The 10 Best ETFs to Buy for Yield-Starved Investors
Yes, shares have been rangebound for a few years now. But a recent proxy fight with activist investor Nelson Peltz has shaken the company awake. And even if the tally in the voting has been disputed by P&G, the message from its investors is crystal clear: pay more attention to the bottom line and to delivering real shareholder value. That should usher in some important changes that help this stock remain dominant as we enter 2018.
As of this writing, Jeff Reeves did not have a position in any of the aforementioned securities.
The post 12 Best Dividend Stocks for the Next 12 Months appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbott Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 15% or better both years thanks to a strong pharmaceutical portfolio. 7 Best Dividend Funds for Retirement MPW is well-positioned to capitalize on this trend thanks to its ownership of community hospitals and acute-care centers - and a recent acquisition of 11 more facilities will certainly boost its numbers in the year ahead. | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbott Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 15% or better both years thanks to a strong pharmaceutical portfolio. As one of the nation's leading utilities with a reliable customer base, SO is sure to prosper in 2018. Dividend Stocks to Buy Now: Phillips 66 Partners (PSXP) Source: Shutterstock Sector: Energy Market Cap: $5 billion Yield: 5.8% YTD Return: -7% vs. 17% for the S&P 500 Many of the most successful MLPs have been created by large energy companies that want the benefit from the unique structure of this kind of business. | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbott Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 15% or better both years thanks to a strong pharmaceutical portfolio. Dividend Stocks to Buy Now: Enterprise Products Partners (EPD) Source: Bilfinger via Flickr Sector: Energy Market Cap: $52 billion Yield: 7% YTD Return: -10% vs. 17% for the S&P 500 Pipeline operator Enterprise Products Partners L.P. (NYSE: EPD ) is a great example of the income potential in energy stocks. | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbott Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 15% or better both years thanks to a strong pharmaceutical portfolio. Dividend Stocks to Buy Now: Enterprise Products Partners (EPD) Source: Bilfinger via Flickr Sector: Energy Market Cap: $52 billion Yield: 7% YTD Return: -10% vs. 17% for the S&P 500 Pipeline operator Enterprise Products Partners L.P. (NYSE: EPD ) is a great example of the income potential in energy stocks. |
25838.0 | 2017-11-27 00:00:00 UTC | Valeant Pharmaceuticals Earns Technical Rating Upgrade | ABBV | https://www.nasdaq.com/articles/valeant-pharmaceuticals-earns-technical-rating-upgrade-2017-11-27 | nan | nan | On Monday, Valeant Pharmaceuticals ( VRX ) earned a positive adjustment to its Relative Strength ( RS ) Rating , from 66 to 71.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves. See if Valeant Pharmaceuticals can continue to show renewed price strength and clear that threshold.
See How IBD Helps You Make More Money In Stocks
Valeant Pharmaceuticals has climbed more than 5% past a 15.84 entry in a first-stage cup with handle , meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
Valeant Pharmaceuticals reported negative growth for both sales and earnings last quarter.
The company holds the No. 15 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. On Monday, Valeant Pharmaceuticals ( VRX ) earned a positive adjustment to its Relative Strength ( RS ) Rating , from 66 to 71. History shows that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves. | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Rising Relative Strength? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Rising Relative Strength? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. On Monday, Valeant Pharmaceuticals ( VRX ) earned a positive adjustment to its Relative Strength ( RS ) Rating , from 66 to 71. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Rising Relative Strength? |
25839.0 | 2017-11-24 00:00:00 UTC | 3 Companies Competing to Gain Lead in Ovarian Cancer Market | ABBV | https://www.nasdaq.com/articles/3-companies-competing-to-gain-lead-in-ovarian-cancer-market-2017-11-24 | nan | nan | Until 2014, very few options were available to treat ovarian cancer and these primarily included chemotherapy, radiation or surgery. Though effective, these treatments had many side-effects. While chemotherapy can destroy a patient's immune system, radiation kills normal cells along with cancerous cells. A surgical process is ineffective when the cancer spreads. With the approval of AstraZeneca AZN /Merck's MRK Lynparza in December 2014, a new targeted therapy for treating ovarian cancer came into the market. The drug inhibits an enzyme in cells - PARP - which helps repair the DNA of the cell, thus destroying the cell.
After that, two other PARP-inhibitors were approved by the FDA - Tesaro, Inc.'s TSRO Zejula and Clovis Oncology, Inc.'s CLVS Rubraca. PARP inhibitors have shown more tolerability and effectiveness in clinical studies. However, none of the three marketed PARP inhibitors - Rubraca, Zejula and Lynparza - have been approved in the first-line setting to date.
There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others.
Let's see how the marketed drugs are performing and which one has better prospects.
Lynparza with its recent label expansion in August 2017 is indicated for maintenance treatment of patients suffering from platinum-sensitive recurrent ("PSR") ovarian cancer regardless of BRCA-mutation status. It is also approved for BRCA-mutated ovarian cancer beyond the third-line setting. The drug is available in capsule and tablet formulations. The drug recorded sales of $70 million in 2015, $94 million in 2016 and $197 million in the first nine months of 2017, growing over 65% annually. The drug is also being developed as first-line maintenance treatment for BRCA-mutated ovarian cancer. AstraZeneca and Merck expect to file for label expansion by mid-2018.
However, Lynparza sales have fallen lately in the United States after the launch of Zejula in April this year. The label expansion in August - including ovarian cancer patients regardless of BRCA-mutation - has brought it on par with Zejula. Moreover, a potential approval in first-line setting next year will give it an edge over the other drugs. Also, AstraZeneca has collaborated with Merck to co-develop Lynparza in combination immunotherapies. Its successful development will be a boon for patients.
Rubraca received accelerated approval from the FDA late last year as monotherapy in advanced ovarian cancer patients with deleterious BRCA mutation, treated with two or more chemotherapies. Clovis is conducting confirmatory studies to convert this approval to a full approval. Meanwhile, the company filed a supplemental New Drug Application last month, seeking label expansion as a maintenance treatment for patients with PSR ovarian cancer. Rubraca is under review in EU. The drug reported sales of $38.5 million in the first nine months of 2017. However, the drug may lag the other two drugs as they are approved to treat ovarian cancer irrespective of the BRCA-mutation. Meanwhile, Clovis is evaluating the drug in a phase III study in combination with Bristol-Myers' BMY Opdivo as first-line maintenance therapy in stage III/IV high-grade ovarian cancer patients who were treated with platinum-based chemotherapy.
Zejula is the first PARP-inhibitor, which was approved as maintenance treatment for recurrent ovarian cancer regardless of BRCA-mutation and was launched in April 2017. As the drug can be used in patients who do not have BRCA mutations, it can be prescribed to a broader patient population. Moreover, it also removes the requirement of diagnosis for BRCA-mutation, thereby reducing treatment cost and time.
Due to this competitive advantage, Zejula has registered impressive growth since its launch and has also encroached upon Lynparza & Rubraca's market share. The drug has generated sales of $65.3 million since its launch. The company has also claimed that it is the most frequently prescribed PARP inhibitor for ovarian cancer. Further boosting the prospect of the drug, the European Commission granted marketing authorization earlier this week. TESARO is also developing Zejula in combination with Merck's anti-PD-1 drug, Keytruda, in patients with platinum-resistant ovarian cancer.
From the above discussion, it is evident that Zejula has an edge due to non-requirement of BRCA-mutation status and has fared better thus far. However, with an expanded label, Lynparza is set to get back its lost share. We believe that Rubraca could be in a relatively weaker position among the three drugs. There is uncertainty over how it performs in Europe as both Lynparza and Zejula are already approved there. However, we have to wait till 2018 end to see the actual performance of these drugs as a few label expansions are expected next year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
TESARO, Inc. (TSRO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. Lynparza with its recent label expansion in August 2017 is indicated for maintenance treatment of patients suffering from platinum-sensitive recurrent ("PSR") ovarian cancer regardless of BRCA-mutation status. | There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. After that, two other PARP-inhibitors were approved by the FDA - Tesaro, Inc.'s TSRO Zejula and Clovis Oncology, Inc.'s CLVS Rubraca. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others. Meanwhile, the company filed a supplemental New Drug Application last month, seeking label expansion as a maintenance treatment for patients with PSR ovarian cancer. | There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. However, none of the three marketed PARP inhibitors - Rubraca, Zejula and Lynparza - have been approved in the first-line setting to date. |
25840.0 | 2017-11-24 00:00:00 UTC | Will New Drug Approvals Boost Novartis (NVS) Portfolio? | ABBV | https://www.nasdaq.com/articles/will-new-drug-approvals-boost-novartis-nvs-portfolio-2017-11-24 | nan | nan | Novartis AGNVS is currently going through a transitional stage. The company's blockbuster drug, Diovan, is facing stiff generic competition in the United States, EU and Japan. The loss of patent protection for these top-selling drugs continues to hurt sales. Exforge is also facing generic competition in the United States and the EU. Oncology drugs are facing new competition from immuno-oncology therapies. Moreover, certain patents and extensions covering Afinitor and Gilenya will expire in 2018, 2019 and 2020. The negative impact of generic competition will impact sales by $2.5 billion in 2017.
CEO Joseph Jimenez will step down from his position in 2018. Vasant Narasimhan, M.D., Global Head of Drug Development and Chief Medical Officer, will replace him effective Feb 1, 2018.
Nevertheless, we believe that the approval of new drugs and label expansion of existing drugs will boost the company's top line.
Psoriasis drug, Cosentyx, was approved for the treatment of two new indications - ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in 2016. The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie Inc.'s ABBV Humira and Amgen, Inc.'s AMGN Enbrel. Cosentyx achieved blockbuster status in 2016 recording over $1 billion of sales. Novartis expects to garner $2 billion and $500 million of sales from Cosentyx and Entresto, respectively in 2017. Other approvals include Farydak, Odomzo and the combination of Tafinlar + Mekinist.
Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and an improved formulation of Exjade. The oncology portfolio received a further boosted with the approval of new drugs. The recent FDA approval of Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will boost the sales. The drug was also approved in Europe. Meanwhile, the FDA also approved a label expansion of Zykadia to include the first-line treatment of patients with metastatic non-small cell lung cancer. The European Commission (EC) has recently approved Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) and pediatric patients with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.
The FDA recently approved breakthrough gene transfer treatment, Kymriah suspension for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah, formerly CTL019, is the first chimeric antigen receptor T cell (CAR-T) therapy approved. The approval provided a major boost to Novartis. The approval opens up new frontiers in the treatment of cancer by advancing immune-cellular therapy for children and young adults with r/r B-cell ALL which comprises approximately 25% of cancer diagnoses among children under 15 years. It is the most common form of childhood cancer in the United States. Kymriah has been launched in the United States.
Moreover, Sandoz holds a leading position in the biosimilars space with a portfolio of five marketed biosimilars currently and a deep pipeline. The biosimilar version of Roche Holdings' RHHBY Rituxan (rituximab). Rixathon was approved by the European Commission in June 2017. It is currently under review in the United States. The biosimilar version of Humira is also under review in the EU.
Novartis' stock has rallied 19.5% year to date compared with the industry 's 18.1% gain. In the first half of 2017, Novartis announced that it is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin-off or an initial public offering. The company believes that the Alcon division has revived and hence a decision on a possible spin-off will be taken in 2019.
Zacks Rank
Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie Inc.'s ABBV Humira and Amgen, Inc.'s AMGN Enbrel. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The recent FDA approval of Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will boost the sales. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie Inc.'s ABBV Humira and Amgen, Inc.'s AMGN Enbrel. Meanwhile, the FDA also approved a label expansion of Zykadia to include the first-line treatment of patients with metastatic non-small cell lung cancer. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie Inc.'s ABBV Humira and Amgen, Inc.'s AMGN Enbrel. Nevertheless, we believe that the approval of new drugs and label expansion of existing drugs will boost the company's top line. | The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie Inc.'s ABBV Humira and Amgen, Inc.'s AMGN Enbrel. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Oncology drugs are facing new competition from immuno-oncology therapies. |
25841.0 | 2017-11-24 00:00:00 UTC | J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space | ABBV | https://www.nasdaq.com/articles/jj-glaxos-jucala-approval-puts-spotlight-on-hiv-space-2017-11-24 | nan | nan | Johnson & JohnsonJNJ and partner GlaxoSmithKline GSK recently announced FDA approval for Juluca - a combination of Glaxo's Tivicay/rilpivirine and J&J's Edurant/dolutegravir into a single tablet - for the treatment of HIV
Most medicines for HIV treatment are made up of three or more antiretroviral drugs. Juluca is the first two-drug regimen that reduces the number of medicines HIV patients take without compromising on the efficacy of a conventional three-drug regimen. The approval of Juluca has shifted investor focus to the HIV disease space. Let's see how companies are trying to tap into this huge market.
A Note on HIV
HIV stands for human immunodeficiency virus. It weakens the immune system by destroying cells that fight diseases and infections and can eventually lead to AIDS (acquired immunodeficiency syndrome). Medicines for the treatment of HIV are called antiretroviral therapy (ART) that slow or put a check on the progression of the virus.
Globally, about 36.7 million people were living with HIV/AIDS at the end of 2016. Of the total, 2.1 million were children (less than 15 years old).
Despite improved medical understanding of HIV and its prevention and treatment as well as significant efforts made by leading government and medical bodies, HIV and AIDS still has no cure. Notably, 1 million people died of AIDS-related illnesses in 2016, reaching the total number since the start of the epidemic to 35.0 million.
Companies Developing HIV Drugs
Marketed Therapies for HIV
Several pharmaceutical companies are marketing drugs/therapies to treat HIV. Gilead GILD is a dominant player in the HIV market with an impressive portfolio. The company was the first to introduce a single-tablet regimen (STR) for the treatment of HIV - Atripla. Gilead's other STRs for HIV include Complera/Eviplera and Stribild. Its TAF-based product Genvoya is a bestseller, surpassing both Truvada and Atripla since fourth-quarter 2016.
Another company, GlaxoSmithKline has a long-standing commitment to HIV and infectious diseases. The company had developed the widely used antibiotic amoxycillin around 40 years ago, and developed the first medicines approved to treat HIV (AZT). The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress.
Another pharmaceutical company Mylan MYL has received a tentative approval from the FDA for its combination tablet, comprising efavirenz, lamivudine and tenofovir disoproxil fumarate, to treat HIV.
What's in the Pipeline?
Companies are working on developing new drugs to treat, prevent and possibly cure HIV. Scientists are exploring new treatment paradigms like two-drug regimens, making therapies/drugs with improved safety profiles and new mechanisms of actions.
Gilead's STR bictegravir for HIV treatment is under priority review in the United States. The FDA is expected to announce its decision next February. The STR is a fixed-dose combination of bictegravir, an INSTI, and emtricitabine/tenofovir alafenamide (FTC/TAF), a dual-NRTI backbone.
Merck is developing an investigational non-nucleoside reverse transcriptase inhibitor MK-1439, doravirine for HIV -1 infection and plans tofile regulatory applications for fixed-dose combination of the same,both as a single-entity tablet and a fixed-dose combination tabletconsisting of fixed-dose combination of doravirine (DOR), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) n late 2017.
Glaxo is also developing two drug regimens are dolutegravir + lamivudineand cabotegravir + rilpivirine.
As an increasing number of companies are developing drugs to treat this life threatening disease, competition has intensified manifold in the space. Meanwhile, it is to be seen how Juluca fares in the market.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. It weakens the immune system by destroying cells that fight diseases and infections and can eventually lead to AIDS (acquired immunodeficiency syndrome). | The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Companies Developing HIV Drugs Marketed Therapies for HIV Several pharmaceutical companies are marketing drugs/therapies to treat HIV. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress. Johnson & JohnsonJNJ and partner GlaxoSmithKline GSK recently announced FDA approval for Juluca - a combination of Glaxo's Tivicay/rilpivirine and J&J's Edurant/dolutegravir into a single tablet - for the treatment of HIV Most medicines for HIV treatment are made up of three or more antiretroviral drugs. | The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ and partner GlaxoSmithKline GSK recently announced FDA approval for Juluca - a combination of Glaxo's Tivicay/rilpivirine and J&J's Edurant/dolutegravir into a single tablet - for the treatment of HIV Most medicines for HIV treatment are made up of three or more antiretroviral drugs. |
25842.0 | 2017-11-21 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2017-11-21 | nan | nan | They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each other in the autoimmune disease market.
Johnson & Johnson has been a longtime favorite among investors. AbbVie has arguably been the best big pharma stock in recent years. But which is the better pick for investors now? Here's how AbbVie and J&J compare in the key categories of growth prospects, dividends, and valuation.
The case for AbbVie
There are several kinds of growth, but they're all intertwined. Revenue growth typically leads to earnings growth, and both tend to drive stock price growth. AbbVie appears to be in good shape on all three counts in the coming years.
The company recently increased its 2020 sales estimate for Humira from $18 billion to $21 billion. With Humira generating nearly two-thirds of AbbVie's total revenue, that's huge for the drugmaker's growth prospects. Other current products should also contribute to AbbVie's growth. Imbruvica is on track to become the fourth-best-selling cancer drug in the world by 2022 . Recently launched hepatitis C drug Mavyret should also be a big winner. Venclexta isn't making much money yet, but additional cancer indications could greatly expand the market for the drug.
AbbVie's pipeline also ranks as one of the best among big pharma companies. Potential blockbuster candidates include elagolix, which targets treatment of endometriosis and uterine fibroids, autoimmune disease drugs upadacitinib and risankizumab, and cancer drug Rova-T.
Although AbbVie is experiencing sales declines for some of its older hepatitis C and HIV drugs, those products combined make up for only a small percentage of total revenue. Overall, Wall Street analysts project average annual earnings growth for AbbVie of nearly 16% over the next five years.
The impressive cash flow produced by Humira and (to a lesser extent) AbbVie's other drugs has allowed the company to reward shareholders with one of the best dividends in healthcare. AbbVie's dividend currently yields a little over 3%. The company has increased its dividend nearly 78% since being spun off by Abbott Labs in 2013.
Despite its year-to-date gains of close to 50%, AbbVie shares trade at only 14.4 times expected earnings. With its strong growth prospects, the stock appears to be a bargain at the current price.
The case for Johnson & Johnson
Johnson & Johnson stands as the largest healthcare company in the world, with three multibillion-dollar business segments. J&J's consumer business, which includes well-known brands such as Band-Aids and Listerine, is growing sales, but only by low single-digit percentages. Its medical device segment is enjoying stronger growth in higher single-digit percentages, thanks primarily to acquisitions.
The most important growth engine for Johnson & Johnson is its largest business: the pharmaceutical segment. Several products are largely responsible for driving that growth, especially Imbruvica (for which J&J receives a smaller percentage of sales than AbbVie, though), blood cancer drug Darzalex, and Stelara, which treats psoriasis and psoriatic arthritis. In addition, J&J's acquisition earlier this year of Actelion gave the company a growing pulmonary hypertension franchise.
What about J&J's pipeline? Market research firm EvaluatePharma ranked the company's apalutamide as the third-most-promising cancer drug in late-stage development . Other promising candidates include antidepressant esketamine, acute myeloid leukemia treatment talacotuzumab, and cancer drug erdafitinib.
The challenge for Johnson & Johnson, though, is overcoming headwinds for several existing drugs. J&J's current top-selling drug, Remicade, faces competition from biosimilars. Several of its top drugs experienced year-over-year sales declines of 10% or more in the last quarter, including neuroscience drugs Concerta and Risperdal Consta, cancer drug Velcade, diabetes drug Invokana, and anemia drug Procrit. Because of some of these issues, Wall Street analysts project that J&J will grow average earnings by only 7% over the next five years despite its promising pipeline.
J&J's dividend is solid, with a yield of 2.37%. The company's track record of 55 consecutive years of dividend hikes is even more impressive.
As for valuation, J&J stock trades at nearly 17.6 times expected earnings. That's not cheap, but it's a little lower than the S&P 500 's forward earnings multiple.
Better buy
AbbVie clearly has better growth prospects than J&J does. Its dividend yield is higher. I don't see that advantage going away any time soon, either, with AbbVie continuing to make double-digit percentage dividend increases each year. And the stock is even a better value than J&J.
Johnson & Johnson is a great long-term pick for investors. However, in my view, AbbVie is the better stock right now.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although AbbVie is experiencing sales declines for some of its older hepatitis C and HIV drugs, those products combined make up for only a small percentage of total revenue. The impressive cash flow produced by Humira and (to a lesser extent) AbbVie's other drugs has allowed the company to reward shareholders with one of the best dividends in healthcare. Several products are largely responsible for driving that growth, especially Imbruvica (for which J&J receives a smaller percentage of sales than AbbVie, though), blood cancer drug Darzalex, and Stelara, which treats psoriasis and psoriatic arthritis. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. Overall, Wall Street analysts project average annual earnings growth for AbbVie of nearly 16% over the next five years. AbbVie has arguably been the best big pharma stock in recent years. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. AbbVie has arguably been the best big pharma stock in recent years. Here's how AbbVie and J&J compare in the key categories of growth prospects, dividends, and valuation. | However, in my view, AbbVie is the better stock right now. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. AbbVie has arguably been the best big pharma stock in recent years. |
25843.0 | 2017-11-20 00:00:00 UTC | Galapagos' CF Candidate Shows Potential in Phase II Study | ABBV | https://www.nasdaq.com/articles/galapagos-cf-candidate-shows-potential-in-phase-ii-study-2017-11-20 | nan | nan | Galapagos NVGLPG announced positive top-line data from a phase II study - ALBATROSS - evaluating its cystic fibrosis transmembrane conductance ("CFTR") corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. It led to improvements in lung function.
So far this year, Galapagos'shares have outperformed the industry . The stock has gained 41.5% compared with an increase of 1.5% registered by the industry.
The phase II study evaluated two once-daily doses - 150 mg and 300 mg - of the candidate in CF patients who have one gating mutation and an F508del mutation and were on long-term stable treatment with Vertex Pharmaceuticals Incorporated's VRTX CF drug, Kalydeco. Treatment with Kalydeco was continued during the course of the study.
The study achieved its primary objective of safety and was well tolerated in the patient population. Data also showed an improvement of 2.2% in mean percent predicted FEV1 (a measure of lung function) compared to baseline in 300 mg arm of the study.
Meanwhile, Vertex is also developing a combination therapy, tezacaftor plus Kalydeco, in similar indication.
Apart from GLPG2222, Galapagos is also developing GLPG2737, a CFTR regulator, in a phase I study and GLPG1837, a CFTR potentiator, in a phase II study in CF patients. All three candidates are being developed in partnership with AbbVie Inc. ABBV . The company has a diverse pipeline with candidates being developed in several other indications including atopic dermatitis, psoriatic arthritis, uveitis and lupus membranous nephropathy among others.
Galapagos NV Price
Galapagos NV Price | Galapagos NV Quote
Zacks Rank & Stock to Consider
Galapagos carries a Zacks Rank #3 (Hold).
Sucampo Pharmaceuticals, Inc. SCMP is a better-ranked health care stock, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Sucampo's earnings per share estimates have increased from $1.01 to $1.12 for 2017 and from $1.06 to $1.19 for 2018 over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 15.63%.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | All three candidates are being developed in partnership with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. Data also showed an improvement of 2.2% in mean percent predicted FEV1 (a measure of lung function) compared to baseline in 300 mg arm of the study. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. All three candidates are being developed in partnership with AbbVie Inc. ABBV . Galapagos NVGLPG announced positive top-line data from a phase II study - ALBATROSS - evaluating its cystic fibrosis transmembrane conductance ("CFTR") corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. All three candidates are being developed in partnership with AbbVie Inc. ABBV . The phase II study evaluated two once-daily doses - 150 mg and 300 mg - of the candidate in CF patients who have one gating mutation and an F508del mutation and were on long-term stable treatment with Vertex Pharmaceuticals Incorporated's VRTX CF drug, Kalydeco. | All three candidates are being developed in partnership with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from GLPG2222, Galapagos is also developing GLPG2737, a CFTR regulator, in a phase I study and GLPG1837, a CFTR potentiator, in a phase II study in CF patients. |
25844.0 | 2017-11-20 00:00:00 UTC | Galapagos Pops To Vertex's Detriment — But Can It Compete? | ABBV | https://www.nasdaq.com/articles/galapagos-pops-vertexs-detriment-can-it-compete-2017-11-20 | nan | nan | Galapagos ( GLPG ) stock popped Monday to Vertex Pharmaceuticals ' ( VRTX ) detriment after it figured out "one piece of its triple-combination puzzle" in treating cystic fibrosis, an analyst said.
[ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challenging Vertex in treating cystic fibrosis, according to Leerink analyst Geoffrey Porges. Vertex already has four potential triple-pill combos in midstage testing, whereas Galapagos just has one potential piece of its triple.
Late Sunday, Galapagos said its drug known as GLPG2222 was safe and tolerable in a group of patients with cystic fibrosis. The drug also helped reduce chloride in patients' sweat - a test of cystic fibrosis - and increased patients' ability to forcefully expel air.
But the lung function results were inferior to Vertex's results of tezacaftor plus ivacaftor in a failed Phase 3 trial, Porges said. On sweat chloride, GLPG2222 was inferior to Vertex's tezacaftor alone in a Phase 2 trial in the same patient population.
"There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. "These results do not yet compel us to alter our cystic fibrosis market."
IBD'S TAKE:Vertex started out in hepatitis C, but its efforts were dampened by Gilead Sciences' massive hepatitis C franchise. So it moved onto cystic fibrosis. See what transitioned the firm from its "crisis" by visiting The New America .
Porges currently forecasts Galapagos having a 25% chance of success in cystic fibrosis, and maintained an outperform rating and 179 price target on Vertex. Vertex is planning to use its drugs tezacaftor and ivacaftor as a backbone for its triple.
By the closing bell on the stock market today , Galapagos lifted 2.8% to end the trading day at 93.39. Vertex dipped 1.9% to finish at 144.64.
RELATED:
Why Roche Cancer Trial Is Kick In The Teeth For Dow Stock Merck
Vertex Pops As Analyst Questions Whether Rival Has 'Viable Drug'
Three Biotech Firms Top Third-Quarter Views - But Only One Pops
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. Galapagos ( GLPG ) stock popped Monday to Vertex Pharmaceuticals ' ( VRTX ) detriment after it figured out "one piece of its triple-combination puzzle" in treating cystic fibrosis, an analyst said. [ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challenging Vertex in treating cystic fibrosis, according to Leerink analyst Geoffrey Porges. | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. [ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challenging Vertex in treating cystic fibrosis, according to Leerink analyst Geoffrey Porges. But the lung function results were inferior to Vertex's results of tezacaftor plus ivacaftor in a failed Phase 3 trial, Porges said. | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. Galapagos ( GLPG ) stock popped Monday to Vertex Pharmaceuticals ' ( VRTX ) detriment after it figured out "one piece of its triple-combination puzzle" in treating cystic fibrosis, an analyst said. [ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challenging Vertex in treating cystic fibrosis, according to Leerink analyst Geoffrey Porges. | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. [ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challenging Vertex in treating cystic fibrosis, according to Leerink analyst Geoffrey Porges. "These results do not yet compel us to alter our cystic fibrosis market." |
25845.0 | 2017-11-17 00:00:00 UTC | Notable ETF Inflow Detected - XLV, JNJ, PFE, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-jnj-pfe-abbv-2017-11-17 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.7 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 212,015,324.0 to 213,765,324.0). Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.28. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.7 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 212,015,324.0 to 213,765,324.0). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.28. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.7 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 212,015,324.0 to 213,765,324.0). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.28. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.7 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 212,015,324.0 to 213,765,324.0). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.28. |
25846.0 | 2017-11-17 00:00:00 UTC | Aristotle Capital Management, LLC Buys DowDuPont Inc, Capital One Financial Corp, Danaher Corp, ... | ABBV | https://www.nasdaq.com/articles/aristotle-capital-management-llc-buys-dowdupont-inc-capital-one-financial-corp-danaher | nan | nan | Aristotle Capital Management, LLC
New Purchases: DWDP , COF , EWBC , CCE, PEYUF, URPTF, SFRRF, KTWIF, KCDMF, GSK,
Added Positions:DHR, PPG, ACHC, NFG, GE, HD, BAX, MLM, PXD, HAL,
Reduced Positions:BBVA, MTB, FRC, UBS, SPY, BBVA, SCHW, BAM, UBS, IX,
Sold Out:TWX, NGG, DE,
For the details of Aristotle Capital Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Aristotle+Capital+Management%2C+LLC
These are the top 5 holdings of Aristotle Capital Management, LLC
Adobe Systems Inc ( ADBE ) - 3,179,765 shares, 3.73% of the total portfolio. Shares added by 1.48%
Baxter International Inc ( BAX ) - 6,961,219 shares, 3.44% of the total portfolio. Shares added by 1.68%
AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. Shares added by 0.08%
Microchip Technology Inc ( MCHP ) - 4,559,729 shares, 3.22% of the total portfolio. Shares added by 1.40%
Microsoft Corp ( MSFT ) - 5,442,288 shares, 3.19% of the total portfolio. Shares added by 1.33%
New Purchase: DowDuPont Inc (DWDP)
Aristotle Capital Management, LLC initiated holdings in DowDuPont Inc. The purchase prices were between $63.11 and $70.41, with an estimated average price of $65.88. The stock is now traded at around $70.80. The impact to the portfolio due to this purchase was 2.44%. The holdings were 4,478,762 shares as of 2017-09-30.
New Purchase: Capital One Financial Corp (COF)
Aristotle Capital Management, LLC initiated holdings in Capital One Financial Corp. The purchase prices were between $78.21 and $87.94, with an estimated average price of $82.42. The stock is now traded at around $87.02. The impact to the portfolio due to this purchase was 2.15%. The holdings were 3,225,609 shares as of 2017-09-30.
New Purchase: East West Bancorp Inc (EWBC)
Aristotle Capital Management, LLC initiated holdings in East West Bancorp Inc. The purchase prices were between $53.03 and $60.06, with an estimated average price of $56.79. The stock is now traded at around $56.94. The impact to the portfolio due to this purchase was 0.47%. The holdings were 1,002,524 shares as of 2017-09-30.
New Purchase: Coca-Cola European Partners PLC (CCE)
Aristotle Capital Management, LLC initiated holdings in Coca-Cola European Partners PLC. The purchase prices were between $40.29 and $44.34, with an estimated average price of $42.4. The stock is now traded at around $38.24. The impact to the portfolio due to this purchase was 0.1%. The holdings were 340,966 shares as of 2017-09-30.
New Purchase: Peyto Exploration & Development Corp (PEYUF)
Aristotle Capital Management, LLC initiated holdings in Peyto Exploration & Development Corp. The purchase prices were between $15.56 and $18.54, with an estimated average price of $17.04. The stock is now traded at around $12.82. The impact to the portfolio due to this purchase was 0.02%. The holdings were 191,590 shares as of 2017-09-30.
New Purchase: Uranium Participation Corp (URPTF)
Aristotle Capital Management, LLC initiated holdings in Uranium Participation Corp. The purchase prices were between $2.81 and $3.09, with an estimated average price of $2.95. The stock is now traded at around $3.20. The impact to the portfolio due to this purchase was 0.01%. The holdings were 319,000 shares as of 2017-09-30.
Added: Danaher Corp (DHR)
Aristotle Capital Management, LLC added to the holdings in Danaher Corp by 33.47%. The purchase prices were between $79.29 and $88.45, with an estimated average price of $83.45. The stock is now traded at around $93.17. The impact to the portfolio due to this purchase was 0.69%. The holdings were 4,079,406 shares as of 2017-09-30.
Added: PPG Industries Inc (PPG)
Aristotle Capital Management, LLC added to the holdings in PPG Industries Inc by 31.13%. The purchase prices were between $100.73 and $113.6, with an estimated average price of $106.52. The stock is now traded at around $113.62. The impact to the portfolio due to this purchase was 0.63%. The holdings were 3,093,928 shares as of 2017-09-30.
Added: Acadia Healthcare Co Inc (ACHC)
Aristotle Capital Management, LLC added to the holdings in Acadia Healthcare Co Inc by 23.88%. The purchase prices were between $44.84 and $53, with an estimated average price of $48.76. The stock is now traded at around $29.48. The impact to the portfolio due to this purchase was 0.43%. The holdings were 5,886,797 shares as of 2017-09-30.
Added: iShares Russell 1000 Value (IWD)
Aristotle Capital Management, LLC added to the holdings in iShares Russell 1000 Value by 59.46%. The purchase prices were between $114.28 and $118.64, with an estimated average price of $116.52. The stock is now traded at around $119.27. The impact to the portfolio due to this purchase was 0.03%. The holdings were 93,444 shares as of 2017-09-30.
Added: iShares MSCI EAFE (EFA)
Aristotle Capital Management, LLC added to the holdings in iShares MSCI EAFE by 54.59%. The purchase prices were between $64.83 and $68.48, with an estimated average price of $66.83. The stock is now traded at around $68.94. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 11,443 shares as of 2017-09-30.
Added: AT&T Inc (T)
Aristotle Capital Management, LLC added to the holdings in AT&T Inc by 26.56%. The purchase prices were between $35.59 and $39.41, with an estimated average price of $37.59. The stock is now traded at around $34.72. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 8,897 shares as of 2017-09-30.
Sold Out: Time Warner Inc (TWX)
Aristotle Capital Management, LLC sold out the holdings in Time Warner Inc. The sale prices were between $99.1 and $103.22, with an estimated average price of $101.43.
Sold Out: National Grid PLC (NGG)
Aristotle Capital Management, LLC sold out the holdings in National Grid PLC. The sale prices were between $60.41 and $65.38, with an estimated average price of $63.15.
Sold Out: Deere & Co (DE)
Aristotle Capital Management, LLC sold out the holdings in Deere & Co. The sale prices were between $115.44 and $132.41, with an estimated average price of $123.26.
Reduced: Banco Bilbao Vizcaya Argentaria SA (BBVA)
Aristotle Capital Management, LLC reduced to the holdings in Banco Bilbao Vizcaya Argentaria SA by 98.33%. The sale prices were between $8.52 and $9.27, with an estimated average price of $8.85. The stock is now traded at around $8.50. The impact to the portfolio due to this sale was -2.4%. Aristotle Capital Management, LLC still held 585,045 shares as of 2017-09-30.
Reduced: M&T Bank Corp (MTB)
Aristotle Capital Management, LLC reduced to the holdings in M&T Bank Corp by 99.91%. The sale prices were between $142.47 and $166.54, with an estimated average price of $157.11. The stock is now traded at around $159.19. The impact to the portfolio due to this sale was -2.04%. Aristotle Capital Management, LLC still held 1,322 shares as of 2017-09-30.
Warning! GuruFocus has detected 4 Warning Signs with DHR. Click here to check it out.
DHR 15-Year Financial Data
The intrinsic value of DHR
Peter Lynch Chart of DHR
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. Aristotle Capital Management, LLC New Purchases: DWDP , COF , EWBC , CCE, PEYUF, URPTF, SFRRF, KTWIF, KCDMF, GSK, Added Positions:DHR, PPG, ACHC, NFG, GE, HD, BAX, MLM, PXD, HAL, Reduced Positions:BBVA, MTB, FRC, UBS, SPY, BBVA, SCHW, BAM, UBS, IX, Sold Out:TWX, NGG, DE, For the details of Aristotle Capital Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Aristotle+Capital+Management%2C+LLC These are the top 5 holdings of Aristotle Capital Management, LLC Adobe Systems Inc ( ADBE ) - 3,179,765 shares, 3.73% of the total portfolio. New Purchase: Peyto Exploration & Development Corp (PEYUF) Aristotle Capital Management, LLC initiated holdings in Peyto Exploration & Development Corp. | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. New Purchase: Coca-Cola European Partners PLC (CCE) Aristotle Capital Management, LLC initiated holdings in Coca-Cola European Partners PLC. New Purchase: Peyto Exploration & Development Corp (PEYUF) Aristotle Capital Management, LLC initiated holdings in Peyto Exploration & Development Corp. | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. Aristotle Capital Management, LLC New Purchases: DWDP , COF , EWBC , CCE, PEYUF, URPTF, SFRRF, KTWIF, KCDMF, GSK, Added Positions:DHR, PPG, ACHC, NFG, GE, HD, BAX, MLM, PXD, HAL, Reduced Positions:BBVA, MTB, FRC, UBS, SPY, BBVA, SCHW, BAM, UBS, IX, Sold Out:TWX, NGG, DE, For the details of Aristotle Capital Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Aristotle+Capital+Management%2C+LLC These are the top 5 holdings of Aristotle Capital Management, LLC Adobe Systems Inc ( ADBE ) - 3,179,765 shares, 3.73% of the total portfolio. Shares added by 1.33% New Purchase: DowDuPont Inc (DWDP) Aristotle Capital Management, LLC initiated holdings in DowDuPont Inc. | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. Added: AT&T Inc (T) Aristotle Capital Management, LLC added to the holdings in AT&T Inc by 26.56%. Aristotle Capital Management, LLC still held 585,045 shares as of 2017-09-30. |
25847.0 | 2017-11-17 00:00:00 UTC | Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval | ABBV | https://www.nasdaq.com/articles/roches-rhhby-hemophilia-a-drug-receives-fda-approval-2017-11-17 | nan | nan | Roche HoldingsRHHBY announced that the FDA has approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
The approval comes three months ahead of the assigned PDUFA date of Feb 23, 2018. The drug was reviewed by the FDA under Priority Review.
Meanwhile, data from HAVEN 1 and HAVEN 2 are being reviewed under accelerated assessment by the European Medicines Agency (EMA).
Roche's legacy drugs like Herceptin, MabThera are already facing competition from biosimilars. Though the approval of new drugs certainly boosts Roche's portfolio, it must be noted that Hemlibra carries a boxed warning of thrombotic microangiopathy (TMA) and blood clots which will limit sales potential.
Moreover, competition is intense in the haemophilia market too. Shire plc's SHPG hemophila drugs like Advate (hemophilia A) and Rixubis (hemophilia B) pose stiff competition to Roche. Also, the presence of Novo Nordisk NVO in the same space is a concern.
Meanwhile, Hemlibra is currently being evaluated in a clinical development program that includes two additional phase III studies. HAVEN 3 is evaluating Hemlibra prophylaxis dosed once weekly or once every other week in people 12 years of age or older with haemophilia A without inhibitors to factor VIII. HAVEN 4 is evaluating Hemlibra prophylaxis dosed every four weeks in people 12 years of age or older with haemophilia A with or without inhibitors.
Roche's stock has gained only 4% year to date compared with industry 's growth of 18%.
Roche also obtained FDA approval for Gazyva in combination with chemotherapy, followed by Gazyva alone in those who responded, for previously untreated advanced follicular lymphoma (stage II bulky, III or IV).
The drug is already approved in combination with chlorambucil to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment.
Roche's hematology portfolio consists of approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvara, and Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Inc . ABBV .
Zacks Rank
Roche carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Shire PLC (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Roche's hematology portfolio consists of approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvara, and Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Inc . ABBV . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio consists of approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvara, and Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Inc . ABBV . | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio consists of approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvara, and Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Inc . ABBV . | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio consists of approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvara, and Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Inc . ABBV . |
25848.0 | 2017-11-17 00:00:00 UTC | Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3 | ABBV | https://www.nasdaq.com/articles/biotechs-trading-lower-in-q4-on-macro-uncertainty-tepid-q3-2017-11-17 | nan | nan | The biotech industry turned around this year after the drug pricing issue crippled its performance last year.
It had a number of things going in its favor. Strong quarterly results, new product sales ramp up with rising demand, successful innovation and product line expansion, strong clinical study results, more frequent FDA approvals and continued strong performance from legacy products played a pivotal role in bringing the sector on track this year.
However, after rising 15.4% in the first nine months of the year (January-September), the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter (Oct 1 - to date). Both macro and industry specific factors resulted in the sudden downfall.
Uncertain Macro Picture
A big component of this sell-off is the confusion over the passing of the tax reform. The reform aims to bring down corporate tax to stimulate economic as well as employment growth.
The proposed tax reforms, if approved, will leave more cash in the hands of biotech companies. The cash can be invested for mergers/acquisitions, which have been relatively fewer this year compared with the last. It goes without saying that significant uncertainty regarding the timely passing of the U.S. tax reform has cast a shadow over the future of the biotech sector.
In October, President Trump once again criticized high drug prices. This came at a time when investors had started to expect that Trump's action on drug prices may not be as onerous as previously feared, sending health-care stocks lower.
Tepid Q3 Results
Coming to some industry specific factors, most big biotechs beat estimates for earnings and sales in Q3. However, shares of most of these companies declined post earnings release for various reasons.
Although Gilead GILD topped both earnings and revenue estimates in the third quarter, it witnessed continued decline in sales of its HCV drugs - Harvoni and Sovaldi - as a result of competitive and pricing pressure.
Amgen AMGN also beat expectations for both earnings and sales in Q3 and raised its earnings guidance for 2017. However sales declined year over year, which resulted in share price decline post the earnings call. Sales of its PCSK9 inhibitor, Repatha, were also disappointing.
Celgene's CELG shares plunged following the release of third-quarter results. Although Celgene's earnings topped estimates, revenues fell short. Moreover, the company lowered its 2017 outlook for Otezla sales as well as its total revenue and earnings outlook for 2020.
Although Biogen's BIIB third-quarter results were better than expected, shares were down 3.9% on concerns regarding the company's multiple sclerosis franchise sales as well as U.S. sales of its recently launched spinal muscular atrophy ("SMA") treatment, Spinraza.
Alexion ALXN topped earnings estimates but missed on revenues in the third quarter.
Vertex VRTX and AbbVie ABBV were the only two outperformers in Q3.
Conclusion
We believe that the biotech space should be back on track if there is more certainty regarding the timing of the tax reforms. This is because the fundamentals of the sector remain strong. Meanwhile, with the Q3 earnings season now behind us, stocks should start picking up. Positive data from key clinical studies can drive the sector up as share price of biotechs is correlated to success in key studies.
The major biotech players need an infusion of new growth drivers in their pipeline/product portfolios - either from internal development or from buying assets from outside. Strategic deals signed by these biotechs can also push the stocks higher.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Vertex VRTX and AbbVie ABBV were the only two outperformers in Q3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This came at a time when investors had started to expect that Trump's action on drug prices may not be as onerous as previously feared, sending health-care stocks lower. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex VRTX and AbbVie ABBV were the only two outperformers in Q3. Strong quarterly results, new product sales ramp up with rising demand, successful innovation and product line expansion, strong clinical study results, more frequent FDA approvals and continued strong performance from legacy products played a pivotal role in bringing the sector on track this year. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex VRTX and AbbVie ABBV were the only two outperformers in Q3. Strong quarterly results, new product sales ramp up with rising demand, successful innovation and product line expansion, strong clinical study results, more frequent FDA approvals and continued strong performance from legacy products played a pivotal role in bringing the sector on track this year. | Vertex VRTX and AbbVie ABBV were the only two outperformers in Q3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Uncertain Macro Picture A big component of this sell-off is the confusion over the passing of the tax reform. |
25849.0 | 2017-11-15 00:00:00 UTC | 3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock | ABBV | https://www.nasdaq.com/articles/3-indisputable-reasons-why-abbvie-best-big-pharma-stock-2017-11-15 | nan | nan | What's the best big pharma stock?
Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others. And if one stock clearly dominates in several of those metrics, it has a strong argument in being named as the best.
AbbVie (NYSE: ABBV) is such a stock. On the measurements that count the most for investors, it outperforms every other major drugmaker in its peer group. Here are three indisputable reasons why AbbVie ranks as the best big pharma stock on the market right now.
1. Total shareholder return
Over the last three years, AbbVie's total shareholder return of more than 65% beats every other big pharma. The next closest rival in the group of drugmakers in AbbVie's peer group is Johnson & Johnson (NYSE: JNJ) , with a three-year total return of close to 40%.
It's not just the previous three years where AbbVie claims the No. 1 title, either. The company's total return over the last five years of more than 220% is also the best among big pharma stocks. J&J again took second place, with a total return of over 125%. But what about more recently? AbbVie again wins. So far in 2017, the stock's total return stands at 57%. That's more than two times higher than runner-up AstraZeneca , with a total return year to date of 26%.
There are two components to total shareholder return: stock appreciation and dividends. AbbVie has delivered on both.
2. Revenue growth
As you might expect, impressive total shareholder returns is accompanied by strong revenue growth. AbbVie has increased its trailing-12-month revenue over the last three years by nearly 37%. That's top among the companies it views as its peers. Bristol-Myers Squibb came in second during the period, with close to 30% trailing-12-month revenue growth.
AbbVie takes the top spot in trailing-12-month revenue growth so far in 2017 as well. Only when we look back over five years does the stock give up its No. 1 ranking. AbbVie increased its trailing-12-month revenue by 48% during the period -- enough to come in second among its peer group. Gilead Sciences took the top spot over a five-year period.
Humira was the primary driver for AbbVie's impressive revenue growth. The autoimmune disease drug generates roughly two-thirds of AbbVie's total revenue. The company does have other rising stars, though, particularly Imbruvica. The drug, which AbbVie co-markets with Johnson & Johnson, is projected to rank among the top five best-selling cancer drugs in the world by 2022 .
3. Adjusted earnings-per-share growth
With revenue increasing rapidly, it isn't surprising that AbbVie's bottom line has also improved significantly. Over the last three years (including estimated full-year earnings for 2017), AbbVie's adjusted earnings per share (EPS) have grown by 29%. Again, the company takes the No. 1 spot.
We can't compare AbbVie against its peers over a five-year period, because the company didn't report adjusted earnings per share in 2012 for use in calculations. Also, AbbVie ranks second in its peer group for estimated adjusted EPS growth in 2017.
Worth noting
There is one thing worth noting. AbbVie's self-defined peer group of big pharma companies includes the ones already mentioned -- J&J, AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences -- plus Amgen , Eli Lilly , GlaxoSmithKline , Merck , Novartis , and Pfizer . But AbbVie left Celgene (NASDAQ: CELG) off its list of peers. Celgene's current market cap is in the same ballpark as AstraZeneca's and was greater than several of AbbVie's peers for much of the last year.
If Celgene were included in the comparisons, AbbVie would come in behind the biotech in revenue growth over the last three years, five years, and 2017 year to date. Also, for most of 2017, Celgene outperformed AbbVie in total shareholder return. A big pipeline disappointment and third-quarter revenue miss caused Celgene's stock price to sink , giving AbbVie the edge in total return this year.
Still, AbbVie clearly leads all other big pharma stocks in total return and adjusted EPS growth. It beats its peer group in revenue growth as well, although it would come in second if that list included Celgene. Even with Celgene in the comparisons, it seems indisputable that AbbVie is the best big pharma stock -- at least for the moment.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie, Celgene, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Celgene, Gilead Sciences, and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's self-defined peer group of big pharma companies includes the ones already mentioned -- J&J, AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences -- plus Amgen , Eli Lilly , GlaxoSmithKline , Merck , Novartis , and Pfizer . A big pipeline disappointment and third-quarter revenue miss caused Celgene's stock price to sink , giving AbbVie the edge in total return this year. *Stock Advisor returns as of November 6, 2017 Keith Speights owns shares of AbbVie, Celgene, Gilead Sciences, and Pfizer. | Over the last three years (including estimated full-year earnings for 2017), AbbVie's adjusted earnings per share (EPS) have grown by 29%. Still, AbbVie clearly leads all other big pharma stocks in total return and adjusted EPS growth. AbbVie (NYSE: ABBV) is such a stock. | Total shareholder return Over the last three years, AbbVie's total shareholder return of more than 65% beats every other big pharma. A big pipeline disappointment and third-quarter revenue miss caused Celgene's stock price to sink , giving AbbVie the edge in total return this year. Still, AbbVie clearly leads all other big pharma stocks in total return and adjusted EPS growth. | AbbVie has increased its trailing-12-month revenue over the last three years by nearly 37%. AbbVie (NYSE: ABBV) is such a stock. Here are three indisputable reasons why AbbVie ranks as the best big pharma stock on the market right now. |
25850.0 | 2017-11-15 00:00:00 UTC | 3 Stocks for Retirees to Grow Their Nest Eggs | ABBV | https://www.nasdaq.com/articles/3-stocks-retirees-grow-their-nest-eggs-2017-11-15 | nan | nan | Retired investors have somewhat different priorities than younger ones. Instead of focusing on growth, retirees' investments need to preserve their capital and also generate reliable income. However, that doesn't mean avoiding stocks -- in fact, there are some stocks that make excellent investments for retirees. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retirement.
A 5% dividend yield and lots of room to grow
Matt Frankel (Welltower): Leading healthcare REIT Welltower is an excellent choice for retirees, with an excellent combination of reliable dividends and long-term growth potential. As far as income is concerned, Welltower yields 5.1% based on its current stock price, and is about to make its 186th consecutive quarterly dividend payment.
On the subject of growth, Welltower makes the bulk of its money from senior-housing properties, which make up about 70% of its property portfolio. Many of them are structured as operating partnerships, as opposed to standard lease deals, allowing Welltower to benefit from the income generated by the services its properties provide. In fact, about two-thirds of Welltower's total revenue comes from resident fees and services as of 2017's third quarter.
The ongoing retirement of baby boomers is expected to cause a spike in senior-housing demand over the next several decades. In fact, the 85-and-over population is expected to double in just 20 years, and by 2030, senior-housing demand will be growing by 96,000 units per year. This should especially benefit urban senior living, where Welltower concentrates its efforts, as most aging baby boomers in cities intend to stay.
This translates into an amazing long-tailed market opportunity, which should translate into a steadily growing income stream for investors, as well as significant upside potential, as the value of Welltower's property portfolio climbs over the years.
No rust growing on Nucor
Rich Smith ( Nucor ): Three months ago, I suggested retirees could " build their nest egg out of steel " by investing in steel minimill operator Nucor. Three months later, I'm of a mind to recommend Nucor again.
Why? As I hoped when I first recommended it, Nucor stock has "gone up" over the past three months. But the thing is, it's only gone up about $0.50 -- and I think there's a whole lot more growth to be had. Earnings may have slipped in Q3, but they were superb earlier in the year. As a result, Nucor stock at just 15.7 times earnings today is arguably cheaper than when I first mentioned it in August, when the price-to-earnings (P/E) ratio was 16.8.
Now as then, Wall Street is predicting that strong growth lies ahead for Nucor. Analysts, on average, estimate the company will grow its profits at better than 20% annually over the next five years -- well into many investors' retirement years. Combined with a still-respectable dividend yield of 2.5%, Nucor's total returns on its stock should be in the neighborhood of 23% annually -- more than enough to justify the stock's mid-teens P/E.
The big unknown with Nucor stock is when -- or if -- it will begin benefiting from President Trump's long-awaited trillion-dollar infrastructure plan. Presumably, that's next on the President's agenda following tax reform. If and when the spending to rebuild America's crumbling roads, bridges, airports (and so on) arrives, it could turbocharge Nucor's results. In the meantime, though, I think Nucor stock looks cheap enough to buy.
A blue-chip biotech
Keith Speights (AbbVie) : Buying a biotech stock might not seem like a good idea for retirees, but I think there's one biotech that's a great choice -- AbbVie. This isn't your stereotypical biotech stock with super-high volatility, though.
Retirees will like AbbVie's dividend, which currently yields north of 3%. Probably even better than that attractive yield, though, is the company's track record of dividend hikes. Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. Since being spun off from Abbott in 2013, AbbVie's dividend has increased 77%.
What about growing your retirement nest egg? AbbVie is expected to increase earnings by 14% annually over the next few years. That kind of growth is definitely attainable, in my view, with continued momentum for the world's top-selling drug, Humira, and cancer drug Imbruvica, plus one of the best pipelines in the biopharmaceutical industry. Among the top candidates in that strong pipeline are several drugs with megablockbuster potential, including cancer drugs Rova-T and Venclexta.
As impressive as AbbVie's current product lineup and pipeline are, the biotech is likely to add even more drugs in the coming years. AbbVie CEO Richard Gonzalez recently stated that the company is interested in beefing up its portfolio through acquisitions and licensing deals, with a special focus in immunology and oncology. Further acquisitions could make this blue chip biotech even more attractive for retirees.
10 stocks we like better than Nucor
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Nucor wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie. Matthew Frankel has no position in any of the stocks mentioned. Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Nucor and Welltower. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie CEO Richard Gonzalez recently stated that the company is interested in beefing up its portfolio through acquisitions and licensing deals, with a special focus in immunology and oncology. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retirement. A blue-chip biotech Keith Speights (AbbVie) : Buying a biotech stock might not seem like a good idea for retirees, but I think there's one biotech that's a great choice -- AbbVie. | A blue-chip biotech Keith Speights (AbbVie) : Buying a biotech stock might not seem like a good idea for retirees, but I think there's one biotech that's a great choice -- AbbVie. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retirement. Retirees will like AbbVie's dividend, which currently yields north of 3%. | Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retirement. A blue-chip biotech Keith Speights (AbbVie) : Buying a biotech stock might not seem like a good idea for retirees, but I think there's one biotech that's a great choice -- AbbVie. Retirees will like AbbVie's dividend, which currently yields north of 3%. | Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. AbbVie is expected to increase earnings by 14% annually over the next few years. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retirement. |
25851.0 | 2017-11-14 00:00:00 UTC | Novartis (NVS) Arm's Biosimilars Study Results Encourage | ABBV | https://www.nasdaq.com/articles/novartis-nvs-arms-biosimilars-study-results-encourage-2017-11-14 | nan | nan | Novartis AG'sNVS generic arm, Sandoz, reported data from four clinical studies. The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively.
The studies included two innovative trials involving switching and two pharmacokinetic (PK) and pharmacodynamic (PD) studies.
A phase III confirmatory efficacy and safety study met its primary endpoint in the proportion of patients who achieved a 75% improvement at week 16. The study confirmed that there were no meaningful clinical differences in efficacy, safety and immunogenicity in patients who continuously received adalimumab, those who continuously received the reference drug and those who switched between biosimilar adalimumab and reference drug on multiple occasion.
In addition, a phase III study evaluated rituximab retreatment in patients with rheumatoid arthritis (RA), who had already received reference rituximab for treatment of RA in the past. The study evaluated the biosimilar and the reference drug in terms of safety and immunogenicity in patients who switched from the reference drug to biosimilar rituximab and in those who continued treatment with the reference drug.
In addition, the PK and PD data demonstrated equivalence as the phase I PK study met its primary endpoint as bioequivalence was demonstrated between the biosimilar adalimumab and the reference drug.
We note Sandoz holds a leading position in the biosimilars space with a portfolio of five marketed biosimilars currently and a deep pipeline.
The biosimilar version of rituximab, Rixathon, was approved by the European Commission in June 2017. It is currently under review in the United States. The biosimilar version of Humira is also under review in the EU.
Meanwhile, Sandoz witnessed strong growth outside the United States buoyed by biosimilar launches of Rixathon and Erelzi, the biosimilar of Amgen, Inc.'s AMGN Enbrel in Europe. However, pricing pressure intensified in the United States. The company expects low single-digit sales decline at Sandoz in the fourth quarter, mainly due to seasonal shipment phasing and continued pricing pressures in the United States.
Novartis' stock has rallied 17% year to date compared with the industry 's 17.6% gain. In the first half of 2017, Novartis announced that it is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin-off or an initial public offering. The company believes that the Alcon division has revived and hence a decision on a possible spin-off will be taken in 2019. The recent approvals of Kymriah and Kisqali will further boost the oncology portfolio and drive growth.
Zacks Rank
Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. A phase III confirmatory efficacy and safety study met its primary endpoint in the proportion of patients who achieved a 75% improvement at week 16. | The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The study confirmed that there were no meaningful clinical differences in efficacy, safety and immunogenicity in patients who continuously received adalimumab, those who continuously received the reference drug and those who switched between biosimilar adalimumab and reference drug on multiple occasion. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively. The study confirmed that there were no meaningful clinical differences in efficacy, safety and immunogenicity in patients who continuously received adalimumab, those who continuously received the reference drug and those who switched between biosimilar adalimumab and reference drug on multiple occasion. | The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. In addition, the PK and PD data demonstrated equivalence as the phase I PK study met its primary endpoint as bioequivalence was demonstrated between the biosimilar adalimumab and the reference drug. |
25852.0 | 2017-11-14 00:00:00 UTC | 3 Top Big Pharma Dividend Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-big-pharma-dividend-stocks-you-can-buy-right-now-2017-11-14 | nan | nan | Big pharma stocks have long been favorites for dividend-seeking investors, and for good reason. Major pharmaceutical companies typically generate strong cash flow, which allows them to pay high dividend yields for decades.
The great cash flow that enables big pharma companies to fund those attractive dividends stems from a stable of drugs that make lots of money while they enjoy patent exclusivity. Even when the drugs lose patent exclusivity, they can continue contributing substantially to the companies' bottom lines. While big pharma companies must continually reinvest into research and development to find the next generation of successful products, many also look to return some of the money they make to shareholders in the form of dividends.
AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. Here's why these are three top big pharma dividend stocks you can buy right now.
AbbVie
The first thing investors like to know about a dividend stock is its yield. AbbVie doesn't disappoint in that category, with its dividend currently yielding close to 3%. That's actually on the low end of the range for AbbVie's yield in recent years, but only because the stock has soared around 50% so far in 2017.
There are big pharma stocks with higher yields than AbbVie (we'll soon discuss a couple of them), but few have the track record of dividend increases AbbVie does. Counting the period in which it was still part of parent company Abbott Labs , AbbVie has raised its dividend for an impressive 45 consecutive years. In the five years since being spun off by Abbott, the company's dividend payout has increased by 77%.
But the past isn't as important to investors as the future. AbbVie also appears to be in better position to keep increasing its dividend in coming years than many of its peers. The drugmaker currently uses less than half of its free cash flow to pay dividends. AbbVie should also be able to increase its earnings and free cash flow significantly over the next several years.
The company's biggest moneymaker, autoimmune-disease drug Humira, should be safe from biosimilar competition through early 2023. Sales for Imbruvica are growing so quickly that the drug is projected to become the No. 4 top-selling cancer drug in the world by 2022 . AbbVie also has a pipeline loaded with promising candidates in multiple therapeutic categories.
Novartis
Swiss pharma company Novartis pays out a dividend that currently yields close to 3.3%. That's near the midpoint of the drugmaker's yield over the past several years.
Novartis has increased its dividend every year since its formation in 1996 with the merger of Ciba-Geigy and Sandoz. In the subsequent period, the company's dividend payout has risen by 550%. Over the past few years, though, Novartis' annual dividend increases have been relatively small.
Investors shouldn't have to worry much about the ability of Novartis to keep the dividends flowing. The drugmaker uses roughly two-thirds of its free cash flow to fund its dividend program. Novartis ranks as one of the most profitable big pharma companies in the world. And although it has seen earnings declines in recent years, things are looking better for the future.
In August, Novartis became the first pharma company to win U.S. regulatory approval for a CAR-T (chimeric antigen T-cell) drug with Kymriah. CAR-T is one of the hottest areas in cancer treatment -- and Novartis stands as a leader in the field. The company also claims a pipeline with more than 200 clinical programs, one of the deepest development programs in the industry.
Pfizer
Pfizer boasts one of the highest dividend yields among big pharma stocks, with its yield currently at more than 3.6%. The drugmaker's yield has rarely gone below 3% over the past decade.
For the much of its history, Pfizer also had a solid track record of annual dividend increases. Its streak was broken in 2009 as the company struggled in the midst of the major financial crisis and slashed its dividend. Since then, though, Pfizer has raised its dividend every year.
More importantly, Pfizer appears to be in good shape to keep dividend increases coming. The company uses around 57% of its free cash flow to pay out dividends. Wall Street analysts think Pfizer will grow earnings by an average of 6% annually over the next five years, significantly higher than the last five years.
There are several reasons to expect the analysts' optimism is well founded. Pfizer's current lineup includes big winners like cancer drug Ibrance and blood thinner Eliquis. The company also ranks third among big pharma companies in investing in research and development . That investment could pay off in a major way: Pfizer expects its pipeline to generate between 25 and 30 regulatory approvals over the next five years, with up to 15 of those having blockbuster potential.
Best pick
If you're dead-set on getting a high yield, Pfizer is probably the best big pharma stock for you. However, I think AbbVie is the best big pharma dividend stock overall.
Even though its yield is lower than those of some of its peers, AbbVie seems likely to grow its dividend faster than either Novartis or Pfizer. I wouldn't be surprised for its yield to surpass Novartis' in the not-too-distant future. But the main reason I think AbbVie is the top pick of the three is its growth potential.
Because of its continued momentum for Humira and Imbruvica and its strong pipeline, AbbVie will probably grow earnings more than twice as fast as Novartis and Pfizer will over the next few years. I fully expect that earnings growth to translate to superior returns. With that kind of growth and higher dividends likely on the way as well, AbbVie looks like the best big pharma dividend stock of all.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. AbbVie The first thing investors like to know about a dividend stock is its yield. AbbVie doesn't disappoint in that category, with its dividend currently yielding close to 3%. | AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. AbbVie The first thing investors like to know about a dividend stock is its yield. AbbVie doesn't disappoint in that category, with its dividend currently yielding close to 3%. | There are big pharma stocks with higher yields than AbbVie (we'll soon discuss a couple of them), but few have the track record of dividend increases AbbVie does. With that kind of growth and higher dividends likely on the way as well, AbbVie looks like the best big pharma dividend stock of all. AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. | However, I think AbbVie is the best big pharma dividend stock overall. AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. AbbVie The first thing investors like to know about a dividend stock is its yield. |
25853.0 | 2017-11-13 00:00:00 UTC | Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study | ABBV | https://www.nasdaq.com/articles/arena-arna-completes-enrolment-in-etrasimod-phase-ii-study-2017-11-13 | nan | nan | Arena Pharmaceuticals, Inc. ARNA announced that it has completed full enrollment with 157 patients in a phase II study evaluating its pipeline candidate etrasimod in ulcerative colitis (UC). Etrasimod (APD334) is an orally available next-generation sphingosine 1-phosphate (S1P) receptor modulator.
The primary endpoint of the study is the improvement in UC symptoms as measured by Mayo Clinic Score at 12 week compared with placebo. Top-line results are expected to be available in the first quarter of 2018.
Meanwhile, Arena continues to progress with its pipeline that targets different therapeutic areas.These include ralinepag (pulmonary arterial hypertension), and APD371 (pain and fibrotic diseases).The company reported positive results from a phase II study on ralinepag in July and is preparing to initiate a phase III study after discussions with the FDA
Arena's shares have outperformed the industry so far this year. While shares of the company have soared 88.4%, the industry has registered an increase of 2.3%.
Several other companies are also evaluating some candidates for UC. Some of them include Pfizer PFE , which is conducting studies to expand the label of its rheumatoid arthritis drug Xeljanz to include the UC indication. Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC. The company has another candidate upadacitinib/ABT-494 which is being evaluated for UC.
Zacks Rank & Stock to Consider
Arena carries a Zacks Rank #3 (Hold). Another better-ranked health care stocks in the same space is Ligand Pharmaceuticals Incorporated LGND sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Ligand's earnings per share estimates have moved up $3.68 to $3.70 for 2018 over the last 60 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 8.22%. The share price of the company has increased 37.6% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report
Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Arena Pharmaceuticals, Inc. ARNA announced that it has completed full enrollment with 157 patients in a phase II study evaluating its pipeline candidate etrasimod in ulcerative colitis (UC). | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC. Meanwhile, Arena continues to progress with its pipeline that targets different therapeutic areas.These include ralinepag (pulmonary arterial hypertension), and APD371 (pain and fibrotic diseases).The company reported positive results from a phase II study on ralinepag in July and is preparing to initiate a phase III study after discussions with the FDA Arena's shares have outperformed the industry so far this year. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC. Meanwhile, Arena continues to progress with its pipeline that targets different therapeutic areas.These include ralinepag (pulmonary arterial hypertension), and APD371 (pain and fibrotic diseases).The company reported positive results from a phase II study on ralinepag in July and is preparing to initiate a phase III study after discussions with the FDA Arena's shares have outperformed the industry so far this year. | Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Arena continues to progress with its pipeline that targets different therapeutic areas.These include ralinepag (pulmonary arterial hypertension), and APD371 (pain and fibrotic diseases).The company reported positive results from a phase II study on ralinepag in July and is preparing to initiate a phase III study after discussions with the FDA Arena's shares have outperformed the industry so far this year. |
25854.0 | 2017-11-13 00:00:00 UTC | Amgen Gets Positive CHMP Opinion to Expand Nplate's Label | ABBV | https://www.nasdaq.com/articles/amgen-gets-positive-chmp-opinion-to-expand-nplates-label-2017-11-13 | nan | nan | Amgen, Inc.AMGN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion to expand the label of Nplate to include the pediatric population.
Nplate is presently marketed for the treatment of chronic immune thrombocytopenic purpura (ITP) - an autoimmune disease characterized by low platelet count - in adults. Amgen is looking to get Nplate approved for use in pediatric patients (one year of age and older) who are refractory to other treatments like corticosteroids and immunoglobulin.
The positive opinion was based on five studies demonstrating that Nplate reduces the rates of bleeding in children with this rare blood disorder.
Amgen's shares have rallied 17.8% this year so far, better than the industry 's growth of 2.3%.
In a separate press release, Amgen and partner Allergan AGN announced that the CHMP has rendered a positive opinion for the marketing application of its biosimilar version of Roche's RHHBY cancer drug Avastin, ABP 215. According to the companies, this may be the first bevacizumab biosimilar, which has been recommended for approval in the EU
The Avastin biosimlar was approved in the United States in September and will be marketed by the trade name of Mvasi.
We remind investors that Amgen and Allergan have collaborated for the worldwide development and commercialization of four oncology antibody biosimilar medicines including Roche's Avastin, Herceptin and Ritixan.
In fact, Amgen has 10 biosimilars in its pipeline. Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this year for the same indications. However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from January 2023
Currently, Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Allergan PLC. (AGN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this year for the same indications. However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from January 2023 Currently, Amgen has a Zacks Rank #3 (Hold). (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this year for the same indications. However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from January 2023 Currently, Amgen has a Zacks Rank #3 (Hold). | However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from January 2023 Currently, Amgen has a Zacks Rank #3 (Hold). (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this year for the same indications. | Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this year for the same indications. However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from January 2023 Currently, Amgen has a Zacks Rank #3 (Hold). (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. |
25855.0 | 2017-11-12 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2017-11-12 | nan | nan | Thousands of stocks pay dividends. Some of those dividends aren't all that attractive, though. And sometimes the dividend looks great, but the stock doesn't. It could be there's a fundamental weakness for the business or simply that the stock's valuation is too pricey.
But there are a select group of stocks with terrific dividends that are worthy of serious consideration by investors. I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. Here's why these are three dividend stocks I'd buy right now.
AbbVie
I've been bullish about AbbVie for quite a while. The biotech has a lot going for it, with its dividend, currently yielding north of 3%, being high on the list. The company has raised its dividend for 45 consecutive years, including the period when it was part of Abbott Labs . And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%.
AbbVie's business has never been better. The company recently reported solid third-quarter results , with its top drugs Humira and Imbruvica posting impressive year-over-year sales growth. It just launched a new hepatitis C virus drug, Mavyret, that has significant potential. AbbVie also claims a deep pipeline and expects to have more than 20 new drug or indication approvals by 2020.
Even with its attractive dividend, solid business fundamentals, and tremendous growth prospects, AbbVie stock is still relatively inexpensive. Shares currently trade at less than 15 times expected earnings. With earnings projected to grow by 14% annually over the next few years, the stock should have plenty of room to run.
Iron Mountain
My colleague Matthew Frankel wrote in August that Iron Mountain is a "dividend investor's dream." I think he's right. The records and data storage company's dividend yield currently stands at 5.8%. As a real estate investment trust (REIT), Iron Mountain must distribute at least 90% of its taxable income to shareholders in the form of dividends. That means the dividends will keep coming as long as Iron Mountain remains profitable -- which shouldn't be a problem.
Iron Mountain has over 230,000 customers, including 95% of the Fortune 1,000. These customers typically sign three-year leases, but the vast majority of them renew those leases and don't leave. It's a lot easier to keep doing business with Iron Mountain, a stable company that's been around almost 70 years, than to go through the hassle of moving items to another storage provider.
At first glance, though, Iron Mountain stock might appear to be pricey. Its shares trade at 29 times expected earnings. But the company should be on track to grow earnings by more than 30% per year, thanks in part to rising demand for data storage. These growth prospects makes Iron Mountain's valuation look much more reasonable.
Medical Properties Trust
Another REIT that I really like is Medical Properties Trust. The company's name pretty much gives away what it does -- owning medical properties, primarily hospitals. Medical Properties Trust's dividend yields a little over 7%.
The company focuses on long-term leases to healthcare providers, usually for terms of 15 years or more. This gives Medical Properties Trust a reliable stream of revenue coming in the door. Thanks to acquisitions in recent years, it's now the second-largest owner of hospital beds in the U.S. but also owns properties in Europe. Aging demographic trends should drive demand for healthcare services, which should in turn give Medical Properties Trust long-term stability.
Medical Properties Trust stock trades at less than 13 times expected earnings, a valuation that's more attractive than several of its peers. Wall Street analysts think the company can grow earnings by close to 8% annually over the next few years. That's not a growth rate that would cause anyone to do cartwheels, but this respectable growth combined with a really high yield could at least make me do a few somersaults.
Top pick?
Selecting the best of these three dividend stocks is tough. I already own AbbVie and plan to hold on to it for a long time to come. But Iron Mountain deserves the nod as the top pick.
It's hard to argue against Iron Mountain's business model. The company has low maintenance and operating costs. It has a moat. And with increasingly more data and records being generated, Iron Mountain has great growth prospects.
Those growth prospects give it an advantage over Medical Properties Trust, in my view. Iron Mountain's exceptional yield gives it an edge over AbbVie. I'd buy all three of these dividend stocks right now, but if I could only choose one, it would be Iron Mountain.
10 stocks we like better than Iron Mountain
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Iron Mountain wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. AbbVie I've been bullish about AbbVie for quite a while. And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. Even with its attractive dividend, solid business fundamentals, and tremendous growth prospects, AbbVie stock is still relatively inexpensive. AbbVie I've been bullish about AbbVie for quite a while. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. AbbVie I've been bullish about AbbVie for quite a while. And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. AbbVie I've been bullish about AbbVie for quite a while. And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%. |
25856.0 | 2017-11-10 00:00:00 UTC | 7 Things AbbVie's Top Executives Just Said That You'll Want to Know | ABBV | https://www.nasdaq.com/articles/7-things-abbvies-top-executives-just-said-youll-want-know-2017-11-10 | nan | nan | It's a good time to be AbbVie (NYSE: ABBV) . And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong third-quarter performance a couple of weeks ago. AbbVie also increased its dividend for the 45th year in a row (including the years it was part of Abbott Labs (NYSE: ABT) ).
But can the good times continue to roll? AbbVie's top executives indirectly answered that question in different ways at the Credit Suisse healthcare conference in Arizona on Wednesday. Here are seven things management said that you'll want to know.
1. Humira
When asked about Humira, AbbVie CEO Richard Gonzalez was able to essentially respond with "see, we told you so." Gonzalez said that the company is seeing the strategy that AbbVie developed in 2013 "play out the way we anticipated." Actually, it's going even better than expected.
AbbVie updated its strategy in 2015, projecting 2020 sales for Humira of $18 billion. That estimate was too pessimistic. The company now thinks Humira will generate revenue of nearly $21 billion by 2020. Gonzalez acknowledged that the drug would see some erosion in international markets from biosimilar competition, but said the U.S. market would continue to drive overall growth, thanks to Humira remaining "the gold standard."
2. Beyond Humira
While AbbVie believes Humira will remain a big moneymaker for years to come, it's looking beyond Humira to the next generation of autoimmune-disease drugs. The two candidates at the top of the list are upadacitinib and risankizumab.
Michael Severino, AbbVie's chief scientific officer, said the company is "very pleased" with the profile seen for upadacitinib so far. The JAK1 selective inhibitor is in late-stage studies targeting treatment of rheumatoid arthritis and psoriatic arthritis, with additional late-stage studies planned for Crohn's disease and ulcerative colitis. Severino also was enthusiastic about the potential for risankizumab, citing its durable efficacy as a key differentiator for the anti-IL-23 antibody.
3. Cancer drugs' market potential
AbbVie has also become a leader in oncology. The biotech projects that Imbruvica will generate roughly $11.5 billion in U.S. sales by 2025. ( Johnson & Johnson markets Imbruvica outside the U.S.) It also anticipates around $6 billion in revenue by 2025 for Venclexta.
Severino said there are two keys for Imbruvica to achieve AbbVie's goals. Moving into front-line treatment areas in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is one important pathway for sales growth. The other is expanding into new indications. For Venclextra, Severino said that "transitioning to a broader relapsed and refractory population [in treating CLL] will be an inflection point."
4. Operating margins
The company doesn't just expect to grow its top line -- it also projects impressive improvement in operating margins, from 42% of sales now to 50% by 2020. AbbVie CFO Bill Chase pointed to two ways the company will be able to hit this projection.
First, Chase said that AbbVie won't have to pay royalties on Humira beginning in 2018. Second, a combination of rapidly growing overall revenue and controlled spending that doesn't increase as fast will improve margins. Even with this spending discipline, though, Chase said that no one should interpret that as meaning AbbVie won't invest in new products.
5. Amazon
Amazon 's (NASDAQ: AMZN) hints at moving into the retail pharmacy business have stirred up much speculation in the industry. How might Amazon impact AbbVie? Not much, according to Gonzalez.
He noted that AbbVie is primarily focused on specialty drugs. Most of its products are distributed through specialty pharmacy channels rather than retail channels. Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business.
6. Tax reform
Bill Chase said that AbbVie is "pleased we're seeing positive progress" on U.S. tax reform. However, he acknowledged that a lot of uncertainties remain. Chase stated that "the No. 1 benefit for the company and the country" relates to repatriation of cash parked overseas.
Gonzalez added, though, that tax reform won't change AbbVie's priorities with capital allocation. He said that the company will continue to invest back into its business first in order to drive growth. AbbVie's second priority, according to Gonzalez, is to return cash to shareholders through dividends and stock buybacks.
7. Potential deals
AbbVie's primary areas of focus for potential deals -- either acquisitions of companies or licensing assets -- are in immunology and oncology. Gonzalez said that lupus and early psoriasis are two areas of high interest for the company. He also stated that AbbVie will invest in early-stage oncology assets.
Will AbbVie make a big acquisition anytime soon? Gonzalez said the company will begin looking at a long-term growth strategy that extends out more than 10 years in the future within the next year or two. He added that AbbVie will make decisions in the 2019 or 2020 time frame that could lead to "something of a more significant size."
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Amazon and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. It's a good time to be AbbVie (NYSE: ABBV) . And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. | Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. Potential deals AbbVie's primary areas of focus for potential deals -- either acquisitions of companies or licensing assets -- are in immunology and oncology. It's a good time to be AbbVie (NYSE: ABBV) . | Beyond Humira While AbbVie believes Humira will remain a big moneymaker for years to come, it's looking beyond Humira to the next generation of autoimmune-disease drugs. Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. Potential deals AbbVie's primary areas of focus for potential deals -- either acquisitions of companies or licensing assets -- are in immunology and oncology. | AbbVie CFO Bill Chase pointed to two ways the company will be able to hit this projection. AbbVie's second priority, according to Gonzalez, is to return cash to shareholders through dividends and stock buybacks. It's a good time to be AbbVie (NYSE: ABBV) . |
25857.0 | 2017-11-09 00:00:00 UTC | XLV, MRK, ABBV, AMGN: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-mrk-abbv-amgn-etf-outflow-alert-2017-11-09 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $106.2 million dollar outflow -- that's a 0.6% decrease week over week (from 213,315,324.0 to 212,015,324.0). Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.61. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $106.2 million dollar outflow -- that's a 0.6% decrease week over week (from 213,315,324.0 to 212,015,324.0). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.61. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $106.2 million dollar outflow -- that's a 0.6% decrease week over week (from 213,315,324.0 to 212,015,324.0). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.61. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $66.97 per share, with $84.31 as the 52 week high point - that compares with a last trade of $81.61. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
25858.0 | 2017-11-08 00:00:00 UTC | United Fire Group Inc Buys DowDuPont Inc, Nuveen Real Asset Income and Growth Fund, Brighthouse ... | ABBV | https://www.nasdaq.com/articles/united-fire-group-inc-buys-dowdupont-inc-nuveen-real-asset-income-and-growth-fund | nan | nan | United Fire Group Inc
New Purchases: DWDP , JRI , BHF ,
Reduced Positions:WFCPRL,
Sold Out:DRA, RBSPRHCL,
For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC
These are the top 5 holdings of UNITED FIRE GROUP INC
US Bancorp ( USB ) - 602,959 shares, 10.88% of the total portfolio.
Cincinnati Financial Corp ( CINF ) - 320,276 shares, 8.26% of the total portfolio.
AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio.
Boeing Co ( BA ) - 75,000 shares, 6.42% of the total portfolio.
Wintrust Financial Corp ( WTFC ) - 230,523 shares, 6.08% of the total portfolio.
New Purchase: DowDuPont Inc (DWDP)
United Fire Group Inc initiated holdings in DowDuPont Inc. The purchase prices were between $63.11 and $70.41, with an estimated average price of $65.88. The stock is now traded at around $71.14. The impact to the portfolio due to this purchase was 3.96%. The holdings were 170,000 shares as of 2017-09-30.
New Purchase: Nuveen Real Asset Income and Growth Fund (JRI)
United Fire Group Inc initiated holdings in Nuveen Real Asset Income and Growth Fund. The purchase prices were between $0 and $17.94, with an estimated average price of $1.42. The stock is now traded at around $17.90. The impact to the portfolio due to this purchase was 0.05%. The holdings were 8,769 shares as of 2017-09-30.
New Purchase: Brighthouse Financial Inc (BHF)
United Fire Group Inc initiated holdings in Brighthouse Financial Inc. The purchase prices were between $53 and $70, with an estimated average price of $59.98. The stock is now traded at around $56.95. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 163 shares as of 2017-09-30.
Sold Out: Diversified Real Asset Income Fund of Beneficial I (DRA)
United Fire Group Inc sold out the holdings in Diversified Real Asset Income Fund of Beneficial I. The sale prices were between $17.44 and $18.27, with an estimated average price of $17.86.
Sold Out: Royal Bank of Scotland Group (The) PLC (RBSPRHCL)
United Fire Group Inc sold out the holdings in Royal Bank of Scotland Group (The) PLC. The sale prices were between $25.28 and $26.9, with an estimated average price of $25.87.
Warning! GuruFocus has detected 6 Warning Sign with DWDP. Click here to check it out.
DWDP 15-Year Financial Data
The intrinsic value of DWDP
Peter Lynch Chart of DWDP
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. United Fire Group Inc New Purchases: DWDP , JRI , BHF , Reduced Positions:WFCPRL, Sold Out:DRA, RBSPRHCL, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These are the top 5 holdings of UNITED FIRE GROUP INC US Bancorp ( USB ) - 602,959 shares, 10.88% of the total portfolio. New Purchase: Nuveen Real Asset Income and Growth Fund (JRI) United Fire Group Inc initiated holdings in Nuveen Real Asset Income and Growth Fund. | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. New Purchase: Nuveen Real Asset Income and Growth Fund (JRI) United Fire Group Inc initiated holdings in Nuveen Real Asset Income and Growth Fund. Sold Out: Diversified Real Asset Income Fund of Beneficial I (DRA) United Fire Group Inc sold out the holdings in Diversified Real Asset Income Fund of Beneficial I. | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. United Fire Group Inc New Purchases: DWDP , JRI , BHF , Reduced Positions:WFCPRL, Sold Out:DRA, RBSPRHCL, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These are the top 5 holdings of UNITED FIRE GROUP INC US Bancorp ( USB ) - 602,959 shares, 10.88% of the total portfolio. New Purchase: Nuveen Real Asset Income and Growth Fund (JRI) United Fire Group Inc initiated holdings in Nuveen Real Asset Income and Growth Fund. | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. United Fire Group Inc New Purchases: DWDP , JRI , BHF , Reduced Positions:WFCPRL, Sold Out:DRA, RBSPRHCL, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These are the top 5 holdings of UNITED FIRE GROUP INC US Bancorp ( USB ) - 602,959 shares, 10.88% of the total portfolio. New Purchase: DowDuPont Inc (DWDP) United Fire Group Inc initiated holdings in DowDuPont Inc. |
25859.0 | 2017-11-07 00:00:00 UTC | Welch Group, LLC Buys Microsoft Corp, DowDuPont Inc, SPDR Select Sector Fund - Energy Select ... | ABBV | https://www.nasdaq.com/articles/welch-group-llc-buys-microsoft-corp-dowdupont-inc-spdr-select-sector-fund-energy-select | nan | nan | Welch Group, LLC
New Purchases: DWDP , XLE , OKE , EUFN,
Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA,
Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE,
Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM,
For the details of Welch Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Welch+Group%2C+LLC
These are the top 5 holdings of Welch Group, LLC
AbbVie Inc ( ABBV ) - 254,231 shares, 3.81% of the total portfolio. Shares reduced by 2.51%
Lockheed Martin Corp ( LMT ) - 64,672 shares, 3.39% of the total portfolio. Shares reduced by 3.11%
The Home Depot Inc ( HD ) - 120,130 shares, 3.32% of the total portfolio. Shares reduced by 1.09%
McDonald's Corp ( MCD ) - 123,234 shares, 3.26% of the total portfolio. Shares reduced by 4.4%
Johnson & Johnson ( JNJ ) - 143,401 shares, 3.15% of the total portfolio. Shares reduced by 4.27%
New Purchase: DowDuPont Inc (DWDP)
Welch Group, LLC initiated holdings in DowDuPont Inc. The purchase prices were between $63.11 and $70.41, with an estimated average price of $65.88. The stock is now traded at around $71.04. The impact to the portfolio due to this purchase was 0.26%. The holdings were 22,224 shares as of 2017-09-30.
New Purchase: SPDR Select Sector Fund - Energy Select Sector (XLE)
Welch Group, LLC initiated holdings in SPDR Select Sector Fund - Energy Select Sector. The purchase prices were between $62 and $68.49, with an estimated average price of $65.05. The stock is now traded at around $70.16. The impact to the portfolio due to this purchase was 0.06%. The holdings were 5,608 shares as of 2017-09-30.
New Purchase: ONEOK Inc (OKE)
Welch Group, LLC initiated holdings in ONEOK Inc. The purchase prices were between $50.36 and $56.88, with an estimated average price of $54.03. The stock is now traded at around $53.07. The impact to the portfolio due to this purchase was 0.05%. The holdings were 5,529 shares as of 2017-09-30.
New Purchase: iShares MSCI Europe Financials Sector Index Fund (EUFN)
Welch Group, LLC initiated holdings in iShares MSCI Europe Financials Sector Index Fund. The purchase prices were between $22.17 and $23.57, with an estimated average price of $22.85. The stock is now traded at around $22.71. The impact to the portfolio due to this purchase was 0.02%. The holdings were 4,426 shares as of 2017-09-30.
Added: Microsoft Corp (MSFT)
Welch Group, LLC added to the holdings in Microsoft Corp by 833.12%. The purchase prices were between $68.17 and $75.44, with an estimated average price of $72.96. The stock is now traded at around $84.05. The impact to the portfolio due to this purchase was 2.63%. The holdings were 235,025 shares as of 2017-09-30.
Added: Facebook Inc (FB)
Welch Group, LLC added to the holdings in Facebook Inc by 37.37%. The purchase prices were between $148.43 and $173.51, with an estimated average price of $166.52. The stock is now traded at around $180.25. The impact to the portfolio due to this purchase was 0.02%. The holdings were 2,191 shares as of 2017-09-30.
Added: NVIDIA Corp (NVDA)
Welch Group, LLC added to the holdings in NVIDIA Corp by 22.79%. The purchase prices were between $139.33 and $187.55, with an estimated average price of $165.66. The stock is now traded at around $211.55. The impact to the portfolio due to this purchase was 0.01%. The holdings were 1,433 shares as of 2017-09-30.
Sold Out: E.I. du Pont de Nemours & Co (DD)
Welch Group, LLC sold out the holdings in E.I. du Pont de Nemours & Co. The sale prices were between $80.81 and $85.49, with an estimated average price of $82.78.
Sold Out: Delphi Automotive PLC (DLPH)
Welch Group, LLC sold out the holdings in Delphi Automotive PLC. The sale prices were between $86.73 and $103.45, with an estimated average price of $94.29.
Sold Out: Franklin Street Properties Corp (FSP)
Welch Group, LLC sold out the holdings in Franklin Street Properties Corp. The sale prices were between $9.74 and $11.3, with an estimated average price of $10.32.
Sold Out: Amgen Inc (AMGN)
Welch Group, LLC sold out the holdings in Amgen Inc. The sale prices were between $167.29 and $191, with an estimated average price of $177.14.
Sold Out: Raytheon Co (RTN)
Welch Group, LLC sold out the holdings in Raytheon Co. The sale prices were between $162.57 and $186.58, with an estimated average price of $176.03.
Sold Out: International Paper Co (IP)
Welch Group, LLC sold out the holdings in International Paper Co. The sale prices were between $52.21 and $58.17, with an estimated average price of $55.54.
Warning! GuruFocus has detected 8 Warning Signs with MSFT. Click here to check it out.
MSFT 15-Year Financial Data
The intrinsic value of MSFT
Peter Lynch Chart of MSFT
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Welch+Group%2C+LLC These are the top 5 holdings of Welch Group, LLC AbbVie Inc ( ABBV ) - 254,231 shares, 3.81% of the total portfolio. New Purchase: iShares MSCI Europe Financials Sector Index Fund (EUFN) Welch Group, LLC initiated holdings in iShares MSCI Europe Financials Sector Index Fund. du Pont de Nemours & Co (DD) Welch Group, LLC sold out the holdings in E.I. | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Welch+Group%2C+LLC These are the top 5 holdings of Welch Group, LLC AbbVie Inc ( ABBV ) - 254,231 shares, 3.81% of the total portfolio. New Purchase: SPDR Select Sector Fund - Energy Select Sector (XLE) Welch Group, LLC initiated holdings in SPDR Select Sector Fund - Energy Select Sector. New Purchase: iShares MSCI Europe Financials Sector Index Fund (EUFN) Welch Group, LLC initiated holdings in iShares MSCI Europe Financials Sector Index Fund. | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Welch+Group%2C+LLC These are the top 5 holdings of Welch Group, LLC AbbVie Inc ( ABBV ) - 254,231 shares, 3.81% of the total portfolio. Shares reduced by 4.27% New Purchase: DowDuPont Inc (DWDP) Welch Group, LLC initiated holdings in DowDuPont Inc. New Purchase: SPDR Select Sector Fund - Energy Select Sector (XLE) Welch Group, LLC initiated holdings in SPDR Select Sector Fund - Energy Select Sector. | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Welch+Group%2C+LLC These are the top 5 holdings of Welch Group, LLC AbbVie Inc ( ABBV ) - 254,231 shares, 3.81% of the total portfolio. Shares reduced by 1.09% McDonald's Corp ( MCD ) - 123,234 shares, 3.26% of the total portfolio. du Pont de Nemours & Co (DD) Welch Group, LLC sold out the holdings in E.I. |
25860.0 | 2017-11-07 00:00:00 UTC | Stocks To Watch: Zoetis Sees RS Rating Rise To 82 | ABBV | https://www.nasdaq.com/articles/stocks-watch-zoetis-sees-rs-rating-rise-82-2017-11-07 | nan | nan | Zoetis ( ZTS ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 79 to 82.
[ibd-display-video id=2102289 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 as they begin their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Zoetis has risen more than 5% past a 63.95 entry in a first-stage flat base , meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Earnings grew 25% last quarter, up from 8% in the prior report. Revenue also increased, from 5% to 9%.
Zoetis earns the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ) is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ) is the No. Zoetis ( ZTS ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 79 to 82. [ibd-display-video id=2102289 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks share price action with a 1 (worst) to 99 (best) score. | AbbVie ( ABBV ) is the No. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ) is the No. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ) is the No. Zoetis earns the No. 1-ranked stock within the group. |
25861.0 | 2017-11-06 00:00:00 UTC | 5 Dividend Aristocrats With the Fastest-Growing Dividends | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-fastest-growing-dividends-2017-11-06 | nan | nan | Many investors like to buy stocks that are known as Dividend Aristocrats. To join this elite group, an S&P 500 company must increase its dividend for at least 25 consecutive years. But just how much those companies increase their dividends varies greatly. Some gain inclusion on the list of Dividend Aristocrats by making only small dividend hikes.
That's not the case for all of the stocks, though. VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. But are these five Dividend Aristocrats with the fastest-growing dividends good picks for income-seeking investors now?
VF Corp.
Clothing maker VF Corp. has raised its dividend for 44 straight years. Over the past three years, the company's dividend has increased by nearly 44%, making VF Corp. the No. 5 Dividend Aristocrat in terms of fastest dividend growth. Its yield currently stands at 2.64%.
The clothing business is highly competitive. VF Corp. has been able to hold its own through the years thanks to well-known brands like Lee, Nautica, The North Face, Timberland, and Wrangler. However, both sales and earnings have declined in recent quarters as traditional retail outlets like malls have encountered challenges from internet retailers. VF Corp. is attempting to navigate the changing retail dynamics by beefing up its own direct-to-consumer channels.
In the meantime, the dividend appears to be solid. The company uses only 60% of earnings to fund the dividend program, which should mean VF's streak of dividend hikes will continue.
AbbVie
Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the company was part of parent Abbott Labs during the period prior to 2013. AbbVie has raised its dividend nearly 45% in the last three years, bumping its yield up to 3.07%.
AbbVie should be in great position to keep those dividend hikes coming. The drugmaker uses less than 60% of earnings to pay out dividends -- and those earnings are expected to grow by nearly 16% annually over the next few years.
The company's dividend isn't the only thing going for it, though. AbbVie stock has soared more than 45% so far in 2017. Its top drug Humira continues to enjoy strong sales growth. AbbVie and partner Johnson & Johnson lay claim to one of the fastest-rising cancer drugs with Imbruvica. The company also boasts one of the top drug pipelines in the biopharmaceutical industry.
Medtronic
Medical device maker Medtronic has increased its dividend for 40 consecutive years. Over the last three of those years, the company's dividend has risen by nearly 51%. Medtronic's dividend currently yields 2.29%.
Investors don't have any reason to worry about Medtronic's ability to increase dividends in the future. The company's payout ratio is less than 59%. Medtronic also generates strong cash flow that should allow it to keep paying out and raising dividends down the road.
Aside from its dividend, there are a couple of reasons for investors to like Medtronic. One is its moat. The company makes a wide range of medical devices that physicians and hospitals rely on. Despite plenty of competition, Medtronic should remain a leader in the medical device industry. Also, aging demographics in the U.S. and elsewhere should increase demand for the products made by Medtronic.
Illinois Tool Works
Illinois Tool Works' dividend has gone up every year for the past 43 years. And the specialized equipment maker's dividend payout has gone up a lot during the past three years -- nearly 61%. The company's yield now stands just over 2%.
Not only does Illinois Tool Works rank No. 2 among Dividend Aristocrats for recent dividend growth, it also has the second-best payout ratio. The company uses a little under 42% of its earnings to fund the dividend program, indicating plenty of flexibility for future dividend hikes.
Even better for investors, Illinois Tool Works stock's gains have outperformed all of the other four Dividend Aristocrats on our list over the past three years. The company has benefited from good economic conditions that drove higher demand for the machinery it manufacturers. There is a cyclical nature to Illinois Tool Works' business, which means the stock could feel the brunt of an economic downturn more than many other stocks do. Over the long run, though, it should be a solid pick for income investors.
Lowe's Companies
The Dividend Aristocrat with the fastest-growing dividend of all is Lowe's. The home-improvement retailer boasts a 55-year streak of annual dividend increases. And over the past three years, Lowe's has boosted its divided by a whopping 78%. Its dividend currently yields a little over 2%.
In addition to taking the top spot in dividend growth, Lowe's also claims the lowest payout ratio of the group. The retailer uses only 41% of earnings to pay dividends. Lowe's impressive track record of dividend hikes doesn't appear to be in any jeopardy.
Lowe's stock tends to drop on any hint of problems with housing. For example, the stock fell after the GOP released its tax plan, which includes a lower cap on mortgage interest deductions. Lowe's also hasn't fared as well as its archrival Home Depot . However, the stock still appears to be a good choice for long-term investors looking for solid dividends.
10 stocks we like better than Lowe's
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Lowe's wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool owns shares of Medtronic and has the following options: long January 2018 $170 calls on Home Depot and long January 2020 $110 calls on Home Depot. The Motley Fool recommends Home Depot and Lowe's. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the company was part of parent Abbott Labs during the period prior to 2013. AbbVie has raised its dividend nearly 45% in the last three years, bumping its yield up to 3.07%. | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the company was part of parent Abbott Labs during the period prior to 2013. AbbVie has raised its dividend nearly 45% in the last three years, bumping its yield up to 3.07%. | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the company was part of parent Abbott Labs during the period prior to 2013. AbbVie has raised its dividend nearly 45% in the last three years, bumping its yield up to 3.07%. | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the company was part of parent Abbott Labs during the period prior to 2013. AbbVie has raised its dividend nearly 45% in the last three years, bumping its yield up to 3.07%. |
25862.0 | 2017-11-04 00:00:00 UTC | These 3 Stocks Just Raised Their Dividends | ABBV | https://www.nasdaq.com/articles/these-3-stocks-just-raised-their-dividends-2017-11-04 | nan | nan | Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that's expected, given that we're in the swing of the fall earnings season. Still, the table was almost overflowing with goodies.
It was nearly impossible to choose only three appetizing raisers from this selection; I went with tradition, selecting a trio of Dividend Aristocrats (stocks that have lifted their payouts at least once every year for at least 25 years running). These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) .
VF Corporation
VF Corporation, the conglomerate behind such noted apparel and accessories brands as The North Face, Vans, and Timberland, is lifting its quarterly distribution by 10% to $0.46 per share.
Concurrent with the announcement of the raise, the company released third-quarter figures that saw modest but encouraging gains in total revenue (up 5% on a year-over-year basis) and adjusted earnings (3% higher). The improvements were due to sales gains in the outdoor and action sports, and workwear segments of its business, not to mention the always-edgy Vans footwear line.
This forward momentum should continue. VF upped its net profit guidance for this fiscal year by $0.05 per share to $3.01. If achieved, that amount would represent an 8% improvement over the 2016 result; meanwhile, the company is anticipating revenue growth of 6% for the year.
Lately, VF's spending on its share buyback program and its dividend payouts have exceeded free cash flow. Although this has become fairly standard practice, and as such the company will probably figure out a way to keep that dividend growing, investors should keep a wary eye on those line items going forward.
VFC Free Cash Flow (TTM) data by YCharts
VF's next dividend will be paid on Dec. 18 to investors of record as of Dec. 8. The payout ratio on it, when matched with the company's Q3 earnings per share (EPS), would be 37%, while the yield would be 2.6%. The latter compares favorably to the current 1.9% average of dividend-paying stocks on the S&P 500.
Aflac
Supplemental insurance provider Aflac (NYSE: AFL) , noted for its duck mascot as well as its reliable dividend payments , is about to quack out the latest in a lengthening series of distribution raises. The company announced a nearly 5% increase in its quarterly payout to $0.45 per share.
AFL Dividend data by YCharts
Yet not every key number for Aflac has been on the rise. In the insurer's Q3, total revenue slipped by 4% (to just over $5.5 billion), although much of this could be ascribed to unfavorable exchange rates -- the company has a thriving business in Japan. On the plus side, net profit saw a 14% rise to $716 million and beat the average analyst estimate.
A retrenchment in the Japanese business, combined with steady growth in the U.S., should help Aflac improve that top-line figure while remaining well in the black. The company's total dividend payout is relatively small compared to its free cash flow; I see no reason why that should change dramatically in the near future, so I'd rate the company's chances to maintain its Aristocrat status as extremely likely.
Aflac will hand out its upcoming dividend on Dec. 1 to shareholders of record as of Nov. 15. At the most recent closing stock price, its yield would be 2.1%. The payout ratio on the new dividend comes in at a very light 25% using the Q3 EPS figure.
AbbVie
Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. This year's raise clocks in at 11%, which amounts to $0.71 per share.
AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. Its top drugs -- autoimmune disease treatment Humira and cancer fighter Imbruvica, in particular -- showed strong sales growth in the company's Q3. This helped power revenue almost 9% higher (to just under $7 billion) while boosting adjusted per-share earnings by nearly 17% to $2.27 billion, or $1.41 per share.
ABBV Net Income (TTM) data by YCharts
This is giving AbbVie the confidence to predict robust future growth. The company lifted its guidance for 2017 adjusted net income, boosting it to $5.53 to $5.55 per share from the previous expectation of $5.44 to $5.54. Better, it believes that figure will rise substantially in fiscal 2018, coming in at $6.37 to $6.57, due in no small part to higher Humira sales.
The company is a very assertive buyer of its own stock; last year it spent over $6 billion on the activity, which swallowed nearly all its free cash flow. That's been a pattern lately. So although times are good and the future looks bright for AbbVie, its spendthrift ways are concerning.
The upcoming AbbVie dividend is to be dispensed on Feb. 15 next year, to stockholders of record as of Jan. 12. It yields a theoretical 3.1%, while its payout ratio is 50%.
More where that came from
We're nearly out of the final earnings season of 2017, so the recent high-number of dividend raise announcements will probably fall. Nevertheless, it's been a great year for hikes from optimistic companies; given that, we'll probably witness many more before the ball drops on New Year's Eve.
10 stocks we like better than Aflac
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Aflac wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Aflac. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. | These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. | These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. | AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. |
25863.0 | 2017-11-03 00:00:00 UTC | Vertex Pops As Analyst Questions Whether Rival Has 'Viable Drug' | ABBV | https://www.nasdaq.com/articles/vertex-pops-analyst-questions-whether-rival-has-viable-drug-2017-11-03 | nan | nan | Vertex Pharmaceuticals ( VRTX ) and Galapagos ( GLPG ) stocks diverged Friday as one analyst suggested that while Galapagos has an interesting molecular formula, it may not have a viable cystic fibrosis drug on its hands.
[ibd-display-video id=2499417 width=50 float=left autostart=true]By the closing bell on the stock market today , Vertex popped 3.5% to finish at 149.97, as Galapagos fell 2.7%, to close at 97.09. The biotechs made presentations Friday during the North American Cystic Fibrosis Conference in Indianapolis.
"Galapagos has well-researched molecules that have intriguing activity in a variety of laboratory systems and molecular models for cystic fibrosis, but so far it is difficult to know if these molecules will actually make viable drugs," Leerink analyst Geoffrey Porges said in a note to clients.
Both biotechs are working on triple-pill combinations to treat the genetic lung condition. Analysts mostly estimate Galapagos is several years behind Vertex, which already has four potential triple-pill combinations in midstage testing.
To catch up, Galapagos appears to be compressing and "attempting to outright skip over" many of the traditional aspects of clinical testing. That has raised some questions for investors, Porges said.
"Given their lack of progress with their combinations in the U.S., we don't foresee the sort of rapid development timeline for Galapagos' combinations in the U.S. that they are proposing and planning for Europe," he said.
IBD'S TAKE:At one point, Vertex looked like it was going to go bust as it worked to pivot to cystic fibrosis after its hepatitis C drug tanked. Visit The New America for more on Vertex's transition and what's next.
During its presentation, Galapagos indicated it plans to introduce molecules via single-drug and add-on studies first, and then advance into novel triple-combination trials very rapidly, Porges said. The goal is seemingly to avoid traditional Phase 2 trials.
But the Food and Drug Administration hasn't endorsed that strategy.
"This means that all the current and soon-to-start trials of the Galapagos combinations will be conducted only in Europe," he said.
Still, Galapagos is aiming to advance their combination to Phase 3 testing in 2019. AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie has to fund and execute the Phase 3 trials.
AbbVie would likely prefer a more traditional and complete path to expensive Phase 3 testing, he said. Before that, AbbVie will have to decide whether to opt in or out of the deal.
"Should AbbVie discontinue, or delay a decision about going forward, this would be viewed negatively for Galapagos and positively for Vertex," he said. "Such a decision doesn't seem imminent, which is fortunate for Galapagos, but will make for challenging times for Galapagos if AbbVie opts out, or doesn't advance any of the combinations."
Porges has an outperform rating and 179 price target on Vertex stock.
RELATED:
Three Biotech Firms Top Third-Quarter Views - But Only One Pops
Ionis Rebounds After Beating Alnylam To Drug Application In Europe
Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie has to fund and execute the Phase 3 trials. AbbVie would likely prefer a more traditional and complete path to expensive Phase 3 testing, he said. | AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie has to fund and execute the Phase 3 trials. AbbVie would likely prefer a more traditional and complete path to expensive Phase 3 testing, he said. | "Such a decision doesn't seem imminent, which is fortunate for Galapagos, but will make for challenging times for Galapagos if AbbVie opts out, or doesn't advance any of the combinations." AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie has to fund and execute the Phase 3 trials. | "Such a decision doesn't seem imminent, which is fortunate for Galapagos, but will make for challenging times for Galapagos if AbbVie opts out, or doesn't advance any of the combinations." AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie has to fund and execute the Phase 3 trials. |
25864.0 | 2017-11-02 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-union-pacific-bristol-myers-weyerhaeuser-and | nan | nan | For Immediate Release
Chicago, IL - November 2, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVieABBV , Union PacificUNP , Bristol-MyersBMY , WeyerhaeuserWY and ColgateCL .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday's Analyst Blog:
Top Stock Reports for AbbVie, Union Pacific and Bristol Myers
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie, Union Pacific and Bristol-Myers. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
AbbVie 's shares have gained +44.1% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +14.6% over the same period. AbbVie reported mixed Q3 results. While earnings beat estimates, revenues came in line. Humira and Imbruvica kept up the strong performance.
Meanwhile, AbbVie raised its earnings outlook for the year backed by a strong year-to-date performance. Despite new competition, it raised its long-term target for Humira sales based on strong demand trends for the drug.
The Zacks analyst stresses that the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies, gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen.
Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition.
(You can read the full research report on AbbVie here >>> ) .
Shares of Buy-rated Union Pacific have outperformed the Zacks Rail Transportation Industry as well as fellow railroad operator Kansas City Southern over the last three months. While the company has gained +13.1%, the industry in belongs to and Kansas City Southern have rallied +8.3% and +2.1%, respectively, so far this year.
Ushering in further good news, Union Pacific reported better-than-expected earnings per share and revenues in the third quarter of 2017. Results were aided by strong performances of the company's intermodal and industrial products units.
The Zacks analyst is impressed by the company's efforts to cut costs to drive its bottom line as well. Efforts to reward investors also raise optimism in the stock. However, declining coal revenues in the third quarter raise concerns. Automotive volumes also decreased due to sluggish vehicle production in the United States.
(You can read the full research report on Union Pacific here >>> ) .
Strong Buy-rated Bristol-Myers shares have underperformed the broader market as well as the Zacks Large Cap Pharmaceuticals industry this year, gaining only +5.5% in the year-to-date period. Bristol-Myers reported mixed results for the third-quarter with earnings missed expectations although revenue beat on the same. The miss in earnings was attributable to lower gross margin which in turn was due to product mix and decline in virology business.
The Zacks analyst thinks the increase in earnings guidance is encouraging. The company's blockbuster immuno-oncology Opdivo continues to perform well along with Eliquis and Orencia. The company is looking to expand Opdivo's label further and recently won FDA approvals for liver and colorectal cancers which should boost performance.
The company is also looking to counter generic threat for its key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie and Halozyme. However, Opdivo is currently facing competitive challenges in the United States. The virology business is also under pressure.
(You can read the full research report on Bristol-Myers here >>> ) .
Other noteworthy reports we are featuring today include Weyerhaeuser and Colgate.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Union Pacific Corporation (UNP): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Weyerhaeuser Company (WY): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include AbbVieABBV , Union PacificUNP , Bristol-MyersBMY , WeyerhaeuserWY and ColgateCL . Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for AbbVie, Union Pacific and Bristol Myers The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie, Union Pacific and Bristol-Myers. | Today's Research Daily features new research reports on 16 major stocks, including AbbVie, Union Pacific and Bristol-Myers. You can see all of today's research reports here >>> AbbVie 's shares have gained +44.1% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +14.6% over the same period. Click to get this free report Union Pacific Corporation (UNP): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Weyerhaeuser Company (WY): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for AbbVie, Union Pacific and Bristol Myers The Zacks Research Daily presents the best research output of our analyst team. You can see all of today's research reports here >>> AbbVie 's shares have gained +44.1% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +14.6% over the same period. Click to get this free report Union Pacific Corporation (UNP): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Weyerhaeuser Company (WY): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for AbbVie, Union Pacific and Bristol Myers The Zacks Research Daily presents the best research output of our analyst team. You can see all of today's research reports here >>> AbbVie 's shares have gained +44.1% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +14.6% over the same period. Stocks recently featured in the blog include AbbVieABBV , Union PacificUNP , Bristol-MyersBMY , WeyerhaeuserWY and ColgateCL . |
25865.0 | 2017-11-01 00:00:00 UTC | Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-amgen-gilead-hit-q3-results-vertex-beats-all-fronts-2017-11 | nan | nan | Major biotech companies reported earnings results over the last five trading days. While companies like Amgen AMGN and Vertex VRTX topped expectations, it was a mixed quarter for companies like Celgene CELG , Alexion (Read more: Alexion Tops Q3 Earnings, Lags Sales, 2017 View Up ) and BioMarin (Read more: BioMarin Q3 Loss Narrows, Profit Guidance Raised ).
Recap of the Week's Most Important Stories
A Look at Earnings Results: It was all about earnings this week with several key names reporting third quarter results. Amgen topped expectations but witnessed a year-over-year decline in revenue. The company also announced that it will not be developing its oral CETP inhibitor, AMG 899, and is exploring out-licensing opportunities for the candidate (Read more: Amgen Q3 Earnings Top, Sales Decline Y/Y, Stock Falls ). Meanwhile, Celgene plunged 16.4% following the release of third quarter results - although Celgene topped earnings estimates, revenues fell short. Moreover, the company lowered its 2017 outlook for Otezla sales as well as its total revenue and earnings outlook for 2020 reflecting the impact of the discontinuation of GED-0301 for Crohn's disease, the market dynamics impacting Otezla, and the opportunities and risks associated with the late-stage data read-outs scheduled for 2018 (Read more: Celgene Tops Q3 Earnings, Sales Miss, Updates View ).
Vertex, which has a strong presence in the cystic fibrosis ("CF") market, reported a strong quarter with earnings and revenues surpassing expectations. The company also raised its guidance for CF franchise sales (Read more: Vertex Beats on Q3 Earnings & Sales, Raises 2017 View ). Vertex has gained 98.5% year to date, outperforming the industry's 3.3% rally.
AbbVie ABBV topped earnings estimates while revenues were in-line (Read more: AbbVie Q3 Earnings Top, Revenues In Line, View Up ). Gilead surpassed expectations but the company's hepatitis C virus ("HCV") franchise remains under immense pressure (Read more: Gilead Down on Weak HCV Sales Despite Q3 Earnings Beat ).
Incyte's Epacadostat to be Studied in Early Lung Cancer with Imfinzi: Incyte Corporation INCY reported strong third quarter results and also announced the expansion of its clinical trial collaboration with AstraZeneca. The companies said that they will evaluate the efficacy and safety of Incyte's investigational selective IDO1 enzyme inhibitor, epacadostat, in combination with AstraZeneca's PD-L1 inhibitor, Imfinzi, compared to Imfinzi alone.
The companies will conduct a late-stage study in patients with locally-advanced (stage III), unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy ("CRT"). The study, which will be co-funded by the companies, will be conducted by AstraZeneca with patient enrolment scheduled to commence in the first half of 2018.
We note that Incyte has a clinical trial collaboration with Merck as well as Bristol-Myers Squibb for epacadostat. Incyte is a Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
Voyager Down as Sanofi Exits Parkinson's Disease Program: Voyager Therapeutics, Inc.'s VYGR shares were down 7.4% on Sanofi's exit from the company's VY-AADC program for advanced Parkinson's disease. Under the deal, signed in February 2015, Sanofi had an exclusive option for ex-U.S. development and commercial rights to VY-AADC. The deal terms included upfront payments of $100 million as well as future potential development and sales milestone payments of up to $745 million, plus tiered royalties on product sales.
According to Voyager, Sanofi decided to exit the deal as the option did not include rights in the United States. With Voyager gaining global rights to the VY-AADC program for advanced Parkinson's disease, the company said that it remains on track to dose the first patient during the second quarter of 2018.
GW Finishes Rolling Drug Submission for Epilepsy Drug: GW Pharmaceuticals plc GWPH announced that it has completed the rolling submission of a New Drug Application ("NDA") in the United States for Epidiolex (cannabidiol) as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome ("LGS") and Dravet syndrome. LGS and Dravet syndrome are two highly treatment-resistant forms of childhood-onset epilepsy and GW has Rare Pediatric Disease and Orphan Drug designations for both indications in the United States. The Dravet syndrome indication has fast track status as well from the FDA. Timely approval would allow the company to launch the product in 2018.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index declined 3.3% over the last five trading sessions. Among major biotech stocks, Celgene lost 16.1% reflecting a sell-off following the release of third quarter results while Alexion was down 12.4%. Over the last six months, Vertex was up 23.6% while Celgene was down 18.6% (See the last biotech stock roundup here: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod ).
What's Next in the Biotech World?
Focus will remain on earnings results from several mid- and small-cap biotech companies.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Incyte Corporation (INCY): Free Stock Analysis Report
Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ABBV topped earnings estimates while revenues were in-line (Read more: AbbVie Q3 Earnings Top, Revenues In Line, View Up ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report To read this article on Zacks.com click here. The company also announced that it will not be developing its oral CETP inhibitor, AMG 899, and is exploring out-licensing opportunities for the candidate (Read more: Amgen Q3 Earnings Top, Sales Decline Y/Y, Stock Falls ). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV topped earnings estimates while revenues were in-line (Read more: AbbVie Q3 Earnings Top, Revenues In Line, View Up ). While companies like Amgen AMGN and Vertex VRTX topped expectations, it was a mixed quarter for companies like Celgene CELG , Alexion (Read more: Alexion Tops Q3 Earnings, Lags Sales, 2017 View Up ) and BioMarin (Read more: BioMarin Q3 Loss Narrows, Profit Guidance Raised ). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV topped earnings estimates while revenues were in-line (Read more: AbbVie Q3 Earnings Top, Revenues In Line, View Up ). While companies like Amgen AMGN and Vertex VRTX topped expectations, it was a mixed quarter for companies like Celgene CELG , Alexion (Read more: Alexion Tops Q3 Earnings, Lags Sales, 2017 View Up ) and BioMarin (Read more: BioMarin Q3 Loss Narrows, Profit Guidance Raised ). | AbbVie ABBV topped earnings estimates while revenues were in-line (Read more: AbbVie Q3 Earnings Top, Revenues In Line, View Up ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report To read this article on Zacks.com click here. Major biotech companies reported earnings results over the last five trading days. |
25866.0 | 2017-11-01 00:00:00 UTC | If I Could Buy Only 1 Stock, This Would Be It | ABBV | https://www.nasdaq.com/articles/if-i-could-buy-only-1-stock-would-be-it-2017-11-01 | nan | nan | What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.
Second, I like dividends. The total return of a given stock includes both share-price appreciation and dividend reinvestment. When you have both, it's a wonderful thing. Finally, like most investors, I like getting a bargain.
The problem is that all three of these attributes can be hard to find in one stock. But it's not an impossible task. There's at least one alternative on the market that is a growth stock, a dividend stock, and a value stock all rolled into one. If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it.
Growth
We can only look back over the past five years to see how well AbbVie stock has performed. That's because the biotech wasn't traded as an independent entity until 2013, after being spun off from parent Abbott Labs (NYSE: ABT) . But during those five years, AbbVie stock has nearly doubled the gains posted by the S&P 500 Index .
Can AbbVie continue its winning ways? I think so. The company appears to be poised for strong earnings growth. Wall Street analysts, for example, project that AbbVie will increase its earnings by more than 14% annually over the next five years.
AbbVie should be able to achieve this level of growth thanks, in large part, to its solid current product lineup. Humira, the top-selling drug in the world, continues to generate impressive sales growth. Worries that AbbVie could face major competition in the U.S. have been largely alleviated after the company struck a deal recently with Amgen . Under the terms of the deal, Amjevita, Amgen's biosimilar to Humira, won't be marketed in the U.S. until early 2023. In addition, AbbVie will get royalties on all sales of Amjevita.
Cancer drug Imbruvica is also gaining momentum. In the third quarter , AbbVie reported sales for the drug totaling $626 million, a 42.5% year-over-year increase. Imbruvica is on track to generate more than $2.3 billion in revenue this year. Market research firm EvaluatePharma projects the drug will rake in $7.5 billion by 2022. However, AbbVie will split this revenue with its partner, Johnson & Johnson (NYSE: JNJ) .
The company has a couple of promising newer products that have already won approval. The U.S. Food and Drug Administration (FDA) gave a thumbs-up in April for Venclexta in treating patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion.
AbbVie and Roche are also evaluating Venclexta in clinical studies for several other indications. The FDA approved hepatitis C virus (HCV) drug Mavyret in August. Both drugs could become blockbusters.
AbbVie's pipeline also looks great. In the autoimmune-disease therapeutic category, upadacitinib and risankizumab are two promising late-stage assets. Turning to oncology, AbbVie has Rova-T and veliparib. Elagolix could be another potential blockbuster in treating endometriosis and uterine fibroids.
Dividend
There aren't many healthcare stocks with more attractive dividends than AbbVie. Its dividend yield currently stands at 3.09%. And that's lower than it's been for most of the last few years, because AbbVie stock has performed so well.
Because of its connection with Abbott Labs, AbbVie boasts an impressive track record of increasing its dividend for 45 consecutive years. That includes growing its dividend by nearly 90% over the last five years, even faster than its parent company has increased its dividend.
AbbVie just announced its latest dividend hike a few days ago. The company appears to be in solid shape to keep the dividend increases coming. AbbVie uses less than 60% of earnings to fund the dividend program. And both earnings and cash flow continue to grow.
Value
You may think that AbbVie, with its excellent growth prospects and mouth-watering dividend, might be priced for perfection. It's not.
The stock currently trades at less than 14 times expected earnings. That's less expensive than several peers with lower growth opportunities and dividend yields. Johnson & Johnson stock, for example, trades at nearly 18 times expected earnings, but Wall Street projects annual earnings growth of around 7%. J&J's dividend yield of 2.37% is also well below AbbVie's.
Some risks
AbbVie isn't without some risks. Humira will face biosimilar competition in Europe beginning in 2018. There's always the possibility that one or more of the company's pipeline candidates could flop.
I'm not too concerned, though. Two-thirds of Humira's sales are made in the U.S. Johnson & Johnson's experience with biosimilar threats to its blockbuster autoimmune-disease drug Remicade hasn't been overly negative so far.
AbbVie probably won't have an immediate revenue cliff when biosimilars to Humira hit the market, either. Although the pipeline risk is real, AbbVie appears to have several solid candidates that should be able to advance to approval.
There's no such thing as a perfect stock. But for investors who, like me, seek growth, dividends, and value, AbbVie checks off the boxes really well.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Worries that AbbVie could face major competition in the U.S. have been largely alleviated after the company struck a deal recently with Amgen . Because of its connection with Abbott Labs, AbbVie boasts an impressive track record of increasing its dividend for 45 consecutive years. If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it. | Because of its connection with Abbott Labs, AbbVie boasts an impressive track record of increasing its dividend for 45 consecutive years. If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it. Growth We can only look back over the past five years to see how well AbbVie stock has performed. | Dividend There aren't many healthcare stocks with more attractive dividends than AbbVie. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it. | If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it. Growth We can only look back over the past five years to see how well AbbVie stock has performed. But during those five years, AbbVie stock has nearly doubled the gains posted by the S&P 500 Index . |
25867.0 | 2017-11-01 00:00:00 UTC | SFE Investment Counsel Buys ONEOK Inc, Amazon. ... | ABBV | https://www.nasdaq.com/articles/sfe-investment-counsel-buys-oneok-inc-amazon-2017-11-01 | nan | nan | SFE Investment Counsel
New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS,
Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI,
Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO,
Sold Out:BBBY, NWL, NAO,
For the details of SFE Investment Counsel's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SFE+Investment+Counsel
These are the top 5 holdings of SFE Investment Counsel
Apple Inc ( AAPL ) - 56,871 shares, 4.21% of the total portfolio. Shares reduced by 9.38%
Thor Industries Inc ( THO ) - 61,693 shares, 3.73% of the total portfolio. Shares reduced by 8.46%
AbbVie Inc ( ABBV ) - 81,166 shares, 3.47% of the total portfolio. Shares reduced by 12.56%
Deluxe Corp ( DLX ) - 96,132 shares, 3.37% of the total portfolio. Shares reduced by 1.65%
Qualcomm Inc ( QCOM ) - 130,893 shares, 3.26% of the total portfolio. Shares reduced by 2.33%
New Purchase: Amazon.com Inc (AMZN)
SFE Investment Counsel initiated holdings in Amazon.com Inc. The purchase prices were between $938.6 and $1052.8, with an estimated average price of $981.92. The stock is now traded at around $1100.84. The impact to the portfolio due to this purchase was 0.69%. The holdings were 1,501 shares as of 2017-09-30.
New Purchase: Sociedad Quimica Y Minera De Chile SA (SQM)
SFE Investment Counsel initiated holdings in Sociedad Quimica Y Minera De Chile SA. The purchase prices were between $33.58 and $61.95, with an estimated average price of $44.78. The stock is now traded at around $61.61. The impact to the portfolio due to this purchase was 0.49%. The holdings were 18,319 shares as of 2017-09-30.
New Purchase: Guggenheim S&P 500 Equal Weight Technology (RYT)
SFE Investment Counsel initiated holdings in Guggenheim S&P 500 Equal Weight Technology. The purchase prices were between $123.87 and $135.03, with an estimated average price of $130.24. The stock is now traded at around $141.79. The impact to the portfolio due to this purchase was 0.22%. The holdings were 3,450 shares as of 2017-09-30.
New Purchase: Microchip Technology Inc (MCHP)
SFE Investment Counsel initiated holdings in Microchip Technology Inc. The purchase prices were between $75.81 and $91.01, with an estimated average price of $83.62. The stock is now traded at around $93.01. The impact to the portfolio due to this purchase was 0.17%. The holdings were 3,929 shares as of 2017-09-30.
New Purchase: DineEquity Inc (DIN)
SFE Investment Counsel initiated holdings in DineEquity Inc. The purchase prices were between $37.29 and $44.83, with an estimated average price of $40.9. The stock is now traded at around $47.16. The impact to the portfolio due to this purchase was 0.14%. The holdings were 6,831 shares as of 2017-09-30.
New Purchase: Bristol-Myers Squibb Company (BMY)
SFE Investment Counsel initiated holdings in Bristol-Myers Squibb Company. The purchase prices were between $54.24 and $63.74, with an estimated average price of $58.38. The stock is now traded at around $62.12. The impact to the portfolio due to this purchase was 0.12%. The holdings were 3,815 shares as of 2017-09-30.
Added: ONEOK Inc (OKE)
SFE Investment Counsel added to the holdings in ONEOK Inc by 754.35%. The purchase prices were between $50.36 and $56.88, with an estimated average price of $54.03. The stock is now traded at around $54.18. The impact to the portfolio due to this purchase was 1.24%. The holdings were 52,628 shares as of 2017-09-30.
Added: FedEx Corp (FDX)
SFE Investment Counsel added to the holdings in FedEx Corp by 338.68%. The purchase prices were between $203.55 and $225.58, with an estimated average price of $213.01. The stock is now traded at around $225.67. The impact to the portfolio due to this purchase was 0.61%. The holdings were 7,304 shares as of 2017-09-30.
Added: SPDR S&P Bank (KBE)
SFE Investment Counsel added to the holdings in SPDR S&P Bank by 38.86%. The purchase prices were between $39.81 and $45.09, with an estimated average price of $42.88. The stock is now traded at around $45.55. The impact to the portfolio due to this purchase was 0.25%. The holdings were 40,825 shares as of 2017-09-30.
Added: Alphabet Inc (GOOG)
SFE Investment Counsel added to the holdings in Alphabet Inc by 43.62%. The purchase prices were between $898.7 and $980.34, with an estimated average price of $930.63. The stock is now traded at around $1024.81. The impact to the portfolio due to this purchase was 0.25%. The holdings were 1,768 shares as of 2017-09-30.
Added: Texas Instruments Inc (TXN)
SFE Investment Counsel added to the holdings in Texas Instruments Inc by 138.43%. The purchase prices were between $76.41 and $89.65, with an estimated average price of $82.03. The stock is now traded at around $96.04. The impact to the portfolio due to this purchase was 0.23%. The holdings were 8,965 shares as of 2017-09-30.
Added: MKS Instruments Inc (MKSI)
SFE Investment Counsel added to the holdings in MKS Instruments Inc by 49.91%. The purchase prices were between $67.3 and $94.05, with an estimated average price of $81.33. The stock is now traded at around $104.35. The impact to the portfolio due to this purchase was 0.16%. The holdings were 10,378 shares as of 2017-09-30.
Sold Out: Bed Bath & Beyond Inc (BBBY)
SFE Investment Counsel sold out the holdings in Bed Bath & Beyond Inc. The sale prices were between $22.25 and $31.15, with an estimated average price of $28.06.
Sold Out: Newell Brands Inc (NWL)
SFE Investment Counsel sold out the holdings in Newell Brands Inc. The sale prices were between $40.96 and $53.9, with an estimated average price of $48.97.
Sold Out: Nordic American Offshore Ltd (NAO)
SFE Investment Counsel sold out the holdings in Nordic American Offshore Ltd. The sale prices were between $1.14 and $1.52, with an estimated average price of $1.28.
Warning! GuruFocus has detected 4 Warning Signs with OKE. Click here to check it out.
OKE 15-Year Financial Data
The intrinsic value of OKE
Peter Lynch Chart of OKE
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SFE+Investment+Counsel These are the top 5 holdings of SFE Investment Counsel Apple Inc ( AAPL ) - 56,871 shares, 4.21% of the total portfolio. Shares reduced by 8.46% AbbVie Inc ( ABBV ) - 81,166 shares, 3.47% of the total portfolio. Shares reduced by 2.33% New Purchase: Amazon.com Inc (AMZN) SFE Investment Counsel initiated holdings in Amazon.com Inc. | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SFE+Investment+Counsel These are the top 5 holdings of SFE Investment Counsel Apple Inc ( AAPL ) - 56,871 shares, 4.21% of the total portfolio. Shares reduced by 8.46% AbbVie Inc ( ABBV ) - 81,166 shares, 3.47% of the total portfolio. New Purchase: Sociedad Quimica Y Minera De Chile SA (SQM) SFE Investment Counsel initiated holdings in Sociedad Quimica Y Minera De Chile SA. | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SFE+Investment+Counsel These are the top 5 holdings of SFE Investment Counsel Apple Inc ( AAPL ) - 56,871 shares, 4.21% of the total portfolio. Shares reduced by 8.46% AbbVie Inc ( ABBV ) - 81,166 shares, 3.47% of the total portfolio. Shares reduced by 2.33% New Purchase: Amazon.com Inc (AMZN) SFE Investment Counsel initiated holdings in Amazon.com Inc. | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SFE+Investment+Counsel These are the top 5 holdings of SFE Investment Counsel Apple Inc ( AAPL ) - 56,871 shares, 4.21% of the total portfolio. Shares reduced by 8.46% AbbVie Inc ( ABBV ) - 81,166 shares, 3.47% of the total portfolio. Shares reduced by 2.33% New Purchase: Amazon.com Inc (AMZN) SFE Investment Counsel initiated holdings in Amazon.com Inc. |
25868.0 | 2017-11-01 00:00:00 UTC | Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come | ABBV | https://www.nasdaq.com/articles/seattle-genetics-inc-double-digit-revenue-growth-best-yet-come-2017-11-01 | nan | nan | Sales of Seattle Genetics 's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially considering that Adcetris has been on the market for six years. Fortunately, sales should accelerate from here with an expanded approval under review at the FDA and another one ready to be submitted soon.
Seattle Genetics results: The raw numbers
Data source: Seattle Genetics.
What happened with Seattle Genetics this quarter?
Besides the aforementioned 13% increase in sales of Adectris in Seattle Genetics's territories, revenue was boosted by a 36% increase in royalties from Takeda for the territories where it sells Adcetris.
The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma.
Don't get too excited about the positive earnings per share; it comes entirely from an accounting benefit from warrants Seattle Genetics holds that give it the right to buy additional shares of partner Immunomedics (NASDAQ: IMMU) . In the third quarter, Immunomedics completed a resale registration statement for the shares issuable under the warrant, which made the warrants mark-to-market , resulting in a one-time accounting gain.
What management had to say
Darren Cline, Seattle Genetics' executive vice president of commercial, commented on doctors' reactions to the ECHELON-1 data that showed Adcetris added to older chemotherapy drugs -- adriamycin, vinblastine, dacarbazine (AVD) -- worked better than the standard of care that includes those three drugs plus another toxic chemotherapy, bleomycin (ABVD):
Looking forward
It's going to be a pretty eventful couple of months for Seattle Genetics. The FDA is scheduled to make a decision about the approval of Adcetris to treat cutaneous T-cell lymphoma on or before Dec. 16. Considering the drug passed the ALCANZA phase 3 trial and two phase 2 trials run by independent investigators, an approval seems likely.
Also in December, investors will get a look at the ECHELON-1 data testing Adcetris in frontline advanced Hodgkin lymphoma at the American Society of Hematology meeting. We'll also get to see some additional data including combining Adcetris with Bristol-Myers Squibb 's (NYSE: BMY) Opdivo, which could help long-term sales of the drug.
Seattle Genetics plans to submit the marketing application for frontline advanced Hodgkin lymphoma supported by the ECHELON-1 data to the FDA soon, putting a potential approval in the first half of 2018.
And that's just for Adcetris.
The biotech has two other programs in or ready for pivotal trials: enfortumab vedotin that it's developing with Astellas, which is in a pivotal trial in patients with locally advanced or metastatic urothelial cancer, and tisotumab vedotin that Seattle Genetics is developing with Genmab, which will start a pivotal phase II trial in women with advanced cervical cancer by the first half of 2018. And further back, there are 10 earlier-stage pipeline drugs for a variety of blood cancers and solid tumors.
10 stocks we like better than Seattle Genetics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Seattle Genetics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. What management had to say Darren Cline, Seattle Genetics' executive vice president of commercial, commented on doctors' reactions to the ECHELON-1 data that showed Adcetris added to older chemotherapy drugs -- adriamycin, vinblastine, dacarbazine (AVD) -- worked better than the standard of care that includes those three drugs plus another toxic chemotherapy, bleomycin (ABVD): Looking forward It's going to be a pretty eventful couple of months for Seattle Genetics. Seattle Genetics plans to submit the marketing application for frontline advanced Hodgkin lymphoma supported by the ECHELON-1 data to the FDA soon, putting a potential approval in the first half of 2018. | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. Also in December, investors will get a look at the ECHELON-1 data testing Adcetris in frontline advanced Hodgkin lymphoma at the American Society of Hematology meeting. Seattle Genetics plans to submit the marketing application for frontline advanced Hodgkin lymphoma supported by the ECHELON-1 data to the FDA soon, putting a potential approval in the first half of 2018. | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. Sales of Seattle Genetics 's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially considering that Adcetris has been on the market for six years. What management had to say Darren Cline, Seattle Genetics' executive vice president of commercial, commented on doctors' reactions to the ECHELON-1 data that showed Adcetris added to older chemotherapy drugs -- adriamycin, vinblastine, dacarbazine (AVD) -- worked better than the standard of care that includes those three drugs plus another toxic chemotherapy, bleomycin (ABVD): Looking forward It's going to be a pretty eventful couple of months for Seattle Genetics. | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. What happened with Seattle Genetics this quarter? And that's just for Adcetris. |
25869.0 | 2017-10-31 00:00:00 UTC | HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View | ABBV | https://www.nasdaq.com/articles/hca-healthcare-hca-posts-in-line-q3-earnings-keeps-view-2017-10-31 | nan | nan | HCA Healthcare, Inc . HCA reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. The bottom line declined nearly 25% year over year.
HCA Holdings, Inc. Price, Consensus and EPS Surprise
HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote
Improvement in revenues was offset by an increase in expenses. Shares were down 0.07% in pre-market trading .
HCA Healthcare posted revenues of $10.7 billion, almost in line with the Zacks Consensus Estimate. The reported figure was up 3.9% from the year-ago quarter.
Provision for doubtful accounts surged 51% year over year to $1.3 million.
Quarterly Details
Adjusted EBITDA totaled $1.8 billion, up 9.2% year over year.
Same facility equivalent admissions inched up 0.3% year over year, while same facility admissions nudged up 0.6%. Same facility revenue per equivalent admission increased 2%.
Salaries and benefits, supplies and other operating expenses increased 7.2% year over year to $8.9 billion.
As of Sep 30, 2017, HCA Healthcare ran 177 hospitals and 119 free-standing surgery centers.
Financial Update
As of Sep 30, 2017, the company had cash and cash equivalents of $718 million, total debt of $32.6 billion and total assets of $35.7 billion.
During the reported quarter, capital expenditures totaled $729 million, excluding acquisitions. Cash flows provided by operating activities totaled $1 billion, down 16.4% year over year.
As of Sep 30, 2017, the company's total debt/adjusted EBITDA was 4.1x compared with 3.8x as of Dec 31, 2016.
During the quarter under review, the company spent $509 million to buy back 6.3 million shares. The board of directors approved an additional share repurchase program for up to $2 billion.
Following the latest authorization, the company has about $2.2 million remaining under its existing repurchase authorization as of Oct 31, 2017.
Guidance
The company expects 2017 revenues in the range of $43-$44 billion, adjusted EBIDTA of $8-$8.2 billion, EPS of $6.45-$6.70 and capital expenditures of about $3 billion.
Zacks Rank and Performance of Other Companies From Medical Sector
HCA Healthcare presently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today's Zacks #1 Rank stocks here .
AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
HCA Holdings, Inc. (HCA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. HCA reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. HCA Holdings, Inc. Price, Consensus and EPS Surprise HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote Improvement in revenues was offset by an increase in expenses. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. HCA Holdings, Inc. Price, Consensus and EPS Surprise HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote Improvement in revenues was offset by an increase in expenses. | AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. HCA reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. |
25870.0 | 2017-10-31 00:00:00 UTC | Artemis Investment Management LLP Buys Zions Bancorp, Equifax Inc, General Motors Co, Sells ... | ABBV | https://www.nasdaq.com/articles/artemis-investment-management-llp-buys-zions-bancorp-equifax-inc-general-motors-co-sells | nan | nan | Artemis Investment Management LLP
New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD,
Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE,
Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX, TTWO, TWO,
Sold Out:VZ, CTL, MET, SWFT, SAVE, TUP, TTMI, MS, MDC, LUV,
For the details of Artemis Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Artemis+Investment+Management+LLP
These are the top 5 holdings of Artemis Investment Management LLP
Citigroup Inc ( C ) - 2,633,512 shares, 3.97% of the total portfolio. Shares added by 36.87%
General Motors Co ( GM ) - 4,595,697 shares, 3.85% of the total portfolio. Shares added by 43.55%
Bank of America Corporation ( BAC ) - 5,226,817 shares, 2.74% of the total portfolio. Shares added by 38.54%
AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Shares added by 27.65%
Western Digital Corp ( WDC ) - 1,351,667 shares, 2.42% of the total portfolio. Shares reduced by 53.11%
New Purchase: The Mosaic Co (MOS)
Artemis Investment Management LLP initiated holdings in The Mosaic Co. The purchase prices were between $19.39 and $24.54, with an estimated average price of $21.69. The stock is now traded at around $20.85. The impact to the portfolio due to this purchase was 0.77%. The holdings were 1,721,444 shares as of 2017-09-30.
New Purchase: Burlington Stores Inc (BURL)
Artemis Investment Management LLP initiated holdings in Burlington Stores Inc. The purchase prices were between $80.27 and $95, with an estimated average price of $87.74. The stock is now traded at around $89.00. The impact to the portfolio due to this purchase was 0.38%. The holdings were 190,682 shares as of 2017-09-30.
New Purchase: Cimarex Energy Co (XEC)
Artemis Investment Management LLP initiated holdings in Cimarex Energy Co. The purchase prices were between $91.6 and $115.51, with an estimated average price of $99.77. The stock is now traded at around $117.14. The impact to the portfolio due to this purchase was 0.37%. The holdings were 156,608 shares as of 2017-09-30.
New Purchase: Caterpillar Inc (CAT)
Artemis Investment Management LLP initiated holdings in Caterpillar Inc. The purchase prices were between $106.51 and $125.23, with an estimated average price of $115.09. The stock is now traded at around $136.49. The impact to the portfolio due to this purchase was 0.35%. The holdings were 136,500 shares as of 2017-09-30.
New Purchase: L Brands Inc (LB)
Artemis Investment Management LLP initiated holdings in L Brands Inc. The purchase prices were between $36.06 and $55.57, with an estimated average price of $41.68. The stock is now traded at around $42.83. The impact to the portfolio due to this purchase was 0.28%. The holdings were 323,731 shares as of 2017-09-30.
New Purchase: Johnson & Johnson (JNJ)
Artemis Investment Management LLP initiated holdings in Johnson & Johnson. The purchase prices were between $129.47 and $136.57, with an estimated average price of $132.54. The stock is now traded at around $140.00. The impact to the portfolio due to this purchase was 0.24%. The holdings were 88,295 shares as of 2017-09-30.
Added: Zions Bancorp (ZION)
Artemis Investment Management LLP added to the holdings in Zions Bancorp by 332.06%. The purchase prices were between $41.33 and $46.94, with an estimated average price of $44.46. The stock is now traded at around $46.80. The impact to the portfolio due to this purchase was 1.31%. The holdings were 1,751,662 shares as of 2017-09-30.
Added: Equifax Inc (EFX)
Artemis Investment Management LLP added to the holdings in Equifax Inc by 478.62%. The purchase prices were between $92.98 and $146.26, with an estimated average price of $132.47. The stock is now traded at around $109.01. The impact to the portfolio due to this purchase was 1.27%. The holdings were 703,006 shares as of 2017-09-30.
Added: General Motors Co ( GM )
Artemis Investment Management LLP added to the holdings in General Motors Co by 43.55%. The purchase prices were between $34.76 and $40.58, with an estimated average price of $36.53. The stock is now traded at around $43.37. The impact to the portfolio due to this purchase was 1.17%. The holdings were 4,595,697 shares as of 2017-09-30.
Added: JPMorgan Chase & Co (JPM)
Artemis Investment Management LLP added to the holdings in JPMorgan Chase & Co by 105.08%. The purchase prices were between $88.42 and $95.51, with an estimated average price of $92.22. The stock is now traded at around $101.41. The impact to the portfolio due to this purchase was 1.08%. The holdings were 1,065,738 shares as of 2017-09-30.
Added: Citigroup Inc ( C )
Artemis Investment Management LLP added to the holdings in Citigroup Inc by 36.87%. The purchase prices were between $65.95 and $72.74, with an estimated average price of $68.28. The stock is now traded at around $73.78. The impact to the portfolio due to this purchase was 1.07%. The holdings were 2,633,512 shares as of 2017-09-30.
Added: Alcoa Corp (AA)
Artemis Investment Management LLP added to the holdings in Alcoa Corp by 126.73%. The purchase prices were between $33.77 and $47.5, with an estimated average price of $39.79. The stock is now traded at around $47.42. The impact to the portfolio due to this purchase was 0.91%. The holdings were 1,677,985 shares as of 2017-09-30.
Sold Out: Verizon Communications Inc (VZ)
Artemis Investment Management LLP sold out the holdings in Verizon Communications Inc. The sale prices were between $42.89 and $49.9, with an estimated average price of $47.03.
Sold Out: CenturyLink Inc (CTL)
Artemis Investment Management LLP sold out the holdings in CenturyLink Inc. The sale prices were between $18.32 and $23.97, with an estimated average price of $21.08.
Sold Out: MetLife Inc (MET)
Artemis Investment Management LLP sold out the holdings in MetLife Inc. The sale prices were between $46.68 and $51.95, with an estimated average price of $48.71.
Sold Out: Swift Transportation Co (SWFT)
Artemis Investment Management LLP sold out the holdings in Swift Transportation Co. The sale prices were between $24.92 and $29.49, with an estimated average price of $26.61.
Sold Out: Spirit Airlines Inc (SAVE)
Artemis Investment Management LLP sold out the holdings in Spirit Airlines Inc. The sale prices were between $32.09 and $53.46, with an estimated average price of $40.29.
Sold Out: Tupperware Brands Corp (TUP)
Artemis Investment Management LLP sold out the holdings in Tupperware Brands Corp. The sale prices were between $56.82 and $70.36, with an estimated average price of $61.79.
Reduced: Western Digital Corp ( WDC )
Artemis Investment Management LLP reduced to the holdings in Western Digital Corp by 53.11%. The sale prices were between $79.19 and $95.01, with an estimated average price of $87.77. The stock is now traded at around $85.79. The impact to the portfolio due to this sale was -3.3%. Artemis Investment Management LLP still held 1,351,667 shares as of 2017-09-30.
Reduced: Corning Inc (GLW)
Artemis Investment Management LLP reduced to the holdings in Corning Inc by 80.64%. The sale prices were between $27.87 and $32.13, with an estimated average price of $29.61. The stock is now traded at around $31.26. The impact to the portfolio due to this sale was -2.37%. Artemis Investment Management LLP still held 778,289 shares as of 2017-09-30.
Reduced: Comcast Corp (CMCSA)
Artemis Investment Management LLP reduced to the holdings in Comcast Corp by 73.01%. The sale prices were between $36.93 and $41.9, with an estimated average price of $39.39. The stock is now traded at around $36.50. The impact to the portfolio due to this sale was -0.8%. Artemis Investment Management LLP still held 311,478 shares as of 2017-09-30.
Reduced: Wells Fargo & Co (WFC)
Artemis Investment Management LLP reduced to the holdings in Wells Fargo & Co by 66.82%. The sale prices were between $49.58 and $55.78, with an estimated average price of $53.16. The stock is now traded at around $55.85. The impact to the portfolio due to this sale was -0.63%. Artemis Investment Management LLP still held 231,365 shares as of 2017-09-30.
Reduced: Apple Inc (AAPL)
Artemis Investment Management LLP reduced to the holdings in Apple Inc by 41.13%. The sale prices were between $142.73 and $164.05, with an estimated average price of $155.13. The stock is now traded at around $166.72. The impact to the portfolio due to this sale was -0.57%. Artemis Investment Management LLP still held 233,240 shares as of 2017-09-30.
Reduced: Starbucks Corp (SBUX)
Artemis Investment Management LLP reduced to the holdings in Starbucks Corp by 99.11%. The sale prices were between $52.7 and $59.5, with an estimated average price of $55.48. The stock is now traded at around $55.17. The impact to the portfolio due to this sale was -0.47%. Artemis Investment Management LLP still held 2,928 shares as of 2017-09-30.
Warning! GuruFocus has detected 4 Warning Sign with ZION. Click here to check it out.
ZION 15-Year Financial Data
The intrinsic value of ZION
Peter Lynch Chart of ZION
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD, Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE, Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX, TTWO, TWO, Sold Out:VZ, CTL, MET, SWFT, SAVE, TUP, TTMI, MS, MDC, LUV, For the details of Artemis Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Artemis+Investment+Management+LLP These are the top 5 holdings of Artemis Investment Management LLP Citigroup Inc ( C ) - 2,633,512 shares, 3.97% of the total portfolio. Sold Out: Tupperware Brands Corp (TUP) Artemis Investment Management LLP sold out the holdings in Tupperware Brands Corp. | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD, Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE, Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX, TTWO, TWO, Sold Out:VZ, CTL, MET, SWFT, SAVE, TUP, TTMI, MS, MDC, LUV, For the details of Artemis Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Artemis+Investment+Management+LLP These are the top 5 holdings of Artemis Investment Management LLP Citigroup Inc ( C ) - 2,633,512 shares, 3.97% of the total portfolio. New Purchase: Johnson & Johnson (JNJ) Artemis Investment Management LLP initiated holdings in Johnson & Johnson. | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD, Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE, Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX, TTWO, TWO, Sold Out:VZ, CTL, MET, SWFT, SAVE, TUP, TTMI, MS, MDC, LUV, For the details of Artemis Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Artemis+Investment+Management+LLP These are the top 5 holdings of Artemis Investment Management LLP Citigroup Inc ( C ) - 2,633,512 shares, 3.97% of the total portfolio. Shares reduced by 53.11% New Purchase: The Mosaic Co (MOS) Artemis Investment Management LLP initiated holdings in The Mosaic Co. | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP still held 1,351,667 shares as of 2017-09-30. Artemis Investment Management LLP still held 778,289 shares as of 2017-09-30. |
25871.0 | 2017-10-31 00:00:00 UTC | iShares Russell 1000 Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-inflow-2017-10-31 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 297,850,000 to 298,500,000). Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average:
Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $130.06 as the 52 week high point - that compares with a last trade of $129.86. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $130.06 as the 52 week high point - that compares with a last trade of $129.86. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $130.06 as the 52 week high point - that compares with a last trade of $129.86. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 297,850,000 to 298,500,000). For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $130.06 as the 52 week high point - that compares with a last trade of $129.86. | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 297,850,000 to 298,500,000). For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $99.57 per share, with $130.06 as the 52 week high point - that compares with a last trade of $129.86. |
25872.0 | 2017-10-30 00:00:00 UTC | Berkshire Asset Management Llc Buys Exxon Mobil Corp, Nucor Corp, Brighthouse Financial Inc, ... | ABBV | https://www.nasdaq.com/articles/berkshire-asset-management-llc-buys-exxon-mobil-corp-nucor-corp-brighthouse-financial-inc | nan | nan | Berkshire Asset Management Llc
New Purchases: BHF , RSP , APA , DWDP, PAYX, OKE, NVS, NVDA, CPRT, CLX,
Added Positions:XOM, NUE, T, GE, JPM, GIS, V, CB, PPL, QCOM,
Reduced Positions:ADP, SPY, VO, VB, HON, SCHF, AMGN, RDS.B, GOOGL, NSC,
Sold Out:GPC, KSS, VOT, BCR, VIA, TOL, TJX, RAI, EOG, EBAY,
For the details of BERKSHIRE ASSET MANAGEMENT LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BERKSHIRE+ASSET+MANAGEMENT+LLC
These are the top 5 holdings of BERKSHIRE ASSET MANAGEMENT LLC
JPMorgan Chase & Co ( JPM ) - 369,422 shares, 3.95% of the total portfolio. Shares added by 1.08%
Microsoft Corp ( MSFT ) - 392,390 shares, 3.27% of the total portfolio. Shares added by 0.10%
AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Shares reduced by 0.73%
Johnson & Johnson ( JNJ ) - 199,426 shares, 2.9% of the total portfolio. Shares added by 0.26%
Cisco Systems Inc ( CSCO ) - 768,714 shares, 2.89% of the total portfolio. Shares reduced by 0.49%
New Purchase: Brighthouse Financial Inc (BHF)
Berkshire Asset Management Llc initiated holdings in Brighthouse Financial Inc. The purchase prices were between $53 and $70, with an estimated average price of $59.98. The stock is now traded at around $62.46. The impact to the portfolio due to this purchase was 0.06%. The holdings were 8,729 shares as of 2017-09-30.
New Purchase: Guggenheim S&P 500 Equal Weight (RSP)
Berkshire Asset Management Llc initiated holdings in Guggenheim S&P 500 Equal Weight. The purchase prices were between $91.58 and $95.54, with an estimated average price of $93.56. The stock is now traded at around $96.40. The impact to the portfolio due to this purchase was 0.06%. The holdings were 5,338 shares as of 2017-09-30.
New Purchase: Apache Corp (APA)
Berkshire Asset Management Llc initiated holdings in Apache Corp. The purchase prices were between $38.37 and $50.22, with an estimated average price of $44.09. The stock is now traded at around $40.81. The impact to the portfolio due to this purchase was 0.04%. The holdings were 8,350 shares as of 2017-09-30.
New Purchase: DowDuPont Inc (DWDP)
Berkshire Asset Management Llc initiated holdings in DowDuPont Inc. The purchase prices were between $63.11 and $70.41, with an estimated average price of $65.88. The stock is now traded at around $71.68. The impact to the portfolio due to this purchase was 0.04%. The holdings were 5,230 shares as of 2017-09-30.
New Purchase: ONEOK Inc (OKE)
Berkshire Asset Management Llc initiated holdings in ONEOK Inc. The purchase prices were between $50.36 and $56.88, with an estimated average price of $54.03. The stock is now traded at around $54.04. The impact to the portfolio due to this purchase was 0.03%. The holdings were 5,300 shares as of 2017-09-30.
New Purchase: Paychex Inc (PAYX)
Berkshire Asset Management Llc initiated holdings in Paychex Inc. The purchase prices were between $54.24 and $60.35, with an estimated average price of $57.05. The stock is now traded at around $64.47. The impact to the portfolio due to this purchase was 0.03%. The holdings were 3,874 shares as of 2017-09-30.
Added: Exxon Mobil Corp (XOM)
Berkshire Asset Management Llc added to the holdings in Exxon Mobil Corp by 38.31%. The purchase prices were between $76.1 and $82.19, with an estimated average price of $79.4. The stock is now traded at around $83.54. The impact to the portfolio due to this purchase was 0.75%. The holdings were 296,709 shares as of 2017-09-30.
Added: Nucor Corp (NUE)
Berkshire Asset Management Llc added to the holdings in Nucor Corp by 49.12%. The purchase prices were between $53.48 and $60.92, with an estimated average price of $56.57. The stock is now traded at around $58.47. The impact to the portfolio due to this purchase was 0.47%. The holdings were 230,408 shares as of 2017-09-30.
Added: Visa Inc (V)
Berkshire Asset Management Llc added to the holdings in Visa Inc by 109.84%. The purchase prices were between $93.25 and $106.21, with an estimated average price of $101.34. The stock is now traded at around $110.04. The impact to the portfolio due to this purchase was 0.03%. The holdings were 5,460 shares as of 2017-09-30.
Added: Campbell Soup Co (CPB)
Berkshire Asset Management Llc added to the holdings in Campbell Soup Co by 45.26%. The purchase prices were between $45.13 and $54.19, with an estimated average price of $50.74. The stock is now traded at around $46.36. The impact to the portfolio due to this purchase was 0.02%. The holdings were 12,036 shares as of 2017-09-30.
Added: NextEra Energy Inc (NEE)
Berkshire Asset Management Llc added to the holdings in NextEra Energy Inc by 35.97%. The purchase prices were between $138.82 and $151.4, with an estimated average price of $146.47. The stock is now traded at around $155.36. The impact to the portfolio due to this purchase was 0.01%. The holdings were 2,767 shares as of 2017-09-30.
Added: Becton, Dickinson and Co (BDX)
Berkshire Asset Management Llc added to the holdings in Becton, Dickinson and Co by 21.04%. The purchase prices were between $191.56 and $205.63, with an estimated average price of $198.67. The stock is now traded at around $208.65. The impact to the portfolio due to this purchase was 0.01%. The holdings were 2,664 shares as of 2017-09-30.
Sold Out: Genuine Parts Co (GPC)
Berkshire Asset Management Llc sold out the holdings in Genuine Parts Co. The sale prices were between $80.48 and $95.19, with an estimated average price of $85.08.
Sold Out: Kohl's Corp (KSS)
Berkshire Asset Management Llc sold out the holdings in Kohl's Corp. The sale prices were between $36.63 and $46.34, with an estimated average price of $40.9.
Sold Out: Vanguard Mid-Cap Growth (VOT)
Berkshire Asset Management Llc sold out the holdings in Vanguard Mid-Cap Growth. The sale prices were between $115.95 and $121.75, with an estimated average price of $119.16.
Sold Out: C.R. Bard Inc (BCR)
Berkshire Asset Management Llc sold out the holdings in C.R. Bard Inc. The sale prices were between $316.39 and $323.91, with an estimated average price of $319.73.
Sold Out: TJX Companies Inc (TJX)
Berkshire Asset Management Llc sold out the holdings in TJX Companies Inc. The sale prices were between $66.9 and $74.16, with an estimated average price of $71.26.
Sold Out: Viacom Inc (VIA)
Berkshire Asset Management Llc sold out the holdings in Viacom Inc. The sale prices were between $36.7 and $42.4, with an estimated average price of $38.82.
Reduced: Automatic Data Processing Inc (ADP)
Berkshire Asset Management Llc reduced to the holdings in Automatic Data Processing Inc by 80.39%. The sale prices were between $101.31 and $118.91, with an estimated average price of $107.02. The stock is now traded at around $116.98. The impact to the portfolio due to this sale was -0.61%. Berkshire Asset Management Llc still held 12,674 shares as of 2017-09-30.
Reduced: Facebook Inc (FB)
Berkshire Asset Management Llc reduced to the holdings in Facebook Inc by 34.5%. The sale prices were between $148.43 and $173.51, with an estimated average price of $166.52. The stock is now traded at around $179.87. The impact to the portfolio due to this sale was -0.02%. Berkshire Asset Management Llc still held 2,400 shares as of 2017-09-30.
Reduced: Boeing Co (BA)
Berkshire Asset Management Llc reduced to the holdings in Boeing Co by 24.09%. The sale prices were between $198.59 and $256.45, with an estimated average price of $232.68. The stock is now traded at around $259.25. The impact to the portfolio due to this sale was -0.01%. Berkshire Asset Management Llc still held 2,152 shares as of 2017-09-30.
Warning! GuruFocus has detected 5 Warning Signs with XOM. Click here to check it out.
XOM 15-Year Financial Data
The intrinsic value of XOM
Peter Lynch Chart of XOM
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Berkshire Asset Management Llc New Purchases: BHF , RSP , APA , DWDP, PAYX, OKE, NVS, NVDA, CPRT, CLX, Added Positions:XOM, NUE, T, GE, JPM, GIS, V, CB, PPL, QCOM, Reduced Positions:ADP, SPY, VO, VB, HON, SCHF, AMGN, RDS.B, GOOGL, NSC, Sold Out:GPC, KSS, VOT, BCR, VIA, TOL, TJX, RAI, EOG, EBAY, For the details of BERKSHIRE ASSET MANAGEMENT LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BERKSHIRE+ASSET+MANAGEMENT+LLC These are the top 5 holdings of BERKSHIRE ASSET MANAGEMENT LLC JPMorgan Chase & Co ( JPM ) - 369,422 shares, 3.95% of the total portfolio. Added: Exxon Mobil Corp (XOM) Berkshire Asset Management Llc added to the holdings in Exxon Mobil Corp by 38.31%. | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Shares reduced by 0.49% New Purchase: Brighthouse Financial Inc (BHF) Berkshire Asset Management Llc initiated holdings in Brighthouse Financial Inc. New Purchase: Apache Corp (APA) Berkshire Asset Management Llc initiated holdings in Apache Corp. | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Berkshire Asset Management Llc New Purchases: BHF , RSP , APA , DWDP, PAYX, OKE, NVS, NVDA, CPRT, CLX, Added Positions:XOM, NUE, T, GE, JPM, GIS, V, CB, PPL, QCOM, Reduced Positions:ADP, SPY, VO, VB, HON, SCHF, AMGN, RDS.B, GOOGL, NSC, Sold Out:GPC, KSS, VOT, BCR, VIA, TOL, TJX, RAI, EOG, EBAY, For the details of BERKSHIRE ASSET MANAGEMENT LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BERKSHIRE+ASSET+MANAGEMENT+LLC These are the top 5 holdings of BERKSHIRE ASSET MANAGEMENT LLC JPMorgan Chase & Co ( JPM ) - 369,422 shares, 3.95% of the total portfolio. Shares reduced by 0.49% New Purchase: Brighthouse Financial Inc (BHF) Berkshire Asset Management Llc initiated holdings in Brighthouse Financial Inc. | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Berkshire Asset Management Llc still held 12,674 shares as of 2017-09-30. Berkshire Asset Management Llc still held 2,400 shares as of 2017-09-30. |
25873.0 | 2017-10-30 00:00:00 UTC | Close Update: Wall Street's Winning Streak Snapped by Drug Sector, Tax Reform | ABBV | https://www.nasdaq.com/articles/close-update-wall-streets-winning-streak-snapped-drug-sector-tax-reform-2017-10-30 | nan | nan | The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well as by reports that lawmakers might consider altering the GOP tax reform plan, and after a member of President Donald Trump's campaign staff was indicted for money laundering.
The healthcare sector took the brunt of Monday's selling pressure with Dow component Merck ( MRK ) adding to Friday's oversized loss by spiralling to a 17-month low. Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%.
Shares were already trending lower overnight with news of one of Trump's campaign team facing charges by the FBI. The knee-jerk reaction to the Bloomberg report about alterations to the president's tax reform plan accelerated selling pressure and cost the Dow Jones Industrial Average all of Friday's modest gains.
The risk-off trade drove Treasury yields lower across the curve, gold up by $5 an ounce and the dollar lower against the yen.
Monday's economic data had little impact on the financial markets even as consumption spending recorded its largest monthly increase since August 2009. Incomes rose an as-expected 0.4% last month.
Tuesday economic agenda kicks off with the Q3 employment cost index, Case-Shiller home price index, the Chicago purchasing manager's index and consumer confidence. Also, the Federal Open Market Committee kicks off its two-day policy meeting.
On the earnings front, Pfizer ( PFE ) and Under Armour ( UAA ) are some of the headliners before the open.
Here's where the markets stood at the close:
US MARKETS
Dow Jones Industrial Index was down 85.45 points (-0.36%)
S&P 500 was down 8.24 points (-0.32%)
Nasdaq Composite Index was down 2.30 points (-0.03%)
GLOBAL SENTIMENT
FTSE 100 was down 0.23%
Nikkei 225 was up 0.01%
Hang Seng Index was down 0.36%
Shanghai China Composite Index was down 0.77%
UPSIDE MOVERS
(+) SPCB (+36.26%) Q3 earnings and sales beat expectations
(+) CPLA (+30.46%) Merging with Strayer Education ( STRA )
(+) MICT (+30.41%) Subsidiary receives $3.1 million order for its SmartHub-TREQr5 product
(+) CAA (+21.34%) Merging with Lennar Homes (LEN)
DOWNSIDE MOVERS
(-) ICON (-62.32%) Danskin Now dropped by Walmart (WMT), renegotiating terms of loan facility
(-) ODP (-18.28%) Downgraded at JP Morgan to underweight from neutral
(-) PSTI (-14.72%) Plans to conduct public offering of up to 9 million shares
(-) S (-9.30%) Softbank reportedly ending negotiations to merge with T-Mobile (TMUS)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well as by reports that lawmakers might consider altering the GOP tax reform plan, and after a member of President Donald Trump's campaign staff was indicted for money laundering. The healthcare sector took the brunt of Monday's selling pressure with Dow component Merck ( MRK ) adding to Friday's oversized loss by spiralling to a 17-month low. | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well as by reports that lawmakers might consider altering the GOP tax reform plan, and after a member of President Donald Trump's campaign staff was indicted for money laundering. The knee-jerk reaction to the Bloomberg report about alterations to the president's tax reform plan accelerated selling pressure and cost the Dow Jones Industrial Average all of Friday's modest gains. | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well as by reports that lawmakers might consider altering the GOP tax reform plan, and after a member of President Donald Trump's campaign staff was indicted for money laundering. Dow Jones Industrial Index was down 85.45 points (-0.36%) S&P 500 was down 8.24 points (-0.32%) Nasdaq Composite Index was down 2.30 points (-0.03%) | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well as by reports that lawmakers might consider altering the GOP tax reform plan, and after a member of President Donald Trump's campaign staff was indicted for money laundering. The healthcare sector took the brunt of Monday's selling pressure with Dow component Merck ( MRK ) adding to Friday's oversized loss by spiralling to a 17-month low. |
25874.0 | 2017-10-30 00:00:00 UTC | How Celgene, Gilead's Pricing Woes Continue To Haunt Biotech Stocks | ABBV | https://www.nasdaq.com/articles/how-celgene-gileads-pricing-woes-continue-haunt-biotech-stocks-2017-10-30 | nan | nan | Biotech stocks toppled last week following disappointing third-quarter results from the likes of Celgene ( CELG ) and Gilead Sciences ( GILD ), an analyst said Monday, noting that "competition and pricing concerns started taking a toll."
[ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Meanwhile, Celgene notes that its Otezla - which treats psoriasis and psoriatic arthritis - is in an "increasingly competitive market."
Gilead topped total sales views, but revenue from hepatitis C drugs declined by a third and narrowly missed analyst forecasts. Celgene's "alarming" results were driven by a major miss in sales of Otezla, leading total sales to lag and guidance cuts.
Instinet analyst Christopher Marai says the competitive and pricing concerns took a hit on the broad biotech market. The Nasdaq Biotechnology Index finished down 4.4%, though the Nasdaq and S&P 500 both wrapped the week at less than 1% higher.
Meanwhile, IBD's 454-company Biotech industry group lost nearly 3% and slipped to third out of 197 groups tracked by IBD. Over the last two weeks it had been ranked first and then second.
IBD'S TAKE:Celgene cut many elements of its 2020 guidance, including in inflammation and immunology drugs. Head to IBD Industry Themes for more on what Celgene's results could mean for the broader group.
Alnylam Pharmaceuticals ( ALNY ) and AveXis ( AVXS ) are more exposed to competitive concerns, Marai said in a note to clients. Alnylam is working on a drug called patisiran to treat a rare disease caused by the buildup of abnormal materials and will rival Ionis Pharmaceuticals (IONS) and Prothena (PRTA).
AveXis is working on therapy for spinal muscular atrophy. There, it rivals Biogen (BIIB) and Ionis, which sell Spinraza to treat the same condition. Marai lists Spinraza alongside Sarepta Therapeutics ' (SRPT) Exondys 51 for Duchenne muscular dystrophy as "fundamentally strong launches."
"We continue to look at strength in select names as an opportunity to take profits in biotech and reinvest in less macro-exposed names that are rich in potential (stock) catalysts over the next 12 months," he said. "We could avoid priced-for-perfection names including Alnylam and AveXis."
Over the next year, Marai sees Prothena, Deciphera Pharmaceuticals (DCPH), Cellectis (CLLS) and MacroGenics (MGNX) as having a slew of potential catalysts.
RELATED:
Dow's Merck Plunges To 17-Month Low On Growing Keytruda Worries
Gilead Beats Third-Quarter Sales, Earnings Views
Three Biotech Firms Top Third-Quarter Views - But Only One Pops
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Biotech stocks toppled last week following disappointing third-quarter results from the likes of Celgene ( CELG ) and Gilead Sciences ( GILD ), an analyst said Monday, noting that "competition and pricing concerns started taking a toll." Alnylam is working on a drug called patisiran to treat a rare disease caused by the buildup of abnormal materials and will rival Ionis Pharmaceuticals (IONS) and Prothena (PRTA). | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Gilead topped total sales views, but revenue from hepatitis C drugs declined by a third and narrowly missed analyst forecasts. Meanwhile, IBD's 454-company Biotech industry group lost nearly 3% and slipped to third out of 197 groups tracked by IBD. | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Biotech stocks toppled last week following disappointing third-quarter results from the likes of Celgene ( CELG ) and Gilead Sciences ( GILD ), an analyst said Monday, noting that "competition and pricing concerns started taking a toll." Alnylam is working on a drug called patisiran to treat a rare disease caused by the buildup of abnormal materials and will rival Ionis Pharmaceuticals (IONS) and Prothena (PRTA). | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Gilead topped total sales views, but revenue from hepatitis C drugs declined by a third and narrowly missed analyst forecasts. IBD'S TAKE:Celgene cut many elements of its 2020 guidance, including in inflammation and immunology drugs. |
25875.0 | 2017-10-29 00:00:00 UTC | In Your 60s? 3 Stocks You Should Consider Buying | ABBV | https://www.nasdaq.com/articles/your-60s-3-stocks-you-should-consider-buying-2017-10-29 | nan | nan | Some say that 60 is the new 40. Maybe so, but your attitude toward investing can be quite different in your 60s than they were in your 40s. With retirement either on the horizon or already a reality, you'll want to put your money in stocks of solid businesses that provide steady income.
Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . But what makes these stocks stand out above others for investors in their 60s?
AbbVie
AbbVie provides the income that investors who are either retired or will be retired in the near future. The drugmaker's dividend yield is close to 3%. AbbVie has also increased its dividend for 46 consecutive years (counting the period where the company was part of Abbott Labs and its just-announced dividend hike for 2018).
Pharma stocks sometimes aren't the steadiest of investments, though, due to cycles where key drugs lose patent exclusivity. AbbVie faces competitive challenges for its top-selling autoimmune disease drug Humira. However, thanks to a recent deal with Amgen , the company appears to be in good position to protect Humira from biosimilar competition in the U.S. through January 2023. That's huge, since two-thirds of AbbVie's revenue from the drug comes from the U.S. market.
In the meantime, AbbVie lays claim to one of the fastest-growing cancer drugs around with Imbruvica. The company won Food and Drug Administration approval in August for pan-genotypic hepatitis C virus (HCV) drug Mavyret, just days after securing European approval for the drug. AbbVie also awaits regulatory approval for elagolix in treating endometriosis.
In addition to these drugs, AbbVie's pipeline ranks in the top three in the biopharmaceutical industry. Two of brightest stars in its pipeline are cancer drug Rova-T and autoimmune disease drug upadacitinib, both of which hold the potential to become megablockbusters. With strong current products and a deep pipeline, AbbVie should provide investors solid growth as well as a solid dividend.
Brookfield Infrastructure Partners
Brookfield Infrastructure Partners' business model is about as steady as they come. Its assets include communications towers, oil and gas pipelines, ports, power lines, railways, and toll roads. In total, Brookfield owns 35 businesses, all of which are infrastructure-related and rake in fees from customers month after month.
With these stable sources of cash flow, Brookfield is able to pay out nice dividends. The company's yield currently stands north of 4%. Brookfield expects to increase its payout by 5% to 9% annually over the long term.
Is this type of growth really attainable? I think so. Brookfield makes nearly half of its total funds from operations (FFO) from its utilities segment. Most of its contracts have inflation increases built in, which the company thinks will cover roughly half of its projected growth.
Additional growth will likely stem from further acquisitions. Brookfield's financial position is strong enough to allow the company to be on the lookout for smart strategic deals. And, of course, it has that steady cash flow from existing assets that it can count on. All of this combines to make Brookfield Infrastructure Partners a great pick for investors in their 60s.
IBM
Some might have written off IBM as a relic from the past. The same thing happened years ago, only for IBM to adapt to technology changes and prove naysayers wrong. It looks like history just might repeat itself for the tech giant.
Although the company went through a painfully long stretch of quarters with year-over-year revenue declines, that streak should soon be over. IBM expects revenue to grow in the fourth quarter , boosted by the introduction of its new z14 mainframe computer.
IBM is already a leader in cloud computing. This cloud services business should continue to grow significantly. It's also part of what IBM refers to as its "strategic imperatives" businesses, along with analytics, mobile, security, and social. Because of its huge investments in research and development, IBM ranks among the leaders in several key technologies for the future, especially artificial intelligence and blockchain.
As a result of its lackluster financial performance over the past few years, IBM shares trade at only 11 times expected earnings. That's a bargain, in my view, especially considering that the company also pays out a dividend that currently yields nearly 3.8%. IBM won't be a go-go growth stock, but it's not a dinosaur that will go extinct. Instead, the company should continue adapting to new waves of technology, while rewarding shareholders each quarter with steady dividend -- just what investors in their 60s like.
10 stocks we like better than IBM
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and IBM wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie. The Motley Fool recommends Brookfield Infrastructure Partners. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . AbbVie AbbVie provides the income that investors who are either retired or will be retired in the near future. AbbVie has also increased its dividend for 46 consecutive years (counting the period where the company was part of Abbott Labs and its just-announced dividend hike for 2018). | Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . With strong current products and a deep pipeline, AbbVie should provide investors solid growth as well as a solid dividend. AbbVie AbbVie provides the income that investors who are either retired or will be retired in the near future. | Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . AbbVie AbbVie provides the income that investors who are either retired or will be retired in the near future. AbbVie has also increased its dividend for 46 consecutive years (counting the period where the company was part of Abbott Labs and its just-announced dividend hike for 2018). | That's huge, since two-thirds of AbbVie's revenue from the drug comes from the U.S. market. Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . AbbVie AbbVie provides the income that investors who are either retired or will be retired in the near future. |
25876.0 | 2017-10-29 00:00:00 UTC | 5 Things You Need to Know From Gilead Sciences' Q3 Update | ABBV | https://www.nasdaq.com/articles/5-things-you-need-know-gilead-sciences-q3-update-2017-10-29 | nan | nan | You could probably fit the number of people surprised by Gilead Sciences ' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug sales plunged. HIV drug sales looked good. And Gilead still has a boatload of cash.
The more interesting aspect of Gilead's third-quarter update, though, wasn't in its numbers, but rather in what the biotech's executives said in the quarterly conference call with analysts. Here are five things you need to know from that call. (Quotes courtesy of S&P Global Market Intelligence .)
1. It's going to get worse for the HCV franchise
As bad as HCV sales looked for Gilead in the third quarter, they're only going to get worse. While the company started to see early signs of competition during the quarter, Jim Meyers, Gilead's executive vice president of worldwide commercial operations, said that the impact of competition "will be more fully reflected beginning in the fourth quarter."
This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. Like Gilead's Epclusa, Mavyret treats all major genotypes of HCV. AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. Meyers said, however, that Gilead expects to retain its market leadership in the commercial and Medicare lines of business.
Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. Patient starts continue to decline, with no signs yet of stabilization. One potential bright spot, though, is in China. Gilead recently announced approval for Sovaldi in China and hopes to win approval for Harvoni and Epclusa as well. The company estimates that 10 million Chinese patients have HCV, but analyst Katherine Xu with William Blair thinks the opportunity could be much larger -- potentially one-third of the U.S. market.
2. Non-HCV drugs are performing better than it might appear
A quick glance at Gilead's third-quarter results might make you think that sales for its non-HCV drugs only grew modestly over the prior-year period. While it's true that year-over-year sales for the biotech's non-HCV drugs increased by just 4%, there's more to the story. A favorable adjustment of $332 million to rebate reserves artificially inflated the 2016 third-quarter numbers. Excluding this adjustment, non-HCV revenue jumped 16% higher than the year-ago period.
Gilead has been sounding the praises for Genvoya's launch for most of 2017, and deservedly so. But another HIV drug, Descovy, is also coming on strong. Meyers noted that "Descovy is on track to surpass both Atripla and Truvada to become the second most successful HIV product launch in U.S. history, behind only Genvoya."
3. No big worries about reimbursement for Yescarta
The FDA delivered a pleasant surprise with its earlier-than-expected approval for Yescarta in treating relapsed or refractory large B-cell lymphoma. Gilead's management isn't too worried about payers reimbursing for the CAR-T therapy gained with the Kite Pharma acquisition.
Meyers said that "all the discussions that Kite folks have had with payers to this point, both government and private payers, have indicated that they believe that they will cover Yescarta beginning at approval." Gilead thinks that around 50% to 60% of the payer mix will be commercial, with the rest primarily Medicare. What will the price for Yescarta be? COO Kevin Young threw out $373,000 per patient as a good number for analysts to use for modeling purposes.
4. Making significant progress on pipeline
Even with its HIV franchise performing well and opportunities for Yescarta, Gilead needs more help in returning to growth. Gilead CEO John Milligan noted an FDA decision on its promising bictegravir combo built on the Descovy backbone in treating HIV is expected in February. He also said the company is making "significant progress" with its liver disease programs focused largely on nonalcoholic steatohepatitis (NASH).
Gilead announced results from a phase 2 study of NASH candidate GS-0976 earlier this week. Milligan highlighted those results in his comments, adding that the company could initiate larger mid-stage combination studies of the experimental drugs with two other NASH pipeline assets next year. Chief scientific officer Norbert Bischofberger later said that Gilead "will almost certainly start combination studies sometime next year." Although it's still early, NASH could present an enormous opportunity for Gilead within a few years.
5. Expect more deals
When Gilead announced its acquisition of Kite, Milligan said that the company would not be "going quietly after this deal," with the business development group staying "very active" evaluating opportunities. He reiterated in the third-quarter call "that M&A [mergers and acquisitions] is going to be an ongoing activity at Gilead," adding that his team is "very, very active" in evaluating opportunities.
Gilead ended the third quarter with a whopping $41.4 billion in cash, cash equivalents, and marketable securities. The big biotech continues to enjoy strong cash flow even with its HCV challenges. Investors should probably take the company at its word and expect more acquisitions in the not-too-distant future.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. | This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. | This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. | AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. |
25877.0 | 2017-10-28 00:00:00 UTC | 3 High-Yield Dividend Aristocrat Stocks | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-aristocrat-stocks-2017-10-28 | nan | nan | If dividend stocks were like golf, there would be an elite group of stocks with green jackets like golfing greats who win the Masters tournament get to wear. This group of winners is called the Dividend Aristocrats. It's comprised of S&P 500 stocks that have raised dividends for at least 25 years in a row.
Not all of these Dividend Aristocrats have particularly impressive yields. But we asked three Motley Fool investors to point out high-yield Dividend Aristocrat stocks that could be good picks right now. Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) .
35 years and counting
Matt DiLallo (ExxonMobil): Big oil behemoth ExxonMobil has paid its investors a dividend for more than a century, including increasing it for the past 35 straight years. That's an impressive feat for an oil company given the volatility of oil prices , especially considering the deep downturn of the last few years, which led several rivals to reduce their payouts. However, because of the strength of Exxon's balance sheet and its underlying operations, the company has had the financial resources to continue returning cash to investors.
ExxonMobil's balance sheet strength, which includes the industry's best credit rating, provided the company with the financial flexibility to continue paying dividends and investing in new growth projects during the sector's recent downturn, giving it time to reposition its cost structure and adjust to lower oil prices. Those strategic initiatives started bearing fruit last quarter, enabling the company to generate a whopping $7.1 billion in cash, which was enough to easily cover the $3.3 billion quarterly dividend outlay as well as the bulk of its $3.9 billion capex tab. Those results show that the oil giant's dividend is on solid ground even in the current low oil price environment.
Meanwhile, because Exxon has kept growing during the downturn, it currently yields an impressive 3.8%. That certainly qualifies it as a high yielder since it's nearly double the yield of the S&P 500. That growing income stream should continue heading to investors for at least the next several years considering that oil demand keeps rising, meaning the oil giant should remain a reliable option for investors seekers.
A sustainable retail dividend
Tim Green(Target): Shares of retailer Target have slumped nearly 13% this year, dragged down by pessimism surrounding brick-and-mortar retailers. This has boosted Target's dividend yield to about 3.9%, making the stock an attractive option for dividend investors. Target has increased its dividend for 46 years in a row, and it has paid a quarterly dividend uninterrupted since 1967.
Target is in the process of adapting to a changing retail industry. It's investing in its e-commerce business, launching initiatives like next-day delivery for household essentials. The e-commerce business grew by 32% year over year during the second quarter, double the rate Target managed during the second quarter of 2016.
Exclusive brands and small-format stores are also part of the plan. Target has launched a handful of private-label brands this year, including A New Day, Goodfellow & Co, and Project 62. More new brands are in the pipeline, with the company betting that these new products will give customers a reason to visit its stores. Target also plans to open dozens of small-format stores in cities over the next couple of years, diversifying away from its big-box model.
Target's dividend growth will likely be slow for the foreseeable future as the company invests in these initiatives. The payout ratio is a bit below 50% for the past 12 months, so there's still some room for the dividend to expand even if earnings growth remains sluggish. Target's dividend growth track record should give investors some confidence that those dividend checks will continue getting a little bigger each year.
A three-in-one aristocrat
Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. Granted, for most of the ensuing period, AbbVie was part of its parent company, Abbott Labs . However, the drugmaker still qualifies as a Dividend Aristocrat. I think AbbVie is a "growth aristocrat" and "value aristocrat," too.
First, though, there's AbbVie's dividend yield of over 3% (boosted by a just-announced dividend hike for 2018). That's lower than its yield for most of its history as a stand-alone company. The reason why is AbbVie's tremendous stock performance in 2017. With the drugmaker continuing to raise its dividend, the yield will either go higher or its stock will. Either way, investors win.
That leads to my view of AbbVie as a "growth aristocrat." The stock has soared close to 50% this year. Wall Street analysts expect AbbVie to grow earnings by more than 15% annually over the next five years. With the top-selling drug in the world (Humira), one of the fastest-growing cancer drugs in the world (Imbruvica), and the third-best pipeline in the biopharmaceutical industry , it's easy to see how that growth can be achieved.
What about the "value aristocrat" status? Despite its huge gains, AbbVie stock trades at only 14 times expected earnings. That's a downright bargain considering the company's excellent dividend and strong growth potential. I have no doubt that AbbVie will remain a Dividend Aristocrat and a "growth aristocrat" for years to come, but that "value aristocrat" designation might not last much longer.
10 stocks we like better than ExxonMobil
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ExxonMobil wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie. Matthew DiLallo has no position in any of the stocks mentioned. Timothy Green has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. | Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. | I have no doubt that AbbVie will remain a Dividend Aristocrat and a "growth aristocrat" for years to come, but that "value aristocrat" designation might not last much longer. Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): 1972. | Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. |
25878.0 | 2017-10-27 00:00:00 UTC | AbbVie: The Dividend Does It? | ABBV | https://www.nasdaq.com/articles/abbvie-dividend-does-it-2017-10-27 | nan | nan | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. AbbVie also reported better-than-expected earnings, and raised its 2017 earnings guidance.
The original quarterly dividend was 40 cents a share, and it has been raised since six times since then. The company is heavily reliant on the prescription drug Humira, whose sales totaled $16.1 billion last year and are expected to top $18 billion this year, according to FactSet. AbbVie predicted that sales of Humira could hit $21 billion by 2020.
Humira is used to treat rheumatoid arthritis and Chrone's disease, among other uses. The market gave AbbVie's stock a boost on Sept. 28 when it was announced that the company had reached a settlement with Amgen (AMGN), which plans to launch a biosmiliar product to compete with Humira. AbbVie's shares rose 5% that day, and they are up nearly 50% this year.
Part of the reason AbbVie was spun off was that, with Humira throwing off a lot of free cash, it could appeal more to income investors. AbbVie yields 2.9%, vs. 1.9% for Abbott.
AbbVie appears to have plenty of room to keep increasing its dividend, partly because its payout ratio - the percentage of earnings paid out as dividends - was 47% last year and in 2015. That should leave more room for dividend hikes.
Analysts expect the company to pay a dividend this year of $2.55 a share, up from $2.28 in 2016, and $2.82 next year.
Shares of AbbVie have gained 1.9% to $91.30 in pre-open trading, while Amgen has slipped 0.3% to $176.05, and Abbott Laboratories has risen 0.8% to $55.90.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. The market gave AbbVie's stock a boost on Sept. 28 when it was announced that the company had reached a settlement with Amgen (AMGN), which plans to launch a biosmiliar product to compete with Humira. Part of the reason AbbVie was spun off was that, with Humira throwing off a lot of free cash, it could appeal more to income investors. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. AbbVie also reported better-than-expected earnings, and raised its 2017 earnings guidance. | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. AbbVie appears to have plenty of room to keep increasing its dividend, partly because its payout ratio - the percentage of earnings paid out as dividends - was 47% last year and in 2015. AbbVie also reported better-than-expected earnings, and raised its 2017 earnings guidance. | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. AbbVie appears to have plenty of room to keep increasing its dividend, partly because its payout ratio - the percentage of earnings paid out as dividends - was 47% last year and in 2015. AbbVie also reported better-than-expected earnings, and raised its 2017 earnings guidance. |
25879.0 | 2017-10-27 00:00:00 UTC | Stocks With Rising Relative Strength: AstraZeneca | ABBV | https://www.nasdaq.com/articles/stocks-rising-relative-strength-astrazeneca-2017-10-27 | nan | nan | AstraZeneca ( AZN ) had its Relative Strength ( RS ) Rating upgraded from 69 to 79 Friday -- a welcome improvement, but still below the 80 or higher score you look for.
[ibd-display-video id=2102289 width=50 float=left autostart=true] IBD's proprietary rating identifies share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an RS Rating of above 80 as they begin their biggest price moves. See if AstraZeneca can continue to show renewed price strength and clear that threshold.
Looking For The Best Stocks To Buy And Watch? Start Here
AstraZeneca is trying to complete a consolidation with a 35.70 entry . See if the stock can clear the breakout price in volume at least 40% above average.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 4% to 5%. Revenue rose from -12% to -10%. Look for the next report on or around Nov. 10.
The company holds the No. 7 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. AstraZeneca ( AZN ) had its Relative Strength ( RS ) Rating upgraded from 69 to 79 Friday -- a welcome improvement, but still below the 80 or higher score you look for. Over 100 years of market history reveals that the best stocks typically have an RS Rating of above 80 as they begin their biggest price moves. | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Improved Price Performance? Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Improved Price Performance? | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. See if AstraZeneca can continue to show renewed price strength and clear that threshold. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Improved Price Performance? |
25880.0 | 2017-10-27 00:00:00 UTC | Dow Stock Merck, AbbVie Top Earnings Views, Light On Sales | ABBV | https://www.nasdaq.com/articles/dow-stock-merck-abbvie-top-earnings-views-light-sales-2017-10-27 | nan | nan | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday.
[ibd-display-video id=2422711 width=50 float=left autostart=true]Merck felt the icy touch of investors as shares fell 4.4% to near 59.30 in morning trades on the stock market today . AbbVie, meanwhile, climbed 3.6% to hit 92.80.
Merck wrapped its third quarter with adjusted income of $1.11 per share, up 4%, and beating the view of analysts polled by Zacks Investment Research for $1.03 a share. But sales of $10.33 billion declined 2% and lagged the $10.51 billion analyst model.
Investors are likely to focus on sales of immuno-oncology drug Keytruda "given the increasingly challenging hepatitis C environment," Leerink analyst Seamus Fernandez said. On Thursday, Gilead Sciences ( GILD ) reported its hepatitis C drug sales fell by a third.
"We expect questions to focus almost entirely on the evolution of Keytruda uptake (as a first treatment) in non-small cell lung cancer," and timing on the readout of the Keynote-189 study confirming Keytruda plus chemotherapy in advanced lung cancer, Fernandez said in a note to clients.
Bright Spot
Still, for Merck hepatitis C was a bright spot in the quarter. Sales of Zepatier posted a yearly sales gain of 185% to $468 million. Its growth only paled in comparison to cancer drug Keytruda, which brought in $1.05 billion, up 194%.
IBD'S TAKE:Merck shares began to form a flat base with a buy point at 66.90 in early March.A flat base is one of several ways of identifying potential breakout stocks. Head to the Investor's Corner for more on how to read this pattern.
Merck's biggest product, a diabetes drug called Januvia/Janumet, declined 2% to $1.53 billion. Other big declines included a 51% dip in sales of cholesterol drug Zetia/Vytorin, and a 22% slide in revenue from human papillomavirus drug Gardasil/Gardasil 9.
Sales were reduced by about $240 million due to changes in the Centers for Disease Control and Prevention stockpile for the Gardasil vaccine after a cyberattack hit Merck in the quarter. Revenue also took a $135 million hit from lost sales in some markets after the cyberattack.
The firm raised and narrowed its full-year guidance. It sees adjusted earnings of $3.91-$3.97, up from its prior target of $3.76-$3.88 and analyst views for $3.87. It also forecast $40 billion to $40.5 billion in sales, above its earlier view for $39.4 billion to $40.4 billion. The consensus saw $40.43 billion.
'Just OK'
AbbVie's quarter was "just OK," Leerink analyst Geoffrey Porges said in a note to clients. It earned $1.41 a share excluding various items, up 16.5% and topping the consensus for $1.39. Its $6.995 billion in sales lagged the consensus for $7.04 billion, though grew from $6.43 billion in the year-ago period.
More importantly, AbbVie outlined its ambitions through 2025 for current products and its late-stage pipeline, Porges said.
The firm sees Humira - which treats rheumatoid arthritis, psoriatic arthritis, spinal arthritis, Crohn's disease and plaque psoriasis - approaching $21 billion in sales by 2020, up from its prior target for $18 billion, Porges said.
For the year, AbbVie now expects adjusted profit of $5.53-$5.55 a share, touching the low-end of the consensus forecast for $5.53. AbbVie guided to adjusted income of $6.37-$6.57 per share in 2018, lagging analysts' view for $6.62.
Humira is AbbVie's biggest drug. During the quarter, sales grew 15.8% to $4.7 billion and were above the consensus for $4.6 billion, Porges said. Cancer drug Imbruvica posted a yearly sales gain of 37.3% to $688 million. In the U.S., Imbruvica sales of $574 million beat analysts' views by 1%, Porges said.
And though Gilead struggled with its hepatitis C drug franchise, AbbVie's hepatitis C unit beat analysts' average by 24%, though sales declined by 26.8%. This followed the U.S. approval in August of Mavyret, which can treat all six genotypes of hepatitis C.
RELATED:
Celgene Results Called 'Alarming,' As Alexion, Bristol Mixed
Boston Scientific Dives As Abbott Rivalry Hits Pacemaker Sales
Three Biotech Firms Top Third-Quarter Views - But Only One Pops
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday. AbbVie, meanwhile, climbed 3.6% to hit 92.80. 'Just OK' AbbVie's quarter was "just OK," Leerink analyst Geoffrey Porges said in a note to clients. | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday. AbbVie, meanwhile, climbed 3.6% to hit 92.80. 'Just OK' AbbVie's quarter was "just OK," Leerink analyst Geoffrey Porges said in a note to clients. | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday. AbbVie, meanwhile, climbed 3.6% to hit 92.80. 'Just OK' AbbVie's quarter was "just OK," Leerink analyst Geoffrey Porges said in a note to clients. | And though Gilead struggled with its hepatitis C drug franchise, AbbVie's hepatitis C unit beat analysts' average by 24%, though sales declined by 26.8%. Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday. AbbVie, meanwhile, climbed 3.6% to hit 92.80. |
25881.0 | 2017-10-27 00:00:00 UTC | AbbVie (ABBV) Q3 Earnings Surpass Estimates, Guidance Raised | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-surpass-estimates-guidance-raised-2017-10-27 | nan | nan | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment).
Humira, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on Viekira's performance as well as pipeline updates.
Meanwhile, the Pharmacyclics acquisition has diversified AbbVie's product portfolio with the addition of Imbruvica.
AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. The average earnings beat over the last four quarters is 0.76%.
Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AbbVie's third-quarter earnings came in at $1.41 per share, beating the Zacks Consensus Estimate of $1.39.
Revenues: AbbVie posted revenues of $7 billion, in line with the Zacks Consensus Estimate.
Key Stats: Humira sales came in at $4.7 billion, up 14.8% year over year excluding currency impact. Third-quarter Imbruvica net revenues were $688 million, up 37.3% year over year.
2017 Outlook: AbbVie updated its outlook for 2017. The company raised its adjusted EPS in the range of $5.53 to $5.55 compared to $5.44-$5.54 expected previously. The Zacks Consensus Estimate is currently pegged at $5.53 per share.
Share Price Impact: Shares were up more than 2% in pre-market trading .
Check back later for our full write up on this AbbVie earnings report.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's third-quarter earnings came in at $1.41 per share, beating the Zacks Consensus Estimate of $1.39. North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. | AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's third-quarter earnings came in at $1.41 per share, beating the Zacks Consensus Estimate of $1.39. Revenues: AbbVie posted revenues of $7 billion, in line with the Zacks Consensus Estimate. |
25882.0 | 2017-10-27 00:00:00 UTC | Q3 GDP Hits 3.0%, Q3 Earnings Take Pre-Market Higher | ABBV | https://www.nasdaq.com/articles/q3-gdp-hits-30-q3-earnings-take-pre-market-higher-2017-10-27 | nan | nan | Friday, October 27, 2017
Before we attempt to get our arms around another deluge of earnings reports ahead of the final opening bell of this trading week, we get a first look at Q3 GDP: 3.0%, up from the consensus estimate of 2.7%, and a second consecutive 3-handle following Q2's final read of 3.1%. This marks the first time since 2014 the U.S. economy had GDP numbers at or above 3% in back-to-back quarters.
Particularly noteworthy about this number is that we did see some negative impact on GDP in the quarter from Hurricanes Harvey, Irma and Maria - most notably in consumer spending, which had ratcheted down from 3.3% the previous quarter to 2.4% this time around. That Q3 GDP could take a 90-basis-point hit and still reach 3% illustrates economic strength beyond the power of the consumer.
Inventories were up 0.7%, but this is normal coming as it does ahead of holiday season. Perhaps surprisingly, the federal government spent more in Q3. And maybe most importantly, as Zacks Chief Strategist John Blank pointed out last week, no major economies in the world are currently experiencing a recession. Growth is now global and synchronized; it is a very rare occurrence to see no geopolitical headwinds from the Americas to Europe to Asia-Pacific.
Q3 Earnings Roll On
Aside from big blowout beats after yesterday's close from Amazon AMZN , Alphabet GOOGL and Microsoft MSFT - which by themselves have already added an additional $80 billion to the market - we see more earnings tonnage, generally from oil & gas and pharma/bio sectors:
ExxonMobil XOM shares are up modestly in today's pre-market following Q3 results that surpassed estimates on both top and bottom lines. Earnings of 93 cents per share topped the Zacks consensus by 4 cents, whereas revenues really outperformed expectations: $66.17 billion far exceeded the $63.51 billion we had been looking for. This marks the fourth beat out of the past five quarters for the largest oil & gas "supermajor," and in an energy sector that has struggled in 2017, XOM looks to be improving.
Chevron CVX also beat estimates for both earnings and sales this morning, with $1.03 per share surpassing the 98-cent consensus on revenues of $36.21 billion, ahead of the $34.06 expected. Outgoing CEO John Watson, who will retire early next year, cited continued improvement in both earnings and cash flow for the supermajor.
Refining company Phillips 66 PSX posted a mixed Q3 during today's pre-market, with earnings of $1.66 per share beating the consensus estimate by 4 cents, though $26.2 billion in revenues fell short of our estimated $29.9 billion. The company's Refining business more than tripled in the quarter, offset by underperformance quarter over quarter from Midstream, Chemicals and Marketing.
Pharmaceuticals major Merck & Co. MRK posted $1.11 per share, ahead of the $1.03 Zacks consensus estimate. However, quarterly sales of $10.33 billion was short of the $10.50 billion we had been expecting. That said, Merck upped its fiscal year earnings guidance from $3.76-3.88 per share last time around to $3.91-3.97 this morning. Following an initial bump up of 1% in the pre-market, shares are now trading down more than 2.5% ahead of the bell.
Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Lymphoma treatment Imbruvica rose 37.3% year over year, and rheumatoid arthritis drug Humira improved 14.8% from the year-ago quarter.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7% and +90.2%, respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN): Free Stock Analysis Report
Alphabet Inc. (GOOGL): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Microsoft Corporation (MSFT): Free Stock Analysis Report
Phillips 66 (PSX): Free Stock Analysis Report
Chevron Corporation (CVX): Free Stock Analysis Report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Q3 Earnings Roll On Aside from big blowout beats after yesterday's close from Amazon AMZN , Alphabet GOOGL and Microsoft MSFT - which by themselves have already added an additional $80 billion to the market - we see more earnings tonnage, generally from oil & gas and pharma/bio sectors: ExxonMobil XOM shares are up modestly in today's pre-market following Q3 results that surpassed estimates on both top and bottom lines. | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Chevron CVX also beat estimates for both earnings and sales this morning, with $1.03 per share surpassing the 98-cent consensus on revenues of $36.21 billion, ahead of the $34.06 expected. | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Q3 Earnings Roll On Aside from big blowout beats after yesterday's close from Amazon AMZN , Alphabet GOOGL and Microsoft MSFT - which by themselves have already added an additional $80 billion to the market - we see more earnings tonnage, generally from oil & gas and pharma/bio sectors: ExxonMobil XOM shares are up modestly in today's pre-market following Q3 results that surpassed estimates on both top and bottom lines. | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. This marks the first time since 2014 the U.S. economy had GDP numbers at or above 3% in back-to-back quarters. |
25883.0 | 2017-10-27 00:00:00 UTC | Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat | ABBV | https://www.nasdaq.com/articles/gilead-gild-down-on-weak-hcv-sales-despite-q3-earnings-beat-2017-10-27 | nan | nan | Gilead Sciences, Inc.'sGILD reported third quarter 2017 results wherein both earnings and revenues surpassed expectations.
However, the stock is expected to open in the red given the decline in hepatitis C virus (HCV) franchise. Nevertheless, Gilead's stock has gained 15.2% year to date as against the industry's decline of 0.2%.
The company's third-quarter earnings (including the impact of stock-based compensation expenses) of $2.27 per share beat the Zacks Consensus Estimate of $2.09. However, earnings were below the year-ago quarter figure of $2.75.
Moreover, total revenues of $6.5 billion topped the Zacks Consensus Estimate of $6.3 billion. However, revenues declined 13.2% year over year.
HIV Impresses Yet Again, Harvoni & Sovaldi Plunges
Product sales came in at $6.4 billion, down 13.5% year over year. The decline was due to lower hepatitis C virus (HCV) sales, partially offset by higher sales across HIV and other therapeutic areas.
Antiviral product sales, which include Gilead's HIV and liver disease portfolio, came in at $5.8 billion in the reported quarter, down 14.7%.
HCV product sales, which include Harvoni, Sovaldi, Epclusa and Vosevi, were $2.2 billion, down from $3.3 billion reported in the year-ago quarter. The downside was mainly attributed to lower sales of Harvoni and Sovaldi across all major markets, partially offset by sales of Epclusa (launched in 2016) and sales of Vosevi (approved in the United States and Europe in July 2017).
Sales of Harvoni declined 47.7% year over year to $973 million in the reported quarter. Further, Sovaldi sales recorded a steep year-over-year decline of 73.4% to $219 million.
Epclusa garnered sales of $882 million in the reported quarter, up from the year-ago figure of $640 million. We note that Epclusa was launched in the U.S. and Europe in June and Jul 2016, respectively.
Meanwhile, HIV and HBV product sales came in at $3.6 billion, up 16.1% year over year. The increase was primarily driven by continuous strong uptake of tenofoviral afenamide (TAF)-based products such as Genvoya, which generated sales of $988 million, up from $461 million in the year-ago quarter, Descovy, which recorded sales of $316 million, up from $88 million, and Odefsey, which registered sales of $296 million, up from $105 million. HIV treatments like Stribild and Complera/Eviplera sales declined 63.1% and 42.3% respectively. Viread sales were down at $274 million, down 9.6%.
Atripla sales tanked 32.4% to $439 million, while Truvada sales fell 5.5% to $811 million.
Other products like Letairis, Ranexa, AmBisome and Zydelig recorded sales of $213 million (down 0.9%), $164 million (down 3.5%), $92 million (up 1.1%) and $40 million (up 2.5%), respectively.
Research & development (R&D) expenses declined 24% to $745 million. On the other hand, selling, general and administrative (SG&A) expenses increased 3.3% to $806 million. Adjusted product gross margin was 87.2% compared to 87.6% in the year-ago period.
2017 Guidance Updated
Gilead now expects net product sales in the range of $24.5-$25.5 billion, up from $24.0-$25.5 billion provided earlier. Non-HCV product sales are projected between $16 billion and $16.5 billion (earlier projection: $15.5 billion and $16 billion). HCV product sales are projected between $8.5 billion and $9.0 billion (earlier projection: $8.5 billion and $9.5 billion). Adjusted R&D expenses and adjusted SG&A expenses are now projected in the range of $3.3-$3.4 billion and $3.3-$3.4 billion, respectively. Adjusted product gross margin is expected in the range of 86-87%. Earnings per share are now projected around $1.02-$1.17 (earlier projection: 86-93 cents).
Kite Acquisition
The company recently acquired Kite Pharma. Last week, the company received FDA approval for Yescarta, a CAR-T therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Dividend and Share Repurchase
Concurrently, Gilead declared a cash dividend of 52 cents per share of common stock for fourth-quarter 2017. The dividend is payable on Dec 28 to stockholders of record at the close of business on Dec 15. During the quarter, the company paid cash dividends of $682 million and repurchased shares for $153 million.
Our Take
Though the company topped both earnings and revenue estimates in the third quarter, it witnessed a decline in HCV sales. The HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. We expect sales to decline further going forward. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. Competition as well as pricing pressure has intensified further with the launch of Merck & Co., Inc.'s MRK Zepatier. Only 39,000 patients began treatment on a Gilead regimen during the quarter, down 9% from the prior quarter.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 56% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. Genvoya is now the company's bestselling HIV product with a treatment-naïve patient share of 41%. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should further boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 145,000 patients using Truvada by the end of the third quarter. The approval of Yescarta also bodes well for Gilead.
However, Gilead has lost exclusivity for Viread and Truva which will further impact performance. We expect the decline in HCV franchise to offset the positive momentum of HIV franchise.
Zacks Rank
Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The company's third-quarter earnings (including the impact of stock-based compensation expenses) of $2.27 per share beat the Zacks Consensus Estimate of $2.09. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. HCV product sales, which include Harvoni, Sovaldi, Epclusa and Vosevi, were $2.2 billion, down from $3.3 billion reported in the year-ago quarter. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. The increase was primarily driven by continuous strong uptake of tenofoviral afenamide (TAF)-based products such as Genvoya, which generated sales of $988 million, up from $461 million in the year-ago quarter, Descovy, which recorded sales of $316 million, up from $88 million, and Odefsey, which registered sales of $296 million, up from $105 million. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. HCV product sales, which include Harvoni, Sovaldi, Epclusa and Vosevi, were $2.2 billion, down from $3.3 billion reported in the year-ago quarter. |
25884.0 | 2017-10-27 00:00:00 UTC | Data and Earnings Deluge | ABBV | https://www.nasdaq.com/articles/data-and-earnings-deluge-2017-10-27 | nan | nan | Before we attempt to get our arms around another deluge of earnings reports ahead of the final opening bell of this trading week, we get a first look at Q3 GDP: 3.0%, up from the consensus estimate of 2.7%, and a second consecutive 3-handle following Q2's final read of 3.1%. This marks the first time since 2014 the U.S. economy had GDP numbers at or above 3% since 2014.
Particularly noteworthy about this number is that we did see some negative impact on GDP in the quarter from Hurricanes Harvey, Irma and Maria - most notably in consumer spending, which had ratcheted down from 3.3% the previous quarter to 2.4% this time around. That Q3 GDP could take a 90-basis-point hit and still reach 3% illustrates economic strength beyond the power of the consumer.
Inventories were up 0.7%, but this is normal coming as it does ahead of holiday season. Perhaps surprisingly, the federal government spent more in Q3. And maybe most importantly, as Zacks Chief Strategist John Blank pointed out last week, no major economies in the world are currently experiencing a recession. Growth is now global and synchronized; it is a very rare occurrence to see no geopolitical headwinds from the Americas to Europe to Asia-Pacific.
Q3 Earnings Roll On
Aside from big blowout beats after yesterday's close from Amazon AMZN , Alphabet GOOGL and Microsoft MSFT - which by themselves have already added an additional $80 billion to the market - we see more earnings tonnage, generally from oil & gas and pharma/bio sectors:
ExxonMobil XOM shares are up modestly in today's pre-market following Q3 results that surpassed estimates on both top and bottom lines. Earnings of 93 cents per share topped the Zacks consensus by 4 cents, whereas revenues really outperformed expectations: $66.17 billion far exceeded the $63.51 billion we had been looking for. This marks the fourth beat out of the past five quarters for the largest oil & gas "supermajor," and in an energy sector that has struggled in 2017, XOM looks to be improving.
Chevron CVX also beat estimates for both earnings and sales this morning, with $1.03 per share surpassing the 98-cent consensus on revenues of $36.21 billion, ahead of the $34.06 expected. Outgoing CEO John Watson, who will retire early next year, cited continued improvement in both earnings and cash flow for the supermajor.
Refining company Phillips 66 PSX posted a mixed Q3 during today's pre-market, with earnings of $1.66 per share beating the consensus estimate by 4 cents, though $26.2 billion in revenues fell short of our estimated $29.9 billion. The company's Refining business more than tripled in the quarter, offset by underperformance quarter over quarter from Midstream, Chemicals and Marketing.
Pharmaceuticals major Merck & Co. MRK posted $1.11 per share, ahead of the $1.03 Zacks consensus estimate. However, quarterly sales of $10.33 billion was short of the $10.50 billion we had been expecting. That said, Merck upped its fiscal year earnings guidance from $3.76-3.88 per share last time around to $3.91-3.97 this morning. Following an initial bump up of 1% in the pre-market, shares are now trading down more than 2.5% ahead of the bell.
Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Lymphoma treatment Imbruvica rose 37.3% year over year, and rheumatoid arthritis drug Humira improved 14.8% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN): Free Stock Analysis Report
Alphabet Inc. (GOOGL): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Microsoft Corporation (MSFT): Free Stock Analysis Report
Phillips 66 (PSX): Free Stock Analysis Report
Chevron Corporation (CVX): Free Stock Analysis Report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Q3 Earnings Roll On Aside from big blowout beats after yesterday's close from Amazon AMZN , Alphabet GOOGL and Microsoft MSFT - which by themselves have already added an additional $80 billion to the market - we see more earnings tonnage, generally from oil & gas and pharma/bio sectors: ExxonMobil XOM shares are up modestly in today's pre-market following Q3 results that surpassed estimates on both top and bottom lines. | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Chevron CVX also beat estimates for both earnings and sales this morning, with $1.03 per share surpassing the 98-cent consensus on revenues of $36.21 billion, ahead of the $34.06 expected. | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Q3 Earnings Roll On Aside from big blowout beats after yesterday's close from Amazon AMZN , Alphabet GOOGL and Microsoft MSFT - which by themselves have already added an additional $80 billion to the market - we see more earnings tonnage, generally from oil & gas and pharma/bio sectors: ExxonMobil XOM shares are up modestly in today's pre-market following Q3 results that surpassed estimates on both top and bottom lines. | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Chevron CVX also beat estimates for both earnings and sales this morning, with $1.03 per share surpassing the 98-cent consensus on revenues of $36.21 billion, ahead of the $34.06 expected. |
25885.0 | 2017-10-27 00:00:00 UTC | AbbVie Inc (ABBV) Earnings: 12 Things to Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-earnings-12-things-know-2017-10-27 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017.
Source: Shutterstock
Here are a few things to know about AbbVie Inc's recent earnings report.
The company reported earnings per share of $1.41 on revenue of $7.00 billion.
Earnings per share and revenue from the same time last year were $1.21 and $6.43 billion.
Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter.
Operating income for the quarter was $2.71 billion, which is up from the $2.36 billion reported in the third quarter of 2016.
Net income was $1.63 billion compared to net income of $1.60 billion in the same period of the year prior.
AbbVie Inc updated its 2017 guidance to include earnings per share ranging from $5.53 to $5.55 .
Wall Street is expecting ABBV to report earnings per share of $5.53 for the year.
The biopharmaceutical research company also says that it is expecting earnings per share for 2018 to come in between $6.37 and $6.57.
Analysts are looking for the company to report earnings per share of $6.56 in 2018.
The company also notes that its Board of Directors have approved increasing its quarterly cash dividend to 71 cents per share from 64 cents per share.
The increase to the quarterly cash dividend for holders of ABBV stock will start with the dividend payable on Feb. 15, 2018.
Investors of ABBV must be on record as of Jan. 12, 2018 to receive the quarterly cash dividend.
7 Spinoff Stocks That Could Be Better Than Their Parents
ABBV stock was up 3% as of noon Friday and is up 48% year-to-date.
More From InvestorPlace
10 Small-Cap Stocks to Buy for Big-Time Growth Potential
7 Investments Every Retirement Investor Should Own
5 Bitcoin Stocks to Buy for Low-Risk Cryptocurrency Profits
As of this writing, William White did not hold a position in any of the aforementioned securities.
The post AbbVie Inc (ABBV) Earnings: 12 Things to Know appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter. Wall Street is expecting ABBV to report earnings per share of $5.53 for the year. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017. | Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter. Wall Street is expecting ABBV to report earnings per share of $5.53 for the year. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017. Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter. Source: Shutterstock Here are a few things to know about AbbVie Inc's recent earnings report. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017. The post AbbVie Inc (ABBV) Earnings: 12 Things to Know appeared first on InvestorPlace . Source: Shutterstock Here are a few things to know about AbbVie Inc's recent earnings report. |
25886.0 | 2017-10-26 00:00:00 UTC | Westchester Capital Management, Inc. Buys Exxon Mobil Corp, Alphabet Inc, JPMorgan Chase, Sells ... | ABBV | https://www.nasdaq.com/articles/westchester-capital-management-inc-buys-exxon-mobil-corp-alphabet-inc-jpmorgan-chase-sells | nan | nan | Westchester Capital Management, Inc.
New Purchases: GOOGL , JPM ,
Added Positions: XOM , PFE, BDX, VLO, MCHP, AGN, LMT, DIS, CVS, CSCO,
Reduced Positions:GLD, SDY, CVX, F,
For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Capital+Management%2C+Inc.
These are the top 5 holdings of Westchester Capital Management, Inc.
AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. Shares added by 0.11%
Apple Inc ( AAPL ) - 79,812 shares, 5.27% of the total portfolio. Shares added by 0.52%
Berkshire Hathaway Inc (BRK.B) - 66,859 shares, 5.26% of the total portfolio. Shares added by 0.65%
Valero Energy Corp ( VLO ) - 131,210 shares, 4.33% of the total portfolio. Shares added by 1.48%
Intel Corp ( INTC ) - 262,470 shares, 4.29% of the total portfolio. Shares added by 0.78%
New Purchase: Alphabet Inc ( GOOGL )
Westchester Capital Management, Inc. initiated holdings in Alphabet Inc. The purchase prices were between $919.46 and $998.31, with an estimated average price of $947.7. The stock is now traded at around $991.46. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 8 shares as of 2017-09-30.
New Purchase: JPMorgan Chase & Co (JPM)
Westchester Capital Management, Inc. initiated holdings in JPMorgan Chase & Co. The purchase prices were between $88.42 and $95.51, with an estimated average price of $92.22. The stock is now traded at around $101.02. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 109 shares as of 2017-09-30.
Added: Exxon Mobil Corp (XOM)
Westchester Capital Management, Inc. added to the holdings in Exxon Mobil Corp by 250.39%. The purchase prices were between $76.1 and $82.19, with an estimated average price of $79.4. The stock is now traded at around $83.17. The impact to the portfolio due to this purchase was 0.11%. The holdings were 4,443 shares as of 2017-09-30.
Warning! GuruFocus has detected 5 Warning Signs with XOM. Click here to check it out.
XOM 15-Year Financial Data
The intrinsic value of XOM
Peter Lynch Chart of XOM
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. Westchester Capital Management, Inc. New Purchases: GOOGL , JPM , Added Positions: XOM , PFE, BDX, VLO, MCHP, AGN, LMT, DIS, CVS, CSCO, Reduced Positions:GLD, SDY, CVX, F, For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Capital+Management%2C+Inc. Added: Exxon Mobil Corp (XOM) Westchester Capital Management, Inc. added to the holdings in Exxon Mobil Corp by 250.39%. | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. Shares added by 0.78% New Purchase: Alphabet Inc ( GOOGL ) Westchester Capital Management, Inc. initiated holdings in Alphabet Inc. New Purchase: JPMorgan Chase & Co (JPM) Westchester Capital Management, Inc. initiated holdings in JPMorgan Chase & Co. | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. Westchester Capital Management, Inc. New Purchases: GOOGL , JPM , Added Positions: XOM , PFE, BDX, VLO, MCHP, AGN, LMT, DIS, CVS, CSCO, Reduced Positions:GLD, SDY, CVX, F, For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Capital+Management%2C+Inc. Shares added by 0.78% New Purchase: Alphabet Inc ( GOOGL ) Westchester Capital Management, Inc. initiated holdings in Alphabet Inc. | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. The holdings were 8 shares as of 2017-09-30. GuruFocus has detected 5 Warning Signs with XOM. |
25887.0 | 2017-10-26 00:00:00 UTC | Gilead Sciences, Inc. Stock Looks Good Regardless of Quarterly Earnings Report | ABBV | https://www.nasdaq.com/articles/gilead-sciences-inc.-stock-looks-good-regardless-of-quarterly-earnings-report-2017-10-26 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
However Gilead Sciences, Inc. (NASDAQ: GILD ) quarterly earnings report ends up after the market close (October 26), the stock's valuation still looks very compelling. Ideally, investors would want the company reporting stronger Hepatitis C drug sales, and so, higher cash flow in the quarter.
Source: Gilead Sciences
In its second quarter report (back in July), Gilead reported improving non-HCV revenue, especially in the U.S. Total revenue topped $7.1 billion, down from $7.8 billion last year. Though product sales fell 8% year-over-year, U.S. product sales rose 2 percent. Sales of HCV products fell. Similarly, in Europe, competitive pressures hurt HCV sales. The company improved its cost structure by cutting expenses (excluding R&D) by 22%, to $812 million.
Gilead ended the quarter with $36.6 billion in cash and investments. Cash flow will fall in the second half of this year, due to both seasonal payments and payments for government rebates. In the next Q4 reporting period, expect cash levels to fall to around $24.7 billion, excluding cash generated in that time. Gilead is acquiring Kite Pharma for $11.9 billion , a deal set to close in the fourth quarter. Gilead said the purchase will give it opportunities to diversify its revenue. In the short term, Kite will be neutral to earnings. It will add positively to profits in the third year of ownership.
10 Healthcare Stocks to Buy for a Dividend Lifeline
For the full year 2017, GILD forecasts net product sales of between $24 billion to $25.5 billion. Non-HCV product sales are expected to be between $15.5 billion to $16 billion. HCV net-product sales are guided between $8.5 billion to $9.5 billion. The company forecasts R&D expenses of between $3.2 billion to $3.4 billion.
HCV Developments
The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Gilead's application for marketing Vosevi last June. In July, the FDA approved the drug for treating HCV genotypes 1 - 6. The success of HCV is a mixed blessing for GILD. Patients cured of HCV no longer need treatment, so the company must find new patients infected with hepatitis. Once introduced into the system, the market potential grows. Then, the medical system may treat these patients.
Competition for HCV Drug
Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch how it markets the drug. Gilead has Vosevi and Epclusa, which may lessen the negative impact of AbbVie's competitive pressures on Gilead's HCV drug.
The impact of AbbVie's competition will not show up in the near term. Last month, GILD stock topped $86.27 and has fallen steadily ever since. The drop is just as likely due to worries over the competition as the general decline in the iShares NasdaqBiotechnologyETF (NASDAQ: IBB ).
Gilead's Valuation
Based on 10 financial models built by finbox.io users, the GILD stock price has an average fair value of around $94, implying upside of 17.6 percent. If Kite Pharma adds positively to earnings within three years, then investors should use a 10Y DCF EBITDA Exit model. Gilead need only stabilize revenues by 2020 while reporting flat or some growth from years 2021 through 2026 . With a discount rate between 9 to 10 percent, the GILD stock price today is worth between $101 - $115 a share.
Weak Industry Group Rank Hampers Gilead Sciences (GILD) Rating
Takeaway for GILD Stock
Gilead's healthy balance sheet will continue, but its cash levels will shrink. It is about time. The drug company needs another blockbuster drug within a few years to offset the rising competition of HCV drugs. Kite Pharma is a big acquisition for Gilead, but growth investors should expect more buyouts on the way to reaccelerate the company's growth.
More From InvestorPlace
4 Dividend Stocks to Buy With Capital Growth Stories
It's Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock
5 Large-Cap Stocks Breaking Down
The post Gilead Sciences, Inc. Stock Looks Good Regardless of Quarterly Earnings Report appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch how it markets the drug. Gilead has Vosevi and Epclusa, which may lessen the negative impact of AbbVie's competitive pressures on Gilead's HCV drug. | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch how it markets the drug. Gilead has Vosevi and Epclusa, which may lessen the negative impact of AbbVie's competitive pressures on Gilead's HCV drug. | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch how it markets the drug. Gilead has Vosevi and Epclusa, which may lessen the negative impact of AbbVie's competitive pressures on Gilead's HCV drug. | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch how it markets the drug. Gilead has Vosevi and Epclusa, which may lessen the negative impact of AbbVie's competitive pressures on Gilead's HCV drug. |
25888.0 | 2017-10-26 00:00:00 UTC | Key Predictions for Q3 Earnings Reports of ABBV, MRK | ABBV | https://www.nasdaq.com/articles/key-predictions-for-q3-earnings-reports-of-abbv-mrk-2017-10-26 | nan | nan | The third-quarter reporting cycle is witnessing revenue acceleration and a positive revisions trend for Q4.
Results from about one-third (164 companies) of the S&P 500 members are already out. The revenue beat ratio for these companies is 68.3%, slightly below the preceding quarter (68.9%), which itself was unusually high comparing historically.
Total earnings for the 164 S&P 500 members that have reported already are up 7% from the same period last year on 4.8% higher revenues, with 72% beating EPS estimates.
According to the latest Earnings Preview report, these 164 S&P 500 companies account for 38.2% of the index's total market capitalization. Per the report, total earnings of S&P 500 companies in Q3 are expected to grow 3.6% year over year on 5% higher revenues.
Among the biotech/pharma bigwigs, Eli Lilly and Company LLY , Biogen Inc. BIIB and Amgen Inc. AMGN have reported their third-quarter results this week.
All the three companies beat expectations for both earnings and sales Lilly also raised its earnings and sales outlook for 2017. While Amgen slightly raised the lower end of the previously issued sales outlook, it raised the earnings guidance on the back of effective cost management.
However, shares of Biogen and Amgen declined following their results announcements. Concerns regarding Biogen's multiple sclerosis franchise sales as well as U.S. sales of its recently launched spinal muscular atrophy ("SMA") treatment, Spinraza, hurt investor sentiment. While for Amgen, the year over year decline in sales led to the share price fall.
Here we have large pharma companies that are set to report third-quarter results on Oct 27. Let's see how things are shaping up for this quarter.
AbbVie Inc.ABBV
AbbVie, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 1.43% last quarter. Lilly's earnings performance has been mixed with earnings breaking even in two of the last four quarters while beating the same in the other two, bringing the average surprise to 0.76%.
For this quarter, Abbvie has an Earnings ESP of almost 0.00% and a Zacks Rank #3 (Hold). The Zacks Consensus Estimate is pegged at $1.39 per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
The company's key drug, Humira, is likely to remain the main growth driver in Q3, backed by higher demand. This quarter, AbbVie expects Humira sales to rise in the high-teens range while internationally, the same are estimated to increase in a mid-single-digit range on an operational basis. Other drugs like Duopa and Creon are also expected to continue to perform well in the soon-to-be-reported quarter.( (Read More: Can AbbVie Spring a Surprise this Earnings Season? )
AbbVie Inc. Price and Consensus
AbbVie Inc. Price and Consensus | AbbVie Inc. Quote
Merck & Co., Inc.MRK
Merck which is scheduled to release earnings before the market opens. Merckhad delivered a positive earnings surprise of 16.09% last quarter. The company's earnings performance has been pretty impressive so far, having delivered a positive surprise in each of the last four quarters. The average earnings beat over the last four quarters is 8.11%.
The company also has an Earnings ESP of almost 0.00%and a Zacks Rank #3,. The Zacks Consensus Estimate is pegged at $1.03 per share. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Merck's new products like Keytruda (cancer), Zepatier (HCV) and Bridion (sugammadex) Injection are likely to drive the top line this quarter. Keytruda sales in the United States are gaining particularly on the back of strong momentum in the new indication of first-line lung cancer. (Read More: Will Merck Keep the Earnings Streak Alive in Q3?)
Our previous article showed that Merck was likely to beat on earnings this quarter. However, estimates changed thereafter and we are not certain of a beat this earnings season.
Merck & Company, Inc. Price and Consensus
Merck & Company, Inc. Price and Consensus | Merck & Company, Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 1.43% last quarter. For this quarter, Abbvie has an Earnings ESP of almost 0.00% and a Zacks Rank #3 (Hold). This quarter, AbbVie expects Humira sales to rise in the high-teens range while internationally, the same are estimated to increase in a mid-single-digit range on an operational basis. | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Merck & Co., Inc.MRK Merck which is scheduled to release earnings before the market opens. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 1.43% last quarter. | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 1.43% last quarter. For this quarter, Abbvie has an Earnings ESP of almost 0.00% and a Zacks Rank #3 (Hold). | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 1.43% last quarter. For this quarter, Abbvie has an Earnings ESP of almost 0.00% and a Zacks Rank #3 (Hold). This quarter, AbbVie expects Humira sales to rise in the high-teens range while internationally, the same are estimated to increase in a mid-single-digit range on an operational basis. |
25889.0 | 2017-10-26 00:00:00 UTC | Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View | ABBV | https://www.nasdaq.com/articles/vertex-vrtx-beats-on-q3-earnings-sales-raises-2017-view-2017-10-26 | nan | nan | Vertex Pharmaceuticals IncorporatedVRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter.
Vertex reported revenues of $578.2 million in the third quarter, up almost 40% year over year driven by strong product revenues. Revenues also beat the Zacks Consensus Estimate of $518.45 million.
CF Franchise Sales Strong
Vertex's third-quarter revenues consisted of sales from cystic fibrosis ("CF") products - Kalydeco and Orkambi, collaborative ($26.3 million) and royalty revenues ($2.2 million). CF product revenues were $549.6 million in the third quarter, up 34% year over year.
Kalydeco sales rose 22% to $213 million following approvals to treat an expanded population.
In May, Kalydeco was approved for use in CF patients 2 years and older who have one of 23 residual function mutations in the CFTR gene. More than 900 people in the United States have one of these mutations. The expanded indication should boost sales of the drug in future quarters. In August, Kalydeco was approved in CF patients (2 years and older) who have one of the five residual function mutations that result in a splicing defect in the CFTR gene, which occurs in more than 600 patients.
Orkambi (lumacaftor/ivacaftor) delivered sales of $336.2 million, up 43.7% year over year. The growth was supported by continued uptake in pediatric patients in the United States and additional revenues from European countries where Vertex has signed reimbursement agreements.
Costs Rise
Adjusted research and development expenses increased 15.3% to $243.2 million in the third quarter due to higher costs related to development of triple combination CF regimens. Adjusted selling, general and administrative (SG&A) expenses increased 7.9% to $90.6 million due to increased investment to support the global commercialization of Orkambi and Kalydeco.
2017 Guidance Raised
Vertex increased its 2017 guidance for Orkambi and Kalydeco sales. However, it maintained its guidance for combined operating costs.
Orkambi revenues are expected in the range of $1.29-$1.32 billion (previously $1.1-$1.3 billion), while Kalydeco revenues are estimated in the range of $810 million - $830 million (previously $770 million - $800 million). Total CF product revenues are expected in the range of $2.1 billion to $2.15 billion in 2017.
We note that the increase in Orkambi sales projection is based on strong demands seen so far this year. Projections for Kalydeco were increased following strong demand in newly approved indications.
Combined adjusted research and development (R&D) and selling, general and administrative (SG&A) expenses in 2017 are still anticipated in the range of $1.33 to $1.36 billion.
Focus on Next Generation CF Regimens
Vertex's tezacaftor/ivacaftor combination for treating CF patients is under review in the United States and Europe. The company is seeking approval in people with CF aged 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function mutation. A decision is expected in February next year in the United States, while approval in Europe is expected in the second half of 2018.
Concurrent with the press release, the company announced data from a phase III study evaluating the combination in CF patients with one copy of the F508del mutation and one copy of a gating mutation. The study has failed to meet its primary endpoint of absolute change in percent predicted forced expiratory volume in one second (ppFEV1), a measure of lung function.
Vertex is also evaluating some next-generation CFTR correctors (VX-152, VX-440, VX-659 and VX-445) as part of a triple combination with VX-661 (tezacaftor) and ivacaftor. Following discussions with regulatory agencies, Vertex will initiate pivotal phase III studies on two of the four triple combination regimens in the first half of 2018.
Other CF Pipeline Update
Vertex's epithelial sodium channel (ENaC) inhibitor candidate, VX-371, is being evaluated in a phase II study in CF patients who are being treated with Orkambi. Per the press release, the study did not meet its primary endpoint of change in ppFEV1.
Another phase II study is developing VX-371 for treating patients with primary ciliary dyskinesia.
Our Take
Vertex's third-quarter results were encouraging. The company beat estimates on both counts as sales of both its CF drugs rose.
Shares declined slightly in after-hours trading probably due to failure of the pivotal tezacaftor/ivacaftor study. However, so far this year, Vertex's share price is up a massive 99.3%, comparing favorably with an increase of 6.9% for the industry .
Vertex's CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Its triple combination CF regimens are considered crucial for long-term growth. If the triple-combo regimes are successful, Vertex can address a significantly larger CF patient population - almost 90% of the patients - in the future.
However, competition is increasing as several major companies are developing interest in CF. Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to Vertex's triple combo regimens.
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise | Vertex Pharmaceuticals Incorporated Quote
Vertex carries a Zacks Rank #3 (Hold).
A better-ranked stock in the health care sector is Adaptimmune Therapeutics PLC ADAP , which carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Adaptimmune's loss estimates narrowed from $1.03 to 95 cents for 2017 and from 95 cents to 90 for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the four trailing quarters with an average beat of 2.56%. The company's shares are up 72.1% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to Vertex's triple combo regimens. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report To read this article on Zacks.com click here. The growth was supported by continued uptake in pediatric patients in the United States and additional revenues from European countries where Vertex has signed reimbursement agreements. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to Vertex's triple combo regimens. Orkambi revenues are expected in the range of $1.29-$1.32 billion (previously $1.1-$1.3 billion), while Kalydeco revenues are estimated in the range of $810 million - $830 million (previously $770 million - $800 million). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to Vertex's triple combo regimens. CF Franchise Sales Strong Vertex's third-quarter revenues consisted of sales from cystic fibrosis ("CF") products - Kalydeco and Orkambi, collaborative ($26.3 million) and royalty revenues ($2.2 million). | Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to Vertex's triple combo regimens. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report To read this article on Zacks.com click here. CF Franchise Sales Strong Vertex's third-quarter revenues consisted of sales from cystic fibrosis ("CF") products - Kalydeco and Orkambi, collaborative ($26.3 million) and royalty revenues ($2.2 million). |
25890.0 | 2017-10-26 00:00:00 UTC | 5 Things You'll Want to Watch With AbbVie's Q3 Results | ABBV | https://www.nasdaq.com/articles/5-things-youll-want-watch-abbvies-q3-results-2017-10-26 | nan | nan | If 2017 ended right now, it would go down as AbbVie 's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a stand-alone company in 2013. AbbVie has enjoyed good news for its current products and its pipeline.
But the year isn't over yet. AbbVie will provide an update on its third-quarter performance on Friday. Will those results allow the company to keep the momentum rolling? Here are five things to watch with AbbVie's third-quarter results.
1. How Humira is holding up against competitors
AbbVie calmed the worries of many investors when it announced a deal last month that keeps Amgen 's biosimilar to Humira, Amjevita, off the U.S. market until 2023. However, Amjevita isn't the only rival that AbbVie is keeping its eyes on.
Humira faces competition not only from established autoimmune disease drugs like Johnson & Johnson 's (NYSE: JNJ) Remicade but also from biosimilars to these drugs. That shouldn't be a big issue for AbbVie in the third quarter. The company expects U.S sales growth for Humira in the high teens and mid-single-digit percentage growth internationally. Still, with Humira generating over two-thirds of AbbVie's total revenue, even a small blip in sales could loom large.
2. Impact of currency rates
One factor that could impact AbbVie in the third quarter is foreign currency rates. The U.S. dollar weakened throughout much of the third quarter. A weaker dollar is usually good news for international sales, which represent one-third of AbbVie's total revenue.
On the other hand, as a company with global operations, AbbVie maintains hedges on key currencies. Bill Chase, Abbvie's CFO, stated in July that a falling U.S. dollar could cause gross margin to be lower due to these hedges.
3. Imbruvica's growth -- especially in first-line CLL
While Humira remains AbbVie's top-selling product, Imbruvica is its fastest-growing drug. AbbVie made $626 million in the second quarter from Imbruvica (including international profits shared with partner Johnson & Johnson), a 43% year-over-year jump.
Look for that growth rate to taper off somewhat in the third quarter to closer to 30%. Imbruvica won Food and Drug Administration approval for first-line chronic lymphocytic leukemia (CLL) in March 2016, so prior-year period comparisons naturally would be stronger against the first full quarter of the drug's launch in the indication. However, there's still plenty of room for Imbruvica to grow sales, especially in the first-line CLL indication where it had roughly 33% market share at the end of the second quarter.
4. Early numbers for Mavyret
AbbVie won U.S. approval for hepatitis C virus (HCV) drug Mavyret in early August and European approval for the drug (known as Maviret in Europe) in late July. Third-quarter results will only reflect early figures that don't include a full quarter, but they could be quite interesting.
Mavyret is AbbVie's first drug that can treat all major genotypes of HCV. The company also priced the drug attractively. If sales results are surprisingly high for a partial quarter, it could bode very well for AbbVie's fortunes in 2018.
5. How big of a dividend hike
Technically, AbbVie's dividend increase announcements are made separately from quarterly results. However, the company tends to announce its dividend hikes simultaneously with its third-quarter results each year.
Last year, AbbVie boosted its dividend by 12.3%. I expect the company to announce a dividend increase of 12.5% to $0.72 per quarter. If I'm right, that would bump its yield to just above 3%. With sustained growth for Humira and Imbruvica, solid potential for Mavyret, and perhaps additional color on the biotech's promising pipeline candidates, another big dividend hike could be icing on the cake for investors.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bill Chase, Abbvie's CFO, stated in July that a falling U.S. dollar could cause gross margin to be lower due to these hedges. If 2017 ended right now, it would go down as AbbVie 's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a stand-alone company in 2013. | Imbruvica's growth -- especially in first-line CLL While Humira remains AbbVie's top-selling product, Imbruvica is its fastest-growing drug. How big of a dividend hike Technically, AbbVie's dividend increase announcements are made separately from quarterly results. If 2017 ended right now, it would go down as AbbVie 's (NYSE: ABBV) best ever. | Imbruvica's growth -- especially in first-line CLL While Humira remains AbbVie's top-selling product, Imbruvica is its fastest-growing drug. AbbVie made $626 million in the second quarter from Imbruvica (including international profits shared with partner Johnson & Johnson), a 43% year-over-year jump. How big of a dividend hike Technically, AbbVie's dividend increase announcements are made separately from quarterly results. | A weaker dollar is usually good news for international sales, which represent one-third of AbbVie's total revenue. If 2017 ended right now, it would go down as AbbVie 's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a stand-alone company in 2013. |
25891.0 | 2017-10-26 00:00:00 UTC | Notable Thursday Option Activity: PX, ABBV, DMRC | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-px-abbv-dmrc-2017-10-26 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Praxair Inc (Symbol: PX), where a total volume of 4,010 contracts has been traded thus far today, a contract volume which is representative of approximately 401,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.5% of PX's average daily trading volume over the past month, of 920,875 shares. Especially high volume was seen for the $150 strike call option expiring January 19, 2018 , with 1,245 contracts trading so far today, representing approximately 124,500 underlying shares of PX. Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past month, of 5.9 million shares. Especially high volume was seen for the $88 strike put option expiring October 27, 2017 , with 2,391 contracts trading so far today, representing approximately 239,100 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $88 strike highlighted in orange:
And Digimarc Corp (Symbol: DMRC) options are showing a volume of 240 contracts thus far today. That number of contracts represents approximately 24,000 underlying shares, working out to a sizeable 42.8% of DMRC's average daily trading volume over the past month, of 56,120 shares. Especially high volume was seen for the $35 strike call option expiring November 17, 2017 , with 105 contracts trading so far today, representing approximately 10,500 underlying shares of DMRC. Below is a chart showing DMRC's trailing twelve month trading history, with the $35 strike highlighted in orange:
For the various different available expirations for PX options , ABBV options , or DMRC options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $88 strike put option expiring October 27, 2017 , with 2,391 contracts trading so far today, representing approximately 239,100 underlying shares of ABBV. Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past month, of 5.9 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $88 strike highlighted in orange: And Digimarc Corp (Symbol: DMRC) options are showing a volume of 240 contracts thus far today. | Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past month, of 5.9 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $88 strike highlighted in orange: And Digimarc Corp (Symbol: DMRC) options are showing a volume of 240 contracts thus far today. Especially high volume was seen for the $88 strike put option expiring October 27, 2017 , with 2,391 contracts trading so far today, representing approximately 239,100 underlying shares of ABBV. | Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past month, of 5.9 million shares. Especially high volume was seen for the $88 strike put option expiring October 27, 2017 , with 2,391 contracts trading so far today, representing approximately 239,100 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $88 strike highlighted in orange: And Digimarc Corp (Symbol: DMRC) options are showing a volume of 240 contracts thus far today. | Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past month, of 5.9 million shares. Especially high volume was seen for the $88 strike put option expiring October 27, 2017 , with 2,391 contracts trading so far today, representing approximately 239,100 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $88 strike highlighted in orange: And Digimarc Corp (Symbol: DMRC) options are showing a volume of 240 contracts thus far today. |
25892.0 | 2017-10-26 00:00:00 UTC | Gilead Tops Sales, Profit Views But Misses On Hep C; Shares Fall | ABBV | https://www.nasdaq.com/articles/gilead-tops-sales-profit-views-misses-hep-c-shares-fall-2017-10-26 | nan | nan | Gilead Sciences ( GILD ) topped sales and adjusted profits views in the third quarter, but shares dropped late Thursday after its hepatitis C drug franchise declined again and narrowly missed consensus expectations.
[ibd-display-video id=2422292 width=50 float=left autostart=true]In after-hours trading on the stock market today , Gilead fell 4.1% to 74.70. Shares closed down 2.5%, at 77.88, as biotech stocks widely sold off before the closing bell Thursday following Celgene 's ( CELG ) sales miss and guidance cut.
Total sales of $6.51 billion declined 13.2% but topped the consensus of analysts polled by Zacks Investment Research for $6.33 billion. Adjusted profit came in at $2.27 a share, down 17.5%, but beat expectations for adjusted earnings of $2.03 per share.
Sales of HIV and hepatitis B drugs climbed nearly 3% to $3.6 billion. Flagship HIV drug Genvoya posted a yearly gain of 114% to $988 million and beat the consensus for $934 million, RBC analyst Brian Abrahams wrote in a note to clients.
Gilead's hepatitis C drugs, meanwhile, continued to struggle, falling by a third to $2.2 billion and missing analyst views for $2.3 billion, Loncar Investments Chief Executive Brad Loncar said in a note. This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C.
RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Epclusa also missed, posting $882 million, which was below the consensus for $958 million.
IBD'S TAKE:Gilead currently has an IBD Relative Strength Rating of 66 out of a best-possible 99. Earlier this month, its RS Rating rose as high as 73. Visit IBD Data Stories for more on what goes into rating a stock.
"Even without explicit 2018 guidance, we believe this directionally should help bring down Street hepatitis C numbers for next year, a welcome reduction that would lessen an overhang on shares," Abrahams said.
Other product sales - which includes drugs to treat high blood pressure in the lungs, angina and fungal infections - declined about 1% to $559 million.
Gilead increased the low-end of its 2017 net product sales guidance to $24.5 billion to $25.5 billion. It sees non-hepatitis C drug sales comprising $16 billion to $16.5 billion. The firm also lowered the top-end of its hepatitis C guidance to reflect $8.5 billion to $9 billion in sales.
RELATED:
Biotechs Amgen, Sarepta, Vertex Top Third-Quarter Expectations
Boston Scientific Dives As Abbott Rivalry Hits Pacemaker Sales
Celgene Crashes On Sales Miss; Alexion, Bristol Results Mixed
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Gilead Sciences ( GILD ) topped sales and adjusted profits views in the third quarter, but shares dropped late Thursday after its hepatitis C drug franchise declined again and narrowly missed consensus expectations. Other product sales - which includes drugs to treat high blood pressure in the lungs, angina and fungal infections - declined about 1% to $559 million. | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Flagship HIV drug Genvoya posted a yearly gain of 114% to $988 million and beat the consensus for $934 million, RBC analyst Brian Abrahams wrote in a note to clients. Gilead's hepatitis C drugs, meanwhile, continued to struggle, falling by a third to $2.2 billion and missing analyst views for $2.3 billion, Loncar Investments Chief Executive Brad Loncar said in a note. | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Gilead Sciences ( GILD ) topped sales and adjusted profits views in the third quarter, but shares dropped late Thursday after its hepatitis C drug franchise declined again and narrowly missed consensus expectations. Gilead's hepatitis C drugs, meanwhile, continued to struggle, falling by a third to $2.2 billion and missing analyst views for $2.3 billion, Loncar Investments Chief Executive Brad Loncar said in a note. | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Gilead Sciences ( GILD ) topped sales and adjusted profits views in the third quarter, but shares dropped late Thursday after its hepatitis C drug franchise declined again and narrowly missed consensus expectations. Sales of HIV and hepatitis B drugs climbed nearly 3% to $3.6 billion. |
25893.0 | 2017-10-26 00:00:00 UTC | Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus | ABBV | https://www.nasdaq.com/articles/bristol-myers-bmy-misses-on-q3-earnings-opdivo-in-focus-2017-10-26 | nan | nan | Bristol-Myers Squibb Company 's BMY third-quarter 2017 earnings of 75 cents per share fell short of the Zacks Consensus Estimate as well as the year-ago quarter earnings of 77 cents.
However, total revenue of $5.25 billion came ahead of the Zacks Consensus Estimate of $5.2 billion as well as $4.9 billion recorded in the year-ago period. Strong sales of Opdivo and Eliquis contributed to the top line in the reported quarter.
Shares of the company were down 1.9% in pre-market trading , presumably due to the lower-than-expected earnings. Bristol-Myers' shares have increased 9.5% so far this year, which compares unfavorably with the industry 's increase of 17.8%.
Quarterly Details
Revenues were up 6% year over year when adjusted for foreign exchange impact. Revenues in the United States increased 3% to $2.9 billion and increased 12% outside the United States. Ex-U.S. revenues were up 11% when adjusted for foreign exchange impact.
Leukemia drug Sprycel raked in sales of $509 million, up 8% year over year. Melanoma drug Yervoy contributed $323 million to the top line during the reported quarter, up 13%.
Opdivo, which is approved for multiple cancer indications, generated revenues of $1.27 billion, up 38% from the year-ago period. The drug received approval for its label expansion in three more indications, which includes hepatocellular carcinoma, metastatic colorectal cancer and recurrent gastric cancer.
However, the performance of key drugs in the Virology unit continues to disappoint. Sales of Baraclude declined 14% to $264 million. The Reyataz and Sustiva franchises deteriorated 27% and 33% year over year to $174 million and $183 million, respectively..
Nevertheless, sales of Eliquis were $1.23 billion during the reported quarter, up 29% year over year. Multiple myeloma drug, Empliciti recorded sales of $60 million, up 46% year over year.
Research and development (R&D) expenses in the quarter increased 36% to $1.5 billion mainly due to a charge of $310 million related to acquisition of IFM Therapeutics, while marketing, selling and administrative expenses remained flat at $1.1 billion.
Gross margin was 70.1% in the quarter compared with 73.5% in the year-ago quarter due to change in product mix and recognition of an inventory charge.
In September 2017, Bristol-Myers completed the acquisition of all outstanding capital stock of IFM and gained full rights to IFM's preclinical STING and NLRP3 agonist programs, which enhance the body's immune response for treating cancer. Moreover, the company signed a global collaboration and license agreement with Halozyme Therapeutics for developing subcutaneous administration of its immuno-oncology medicines using Halozyme's ENHANZE drug delivery technology.
During the quarter, Bristol-Myers entered into multiple collaborations to develop Opdivo in combination with two antibody drug conjugates, a PARP inhibitor or tyrosine kinases inhibitor in several tumor types. These include Daiichi Sankyo's investigational candidate DS-8201, AbbVie Inc's ABBV ABBV-399, Exelixis, Inc.'s EXEL Cabometyx and Clovis Oncology, Inc.'s CLVS Rubraca.
Pipeline Update
In September, Bristol Myers announced data from a phase III study, CheckMate -238, which showed significant improvement in recurrence-free survival in stage IIIb/c or stage IV melanoma treated with Opdivo - Yervoy combination compared to Yervoy alone. Meanwhile, another phase III study, CheckMate -214 was stopped early as Opdivo + Yervoy achieved superior overall survival compared to current standard of care sunitinib. The study was conducted on previously untreated patients with advanced or metastatic renal cell carcinoma.
However, three studies were placed under partial clinical hold evaluating Opdivo-based combinations in patients with relapsed or refractory multiple myeloma. The hold was placed based on risk observed in studies evaluating another anti-PD-1 agent, pembrolizumab, in multiple myeloma patients.
2017 Earnings Guidance Revised
Bristol-Myers has raised its adjusted earnings expectations for 2017. The company now projects earnings in the range of $2.95 to $3.05 per share (old guidance: $2.90 to $3.00). The Zacks Consensus Estimate for earnings is pegged at $2.99.
Our Take
Bristol-Myers missed earnings expectations primarily due to an increase in R&D expenses. However, robust sales of drugs like Opdivo, Eliquis and Yervoy in the quarter drove the top line. The revised 2017 guidance was also encouraging. Meanwhile, we are positive on Bristol-Myers' efforts to develop its pipeline, especially Opdivo.
Bristol-Myers Squibb Company Price, Consensus and EPS Surprise
Bristol-Myers Squibb Company Price, Consensus and EPS Surprise | Bristol-Myers Squibb Company Quote
Bristol-Myers carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Exelixis, Inc. (EXEL): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | These include Daiichi Sankyo's investigational candidate DS-8201, AbbVie Inc's ABBV ABBV-399, Exelixis, Inc.'s EXEL Cabometyx and Clovis Oncology, Inc.'s CLVS Rubraca. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, another phase III study, CheckMate -214 was stopped early as Opdivo + Yervoy achieved superior overall survival compared to current standard of care sunitinib. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. These include Daiichi Sankyo's investigational candidate DS-8201, AbbVie Inc's ABBV ABBV-399, Exelixis, Inc.'s EXEL Cabometyx and Clovis Oncology, Inc.'s CLVS Rubraca. Pipeline Update In September, Bristol Myers announced data from a phase III study, CheckMate -238, which showed significant improvement in recurrence-free survival in stage IIIb/c or stage IV melanoma treated with Opdivo - Yervoy combination compared to Yervoy alone. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. These include Daiichi Sankyo's investigational candidate DS-8201, AbbVie Inc's ABBV ABBV-399, Exelixis, Inc.'s EXEL Cabometyx and Clovis Oncology, Inc.'s CLVS Rubraca. Bristol-Myers Squibb Company 's BMY third-quarter 2017 earnings of 75 cents per share fell short of the Zacks Consensus Estimate as well as the year-ago quarter earnings of 77 cents. | These include Daiichi Sankyo's investigational candidate DS-8201, AbbVie Inc's ABBV ABBV-399, Exelixis, Inc.'s EXEL Cabometyx and Clovis Oncology, Inc.'s CLVS Rubraca. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Nevertheless, sales of Eliquis were $1.23 billion during the reported quarter, up 29% year over year. |
25894.0 | 2017-10-26 00:00:00 UTC | Must-Watch Earnings Charts to End the Week | ABBV | https://www.nasdaq.com/articles/must-watch-earnings-charts-end-week-2017-10-26 | nan | nan | This is a big week for earnings, with over 800 companies expected to report, including many Dow Industrial and S&P 500 companies.
In addition to some of the top technology titans, there are also a handful of other companies that you should keep an eye on.
These companies are on everyone's list because they are breaking out, are widely held, or they just have fantastic earnings track records.
It's not easy to beat the earnings consensus every quarter for years, but some of these companies are doing just that.
5 Earnings Reports You Must Watch
1. Baidu BIDU hasn't missed since 2014. Shares had been stuck in a narrow trading range but have recently busted out to new 5-year highs. Can it build even more momentum off another earnings beat?
2. AbbVie ABBV has missed only once since its 2013 spin-off from Abbott Labs. Shares have soared in 2017 but the healthcare stocks are out of favor. Can it continue to hit new highs?
3. Expedia EXPE has missed 4 quarters in a row but shares are still trading near 5-year highs. Does the miss or the beat matter with this company?
4. Colgate-Palmolive CL has only missed once in the last 5 years but shares aren't going anywhere as the consumer products companies remain out of favor.
5. Columbia Sportswear COLM is in the dreaded retail sector so shares have been stuck. But it has a great earnings track record, with just one miss in the last 5 years.
Want to Learn How to Trade Options?
Have you always wanted to trade stock options but are unsure where to begin or what to look for?
Each week, Zacks' Dave Bartosiak will bring you a detailed explanation of the trades "live" on YouTube.
Watch him go through the trade as he answers your questions in real time.
Become one of Dave's minions. Join the Zacks Live Trader community today. It's free!
Click here to join Dave >>>
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Expedia, Inc. (EXPE): Free Stock Analysis Report
Baidu, Inc. (BIDU): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
Columbia Sportswear Company (COLM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ABBV has missed only once since its 2013 spin-off from Abbott Labs. Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report To read this article on Zacks.com click here. Colgate-Palmolive CL has only missed once in the last 5 years but shares aren't going anywhere as the consumer products companies remain out of favor. | Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV has missed only once since its 2013 spin-off from Abbott Labs. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV has missed only once since its 2013 spin-off from Abbott Labs. This is a big week for earnings, with over 800 companies expected to report, including many Dow Industrial and S&P 500 companies. | Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV has missed only once since its 2013 spin-off from Abbott Labs. It's not easy to beat the earnings consensus every quarter for years, but some of these companies are doing just that. |
25895.0 | 2017-10-25 00:00:00 UTC | Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-q3-earnings-gileads-car-t-drug-gets-fda-nod-2017-10-25 | nan | nan | Biogen's BIIB third quarter results surpassed both top-and bottom-line expectations. Meanwhile, Gilead's GILD CAR T therapy gained earlier-than-expected FDA approval. Alexion ALXN also got a regulatory boost with the FDA expanding the label of the company's flagship product, Soliris.
Recap of the Week's Most Important Stories
Biogen Beats on All Fronts: Although Biogen's third quarter results were better than expected with the company surpassing both earnings and revenue expectations, shares were down 3.9% on concerns regarding the company's multiple sclerosis franchise sales as well as U.S. sales of its recently launched spinal muscular atrophy ("SMA") treatment, Spinraza. Spinraza U.S. sales were $198 million in the third quarter, more or less flat from second quarter sales of $195 million though the company reported a 75% increase in the number of patients on therapy in the United States compared to the end of the second quarter. However, second quarter sales included inventory buildup of $30 million (Read more: Biogen Tops Q3 Earnings & Sales, Spinraza Sales Up ).
Biogen has gained 11.3% year to date, outperforming the industry's 8.2% rally.
Gilead CAR T Therapy Yescarta Approved: Gilead's Yescarta, which became a part of the company's portfolio following the $11.9 billion Kite Pharma acquisition, gained FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This makes Yescarta the first chimeric antigen receptor T cell (CAR T) therapy to gain approval for use in this patient population.
Yescarta is the second gene therapy to gain approval in the United States, the first being Novartis's Kymriah. Both treatments come with a Boxed Warning regarding the risks of cytokine release syndrome ("CRS") and neurologic toxicities.
Yescarta's approval is a major boost for Gilead which is currently facing declining sales from its hepatitis C virus ("HCV") franchise. According to information provided by the company, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma ("NHL") - about 7,500 patients with refractory DLBCL are eligible for CAR T therapy every year. Yescarta represents a new treatment option for these patients who have run out of treatment options and face a poor prognosis. Yescarta will be launched with a list price of $373,000 in the United States and is currently under review in the EU where a response is expected in the first half of 2018 (Read more: Gilead CAR-T Therapy Yescarta Clinches FDA Approval ).
Gilead also announced phase II results on its investigational treatment for nonalcoholic steatohepatitis ("NASH"). The company said that the higher dose (20 mg) of GS-0976, an oral ACC inhibitor, achieved significant reductions in buildup of fat in the liver and a noninvasive marker of fibrosis (TIMP-1) compared to placebo. However, statistical significance was not achieved for other parameters like liver stiffness (by FibroScan and MRE), serum ALT and PIII-NP, a serum marker of fibrogenesis. Meanwhile, differences between the lower dose (5 mg) of GS-0976 and placebo were not statistically significant.
Celgene Hit by Crohn's Disease Study Discontinuation: Celgene's CELG shares were down 10.8% on news that the company will be discontinuing studies (phase III REVOLVE study and the extension study (SUSTAIN)) being conducted with its investigational Crohn's disease drug, GED-0301 (mongersen). The decision was based on a recommendation from the Data Monitoring Committee in October following an interim futility analysis. No meaningful safety imbalances were observed in the analysis.
Celgene also said that it will wait to review the full dataset from the phase II ulcerative colitis study on GED-0301 before deciding the path forward. The company will not be initiating the phase III DEFINE study for Crohn's disease (Read more: Celgene Down on Discontinued Crohn's Disease Drug Study ).
AbbVie Announces Immuno-Therapy Focused Deals: AbbVie ABBV announced a couple of deals this week. While one deal is focused on immuno-neurology, the other is focused on immuno-oncology.
The immuno-neurology deal will see AbbVie collaborating with Alector for the use of the latter's immuno-neurology discovery platform for innovative new therapies for Alzheimer's disease and other neurological disorders.
Immuno-neurology, a rapidly evolving scientific area, is focused on harnessing the power of the immune system to attack neurodegenerative disorders like Alzheimer's disease.
While development and commercialization costs as well as profits will be shared equally by the companies, Alector will get an upfront payment of $205 million and a potential, future equity investment of up to $20 million.
Meanwhile, the immuno-oncology deal will see AbbVie teaming up with Harpoon Therapeutics for the use of Harpoon's tri-specific T-cell activating construct (TriTAC) platform with AbbVie's research-stage immuno-oncology targets to develop cancer therapeutics (Read more: AbbVie Inks Immuno-Oncology Deal with Harpoon Therapeutics ).
Label Expansion for Alexion's Soliris: The FDA granted approval to Alexion for the use of its flagship product, Soliris (eculizumab) in adult patients with generalized myasthenia gravis (gMG) who are AchR antibody-positive. Soliris, already approved in the United States for serious ultra-rare disorders like paroxysmal nocturnal hemoglobinuria ("PNH") and atypical hemolytic uremic syndrome (aHUS), brought in sales of $1.6 billion in the first half of the year. The gMG indication represents incremental growth opportunity for Soliris.
Alexion is a Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index declined 3.9% over the last five trading sessions. Among major biotech stocks, Celgene lost 13.3% reflecting a sell-off following the Crohn's disease update while Biogen was down 8.3%. Over the last six months, Vertex VRTX was up 28.4% while Celgene was down 2.3% (See the last biotech stock roundup here: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug ).
What's Next in the Biotech World?
This week, companies like Amgen AMGN , Vertex, Alexion, Gilead, Celgene and AbbVie will be reporting third quarter results.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Announces Immuno-Therapy Focused Deals: AbbVie ABBV announced a couple of deals this week. The immuno-neurology deal will see AbbVie collaborating with Alector for the use of the latter's immuno-neurology discovery platform for innovative new therapies for Alzheimer's disease and other neurological disorders. Meanwhile, the immuno-oncology deal will see AbbVie teaming up with Harpoon Therapeutics for the use of Harpoon's tri-specific T-cell activating construct (TriTAC) platform with AbbVie's research-stage immuno-oncology targets to develop cancer therapeutics (Read more: AbbVie Inks Immuno-Oncology Deal with Harpoon Therapeutics ). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Announces Immuno-Therapy Focused Deals: AbbVie ABBV announced a couple of deals this week. The immuno-neurology deal will see AbbVie collaborating with Alector for the use of the latter's immuno-neurology discovery platform for innovative new therapies for Alzheimer's disease and other neurological disorders. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Announces Immuno-Therapy Focused Deals: AbbVie ABBV announced a couple of deals this week. The immuno-neurology deal will see AbbVie collaborating with Alector for the use of the latter's immuno-neurology discovery platform for innovative new therapies for Alzheimer's disease and other neurological disorders. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Announces Immuno-Therapy Focused Deals: AbbVie ABBV announced a couple of deals this week. The immuno-neurology deal will see AbbVie collaborating with Alector for the use of the latter's immuno-neurology discovery platform for innovative new therapies for Alzheimer's disease and other neurological disorders. |
25896.0 | 2017-10-25 00:00:00 UTC | 10 Healthcare Stocks to Buy for a Dividend Lifeline | ABBV | https://www.nasdaq.com/articles/10-healthcare-stocks-to-buy-for-a-dividend-lifeline-2017-10-25 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Healthcare stocks are no strangers to uncertainty. There's continued talk about changes to U.S. healthcare laws, and disruption to the statewide insurance exchanges that were created as part of the Affordable Care Act.
Source: Shutterstock
But for long-term investors focused on dividends, the sector holds a lot of potential regardless of short-term volatility. After all, healthcare stocks are one of the few recession-proof investments on Wall Street; patients cut back on all manner of spending before they allow their health or quality of life to suffer.
Similarly, healthcare is one of the most reliable sectors for future price appreciation given the non-stop inflation of medical spending in the U.S. and ever-growing demand abroad for 21st century cures.
When you throw in the fact that many healthcare stocks also provide robust and regular dividend payments, the appeal of the sector becomes very clear.
10 Stocks Set to Benefit From Self-Driving Cars
Thus, if you can stomach ups and downs as Congress debates healthcare, then consider these dividend payers in the sector as long-term investments.
Healthcare Stocks to Buy: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Market Cap: $145 billion
Dividend Yield: 2.8%
2017 Return: 47% vs. 15% for the S&P 500
AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. It's home to current blockbusters, including psoriasis treatment Humira as well as a research-driven drugmaker looking for the next generation of big-name cures.
Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 30% or better thanks to a strong pharmaceutical portfolio. And that success has translated into generous dividends, as the company has ramped up its payout from 40 cents after its initial spin-off to 64-cents-per-share just four years later.
With decent profit growth resulting in continued dividend growth, investors can enjoy not just a robust payout now but the hopes of continued payouts from this healthcare giant going forward.
Healthcare Stocks to Buy: Merck (MRK)
Source: Ryan via Wikimedia (Modified)
Market Cap: $170 billion
Dividend Yield: 3.0%
2017 Return: 7% vs. 15% for the S&P 500
Merck & Co., Inc. (NYSE: MRK ) continues to see growth as its drugs look to fight common American health conditions. Its blockbuster diabetes drug Januvia, which helps lower blood sugar, accounts for some $4 billion in annual sales and its Zetia cholesterol medication racks up over $2 billion in annual sales.
And it's not done, either, with a strong product pipeline that includes cancer drug Keytruda. The pipeline could open avenues to much bigger revenue after a very nice showing so far in 2017. The marriage of so-called "maintenance" drugs to provide regular revenue will fuel dividends now, and new drugs could yield continued dividend growth going forward.
4 Dividend Stocks to Buy With Capital Growth Stories
With one of the biggest and most stable brands in medicine, this healthcare stock is a rock-solid long-term play for dividend investors.
Healthcare Stocks to Buy: Johnson & Johnson (JNJ)
Source: Shutterstock
Market Cap: $380 billion
Dividend Yield: 2.4%
2017 Return: 22% vs. 15% for the S&P 500
If you're looking for a low risk dividend stock, you'd be hard pressed to find a better play than Johnson & Johnson (NYSE: JNJ ). As one of two U.S. corporations with a AAA credit rating, JNJ is as stable as they come. And why not, since the healthcare giant generates about $19 billion annually in cash flow and boasts over $39 billion in cash in the bank?
That stable balance sheet comes from a reliable revenue stream that is hard to match in any sector. In addition to top-notch clinical products and pharmaceuticals, the company has the benefit of big-brand consumer products that include Band-Aid, Tylenol and Benadryl just to name a few.
There admittedly isn't a ton of growth potential here, but patient investors will be richly rewarded with slow and steady profits.
Healthcare Stocks to Buy: Novo Nordisk (NVO)
Source: Shutterstock
Market Cap: $100 billion
Dividend Yield: 2.3%
2017 Return: 40% vs. 15% for the S&P 500
Novo Nordisk A/S (ADR) (NYSE: NVO ) is a great long-term play on a great long-term trend. And while the current dividend yield is only a hair bigger than the yield on 10-year Treasury bonds, the potential for total return is much higher.
That's because one of the biggest healthcare challenges right now is the rise in diabetes over the last few decades. The Center for Disease Control and Prevention estimates that the percentage of Americans with diabetes has soared from about 2% in 1970 to about 7% currently.
5 Dirt Cheap Dividend ETFs to Buy Now
That is a disturbing trend, but also a big opportunity for Novo Nordisk since it specializes in diabetes care and prevention. That includes insulin injection technology like "pen needles" as well as weight management products that can help at-risk patients.
Healthcare Stocks to Buy: Cardinal Health (CAH)
Source: Via Wikimedia
Market Cap: $21 billion
Dividend Yield: 2.8%
2017 Return: -7% vs. 15% for the S&P 500
Cardinal Health Inc. (NYSE: CAH ) is part of a boring but reliable segment of the healthcare business via medical supplies. And as one of the biggest healthcare products companies in the world, Cardinal dominates this field with everything from antiseptic wipes to patient slippers to advanced wound care products. If you're ever in a hospital, chances are you're surrounded by Cardinal items and don't even know it.
Like many other stocks on this list, the reliability of this business leads to consistent profits and consistent dividend growth. In fact, its most recent payout of about 46 cents is double the 21.5 cents paid to shareholders at the beginning of 2012.
Healthcare Stocks to Buy: Omega Healthcare (OHI)
Source: Shutterstock
Market Cap: $6 billion
Dividend Yield: 8.2%
2017 Return: 2% vs. 15% for the S&P 500
Omega Healthcare Investors Inc (NYSE: OHI ) is classified as a "real estate investment trust" or REIT. However, it focuses on senior living and long-term care properties that make it very much a healthcare play.
Omega mainly operates "triple-net lease" properties, which means it's not liable for three burdensome costs that can plague landlords - namely, taxes, maintenance and insurance. Think of Omega as a middleman that just collects the rent.
5 Battered Stocks That Can Come Back From the Grave
Reliable rent checks result in reliable dividend payments, too, and since REITs must past 90% of taxable income on to shareholders, the result is a juicy yield and high-yield healthcare play that should pay off nicely for long-term investors.
Healthcare Stocks to Buy: Amgen (AMGN)
Source: Shutterstock
Market Cap: $130 billion
Dividend Yield: 2.6%
2017 Return: 23% vs. 15% for the S&P 500
Amgen, Inc. (NASDAQ: AMGN ) was all the rage as Wall Street focused on the potential of next-generation cures out of the biotechnology industry a few years ago. But the company has since settled down lately as revenue has plateaued. But this happens to many stocks as they mature.
The good news is that Amgen has embraced its role as a $120 billion healthcare powerhouse, choosing to satisfy shareholders via dividends instead of wasting money on knee-jerk acquisitions or other fruitless efforts to chase unrealistic growth. AMGN has increased payouts a massive 310% since instituting regular dividends in 2011, but those payouts remain roughly a third of earnings and are ripe for future increases as well.
Healthcare Stocks to Buy: Pfizer (PFE)
Source: Kojach Via Flickr
Market Cap: $215 billion
Dividend Yield: 3.5%
2017 Return: 12% vs. 15% for the S&P 500
Like other healthcare megacaps on this list, Pfizer Inc. (NYSE: PFE ) doesn't have a lot of growth potential to offer investors. It is already a $200 billion company and its product pipeline is largely replacing revenue lost by patent expirations on treatments such as its blockbuster Viagra, among others.
But remember, dividend stock investing is a long-term endeavor and isn't about short-term revenue trends. It's about consistent payouts and a stable business that will be there to keep paying you in several years, if not several decades.
10 More Retirement Stocks to Buy and Hold for the Rest of Your Life
Pfizer has that in spades. The company has paid dividends in some form or fashion since 1901, and while distributions were slashed during the Financial Crisis of 2009 it has re-attained those payout levels once more and it should see dividends continue to grow going forward.
Healthcare Stocks to Buy: CVS
Source: Mike Mozart via Flickr
Market Cap: $77 billion
Dividend Yield: 2.6%
2017 Return: -3% vs. 15% for the S&P 500
You may think of CVS Health Corp (NYSE: CVS ) as just a drugstore, but it's also increasingly a core healthcare play thanks to its pharmacy benefits footprint. This includes its Omnicare arm that exclusively services long-term care facilities, as well as corporate pharmacy benefits programs that manage claims and payments. Throw in its growing "MinuteClinic" operations that provide in-store checkups and you can see this is more than just a retail stock.
It isn't a high margin business to be involved in the fulfillment of prescription drugs, but CVS has a huge footprint that allows it to be efficient and it has a great brand that makes it a force to be reckoned with. Those operations also help support reliable revenue that pays a nice dividend to shareholders.
Healthcare Stocks to Buy: GlaxoSmithKline (GSK)
Source: Shutterstock
Market Cap: $99 billion
Dividend Yield: 5.0%
2017 Return: 5% vs. 15% for the S&P 500
GlaxoSmithKline plc (ADR) (NYSE: GSK ) is a Big Pharma name you may be familiar with, but its stability and dividends don't come simply from branded drugs. This healthcare giant is a leader in vaccines as well as over-the-counter products, including Excedrin pain relievers and Sensodyne oral care products.
The 5 Best Retirement Funds for 2018
Shares have been sleepy for the last few years as the product portfolio hasn't really delivered any breakout winners. However, dividend investors shouldn't be looking for a flashy new drug but rather reliable performance - and GSK has that in spades thanks to over $3 billion free cash flow last fiscal year.
As of this writing, Jeff Reeves did not own a position in any of the aforementioned securities.
The post 10 Healthcare Stocks to Buy for a Dividend Lifeline appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 30% or better thanks to a strong pharmaceutical portfolio. Similarly, healthcare is one of the most reliable sectors for future price appreciation given the non-stop inflation of medical spending in the U.S. and ever-growing demand abroad for 21st century cures. | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 30% or better thanks to a strong pharmaceutical portfolio. Healthcare Stocks to Buy: Johnson & Johnson (JNJ) Source: Shutterstock Market Cap: $380 billion Dividend Yield: 2.4% 2017 Return: 22% vs. 15% for the S&P 500 If you're looking for a low risk dividend stock, you'd be hard pressed to find a better play than Johnson & Johnson (NYSE: JNJ ). | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 30% or better thanks to a strong pharmaceutical portfolio. Healthcare Stocks to Buy: Johnson & Johnson (JNJ) Source: Shutterstock Market Cap: $380 billion Dividend Yield: 2.4% 2017 Return: 22% vs. 15% for the S&P 500 If you're looking for a low risk dividend stock, you'd be hard pressed to find a better play than Johnson & Johnson (NYSE: JNJ ). | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previous company. Analysts are projecting revenue growth at ABBV of almost 10% this year and next, and profit expansion of 30% or better thanks to a strong pharmaceutical portfolio. With decent profit growth resulting in continued dividend growth, investors can enjoy not just a robust payout now but the hopes of continued payouts from this healthcare giant going forward. |
25897.0 | 2017-10-25 00:00:00 UTC | Gierl Augustine Investment Management Inc Buys iShares International Select Dividend, Vanguard ... | ABBV | https://www.nasdaq.com/articles/gierl-augustine-investment-management-inc-buys-ishares-international-select-dividend | nan | nan | Gierl Augustine Investment Management Inc
New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO,
Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM,
Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG,
Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP,
For the details of Gierl Augustine Investment Management Inc's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gierl+Augustine+Investment+Management+Inc
These are the top 5 holdings of Gierl Augustine Investment Management Inc
AbbVie Inc ( ABBV ) - 54,131 shares, 3.76% of the total portfolio. Shares reduced by 0.47%
Caterpillar Inc ( CAT ) - 38,344 shares, 3.74% of the total portfolio. Shares reduced by 0.95%
Johnson & Johnson ( JNJ ) - 32,028 shares, 3.26% of the total portfolio. Shares added by 1.79%
Cisco Systems Inc ( CSCO ) - 122,279 shares, 3.22% of the total portfolio. Shares added by 1.66%
Emerson Electric Co ( EMR ) - 65,173 shares, 3.2% of the total portfolio. Shares added by 0.10%
New Purchase: iShares International Select Dividend (IDV)
Gierl Augustine Investment Management Inc initiated holdings in iShares International Select Dividend. The purchase prices were between $32.54 and $34.08, with an estimated average price of $33.39. The stock is now traded at around $33.30. The impact to the portfolio due to this purchase was 2.98%. The holdings were 112,986 shares as of 2017-09-30.
New Purchase: Vanguard Mid-Cap Growth (VOT)
Gierl Augustine Investment Management Inc initiated holdings in Vanguard Mid-Cap Growth. The purchase prices were between $115.95 and $121.75, with an estimated average price of $119.16. The stock is now traded at around $123.08. The impact to the portfolio due to this purchase was 2.13%. The holdings were 22,394 shares as of 2017-09-30.
New Purchase: Vanguard REIT (VNQ)
Gierl Augustine Investment Management Inc initiated holdings in Vanguard REIT. The purchase prices were between $81.16 and $85.71, with an estimated average price of $83.58. The stock is now traded at around $82.32. The impact to the portfolio due to this purchase was 2.06%. The holdings were 31,730 shares as of 2017-09-30.
New Purchase: Vanguard Total Stock Market (VTI)
Gierl Augustine Investment Management Inc initiated holdings in Vanguard Total Stock Market. The purchase prices were between $123.66 and $129.52, with an estimated average price of $126.62. The stock is now traded at around $131.00. The impact to the portfolio due to this purchase was 0.23%. The holdings were 2,225 shares as of 2017-09-30.
New Purchase: SPDR S&P 400 Mid Cap Growth ETF (based on S&P MidC (MDYG)
Gierl Augustine Investment Management Inc initiated holdings in SPDR S&P 400 Mid Cap Growth ETF (based on S&P MidC. The purchase prices were between $139.75 and $147.46, with an estimated average price of $143.71. The stock is now traded at around $150.03. The impact to the portfolio due to this purchase was 0.1%. The holdings were 838 shares as of 2017-09-30.
New Purchase: Schwab U.S. REIT (SCHH)
Gierl Augustine Investment Management Inc initiated holdings in Schwab U.S. REIT. The purchase prices were between $40.12 and $42.09, with an estimated average price of $41.21. The stock is now traded at around $40.74. The impact to the portfolio due to this purchase was 0.09%. The holdings were 2,892 shares as of 2017-09-30.
Added: MSA Safety Inc (MSA)
Gierl Augustine Investment Management Inc added to the holdings in MSA Safety Inc by 2233.33%. The purchase prices were between $66.16 and $80.79, with an estimated average price of $74.84. The stock is now traded at around $79.06. The impact to the portfolio due to this purchase was 0.21%. The holdings were 3,570 shares as of 2017-09-30.
Added: Apple Inc (AAPL)
Gierl Augustine Investment Management Inc added to the holdings in Apple Inc by 23.88%. The purchase prices were between $142.73 and $164.05, with an estimated average price of $155.13. The stock is now traded at around $156.78. The impact to the portfolio due to this purchase was 0.19%. The holdings were 8,176 shares as of 2017-09-30.
Added: McDonald's Corp (MCD)
Gierl Augustine Investment Management Inc added to the holdings in McDonald's Corp by 861.32%. The purchase prices were between $151.85 and $161.53, with an estimated average price of $156.71. The stock is now traded at around $164.72. The impact to the portfolio due to this purchase was 0.12%. The holdings were 1,019 shares as of 2017-09-30.
Added: FirstEnergy Corp (FE)
Gierl Augustine Investment Management Inc added to the holdings in FirstEnergy Corp by 767.77%. The purchase prices were between $29.06 and $32.93, with an estimated average price of $31.46. The stock is now traded at around $31.38. The impact to the portfolio due to this purchase was 0.12%. The holdings were 5,493 shares as of 2017-09-30.
Added: BP PLC (BP)
Gierl Augustine Investment Management Inc added to the holdings in BP PLC by 141.22%. The purchase prices were between $34 and $38.43, with an estimated average price of $35.45. The stock is now traded at around $38.77. The impact to the portfolio due to this purchase was 0.08%. The holdings were 4,436 shares as of 2017-09-30.
Added: ConocoPhillips (COP)
Gierl Augustine Investment Management Inc added to the holdings in ConocoPhillips by 88.51%. The purchase prices were between $42.5 and $50.22, with an estimated average price of $44.93. The stock is now traded at around $50.37. The impact to the portfolio due to this purchase was 0.06%. The holdings were 2,954 shares as of 2017-09-30.
Sold Out: iShares Russell 1000 (IWB)
Gierl Augustine Investment Management Inc sold out the holdings in iShares Russell 1000. The sale prices were between $133.83 and $139.88, with an estimated average price of $137.21.
Sold Out: iShares MSCI EAFE (EFA)
Gierl Augustine Investment Management Inc sold out the holdings in iShares MSCI EAFE. The sale prices were between $64.83 and $68.48, with an estimated average price of $66.83.
Sold Out: E.I. du Pont de Nemours & Co (DD)
Gierl Augustine Investment Management Inc sold out the holdings in E.I. du Pont de Nemours & Co. The sale prices were between $80.81 and $85.49, with an estimated average price of $82.78.
Sold Out: Vanguard FTSEEuropean (VGK)
Gierl Augustine Investment Management Inc sold out the holdings in Vanguard FTSEEuropean. The sale prices were between $54.93 and $58.43, with an estimated average price of $56.72.
Sold Out: iShares Russell 2000 (IWM)
Gierl Augustine Investment Management Inc sold out the holdings in iShares Russell 2000. The sale prices were between $134.83 and $148.18, with an estimated average price of $140.72.
Sold Out: Shopify Inc (SHOP)
Gierl Augustine Investment Management Inc sold out the holdings in Shopify Inc. The sale prices were between $86 and $122.94, with an estimated average price of $102.01.
List of 52-Week Lows
List of 3-Year Lows
List of 5-Year Lows
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the details of Gierl Augustine Investment Management Inc's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gierl+Augustine+Investment+Management+Inc These are the top 5 holdings of Gierl Augustine Investment Management Inc AbbVie Inc ( ABBV ) - 54,131 shares, 3.76% of the total portfolio. New Purchase: SPDR S&P 400 Mid Cap Growth ETF (based on S&P MidC (MDYG) Gierl Augustine Investment Management Inc initiated holdings in SPDR S&P 400 Mid Cap Growth ETF (based on S&P MidC. du Pont de Nemours & Co (DD) Gierl Augustine Investment Management Inc sold out the holdings in E.I. | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the details of Gierl Augustine Investment Management Inc's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gierl+Augustine+Investment+Management+Inc These are the top 5 holdings of Gierl Augustine Investment Management Inc AbbVie Inc ( ABBV ) - 54,131 shares, 3.76% of the total portfolio. Shares added by 0.10% New Purchase: iShares International Select Dividend (IDV) Gierl Augustine Investment Management Inc initiated holdings in iShares International Select Dividend. New Purchase: Vanguard Total Stock Market (VTI) Gierl Augustine Investment Management Inc initiated holdings in Vanguard Total Stock Market. | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the details of Gierl Augustine Investment Management Inc's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gierl+Augustine+Investment+Management+Inc These are the top 5 holdings of Gierl Augustine Investment Management Inc AbbVie Inc ( ABBV ) - 54,131 shares, 3.76% of the total portfolio. Shares added by 0.10% New Purchase: iShares International Select Dividend (IDV) Gierl Augustine Investment Management Inc initiated holdings in iShares International Select Dividend. New Purchase: Vanguard Total Stock Market (VTI) Gierl Augustine Investment Management Inc initiated holdings in Vanguard Total Stock Market. | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the details of Gierl Augustine Investment Management Inc's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gierl+Augustine+Investment+Management+Inc These are the top 5 holdings of Gierl Augustine Investment Management Inc AbbVie Inc ( ABBV ) - 54,131 shares, 3.76% of the total portfolio. New Purchase: Vanguard Total Stock Market (VTI) Gierl Augustine Investment Management Inc initiated holdings in Vanguard Total Stock Market. du Pont de Nemours & Co (DD) Gierl Augustine Investment Management Inc sold out the holdings in E.I. |
25898.0 | 2017-10-24 00:00:00 UTC | Can AbbVie (ABBV) Spring a Surprise this Earnings Season? | ABBV | https://www.nasdaq.com/articles/can-abbvie-abbv-spring-a-surprise-this-earnings-season-2017-10-24 | nan | nan | AbbVie Inc.ABBV is scheduled to release third-quarter 2017 earnings on Oct 27, before the opening bell.
AbbVie's shares have soared 47.8% so far this year, while the industry has recorded an increase of 20.2%.
Last quarter, the company delivered a positive surprise of 1.43%. Notably, AbbVie's earnings history is a mixed bag as the pharmaceuticals company beat estimates in two of the last four quarters and recorded in-line earnings in the other two. The four-quarter average beat is 0.76%.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Let's see how things are shaping up for the company this quarter.
Factors to Consider
AbbVie expects third-quarter 2017 earnings in the range of $1.36-$1.38 per share. Revenues are estimated to grow approximately 9% on an operational basis. Foreign exchange is not expected impact the sales in the third quarter.
The company's key drug, Humira, is likely to remain the main growth driver in the third quarter, backed by higher demand. This quarter, AbbVie expects Humira sales to rise in the high-teens range while internationally, sales are estimated to increase in a mid-single-digit range on an operational basis. The Zacks Consensus Estimates for Humira is $4.6 billion for the third quarter.
Significantly, cancer drug Imbruvica recorded strong sales since the past few quarters, a trend that we expect to continue. In the quarter to be reported, Imbruvica was approved by the FDA for treating adult patients with chronic graft versus host disease (cGVHD) disease after failure of one or more lines of systemic therapy. Imbruvica's expanded label should also contribute to its sales growth. The company expects the drug's U.S. sales growth to approach 30% in the third quarter. The Zacks Consensus Estimate for Imbruvica is $676 million for this quarter.
Other drugs like Duopa and Creon are also expected to continue to perform well in the soon-to-be-reported quarter.
However, Abbvie's Hepatitis C virus (HCV) treatment, Viekira, will continue to be adversely impacted by an intense pricing and competitive pressure in the HCV market.
Notably, AbbVie's eight-week, pan-genotypic, ribavirin-free, once-daily HCV treatment, Mavyret/Maviret, gained approval in the United States, EU and Canada earlier in July/August.
The company believes that Maviret has potential to rejuvenate growth in the HCV franchiseas compared to the competitive dynamics in the HCV market. We expect management to update on commercialization plans of Maviret at the conference call.
Maviret is expected to contribute considerably to revenues only from 2018 onward.
The company has made significant progress with its pipeline during the quarter, which will be another focus for investors to keep tabs on. AbbVie and partner Roche RHHBY announced positive data from a phase III MURANO study of Venclexta plus Rituxan in September to expand the label to address the broader relapsed/refractory CLL (chronic lymphocytic leukemia) patient population. Label expansion for this indication should increase the patient population for Venclexta significantly and boost its commercial potential. Also, in the same month, the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase III study for treatment of RA (rheumatoid arthritis).
Additionally, AbbVie and partner Neurocrine Biosciences announced that the new drug application (NDA) for elagolix has been submitted to the FDA in September. AbbVie is looking to get elagolix approved as an oral medicine for pain management associated with endometriosis.
Earnings Whispers
Our proven model does not conclusively show that AbbVie is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a bullish Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here, as you will see below.
Zacks ESP: AbbVie has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.39 per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of ESP, its 0.00% Earnings ESP makes the surprise prediction difficult.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider as per our model, these have the right combination of elements to beat on earnings this quarter:
Merck & Company, Inc. MRK is scheduled to release results on Oct 27. This Zacks #3 Ranked company has an Earnings ESP of +0.61%. You can see the complete list of today's Zacks #1 Rank stocks here .
Pfizer, Inc. PFE is scheduled to release results on Oct 31. The company has an Earnings ESP of +0.94% and also carries a Zacks Rank of 3.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Notably, AbbVie's eight-week, pan-genotypic, ribavirin-free, once-daily HCV treatment, Mavyret/Maviret, gained approval in the United States, EU and Canada earlier in July/August. AbbVie and partner Roche RHHBY announced positive data from a phase III MURANO study of Venclexta plus Rituxan in September to expand the label to address the broader relapsed/refractory CLL (chronic lymphocytic leukemia) patient population. AbbVie Inc.ABBV is scheduled to release third-quarter 2017 earnings on Oct 27, before the opening bell. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of ESP, its 0.00% Earnings ESP makes the surprise prediction difficult. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks ESP: AbbVie has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.39 per share. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Zacks ESP: AbbVie has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.39 per share. AbbVie Inc.ABBV is scheduled to release third-quarter 2017 earnings on Oct 27, before the opening bell. AbbVie's shares have soared 47.8% so far this year, while the industry has recorded an increase of 20.2%. |
25899.0 | 2017-10-24 00:00:00 UTC | 3 Healthcare Value Stocks | ABBV | https://www.nasdaq.com/articles/3-healthcare-value-stocks-2017-10-24 | nan | nan | The words "healthcare" and "value" don't seem to go together in the stock market right now as the sector has been hot in 2017, but that's only if you look at traditional valuation metrics and not the long-term potential.
While you can still find a few stocks that offer up an attractive price right now, foresighted investors looking for value in healthcare have to have a different mindset and look beyond the obvious. Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of good value and good potential.
The growth play that became a value play
Leo Sun(Gilead Sciences): The strength of Gilead Sciences' HIV and hepatitis portfolio once made it a favorite growth play for biotech investors. Unfortunately, Gilead's heyday passed as key HIV patents expired and major competitors entered the hepatitis C market.
Instead of spending its cash on big acquisitions to expand its pipeline and reach new markets, Gilead repurchased a lot of stock ($2.5 billion over the past 12 months) and paid out dividends ($2.6 billion during the same period) to appease nervous shareholders.
It eventually agreed to buyKite Pharma (NASDAQ: KITE) , a maker of adoptive cell therapies, for $11.9 billion. Kite's CAR-T (Chimeric Antigen Receptor T-Cell Therapies) treatment could generate nearly $7.9 billion in sales by 2022 -- which could offset Gilead's ongoing declines in HIV and hepatitis drug revenues.
Analysts still expect Gilead's revenue and earnings to respectively fall by the double-digits over the next two years. Those forecasts look bleak, but they don't fully include the projected impact of the Kite acquisition, which was announced in mid-September.
Barclays analyst Geoff Meacham recently claimed that Kite's CAR-T treatments could be the beginning of a "third act" that follows up the blockbuster success of its HIV and HCV franchises. Gilead's stock also looks very cheap at 9 times earnings, compared to the industry average of 71 for biotech companies, and its forward yield of 2.6% is supported by a low payout ratio of 22%. Those factors should limit its downside potential, even as its near-term future looks blurry.
Got oxygen?
Danny Vena(Masimo): Masimo may not be a household name, but the company is the undisputed leader in noninvasive patient monitoring technologies, with a focus on pulse oximetry. That sounds pretty complicated, but it's really quite simple. A pulse oximeter is a small device that clips to your finger to measure the amount of oxygen in your blood -- which you probably saw at the doctor's office the last time you went for a checkup.
This device and others like it provide vitally important information to healthcare providers, and Masimo has more than 1.5 million of the devices at work with medical professionals around the globe.
As the settlement of a recent patent infringement lawsuit, medical device company Koninklijke Philips NV (NYSE: PHG) paid Masimo $300 million, and the two companies have now entered a multiyear partnership to license Masimo's technology and jointly develop products. This move could significantly boost Masimo's revenue since the Dutch company controls more than 50% of the high-acuity monitoring market, and other industry players could soon follow its lead.
In its most recent quarter , Masimo produced revenue of $193 million, a 12% increase over the prior-year quarter. Discounting one-time items, net income grew a sizable 27% as expenses grew by only 4% year over year. The company recently increased its long-term growth projections by a full percent to 8% as the result of this collaboration, while increasing its earnings per share forecast by an additional 6% to $2.80.
All of this while trading at a mere 14 times trailing earnings.
A pipeline to future growth
Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer AbbVie still fits the bill. Its shares go for 23 times trailing earnings and 14 times estimates, putting it on par with the broad market indexes, but with analysts expecting it to enjoy 14% annual earnings growth over the next five years, it's clear there's lots of room for further expansion.
While much focus is rightly placed on AbbVie's Humira, from which the company derives about two-thirds of its $25.6 billion in annual revenue, it's the pipeline of therapies the drugmaker has in its portfolio that really argues in favor of its stock being discounted now.
Imbruvica is AbbVie's second biggest-selling drug with annual sales of over $1.8 billion. It estimates the hematologic oncology drug will achieve $5 billion in sales by 2020 and some $7 billion in peak sales over its lifecycle. It's also investigating dozens of other molecules for treatment of various disorders and illnesses, some with significant potential for success, including Rova-T, an experimental cancer drug, that could reach $5 billion in peak annual sales if approved, and Upadacitinib, a rheumatoid arthritis treatment with expected peak annual sales of $3.5 billion.
Obviously, biotechs carry risks, and AbbVie has paid a lot of money to acquire some of the therapies that ultimately may not pay off for it. Assuming it continues to steward their passage through clinical trial and onto the market, AbbVie's stock price today could look very discounted when looking back on it in the future.
10 stocks we like better than Masimo
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Masimo wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Danny Vena owns shares of Gilead Sciences. Leo Sun has no position in any of the stocks mentioned. Rich Duprey has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences and Masimo. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | While much focus is rightly placed on AbbVie's Humira, from which the company derives about two-thirds of its $25.6 billion in annual revenue, it's the pipeline of therapies the drugmaker has in its portfolio that really argues in favor of its stock being discounted now. Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of good value and good potential. A pipeline to future growth Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer AbbVie still fits the bill. | Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of good value and good potential. A pipeline to future growth Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer AbbVie still fits the bill. While much focus is rightly placed on AbbVie's Humira, from which the company derives about two-thirds of its $25.6 billion in annual revenue, it's the pipeline of therapies the drugmaker has in its portfolio that really argues in favor of its stock being discounted now. | A pipeline to future growth Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer AbbVie still fits the bill. Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of good value and good potential. While much focus is rightly placed on AbbVie's Humira, from which the company derives about two-thirds of its $25.6 billion in annual revenue, it's the pipeline of therapies the drugmaker has in its portfolio that really argues in favor of its stock being discounted now. | A pipeline to future growth Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer AbbVie still fits the bill. Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of good value and good potential. While much focus is rightly placed on AbbVie's Humira, from which the company derives about two-thirds of its $25.6 billion in annual revenue, it's the pipeline of therapies the drugmaker has in its portfolio that really argues in favor of its stock being discounted now. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.